EP2961750A1 - Substituted 7-oxo-pyrido [2, 3-d]pyrimidines and their use for the treatment of egfr / erbb2 related disorders - Google Patents

Substituted 7-oxo-pyrido [2, 3-d]pyrimidines and their use for the treatment of egfr / erbb2 related disorders

Info

Publication number
EP2961750A1
EP2961750A1 EP14710724.7A EP14710724A EP2961750A1 EP 2961750 A1 EP2961750 A1 EP 2961750A1 EP 14710724 A EP14710724 A EP 14710724A EP 2961750 A1 EP2961750 A1 EP 2961750A1
Authority
EP
European Patent Office
Prior art keywords
phenyl
methyl
amino
pyrimidin
oxopyrido
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP14710724.7A
Other languages
German (de)
French (fr)
Inventor
Ryan Wurz
Andrew Tasker
Seifu Tadesse
Liping H. Pettus
Thomas T. Nguyen
Fang-Tsao Hong
Bradley J. Herberich
Essa HARRINGTON
Jian J. Chen
James Brown
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of EP2961750A1 publication Critical patent/EP2961750A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • This invention is in the field of pharmaceutical agents and specifically relates to compounds, compositions, uses and methods for treating cancer.
  • Protein kinases represent a large family of proteins which play a central role in the regulation of a wide variety of cellular processes, maintaining control over cellular function.
  • a partial list of such kinases includes abl, Atk, bcr-abl, Blk, Brk, Btk, c-kit, c-
  • c-src CDKl, CDK2, CDK3, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDKIO, cRafl, CSF1R, CSK, EGFR, ErbB2, ErbB3, ErbB4, Erk, Fak, fes, FGFR1, FGFR2, FGFR3, FGFR4, FGFR5, Fgr, flt-1, Fps, Frk, Fyn, Hck, IGF-1R, INS-R, Jak, KDR, Lck, Lyn, MEK, p38, PDGFR, PIK, PKC, PYK2, ros, tie, tie2, TRK, Yes, and Zap70.
  • the ErbB receptor family belongs to the subclass I receptor tyrosine kinase superfamily and includes four distinct receptors including epidermal growth factor receptor (EGFR or ErbB 1). ⁇ 132 (HER22 or pl 85neu). Erbl33 (HER3), and Erbl34 (HER4 or rvro2). Over 60% of all solid tumors overexpress at least one of these proteins or their ligands.
  • EGFR or ErbBl has been implicated in human malignancy. Overexpression of EGFR is commonly found in breast, lung, head and neck, bladder tumors. Monoclonal antibodies directed against the EGFR, or its ligands TGF-alpha and EGF have been evaluated as therapeutic agents in the treatment of such malignancies.
  • the reversible inhibitors Tarceva (erlotinib) and Iressa (gefitinib) currently are first-line therapy for non- small cell lung cancer patients with activating mutations.
  • Activating mutations in the tyrosine kinase domain of EGFR have been identified in patients with non-small cell lung cancer (Lin, N. U.; Winer, E. P., Breast Cancer Res 6: 204-210, 2004). The most common activating mutations are L858R and delE746-A750. Another mutant, T790M, has been detected in at least half of such clinically resistant patients. Moreover, T790M may also be pre-existing, there may be an independent, oncogenic role for the T790M mutation. In addition, germline EGFR T790M mutations are linked with certain familial lung cancers.
  • the present invention comprises a new class of 7-oxo-pyrido[2,3-d]pyrimidines useful in the treatment of diseases, such as EGFR mutant-mediated diseases, for example cancer.
  • the invention also comprises pharmaceutical compositions comprising the compounds, methods for the treatment of EGFR mutant-mediated diseases and other maladies, such as treatment of solid tumors, for example breast, lung, head and neck, bladder cancers, using the compounds and compositions of the invention, and intermediates and processes useful for the preparation of the compounds of the invention.
  • the compounds of the invention are represented by the following general structure:
  • R; R n ; R 12 ; and R 14 are defined below.
  • One aspect of the current invention relates to compounds having the general structure of formula 1 :
  • Ring A is 5 membered heteroaryl
  • Ring T is phenyl or 6 membered heteroaryl
  • R 2 is H, F, CI or methyl
  • R 3 is H, C ⁇ -Ce alkyl or C ⁇ -Ce dialkylamino- C ⁇ -Ce alkyl;
  • R 5 is unsubstituted or substituted 5-6 membered saturated heterocyclyl or substituted 4-7 membered heterocyclylamino;
  • R 6 is H, C ⁇ -Ce alkoxy, C ⁇ -Ce haloalkoxy or halo;
  • X is CH or N
  • R 5 is not 4-morpholinyl
  • the group X is CH.
  • the group R 3 is H.
  • the group R 2 is H or methyl.
  • the group R 2 is methyl.
  • the group R 1 is substituted phenyl.
  • R 1 is substituted pyridyl or substituted pyrimidinyl.
  • R 5 is optionally substituted piperazinyl, optionally substituted piperidinyl, optionally substituted pyrrolidinyl, optionally substituted diazepanyl, or optionally substituted azetidinylamino; wherein the piperazinyl, piperidinyl, pyrrolidinyl, diazepanyl, and azetidinyl rings are optionally substituted with one or more substituents selected from Cu alkyl, Cu haloalkyl, Ci_ 4 alkoxycarbonyl, Cu alkylamino, optionally substituted 5-6 membered heterocyclyl, C1.4 alkylcarbonyl, C1.4 alkylsulfonyl, aminosulfonyl, C1.4 hydroxyalkylcarbonyl, C1.4 alkylaminocarbonyl, and C1.4 haloalkylcarbonyl.
  • the group R 1 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • R 5 is l-fluoroethylazetidin-3-ylamino.
  • R 6 is H, methoxy or chloro.
  • Another aspect of the current invention relates to compounds having the general structure of Formula II
  • R 2 is H or methyl
  • R a is optionally substituted piperazinyl, optionally substituted piperidinyl,
  • R b is H or methoxy
  • the group R 2 is methyl.
  • the group R b is located at position 3 on the phenyl ring.
  • the group R a is optionally substituted piperazinyl, optionally substituted piperidinyl, optionally substituted pyrrolidinyl, or optionally substituted diazepanyl; wherein the piperazinyl, piperidinyl, pyrrolidinyl and diazepanyl rings are optionally substituted with one or more substituents selected from Cu alkyl, Q_ 3 haloalkyl, C1.4 alkoxycarbonyl, Cu alkylamino, optionally substituted 5-6 membered heterocyclyl, Ci_ 4 alkylcarbonyl, Ci_ 4 alkylsulfonyl, aminosulfonyl, C1
  • the group R a is azetidinylamino; wherein the azetindinyl is optionally substituted with one or more substituents selected from Cu alkyl, Cu haloalkyl, C1.4 alkoxycarbonyl, Cu alkylamino, optionally substituted 5-6 membered heterocyclyl, Ci_ 4 alkylcarbonyl, Ci_ 4 alkylsulfonyl, aminosulfonyl, C1
  • a family of specific compounds of particular interest within Formula 1 consists of compounds and pharmaceutically-acceptable derivatives thereof as follows:
  • R n is unsubstituted or substituted phenyl or unsubstituted or substituted 4-6
  • R 12 is H, or methyl
  • R 14 is H, Ci-C 6 alkyl, Ci-C 6 alkoxy or phenyl- Ci-C 6 alkyl;
  • R 17 is H or methyl
  • R n is not 3-methoxy-4-methylpiperazin-l -yl-phenyl or phenyl when R is benzacrylamide, R 12 is methyl and R 14 is H;
  • R n is not 3-methoxy-4-methylpiperazin-l -yl-phenyl when R is 3- benzacrylamide, R 12 is H and R 14 is benzyl;
  • R 14 is not methyl or methoxy when R 12 is H.
  • R is
  • R 14 is H, benzyl, or methoxy; and pharmaceutically acceptable salts thereof.
  • R 14 is H; and pharmaceutically acceptable salts thereof.
  • R 12 is methyl; and pharmaceutically acceptable salts thereof.
  • R n is or f V!_/ ; wherein
  • Ring A is 5 membered heteroaryl; wherein Ring T is phenyl; wherein R 15 is unsubstituted or substituted 6-membered nitrogen containing heterocyclyl, C1.4 alkylamino- C1.4 alkylamino, C1.4 hydroxylalkylamino, 5-membered nitrogen containing heterocyclyl-Ci.4 alkylamino, 5-membered nitrogen containing heterocyclyl-oxy, C1.4 alkylamino- C1.4 alkoxy, or C1.4 alkoxy- C1.4 alkoxy; wherein R 16 is one or more substituents selected from Ci_4 alkyl, C1.4 alkoxy, chloro, fluoro, H, C ⁇ haloalkoxy and C ⁇ haloalkyl; and wherein R 18 is Ci_4 alkyl, Ci_ 4 alkylamino- Ci_ 4 alkyl, unsubstituted or substituted 5-membered nitrogen containing heterocyclyl or unsubstituted or substituted 6-membered nitrogen
  • R n is substituted phenyl; and pharmaceutically acceptable salts thereof.
  • R n is substituted pyrazolyl; and pharmaceutically acceptable salts thereof.
  • R 15 is optionally substituted piperazinyl, optionally substituted piperidinyl, N-(N',N'-dimethylaminoethyl)-N-methylamino, N-hydroxyethyl- N-methylamino, N-(2-oxo-l -pyrrolidinylethyl)-N-methylamino, N-(l -pyrrolidinylethyl)- N-methylamino, l -methyl-3-pyrrolidinyoxy, ⁇ , ⁇ -dimethylaminopropoxy, N,N- dimethylaminoethoxy, or methoxyethoxy; wherein the piperazinyl, and piperidinyl rings are optionally substituted with one or more substituents selected from methyl, trifluoromethyl, 1 -hydroxy- 1-methylethyl and acetyl; and pharmaceutically acceptable salts thereof.
  • R 16 is methyl, methoxy, chloro, fluoro, H,
  • R 18 is methyl, ethyl, isopropyl, N,N- dimethylaminoethyl, 1 -methyl-pyrrolidinyl, or 1-methylpiperidinyl;
  • R n is
  • Another aspect of the current invention relates to compounds having the general structure of Formula Ila
  • R a is unsubstituted or substituted 6-membered nitrogen containing heterocyclyl; and wherein R bl is one or more substituents selected from C1.4 alkyl, C1.4 alkoxy, chloro, fluoro, H, C ⁇ haloalkoxy and C ⁇ haloalkyl; and pharmaceutically acceptable salts thereof;
  • R al is not 1 -methyl-4-piperazinyl when R bl is 3-methoxy.
  • R bl is located at position 3 on the phenyl ring; and pharmaceutically acceptable salts thereof.
  • R al is piperidinyl or piperazinyl; wherein the piperidinyl or piperazinyl ring is optionally substituted with one or more substituents selected from Ci-3 alkyl, C1.4 alkylcarbonyl, or C1.4 hydroxyalkyl; and pharmaceutically acceptable salts thereof.
  • R al is
  • R bl is methyl, methoxy, chloro, fliioro, H, trifluoromethyl or difluormethoxy; and pharmaceutically acceptable salts thereof.
  • Another aspect of the current invention relates to compounds having the general structure of Formula Ilia
  • R 31 is substituted 5 membered heteroaryl
  • R 32 is H or methyl
  • R 34 is H, Ci-C 6 alkyl, Ci-C 6 alkoxy or phenyl-Ci-C 6 alkyl;
  • R 31 is substituted with one or more substituents selected from C1.4 alkyl, C1.4 alkoxy, chloro, fluoro, C ⁇ haloalkoxy, C ⁇ haloalkyl, C 1 .4 alky lamino-C 1.4 alkyl, unsubstituted or substituted 5 -membered nitrogen containing heterocyclyl and unsubstituted or substituted 6-membered nitrogen containing heterocyclyl; and and pharmaceutically acceptable salts thereof.
  • R 31 is optionally substituted pyrazolyl, optionally substituted isoxazolyl, optionally substituted thiadiazolyl, or optionally substituted imidazolyl; wherein the pyrazolyl, isoxazolyl, thiadiazolyl, or imidazolyl rings are substituted with one or more substituents selected from methyl, ethyl, isopropyl, methoxy, chloro, fluoro, trifluoromethyl, difluoromethoxy, ⁇ , ⁇ -dimethylaminoethyl, 1 - methyl-pyrrolidinyl or 1-methylpiperidinyl; and pharmaceutically acceptable salts thereof.
  • R 31 is optionally substituted pyrazolyl; wherein the pyrazolyl ring is substituted with one or more substituents selected from methyl, ethyl, isopropyl, methoxy, chloro, fluoro, trifluoromethyl, difluoromethoxy, N,N- dimethylaminoethyl, 1-methyl-pyrrolidinyl and 1 -methylpiperidinyl; and
  • R 31 is
  • R 34 is H, benzyl, or methoxy; and pharmaceutically acceptable salts thereof.
  • Another aspect of the current invention relates to compounds having the general structure of Formula IVa
  • R a is C1.4 alky lamino-C 1.4 alkylamino, C1.4 hydroxylalkylamino, 5-membered nitrogen containing heterocyclyl-Ci.4 alkylamino, 5-membered nitrogen containing heterocyclyl-oxy, C1.4 alkoxy, or C1.4 alkoxy-Ci.4 alkoxy; and wherein R is one or more substituents selected from Ci_ 4 alkyl, Ci_ 4 alkoxy, chloro, fluoro, H, and pharmaceutically acceptable salts thereof.
  • R a4 is N-(N',N'-dimethylaminoethyl)-N-methylamino, N-hydroxyethyl-N-methylamino, N-(2-oxo- 1 -pyrrolidinylethyl)-N-methylamino, N-( 1 - pyrrolidinylethyl)-N-methylamino, l-methyl-3-pyrrolidinyoxy, N,N- dimethylaminopropoxy, ⁇ , ⁇ -dimethylaminoethoxy, or methoxyethoxy; and pharmaceutically acceptable salts thereof.
  • R M is methyl, methoxy, chloro, fluoro, H,
  • a family of specific compounds of particular interest within Formula la consists of compounds and pharmaceutically-acceptable derivatives thereof as follows:
  • One aspect of the current invention relates to compounds having the general structure of formula lb:
  • X is CH or N
  • R 21 is unsubstituted or substituted phenyl or unsubstituted or substituted 4-6
  • R 22 is H, fluoro, chloro or methyl
  • R 24 is H, Ci-C 6 alkyl, Ci-C 6 alkoxy or phenyl- Ci-C 6 alkyl;
  • R 27 is H, Ci-C 6 alkyl or Ci-C 6 dialkylamino- Ci-C 6 alkyl;
  • R is or ; wherein Ring A is 5 membered heteroaryl; wherein Ring T is phenyl or 6 membered heteroaryl; wherein R 5 is unsubstituted or substituted 5-6 membered saturated heterocyclyl or substituted 4-7 membered heterocyclylamino; and wherein R 6 is H, alkoxy, haloalkoxy or halo.
  • R 21 is unsubstituted or substituted phenyl or unsubstituted or substituted 4-6 membered heterocyclyl.
  • R 22 is H, or methyl.
  • R 24 is H.
  • provided compounds are selective inhibitors of at least one mutation of EGFR. It has been surprisingly found that provided compounds are selective inhibitors of at least one mutation of EGFR as compared to wild-type ("WT") EGFR.
  • WT wild-type
  • the mutation of EGFR is T790M. In certain embodiments, the mutation of EGFR is a deletion mutation.
  • the mutation of EGFR is an activating mutation.
  • a compound of the invention selectively inhibits at least one resistant mutation and at least one activating mutation as compared to WT EGFR.
  • a compound of the invention selectively inhibits at least one deletion mutation and/or at least one point mutation, and is sparing as to WT EGFR inhibition.
  • a mutation of EGFR can be selected from T790M (resistant or oncogenic), L858R (activating), delE746-A750 (activating), G719S (activating), or a combination thereof.
  • the term "selectively inhibits,” as used in comparison to inhibition of WT EGFR, means that a provided compound inhibits at least one mutation of EGFR (i.e., at least one deletion mutation, at least one activating mutation, at least one resistant mutation, or a combination of at least one deletion mutation and at least one point mutation) in at least one assay described herein (e.g., biochemical or cellular).
  • the term "selectively inhibits,” as used in comparison to WT EGFR inhibition means that a provided compound is at least 20 times more potent, at least 25 times, at least 30, at least 35, at least 40, at least 45, or at least 50 times more potent as an inhibitor of at least one mutation of EGFR, as defined and described herein, as compared to WT EGFR.
  • the term “sparing as to WT EGFR” means that a selective inhibitor of at least one mutation of EGFR, as defined and described above and herein, inhibits EGFR at the upper limit of detection of at least one assay as described herein (e.g., biochemical or cellular as described in detail below).
  • the term “sparing as to WT EGFR” means that a provided compound inhibits WT EGFR with an IC50 of at least 1 ⁇ , at least 2 ⁇ , at least 5 ⁇ , or at least 10 ⁇ .
  • a provided compound selectively inhibits (a) at least one activating mutation; and (b) T790M; and (c) is sparing as to WT.
  • the activating mutation is a deletion mutation.
  • the activating mutation is a point mutation.
  • an activating mutation is delE746- A750.
  • an activating mutation is L858R.
  • an activating mutation is G719S.
  • the at least one mutation of EGFR is L858R and/or
  • the present invention provides a method for inhibiting an activating mutation in a patient comprising administering to the patient a provided compound or composition thereof, as described herein.
  • the present invention provides a method for inhibiting oncogenic T790M in a patient comprising administering to the patient a provided compound or composition thereof, as described herein.
  • Compounds of the present invention would be useful for, but not limited to, the prevention or treatment of EGFR mutant-mediated diseases.
  • the compounds of the invention have kinase inhibitory activity, such as T790M inhibitory activity.
  • Compounds of the invention are useful for the treatment of neoplasia including cancer and metastasis, including, but not limited to: carcinoma such as cancer of solid tumors, for example breast, lung, head and neck, bladder cancers.
  • these compounds are also useful for veterinary treatment of companion animals, exotic animals and farm animals, including mammals, rodents, and the like. More preferred animals include horses, dogs, and cats.
  • the present invention includes all pharmaceutically acceptable isotopically- labelled compounds of the present invention wherein one or more atoms are replaced by atoms having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number which predominates in nature.
  • isotopes suitable for inclusion in the compounds of the invention include, but are not limited to, isotopes of hydrogen, such as 2 H and 3 H, carbon, such as n C, 13 C and 14 C, chlorine, such as 38 C1, fluorine, such as 18 F, iodine, such as 123 I and 125 I, nitrogen, such as 13 N and 15 N, oxygen, such as 15 0, 17 0 and ls O, phosphorus, such as 32 P, and sulphur, such as 35 S.
  • isotopes of hydrogen such as 2 H and 3 H
  • carbon such as n C, 13 C and 14 C
  • chlorine such as 38 C1
  • fluorine such as 18 F
  • iodine such as 123 I and 125 I
  • nitrogen such as 13 N and 15 N
  • oxygen such as 15 0, 17 0 and ls O
  • phosphorus such as 32 P
  • sulphur such as 35 S.
  • isotopically-labelled compounds of the present invention for example, those incorporating a radioactive isotope, are useful in drug and/or substrate tissue distribution studies.
  • the radioactive isotopes tritium, i.e. 3 H, and carbon-14, i.e. 14 C, are particularly useful for this purpose in view of their ease of incorporation and ready means of detection.
  • substitution with heavier isotopes such as deuterium, i.e. 2 H, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances.
  • Isotopically -labeled compounds of the present invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples and Preparations using an appropriate isotopically-labeled reagent in place of the non-labeled reagent previously employed.
  • the compounds of the present invention include the
  • treatment includes therapeutic treatment as well as prophylactic treatment (either preventing the onset of disorders altogether or delaying the onset of a preclinically evident stage of disorders in individuals).
  • prevention includes either preventing the onset of
  • a “pharmaceutically-acceptable derivative” denotes any salt, ester of a compound of this invention, or any other compound which upon administration to a patient is capable of providing (directly or indirectly) a compound of this invention, or a metabolite or residue thereof, characterized by being therapeutically effective in vivo.
  • neoplastic therapeutic agents prolong the survivability of the patient, inhibit the rapidly-proliferating cell growth associated with the neoplasm, or effect a regression of the neoplasm.
  • H denotes a single hydrogen atom. This radical may be attached, for example, to an oxygen atom to form a hydro xyl radical.
  • alkyl is used, either alone or within other terms such as “haloalkyl” and “alkylamino”, it embraces linear or branched radicals having one to about twelve carbon atoms. More preferred alkyl radicals are “lower alkyl” radicals having one to about six carbon atoms. Examples of such radicals include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, teri-butyl, pentyl, isoamyl, hexyl and the like.
  • alkylenyl embraces bridging divalent alkyl radicals such as methylenyl and ethylenyl.
  • halo means halogens such as fluorine, chlorine, bromine or iodine atoms.
  • haloalkyl embraces radicals wherein any one or more of the alkyl carbon atoms is substituted with halo as defined above. Specifically embraced are monohaloalkyl, dihaloalkyl and polyhaloalkyl radicals.
  • a monohaloalkyl radical for one example, may have either an iodo, bromo, chloro or fluoro atom within the radical.
  • Dihalo and polyhaloalkyl radicals may have two or more of the same halo atoms or a combination of different halo radicals.
  • “Lower haloalkyl” embraces radicals having 1-6 carbon atoms. Even more preferred are lower haloalkyl radicals having one to three carbon atoms.
  • haloalkyl radicals include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl and dichloropropyl.
  • Perfluoroalkyl means alkyl radicals having all hydrogen atoms replaced with fluoro atoms. Examples include trifluoromethyl and pentafluoroethyl.
  • hydroxyalkyl embraces linear or branched alkyl radicals having one to about ten carbon atoms any one of which may be substituted with one or more hydroxyl radicals. More preferred hydroxyalkyl radicals are "lower hydroxyalkyl” radicals having one to six carbon atoms and one or more hydroxyl radicals. Examples of such radicals include hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl and hydroxyhexyl. Even more preferred are lower hydroxyalkyl radicals having one to three carbon atoms.
  • alkoxy embrace linear or branched oxy-containing radicals each having alkyl portions of one to about ten carbon atoms. More preferred alkoxy radicals are "lower alkoxy" radicals having one to six carbon atoms. Examples of such radicals include methoxy, ethoxy, propoxy, butoxy and teri-butoxy. Even more preferred are lower alkoxy radicals having one to three carbon atoms. Alkoxy radicals may be further substituted with one or more halo atoms, such as fluoro, chloro or bromo, to provide "haloalkoxy" radicals. Even more preferred are lower haloalkoxy radicals having one to three carbon atoms. Examples of such radicals include fluoromethoxy, chloromethoxy, trifluoromethoxy, trifluoroethoxy, fluoroethoxy and fluoropropoxy.
  • aryl alone or in combination, means a carbocyclic aromatic system containing one or two rings wherein such rings may be attached together in a fused manner.
  • aryl embraces aromatic radicals such as phenyl, naphthyl, indenyl, tetrahydronaphthyl, and indanyl. More preferred aryl is phenyl.
  • Said "aryl” group may have 1 to 3 substituents such as lower alkyl, hydroxyl, halo, haloalkyl, nitro, cyano, alkoxy and lower alkylamino.
  • heterocyclyl embraces saturated, partially saturated and unsaturated heteroatom-containing ring-shaped radicals, where the heteroatoms may be selected from nitrogen, sulfur and oxygen. It does not include rings containing - ⁇ - ⁇ -,- ⁇ -S- or -S-S- portions.
  • Said "heterocyclyl” group may have 1 to 3 substituents such as hydroxyl, halo, haloalkyl, cyano, lower alkyl, lower aralkyl, oxo, lower alkoxy, amino and lower alkylamino.
  • saturated heterocyclic radicals include saturated 3 to 6-membered heteromonocyclic group containing 1 to 4 nitrogen atoms [e.g. pyrrolidinyl, imidazolidinyl, piperidinyl, pyrrolinyl, piperazinyl]; saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms [e.g. morpholinyl]; saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms [e.g., thiazolidinyl].
  • nitrogen atoms e.g. pyrrolidinyl, imidazolidinyl, piperidinyl, pyrrolinyl, piperazinyl
  • saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms e.g. morpholinyl
  • heterocyclyl radicals examples include dihydrothienyl, dihydropyranyl, dihydrofuryl and dihydrothiazolyl.
  • unsaturated heterocyclic radicals also termed "heteroaryl” radicals, include unsaturated 5 to 6 membered heteromonocyclyl group containing 1 to 4 nitrogen atoms, for example, pyrrolyl, imidazolyl, pyrazolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazolyl [e.g., 4H-l,2,4-triazolyl, lH-l,2,3-triazolyl, 2H-l,2,3-triazolyl]; unsaturated 5- to 6-membered heteromonocyclic group containing an oxygen atom, for example, pyranyl, 2-furyl, 3-furyl, etc.; unsaturated 5 to
  • heterocyclic radicals are fused/condensed with aryl radicals: unsaturated condensed heterocyclic group containing 1 to 5 nitrogen atoms, for example, indolyl, isoindolyl, indolizinyl, benzimidazolyl, quinolyl, isoquinolyl, indazolyl, benzotriazolyl, tetrazolopyridazinyl [e.g., tetrazolo [1,5- b]pyridazinyl]; unsaturated condensed heterocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms [e.g.
  • heterocyclic radicals include five to ten membered fused or unfused radicals. More preferred examples of heteroaryl radicals include quinolyl, isoquinolyl, imidazolyl, pyridyl, thienyl, thiazolyl, oxazolyl, furyl, and pyrazinyl.
  • heteroaryl radicals are 5- or 6-membered heteroaryl, containing one or two heteroatoms selected from sulfur, nitrogen and oxygen, selected from thienyl, furyl, pyrrolyl, indazolyl, pyrazolyl, oxazolyl, triazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, pyridyl, piperidinyl and pyrazinyl.
  • Heterocycle means a ring comprising at least one carbon atom and at least one other atom selected from N, O and S. Examples of heterocycles that may be found in the claims include, but are not limited to, the following:
  • sulfonyl whether used alone or linked to other terms such as alkylsulfonyl, denotes respectively divalent radicals -SO 2 -.
  • carboxy or “carboxyl”, whether used alone or with other terms, such as “carboxyalkyl”, denotes -C0 2 H.
  • alkylamino embraces "N-alkylamino” and “ ⁇ , ⁇ -dialkylamino” where amino groups are substituted with one alkyl radical and with two alkyl radicals, respectively. More preferred alkylamino radicals are “lower alkylamino” radicals having one or two alkyl radicals of one to six carbon atoms, attached to a nitrogen atom. Even more preferred are lower alkylamino radicals having one to three carbon atoms. Suitable alkylamino radicals may be mono or dialkylamino such as N-methylamino, N- ethylamino, N,N-dimethylamino, ⁇ , ⁇ -diethylamino or the like.
  • heterocyclylamino embraces amino groups substituted with a heterocyclyl radical.
  • alkylcarbonyl denotes a carbonyl radical substituted with an alkyl group. Even more preferred are alkylcarbonyl radicals having alkyl lengths of one to four carbon atoms.
  • alkoxycarbonyl denotes an ester group, containing an alkoxy substituted carbonyl. Even more preferred are alkoxycarbonyl radicals having alkoxy lengths of one to four carbon atoms.
  • haloalkylcarbonyl denotes a carbonyl radical substituted with a haloalkyl group. Even more preferred are haloalkylcarbonyl radicals having haloalkyl lengths of one to four carbon atoms.
  • hydroxyalkylcarbonyl denotes a carbonyl radical substituted with an hydroxyalkyl group. Even more preferred are hydroxyalkylcarbonyl radicals having hydroxyalkyl lengths of one to four carbon atoms.
  • alkylaminocarbonyl denotes a carbonyl radical substituted with an alkylamino group. Even more preferred are alkylaminocarbonyl radicals having alkyl lengths of one to four carbon atoms.
  • alkylsulfonyl denotes a sulfonyl radical substituted with an alkyl group. Even more preferred are alkylsulfonyl radicals having alkyl lengths of one to four carbon atoms.
  • aminosulfonyl denotes a sulfonyl radical substituted with an amino group. This substituent is alternatively named sulfonamidyl or sulfamyl.
  • sulfinyl whether used alone or linked to other terms such as alkylsulfinyl, denotes respectively divalent radicals -SO-.
  • aralkyl embraces aryl-substituted alkyl radicals.
  • Preferable aralkyl radicals are "lower aralkyl” radicals having aryl radicals attached to alkyl radicals having one to six carbon atoms. Even more preferred are “phenylalkylenyl” attached to alkyl portions having one to three carbon atoms. Examples of such radicals include benzyl, diphenylmethyl and phenylethyl.
  • the aryl in said aralkyl may be additionally substituted with halo, alkyl, alkoxy, halkoalkyl and haloalkoxy.
  • heterocyclyloxy embraces optionally substituted heterocyclyl radicals, as defined above, attached to an oxygen atom.
  • heterocyclylalkylamino embraces optionally substituted heterocyclyl radicals, as defined above, attached to an alkylamino group.
  • alkylaminoalkyl embraces alkyl radicals substituted with alkylamino radicals. More preferred alkylaminoalkyl radicals are "lower alkylaminoalkyl” radicals having alkyl radicals of one to six carbon atoms. Even more preferred are lower alkylaminoalkyl radicals having alkyl radicals of one to three carbon atoms. Suitable alkylaminoalkyl radicals may be mono or dialkyl substituted, such as N- methylaminomethyl, N,N-dimethyl-aminoethyl, ⁇ , ⁇ -diethylaminomethyl and the like.
  • alkylaminoalkylamino embraces alkylamino radicals, as defined above, attached to an alkylamino group.
  • alkylaminoalkoxy embraces alkylamino radicals, as defined above, attached to an alkoxy group.
  • hydroxyalkylamino denotes an amino radical substituted with an hydroxyalkyl group. Even more preferred are hydroxyalkylamino radicals having hydroxyalkyl lengths of one to four carbon atoms.
  • alkoxyalkoxy embraces alkoxy radicals attached through an oxygen atom to other alkoxy radicals, as described above. More preferred alkoxyalkoxy radicals are "lower alkoxyalkoxy" radicals having lower alkoxy radicals attached to other lower alkoxy radical.
  • “Saturated, partially-saturated or unsaturated” includes substituents saturated with hydrogens, substituents completely unsaturated with hydrogens and substituents partially saturated with hydrogens.
  • leaving group generally refers to groups readily displaceable by a nucleophile, such as an amine, a thiol or an alcohol nucleophile. Such leaving groups are well known in the art. Examples of such leaving groups include, but are not limited to, N-hydroxysuccinimide, N-hydroxybenzotriazole, halides, triflates, tosylates and the like. Preferred leaving groups are indicated herein where appropriate.
  • Protecting group generally refers to groups well known in the art which are used to prevent selected reactive groups, such as carboxy, amino, hydroxy, mercapto and the like, from undergoing undesired reactions, such as nucleophilic, electrophilic, oxidation, reduction and the like. Preferred protecting groups are indicated herein where appropriate. Examples of amino protecting groups include, but are not limited to, aralkyl, substituted aralkyl, cycloalkenylalkyl and substituted cycloalkenyl alkyl, allyl, substituted allyl, acyl, alkoxycarbonyl, aralkoxycarbonyl, silyl and the like.
  • aralkyl examples include, but are not limited to, benzyl, ortho-methylbenzyl, trityl and benzhydryl, which can be optionally substituted with halogen, alkyl, alkoxy, hydroxy, nitro, acylamino, acyl and the like, and salts, such as phosphonium and ammonium salts.
  • aryl groups include phenyl, naphthyl, indanyl, anthracenyl, 9-(9-phenylfluorenyl), phenanthrenyl, durenyl and the like.
  • Examples of cycloalkenylalkyl or substituted cycloalkylenylalkyl radicals preferably have 6-10 carbon atoms, include, but are not limited to, cyclohexenyl methyl and the like.
  • Suitable acyl, alkoxycarbonyl and aralkoxycarbonyl groups include benzyloxycarbonyl, t-butoxycarbonyl, iso- butoxycarbonyl, benzoyl, substituted benzoyl, butyryl, acetyl, trifluoroacetyl, trichloro acetyl, phthaloyl and the like.
  • a mixture of protecting groups can be used to protect the same amino group, such as a primary amino group can be protected by both an aralkyl group and an aralkoxycarbonyl group.
  • Amino protecting groups can also form a heterocyclic ring with the nitrogen to which they are attached, for example,
  • heterocyclic groups can further include adjoining aryl and cycloalkyl rings.
  • heterocyclic groups can be mono-, di- or tri-substituted, such as nitrophthalimidyl.
  • Amino groups may also be protected against undesired reactions, such as oxidation, through the formation of an addition salt, such as hydrochloride, toluenesulfonic acid, trifluoroacetic acid and the like.
  • an addition salt such as hydrochloride, toluenesulfonic acid, trifluoroacetic acid and the like.
  • Many of the amino protecting groups are also suitable for protecting carboxy, hydroxy and mercapto groups.
  • Alkyl groups are also suitable groups for protecting hydroxy and mercapto groups, such as tert-butyl.
  • Silyl protecting groups are silicon atoms optionally substituted by one or more alkyl, aryl and aralkyl groups. Suitable silyl protecting groups include, but are not limited to, trimethylsilyl, triethylsilyl, triisopropylsilyl, tert-butyldimethylsilyl, dimethylphenylsilyl, l,2-bis(dimethylsilyl)benzene, l,2-bis(dimethylsilyl)ethane and diphenylmethylsilyl.
  • Silylation of an amino groups provide mono- or di-silylamino groups. Silylation of aminoalcohol compounds can lead to a ⁇ , ⁇ , ⁇ -trisilyl derivative.
  • silyl function from a silyl ether function is readily accomplished by treatment with, for example, a metal hydroxide or ammonium fluoride reagent, either as a discrete reaction step or in situ during a reaction with the alcohol group.
  • Suitable silylating agents are, for example, trimethylsilyl chloride, tert-butyl-dimethylsilyl chloride, phenyldimethylsilyl chloride, diphenylmethyl silyl chloride or their combination products with imidazole or DMF.
  • Methods for silylation of amines and removal of silyl protecting groups are well known to those skilled in the art.
  • Methods of preparation of these amine derivatives from corresponding amino acids, amino acid amides or amino acid esters are also well known to those skilled in the art of organic chemistry including amino acid/amino acid ester or aminoalcohol chemistry.
  • Protecting groups are removed under conditions which will not affect the remaining portion of the molecule. These methods are well known in the art and include acid hydrolysis, hydrogenolysis and the like.
  • a preferred method involves removal of a protecting group, such as removal of a benzyloxycarbonyl group by hydrogenolysis utilizing palladium on carbon in a suitable solvent system such as an alcohol, acetic acid, and the like or mixtures thereof.
  • a t-butoxycarbonyl protecting group can be removed utilizing an inorganic or organic acid, such as HC1 or trifluoroacetic acid, in a suitable solvent system, such as dioxane or methylene chloride. The resulting amino salt can readily be neutralized to yield the free amine.
  • Carboxy protecting group such as methyl, ethyl, benzyl, tert-butyl, 4-methoxyphenylmethyl and the like, can be removed under hydrolysis and hydrogenolysis conditions well known to those skilled in the art.
  • the present invention also comprises the use of a compound of the invention, or pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment either acutely or chronically of an angiogenesis mediated disease state, including those described previously.
  • the compounds of the present invention are useful in the manufacture of an anti-cancer medicament.
  • the compounds of the present invention are also useful in the manufacture of a medicament to attenuate or prevent disorders through inhibition of EGFR mutants.
  • the present invention comprises a pharmaceutical composition comprising a therapeutically-effective amount of a compound of Formulas I-IVa in association with a least one pharmaceutically -acceptable carrier, adjuvant or diluent.
  • the present invention also comprises a method of treating EGFR mutant related disorders, such as cancer in a subject, the method comprising treating the subject having or susceptible to such disorder with a therapeutically-effective amount of a compound of Formulas I-IVa. This includes first line therapies and second line therapies.
  • the compounds of the invention can be administered as the sole active pharmaceutical agent, they can also be used in combination with one or more compounds of the invention or other agents.
  • the therapeutic agents can be formulated as separate compositions that are administered at the same time or sequentially at different times, or the therapeutic agents can be given as a single composition.
  • co-therapy in defining use of a compound of the present invention and another pharmaceutical agent, is intended to embrace administration of each agent in a sequential manner in a regimen that will provide beneficial effects of the drug combination, and is intended as well to embrace coadministration of these agents in a substantially simultaneous manner, such as in a single capsule having a fixed ratio of these active agents or in multiple, separate capsules for each agent.
  • the administration of compounds of the present invention may be in conjunction with additional therapies known to those skilled in the art in the prevention or treatment of neoplasia, such as with radiation therapy or with cytostatic or cytotoxic agents.
  • Such combination products employ the compounds of this invention within the accepted dosage ranges.
  • Compounds of Formula I may also be administered sequentially with known anticancer or cytotoxic agents when a combination formulation is inappropriate. The invention is not limited in the sequence of administration; compounds of Formula I may be administered either prior to, at the same time as, or after administration of the known anticancer or cytotoxic agent.
  • the typical chemotherapy regime consists of either DNA alkylating agents, DNA intercalating agents, CDK inhibitors, or microtubule poisons.
  • the chemotherapy doses used are just below the maximal tolerated dose and therefore dose limiting toxicities typically include, nausea, vomiting, diarrhea, hair loss, neutropenia and the like.
  • antineoplastic agents available in commercial use, in clinical evaluation and in pre-clinical development, which would be selected for treatment of neoplasia by combination drug chemotherapy.
  • Such antineoplastic agents fall into several major categories, namely, antibiotic-type agents, alkylating agents, antimetabolite agents, hormonal agents, immunological agents, interferon-type agents and a category of miscellaneous agents.
  • a first family of antineoplastic agents which may be used in combination with compounds of the present invention consists of antimetabolite-type/thymidilate synthase inhibitor antineoplastic agents.
  • Suitable antimetabolite antineoplastic agents may be selected from but not limited to the group consisting of 5 -FU- fibrinogen, acanthifolic acid, aminothiadiazole, brequinar sodium, carmofur, Ciba-Geigy CGP-30694, cyclopentyl cytosine, cytarabine phosphate stearate, cytarabine conjugates, Lilly DATHF, Merrel Dow DDFC, dezaguanine, dideoxycytidine, dideoxyguanosine, didox, Yoshitomi DMDC, doxifluridine, Wellcome EHNA, Merck & Co.
  • EX-015 benzrabine, floxuridine, fludarabine phosphate, 5-fluorouracil, N-(2'-furanidyl)-5-fluorouracil, Daiichi Seiyaku FO-152, isopropyl pyrrolizine, Lilly LY-188011, Lilly LY-264618, methobenzaprim, methotrexate, Wellcome MZPES, norspermidine, NCI NSC-127716, NCI NSC-264880, NCI NSC-39661, NCI NSC-612567, Warner-Lambert PALA, pentostatin, piritrexim, plicamycin, Asahi Chemical PL-AC, Takeda TAC-788, thioguanine, tiazofurin, Erbamont TIF, trimetrexate, tyrosine kinase inhibitors, tyrosine protein kinase inhibitors, Taiho UFT and uricy
  • a second family of antineoplastic agents which may be used in combination with compounds of the present invention consists of alkylating-type antineoplastic agents.
  • Suitable alkylating-type antineoplastic agents may be selected from but not limited to the group consisting of Shionogi 254-S, aldo-phosphamide analogues, altretamine, anaxirone, Boehringer Mannheim BBR-2207, bestrabucil, budotitane, Wakunaga CA-102, carboplatin, carmustine, Chinoin-139, Chinoin-153, chlorambucil, cisplatin,
  • prednimustine Proter PTT-119, ranimustine, semustine, SmithKline SK&F-101772, Yakult Honsha SN-22, spiromus-tine, Tanabe Seiyaku TA-077, tauromustine, temozolomide, teroxirone, tetraplatin and trimelamol.
  • a third family of antineoplastic agents which may be used in combination with compounds of the present invention consists of antibiotic-type antineoplastic agents.
  • Suitable antibiotic-type antineoplastic agents may be selected from but not limited to the group consisting of Taiho 4181-A, aclarubicin, actinomycin D, actinoplanone, Erbamont ADR-456, aeroplysinin derivative, Ajinomoto AN-201-II, Ajinomoto AN-3, Nippon Soda anisomycins, anthracycline, azino-mycin-A, bisucaberin, Bristol-Myers BL-6859, Bristol-Myers BMY-25067, Bristol-Myers BMY-25551, Bristol-Myers BMY-26605, Bristol-Myers BMY-27557, Bristol-Myers BMY-28438, bleomycin sulfate, bryostatin-1, Taiho C-1027, calichemycin, chromoxi
  • a fourth family of antineoplastic agents which may be used in combination with compounds of the present invention consists of a miscellaneous family of antineoplastic agents, including tubulin interacting agents, topoisomerase II inhibitors, topoisomerase I inhibitors and hormonal agents, selected from but not limited to the group consisting of a-carotene, a-difluoromethyl-arginine, acitretin, Biotec AD-5, Kyorin AHC-52, alstonine, amonafide, amphethinile, amsacrine, Angiostat, ankinomycin, anti-neoplaston A10, antineoplaston A2, antineoplaston A3, antineoplaston A5, antineoplaston AS2-1, Henkel APD, aphidicolin glycinate, asparaginase, Avarol, baccharin, batracylin, benfluron, benzotript, Ipsen-Beaufour BIM-23015, bisant
  • the present compounds may also be used in co-therapies with other anti-neoplastic agents, such as acemannan, aclarubicin, aldesleukin, alemtuzumab, alitretinoin, altretamine, amifostine, aminolevulinic acid, amrubicin, amsacrine, anagrelide, anastrozole, ANCER, ancestim, ARGLABIN, arsenic trioxide, BAM 002 (Novelos), bexarotene, bicalutamide, broxuridine, capecitabine, celmoleukin, cetrorelix, cladribine, clotrimazole, cytarabine ocfosfate, DA 3030 (Dong-A), daclizumab, denileukin diftitox, deslorelin, dexrazoxane, dilazep, docetaxel, docosanol,
  • doxercalciferol doxifluridine, doxorubicin, bromocriptine, carmustine, cytarabine, fluorouracil, HIT diclofenac, interferon alfa, daunorubicin, doxorubicin, tretinoin, edelfosine, edrecolomab, eflornithine, emitefur, epirubicin, epoetin beta, etoposide phosphate, exemestane, exisulind, fadrozole, filgrastim, finasteride, fludarabine phosphate, formestane, fotemustine, gallium nitrate, gemcitabine, gemtuzumab zogamicin, gimeracil/oteracil/tegafur combination, glycopine, goserelin, heptaplatin, human chorionic gonadotropin, human fetal alpha fetoprotein,
  • melanoma oncolysate vaccine New York Medical College
  • viral melanoma cell lysates vaccine Royal Newcastle Hospital
  • valspodar melanoma oncolysate vaccine
  • the present compounds may also be used in co-therapies with other anti-neoplastic agents, such as other kinase inhibitors, TNF inhibitors, metallomatrix proteases inhibitors (MMP) and VEGFR inhibitors.
  • other anti-neoplastic agents such as other kinase inhibitors, TNF inhibitors, metallomatrix proteases inhibitors (MMP) and VEGFR inhibitors.
  • compositions of this invention comprise a combination of a kinase inhibitor of the Formulas described herein and one or more additional therapeutic or prophylactic agents
  • both the kinase inhibitor and the additional agent should be present at dosage levels of between about 10 to 100%, and more preferably between about 10 to 80% of the dosage normally administered in a monotherapy regimen.
  • additional kinase inhibitory agents were those which may modulate, regulate or otherwise affect kinase enzyme activity. Such effects may lead to modulation of disease pathology and/or symptoms.
  • Kinase inhibitory agents include, for example, small molecules, polypeptides, antibodies (including for example, monoclonals, chimeric, humanized, single chain, immunokines, etc.), and the like.
  • additional kinase inhibitory small molecule agents include, but were not limited to, CDK inhibitors and p38 inhibitors, including SU- 6668, SU-5416, ZD-4190, ZD-1839, STI-571, CP-358774, LY-333531 and the like.
  • compositions of this invention comprise an additional immunosuppression agent.
  • additional immunosuppression agents include, but were not limited to, cyclosporin A, FK506, rapamycin, leflunomide, deoxyspergualin, prednisone, azathioprine, mycophenolate mofetil, OKT3, ATAG, interferon and mizoribine.
  • compositions of this invention may additionally comprise antibodies (including for example, monoclonals, chimeric, humanized, single chain, immunokines, etc.), cytotoxic or hormonal anti-cancer agents or combinations thereof.
  • antibodies including for example, monoclonals, chimeric, humanized, single chain, immunokines, etc.
  • cytotoxic or hormonal anti-cancer agents or combinations thereof.
  • the present invention comprises a process for the preparation of a compound of Formulas I-IVa.
  • optical isomers can be obtained by resolution of the racemic mixtures according to conventional processes, e.g., by formation of diastereoisomeric salts, by treatment with an optically active acid or base.
  • appropriate acids are tartaric, diacetyltartaric, dibenzoyltartaric, ditoluoyltartaric, and camphorsulfonic acid and then separation of the mixture of diastereoisomers by crystallization followed by liberation of the optically active bases from these salts.
  • a different process for separation of optical isomers involves the use of a chiral chromatography column optimally chosen to maximize the separation of the enantiomers.
  • Still another available method involves synthesis of covalent diastereoisomeric molecules by reacting compounds of the invention with an optically pure acid in an activated form or an optically pure isocyanate.
  • the synthesized diastereoisomers can be separated by conventional means such as chromatography, distillation, crystallization or sublimation, and then hydro lyzed to deliver the enantiomerically pure compound.
  • the optically active compounds of the invention can likewise be obtained by using active starting materials. These isomers may be in the form of a free acid, a free base, an ester or a salt.
  • pharmaceutically-acceptable salts are also included in the family of compounds of Formulas I-IVa.
  • pharmaceutically-acceptable salts embraces salts commonly used to form alkali metal salts and to form addition salts of free acids or free bases. The nature of the salt is not critical, provided that it is
  • Suitable pharmaceutically-acceptable acid addition salts of compounds of Formulas I-IVa may be prepared from an inorganic acid or from an organic acid.
  • inorganic acids are hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuric and phosphoric acid.
  • organic acids may be selected from aliphatic, cycloaliphatic, aromatic, arylaliphatic, heterocyclic, carboxylic and sulfonic classes of organic acids, example of which are acetic, adipic, algenic, anthranilic, ascorbic, aspartic, benzoic, benzenesulfonic, butyric, camphoric, camphorsulfonic, citric, cyclopentanepropionic, cyclohexylaminosulfonic, digluconic, dodecylsulfonic, ethanesulfonic, formic, fumaric, galactaric, galacturonic, glycolic, gluconic, glucuronic, glucoheptanoic, glutamic, glycerophosphonic, heptanoic, hexanoic, 4-hydroxybenzoic, 2 -hydroxy ethanesulfonic, ⁇ -hydroxybutyric, lactic, malic, male
  • Formulas I-IVa include metallic salts, such as salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc, or salts made from organic bases including primary, secondary and tertiary amines, substituted amines including cyclic amines, such as caffeine, arginine, diethylamine, N-ethyl piperidine, histidine, glucamine, isopropylamine, lysine, morpholine, N-ethyl morpholine, piperazine, piperidine, triethylamine, trimethylamine. All of these salts may be prepared by conventional means from the corresponding compound of the invention by reacting, for example, the appropriate acid or base with the compound of Formulas I-IVa.
  • the basic nitrogen-containing groups can be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl, and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides, and others. Water or oil-soluble or dispersible products are thereby obtained. Additional examples of such salts can be found in Berge et al., J. Pharm. Sci., 66, 1 (1977).
  • the invention also relates to a method of making a compound of the formulas described herein, comprising synthesizing any one or more intermediates illustrated in the synthetic schemes herein and then converting that intermediate(s) to a compound of the formulas described herein.
  • the invention also relates to a method of making a compound of the formulas described herein, comprising synthesizing any one or more intermediates illustrated in the examples herein and then converting that intermediate(s) to a compound of the formulas described herein.
  • LiHMDS Lithium bis(trimethylsilyl)amide mg milligram g gram
  • Acrylamide substituted 7-oxo-pyrido[2,3-d]pyrimidines can be prepared according to the methods set out in Scheme 1.
  • 2-(Methylthio)-7-oxopyrido[2,3- djpyrimidines (I) is treated with an oxidizing agent such as MCPBA, in an appropriate solvent such as in DCM, to furnish 2-(methylsulfonyl)-7-oxopyrido[2,3-d]pyrimidines (II).
  • the 2-(methylsulfonyl)-7-oxopyrido[2,3-d]pyrimidines (II) is treated with a base, such as with DIEA, and heated at a temperature above RT, preferably above about 50 °C, more preferably at about 80 °C to yield the amino substituted 7-oxopyrido[2,3- d]pyrimidines (III).
  • a base such as with DIEA
  • a temperature above RT preferably above about 50 °C, more preferably at about 80 °C
  • Deprotection such as with treatment with acid, followed by treatment with an unsaturated acid chloride, such as acryloyl chloride yields the desired product (IV).
  • the acrylamide (V) is formed from the starting material (I) by a method similar to that described above.
  • the 2-(methylthio)-7-oxopyrido[2,3- djpyrimidinyl acrylamides (V) can be oxidized, by a method similar to that described above followed by amination to yield the desired product (IV).
  • Acrylamide substituted 7-oxo-pyrido[2,3-d]pyrimidines can be prepared from the di-Boc protected compound, according to the method set out in Scheme 2.
  • the 2- (methylsulfonyl)-7-oxopyrido[2,3-d]pyrimidines (57) is treated with a base, such as with DIEA, and heated at a temperature above RT, preferably above about 50 °C, more preferably at about 80 °C to yield the amino substituted 7-oxopyrido[2,3-d]pyrimidines (VII).
  • Deprotection such as with treatment with acid, followed by treatment with an unsaturated acid chloride, such as acryloyl chloride yields the desired product (IV).
  • a solution of protected (R)- 3-((2-chloro-5-methyl-7-oxopyrido[2,3-d]pyrimidin- 8(7H)-yl)methyl)pyrrolidine is treated with deprotected, such as with acid, for example TFA, yields the free amine.
  • deprotected such as with acid, for example TFA
  • base such as DIPEA and an acyl chloride at a temperature below RT, preferably at about 0 °C affords the acrylamide derivative VIIx.
  • the desired compounds of the invention VIIIx are prepared by coupling of the acrylamide derivative VIIx with a substituted amine.
  • One example of such coupling involves heating the reactants in the presence of acid, such as TFA, at a temperature above RT, preferably above about 50 °C and more preferably at about 100 °C.
  • the starting compounds defined in Schemes l-3a may also be present with functional groups in protected form if necessary and/or in the form of salts, provided a salt- forming group is present and the reaction in salt form is possible. If so desired, one compound of formula I can be converted into another compound of formula I or a N- oxide thereof; a compound of formula I can be converted into a salt; a salt of a compound of formula I can be converted into the free compound or another salt; and/or a mixture of isomeric compounds of formula I can be separated into the individual isomers.
  • N-Oxides can be obtained in a known manner by reacting a compound of formula I with hydrogen peroxide or a peracid, e.g. 3-chloroperoxy-benzoic acid, in an inert solvent, e.g. CH 2 C1 2 , at a temperature between about -10 to about 35°C, such as about 0°C to about RT.
  • hydrogen peroxide or a peracid e.g. 3-chloroperoxy-benzoic acid
  • an inert solvent e.g. CH 2 C1 2
  • one or more other functional groups for example carboxy, hydroxy, amino, or mercapto, are or need to be protected in a compound of Formulas I-IVa, because they should not take part in the reaction, these are such groups as are usually used in the synthesis of peptide compounds, and also of cephalosporins and penicillins, as well as nucleic acid derivatives and sugars.
  • the protecting groups may already be present in precursors and should protect the functional groups concerned against unwanted secondary reactions, such as acylations, etherifications, esterifications, oxidations, solvolysis, and similar reactions. It is a characteristic of protecting groups that they lend themselves readily, i.e. without undesired secondary reactions, to removal, typically by solvolysis, reduction, photolysis or also by enzyme activity, for example under conditions analogous to physiological conditions, and that they are not present in the end-products.
  • the specialist knows, or can easily establish, which protecting groups are suitable with the reactions mentioned above and hereinafter.
  • functional groups of the starting compounds which should not take part in the reaction may be present in unprotected form or may be protected for example by one or more of the protecting groups mentioned above under "protecting groups".
  • the protecting groups are then wholly or partly removed according to one of the methods described there.
  • Salts of a compound of formula I with a salt-forming group may be prepared in a manner known per se. Acid addition salts of compounds of formula I may thus be obtained by treatment with an acid or with a suitable anion exchange reagent. A salt with two acid molecules (for example a dihalogenide of a compound of formula I) may also be converted into a salt with one acid molecule per compound (for example a
  • this may be done by heating to a melt, or for example by heating as a solid under a high vacuum at elevated temperature, for example from about 130°C to about 170°C, one molecule of the acid being expelled per molecule of a compound of formula I.
  • Salts can usually be converted to free compounds, e.g. by treating with suitable basic agents, for example with alkali metal carbonates, alkali metal hydrogen carbonates, or alkali metal hydroxides, typically K 2 CO 3 or NaOH.
  • suitable basic agents for example with alkali metal carbonates, alkali metal hydrogen carbonates, or alkali metal hydroxides, typically K 2 CO 3 or NaOH.
  • All process steps described here can be carried out under known reaction conditions, preferably under those specifically mentioned, in the absence of or usually in the presence of solvents or diluents, preferably such as are inert to the reagents used and able to dissolve these, in the absence or presence of catalysts, condensing agents or neutralizing agents, for example ion exchangers, typically cation exchangers, for example in the H+ form, depending on the type of reaction and/or reactants at reduced, normal, or elevated temperature, for example in the range from about -100°C to about 190°C, preferably from about -80°C to about 150°C, for example at about -80°C to about 60°C, at RT, at about -20°C to about 40°C or at the boiling point of the solvent used, under atmospheric pressure or in a closed vessel, where appropriate under pressure, and/or in an inert atmosphere, for example under argon or nitrogen.
  • Salts may be present in all starting compounds and transients, if these
  • the solvents from which those can be selected which are suitable for the reaction in question include for example water, esters, e.g EtOAc, ethers, typically aliphatic ethers, e.g. Et 2 0, or cyclic ethers, e.g. THF, liquid aromatic hydrocarbons, typically benzene or toluene, alcohols, typically MeOH, EtOH, iPOH or 1-propanol, nitriles, typically AcCN, halogenated hydrocarbons, typically CH 2 C1 2 , amides, e.g. DMF, bases, typically heterocyclic nitrogen bases, e.g. pyridine, carboxylic acids, typically lower alkanecarboxylic acids, e.g.
  • esters e.g EtOAc
  • ethers typically aliphatic ethers, e.g. Et 2 0, or cyclic ethers, e.g. THF
  • liquid aromatic hydrocarbons typically benzene or toluene
  • carboxylic acid anhydrides typically lower alkane acid anhydrides, e.g. acetic anhydride, cyclic, linear, or branched hydrocarbons, typically cyclohexane, hexane, or isopentane, or mixtures of these solvents, e.g. aqueous solutions, unless otherwise stated in the description of the process.
  • lower alkane acid anhydrides e.g. acetic anhydride
  • cyclic, linear, or branched hydrocarbons typically cyclohexane, hexane, or isopentane, or mixtures of these solvents, e.g. aqueous solutions, unless otherwise stated in the description of the process.
  • the invention relates also to those forms of the process in which one starts from a compound obtainable at any stage as a transient and carries out the missing steps, or breaks off the process at any stage, or forms a starting material under the reaction conditions, or uses said starting material in the form of a reactive derivative or salt, or produces a compound obtainable by means of the process according to the invention and processes the said compound in situ.
  • a compound of any of the formulas delineated herein may be synthesized according to any of the processes delineated herein.
  • the steps may be performed in an alternate order and may be preceded, or followed, by additional protection/deprotection steps as necessary.
  • the processes may further comprise use of appropriate reaction conditions including inert solvents, additional reagents, such as bases (e.g., LDA, DIEA, pyridine, K 2 C0 3 , and the like), catalysts, and salt forms of the above.
  • bases e.g., LDA, DIEA, pyridine, K 2 C0 3 , and the like
  • Purification methods include, for example, crystallization, chromatography (liquid and gas phase, simulated moving bed (“SMB”)), extraction, distillation, trituration, reverse phase HPLC and the like.
  • Reactions conditions such as temperature, duration, pressure, and atmosphere (inert gas, ambient) are known in the art and may be adjusted as appropriate for the reaction.
  • the compounds of formula I-IVa are also obtainable in the form of hydrates, or their crystals can include for example the solvent used for crystallization (present as solvates).
  • New starting materials and/or intermediates, as well as processes for the preparation thereof, are likewise the subject of this invention.
  • such starting materials are used and reaction conditions so selected as to enable the preferred compounds to be obtained.
  • the compounds of this invention may contain one or more asymmetric centers and thus occur as racemates and racemic mixtures, scalemic mixtures, single enantiomers, individual diastereomers and diastereomeric mixtures. All such isomeric forms of these compounds are expressly included in the present invention.
  • the invention expressly includes all tautomeric forms of the compounds described herein.
  • the compounds may also occur in cis- or trans- or E- or Z- double bond isomeric forms. All such isomeric forms of such compounds are expressly included in the present invention. All crystal forms of the compounds described herein are expressly included in the present invention.
  • Substituents on ring moieties may be attached to specific atoms, whereby they are intended to be fixed to that atom, or they may be drawn unattached to a specific atom (see below), whereby they are intended to be attached at any available atom that is not already substituted by an atom other than H.
  • heterocyclic ring systems may be attached through a carbon atom or a heteroatom in the ring system.
  • a heterocyclic or heteroaryl ring system is stated to be attached at a heteroatom (e.g., nitrogen atom)
  • all materials were obtained from commercial suppliers and used without further purification. All parts are by weight and temperatures are in Degrees centigrade unless otherwise indicated. All compounds showed NMR spectra consistent with their assigned structures.
  • HPLC analyses were run on a HP- 1050 system with an HP Zorbax SB-Cis (5 ⁇ ) reverse phase column (4.6 x 150mm) run at 30°C with a flow rate of 1.00 mL/min.
  • the mobile phase used solvent A (H 2 O/0.1 % TFA) and solvent B (AcCN/0.1% TFA) with a 20 min gradient from 10% to 90% AcCN. The gradient was followed by a 2 min return to 10% AcCN and a 3 min flush.
  • the mobile phase used solvent A (H 2 O/0.1 % HOAc) and solvent B (AcCN/0.1 % HOAc) with a 5 min gradient from 10% to 90% AcCN. The gradient was followed by a 0.5 min return to 10% AcCN and a 1.5 min flush.
  • Preparative HPLC Where indicated, compounds of interest were purified via preparative HPLC using a Gilson workstation with a 20 x 50 mm column at 45 ml/min.
  • the mobile phase used solvent A (H 2 O/0.1% TFA) and solvent B (AcCN/0.1% TFA) with a 10 min gradient from 10% to 95% AcCN. The gradient was followed by a 2 min return to 20% AcCN.
  • Step 1 A mixture of N-Boc-m-phenylenediamine (50a, prepared according to the procedures reported in: Duceppe, J.-S. et al. Org. Process. Res. Dev. 2009, 13, 1156- 1160) (280 g, 1.35 mol) and ethyl 4-chloro-2-(methylthio)pyrimidine-5-carboxylate (Sigma-Aldrich; 303.7 g, 1.32 mol) in DMF (200 mL) at RT was treated with K 2 C0 3
  • Step 2 To a suspension of ethyl 4-((3-((tert- butoxycarbonyl)amino)phenyl)amino)-2-(methylthio)pyrimidine-5-carboxylate (50c) (340 g, 0.84 mol) in THF (200 mL) at -40 °C was added LiAlH 4 (2.57 L of 1.0 M solution in THF, 2.57 mol) dropwise. The reaction mixture was stirred at 0 °C for 13 h, then cooled to -20 °C and carefully quenched with solid Na 2 S04* 10H 2 O. The reaction mixture was filtered and rinsed with 2 X 150 mL of EtOAc.
  • Step 3 At RT, manganese (IV) oxide (358 g, 4.1 mol) was added to a solution of teri-butyl (3-((5-(hydroxymethyl)-2-(methylthio)pyrimidin-4-yl)amino)phenyl)carbamate (50d) (140 g, 386.8 mmol) in CHCI 3 . After 18 h, the reaction mixture was filtered through a pad of Celite washing with 3 x 100 mL of CHCI 3 .
  • LiHMDS (41.6 mL of 1.0 M in THF solution, 41.6 mmol) was added to 2- MeTHF (70 mL) at -78 °C and treated with EtOAc (4.34 mL, 44.4 mmol). The solution was stirred at -78 °C for 10 min, then solid teri-butyl (3-((5-formyl-2- (methylthio)pyrimidin-4-yl)amino)phenyl)carbamate (50) (5.00 g, 13.87 mmol) was added in one portion and the solution was stirred at -78 °C for 10 min then removed from the cooling bath warmed to RT for 3 h.
  • Step 1 A 3-necked 2 L RBF equipped with an addition funnel, temperature probe and nitrogen inlet was charged with teri-butyl (3-((5-formyl-2-(methylthio)pyrimidin-4- yl)amino)phenyl)carbamate (50) (25.0 g, 69.4 mmol) and THF (400 mL). The mixture was cooled to 0.5 °C using an ice water bath. Methylmagnesium bromide (3.0 M in Et 2 0, 74.0 mL, 222 mmol) was added dropwise via an addition funnel over 35 min. The temperature was kept below 8 °C during the addition.
  • Step 2 Tetrapropylammonium perruthenate (1.05 g, 2.99 mmol) was added to a heterogenous mixture of tert-butyl (3-((5-(l-hydroxyethyl)-2-(methylthio)pyrimidin-4- yl)amino)phenyl)carbamate (22.5 g, 59.8 mmol) and 4-methylmorpholine N-oxide (8.75 g, 74.7 mmol) in DCM (460 mL) at RT. The mixture was stirred at RT for 3 h and concentrated under reduced pressure. The dark solid was dissolved in 10%> MeOH in DCM and the material was adsorbed on to silica gel.
  • the material was purified by silica gel pad (2-L sintered medium frit filled halfway with silica gel) eluted with 10% EtOAc in DCM (2 L) followed by 20% EtOAc in DCM (2 L). The fractions containing the desired product was concentrated to afford a white solid. 1.2 L of 1/1 MeOH/EtOAc was added to the solid and the mixture was heated to reflux and cooled to RT slowly. The mixture sat at RT overnight.
  • tert-butyl (3-(5-methyl-2-(methylthio)-7-oxopyrido[2,3-d]pyrimidin- 8(7H)-yl)phenyl)carbamate (440 mg, 1.10 mmol) in DCM (10 mL) was treated with MCPBA (75 wt. %, 681 mg, 2.76 mmol) and stirred for 90 min. The reaction mixture was diluted with DCM (25 mL), treated with ice and 1 N NaOH (30 mL).
  • the DCM layer was separated and the aqueous layer was extracted with an additional amount of DCM (2 x 20 mL), dried over Na 2 S0 4 and concentrated to furnish tert-butyl (3-(5- methyl-2-(methylsulfonyl)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)carbamate (451 mg, 1.05 mmol, 95% yield) as an off-white foam.
  • the crude material was used without purification, m/z (ESI, +ve ion) 453.0 (M+Na) + . ! H NMR (400 MHz, CDCl 3 ) ⁇ ppm 9.11 (1 H, s), 7.60 (1 H, br.
  • Step 1 In a 20 mL glass microwave tube, 2-(methylthio)pyrido[2,3-d]pyrimidin- 7(8H)-one (57a, Matrix Scientific; 500 mg, 2.59 mmol) was treated with K 2 C0 3 (715 mg, 5.18 mmol), Cul (99 mg, 0.52 mmol) and 4,7-dimethoxy-l,10-phenanthroline (Sigma Aldrich, 187 mg, 0.77 mmol) followed by purging with argon for 3 min. The solids were then treated with DMSO (6.0 mL) and 3-iodoaniline (0.31 mL, 2.59 mmol). The tube was sealed and heated to 110 °C for 20 h.
  • Step 2 At 0 °C, 8-(3-aminophenyl)-2-(methylthio)pyrido[2,3-d]pyrimidin-7(8H)- one 2,2,2-trifluoroacetate (57b) (150 mg, 0.38 mmol) in THF (5.0 mL), and treated with NaH (60 wt. % dispersion in mineral oil, 60 mg, 1.51 mmol) in one portion. It was stirred at this temperature for 30 min then treated with di-t-butyldicarbonate (205 mg, 0.94 mmol) and heated to 70 °C for 6 h.
  • reaction mixture was cooled to RT, quenched with ice water and extracted with EtOAc (2 x 30 mL), dried over MgS0 4 , concentrated and purified on silica gel column (10-90% EtOAc in hexanes) affording bis(teri-butyl (3-(2-(methylthio)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)) carbamate (57c) (158 mg, 0.33 mmol, 87%o yield) as a yellow film, m/z (ESI, +ve ion) 485.1 (M+l) + .
  • a suspension of teri-butyl (4-fluoro-3-(2-(methylthio)-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)carbamate (59) (270 mg, 0.67 mmol) in DCM (10 mL) was treated with MCPBA (77 wt. %, 161 mg, 0.72 mmol) in one portion and stirred at 0 °C for 1 h.
  • the reaction mixture was diluted with DCM (50 mL), and treated with ice and water (30 mL) followed by 10% Na 2 C0 3 (ca. 10 mL).
  • Step 1 A mixture of 5-bromo-2,4-dichloro-pyrimidine (180 g, 0.79 mol, Matrix Scientific), A-Boc-m-phenylenediamine (170 g, 0.82 mol, Synchem Inc), and Na 2 C0 3 (90 g, 0.85 mol) in THF (620 mL) and DMF (310 mL) was stirred at RT for 18 h under nitrogen. It was treated with water (6 L) and EtOAc (6 L). The insoluble solid containing the desired product [m/z (ESI, +ve ion) 400.9/422.9 (M+l) + ] was filtered and washed with EtOAc (2 x 1 L) and collected.
  • Step 2 To a 3 -L 3 -neck round-bottomed flask armed with a mechanical stirrer was added teri-butyl (3-((5-bromo-2-chloropyrimidin-4-yl)amino)phenyl)carbamate (100a, 92 g, 230 mmol), crotonic acid (78.95 g, 920 mmol), bis(benzonitrile)palladium(ii) chloride (4.41 g, 11.51 mmol, Sigma-Aldrich), tri(o-toly)lphosphine (3.50 g, 11.51 mmol, Sigma- Aldrich), THF (319 mL), DIPEA (400 mL, 2302 mmol).
  • the suspension was purged with argon for 5 min. It was stirred at 68 °C in an oil bath overnight.
  • the reaction mixture was cooled to RT, and treated in one portion with acetic anhydride (58.6 mL, 622 mmol).
  • the reaction mixture was stirred at 68 °C in an oil bath for 1 h. It was cooled to RT, diluted with 2.1 L of EtOAc.
  • the mixture was washed with 1.12 L of 1 N HC1 followed by 1.12 L of saturated NaHCC>3 solution.
  • the organic layer was dried over
  • Step 3 In a 3-L three-neck RBF equipped with a thermometer, a suspension of tert-butyl (3-(2-chloro-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)- yl)phenyl)carbamate (100b, 31 g, 80 mmol) in 4.0 M hydrochloric acid in dioxane (200 mL, 801 mmol) was stirred at 50 °C for 2.5 h. LCMS indicated the completed removal of N-Boc protecting group.
  • the overall mixture was cooled in an ice bath, and treated with NaOH 10.0 N solution (88 mL, 882 mmol) in a rate that the internal temperature did not exceed 15 °C.
  • the resulting mixture was treated with acryloyl chloride (8.46 mL, 104 mmol) at 0 °C and the mixture was stirred at 0 °C for 1 h.
  • Step 1 A mixture of N-Boc-m-phenylenediamine (280 g, 1.35 mol) and ethyl 4- chloro-2-(methylthio)pyrimidine-5-carboxylate ( Sigma -Aldrich; 303.7 g, 1.32 mol) in DMF (200 mL) at RT was treated with potassium carbonate (361 g, 2.6 mol). The mixture was stirred at 80 °C in an oil bath overnight. It was cooled to RT and treated with ice water. The resulting white suspension was filtered and washed with water. The white solid was collected and dried to afford crude ethyl 4-((3-((tert- butoxycarbonyl)amino)phenyl)amino)-2-(methylthio)pyrimidine-5-carboxylate (101a)
  • Step 3 At RT, manganese (IV) oxide (358 g, 4.1 mol) was added to a solution of tert-butyl (3-((5-(hydroxymethyl)-2-(methylthio)pyrimidin-4-yl)amino)phenyl)carbamate (101c) (140 g, 386.8 mmol) in CHCI 3 . After 18 h, the reaction mixture was filtered through a pad of celite washing with 3 x 100 mL of CHCI 3 .
  • Step 1 A 3-necked 2-L RBF equipped with an addition funnel, temperature probe and nitrogen inlet was charged with teri-butyl (3-((5-formyl-2-(methylthio)pyrimidin-4- yl)amino)phenyl)carbamate (25.0 g, 69.4 mmol) and THF (400 mL). The mixture was cooled to 0.5 °C using an ice water bath. Methylmagnesium bromide (3.0 M in Et 2 0, 74.0 mL, 222 mmol) was added dropwise via an addition funnel over 35 min. The temperature was kept below 8 °C during the addition.
  • Step 2 Tetrapropylammonium perruthenate (1.05 g, 2.99 mmol) was added to a heterogeneous mixture of tert-butyl (3-((5-(l-hydroxyethyl)-2-(methylthio)pyrimidin-4- yl)amino)phenyl)carbamate (22.5 g, 59.8 mmol) and 4-methylmorpholine N-oxide (8.75 g, 74.7 mmol) in DCM (460 mL) at RT. The mixture was stirred at RT for 3 h and concentrated under reduced pressure. The dark solid was dissolved in 10% MeOH in DCM and the material was adsorbed on to silica gel.
  • the material was purified by silica gel pad (2-L sintered medium frit filled halfway with silica gel) eluted with 10% EtOAc in DCM (2 L) followed by 20% EtOAc in DCM (2 L). The fractions containing the desired product were concentrated to afford a white solid with black stripes. 1.2 L of 1/1 MeOH/EtOAc was added to the solid and the mixture was heated to reflux and cooled to RT slowly. The mixture was kept at RT overnight.
  • Step 1 In a RBF equipped a with magnetic stirrer was charged with tert-butyl (3- ((5-acetyl-2-(methylthio)pyrimidin-4-yl)amino)phenyl)carbamate (102) (49.5 g, 132 mmol) and THF (1300 mL). The mixture was stirred for 30 min at RT and filtered through a fritted funnel. The resulting filtrate containing 102 was charged to an addition funnel, degassed and purged with nitrogen. In a separate 5 L 3-necked RBF equipped with an overhead stirrer, a thermocouple and a nitrogen inlet was charged with THF (325 mL). The solvent was degassed and purged with nitrogen.
  • reaction mixture was poured into a biphasic mixture of EtOAc (1000 mL) and saturated NH 4 C1 solution (200 mL) cooled with an ice bath. The mixture was stirred for 30 min. The layers were separated. The organic layer was washed with brine (950 mL), dried over Na 2 S0 4 and concentrated to dryness upon which the desired product crystallized out of solution. MTBE was flushed in several times.
  • Step 2 To a suspension of tert-butyl (3-(5-methyl-2-(methylthio)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)carbamate (103a, 6.52 g, 16.36 mmol) in DCM (50 mL) was added TFA (30 mL). The resulting homogeneous solution was stirred at RT for 30 min. The reaction mixture was concentrated under reduced pressure (rotary evaporator) and then under high vacuum for 20 min to give 103b as a viscous brown oil. m/z (ESI, +ve ion) 299.1 (M+H) + .
  • Step 3 The crude residue of 103b was taken up in DCM (75 mL), cooled to 0 °C and treated with DIEA (14.23 mL, 82 mmol) followed by acryloyl chloride (1.60 mL, 19.63 mmol). The resulting yellow suspension was kept at 0 °C for 50 min. The reaction mixture was quenched by the addition of an aqueous solution of ca. 1.0 M K2CO3 (50 mL) and the resulting light yellow suspension was filtered through a medium porosity sintered glass frit washing with water and then with Et20 affording N-(3-(5-methyl-2-
  • Step 4 To a suspension of N-(3-(5-methyl-2-(methylthio)-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)acrylamide (103c, 5.46 g, 15.49 mmol) in DCM (100 mL) at 0 °C was treated with 3-chlorobenzoperoxoic acid (77% max. wt. from Aldrich) (3.72 g, 16.58 mmol) in 1 portion and stirred at 0 °C for 1 h. The reaction mixture was diluted with DCM (150 mL) and treated with an ice cold solution of ca. 1.0 M K2CO3 (25 mL).
  • Step 1 LiHMDS (41.6 mL of 1.0 M in THF solution, 41.6 mmol) was added to 2-MeTHF (70 mL) at -78 °C and treated with EtOAc (4.34 mL, 44.4 mmol). The solution was stirred at -78 °C for 10 min, then solid tert-butyl (3-((5-formyl-2- (methylthio)pyrimidin-4-yl)amino)phenyl)carbamate (101) (5.00 g, 13.87 mmol) was added in one portion and the solution was stirred at -78 °C for 10 min then removed from the cooling bath and warmed to RT for 3 h.
  • Step 2 To a suspension of tert-butyl (3-(2-(methylthio)-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)carbamate (104a, 3.30 g, 8.58 mmol) in DCM (30 mL) was added 20 mL of TFA. The resulting homogeneous solution was stirred at RT for 30 min, and concentrated under reduced pressure to afford 104b as a viscous orange oil. Step 3.
  • Step 4 To a suspension of N-(3-(2-(methylthio)-7-oxopyrido[2,3-d]pyrimidin- 8(7H)-yl)phenyl)acrylamide (104c, 2.20 g, 6.50 mmol) in DCM (100 mL) at 0 °C was treated with MCPBA (1.559 g, 6.96 mmol, 77% max. wt. from Aldrich) and stirred at 0 °C for 75 min. The reaction mixture was treated with crushed ice followed by saturated K 2 CO 3 solution (15 mL).
  • the mixture was cooled to 0 °C using an ice/brine bath and treated slowly dropwise via addition funnel with 10 N NaOH (8.79 mL, 88 mmol), keeping the temperature below 15 °C. After the addition was completed, the pH was checked to ensure basic. The mixture was stirred at 0 °C and treated dropwise via a syringe with (is)-crotonoyl chloride (Sigma Aldrich, 0.64 mL, 6.72 mmol) and progress was followed with LC/MS.
  • Step 1 To a mixture of 2-methoxy-4-(4-methylpiperazin-l-yl)aniline (Combi-Blocks Inc; 342 mg, 1.55 mmol) and tert-butyl (3-(2-(methylsulfmyl)-7-oxopyrido[2,3-d]pyrimidin- 8(7H)-yl)phenyl)carbamate (52) (521 mg, 1.30 mmol) in teri-butanol (10 mL, 105 mmol) was added DIEA (0.57 mL, 3.25 mmol). The reaction mixture was heated at 80 °C in an oil bath for 21 h.
  • Step 2 The crude la from above was treated with DCM (20 mL) and TFA (20 mL) and stirred at RT for 30 min. The reaction mixture was concentrated under reduced pressure (rotary evaporator) and purified on a silica gel column (1-20% 2M NH 3 /MeOH in DCM) affording 8-(3-aminophenyl)-2-((2-methoxy-4-(4-methylpiperazin-l- yl)phenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one (lb) (470 mg, 1.03 mmol, 79% yield) as a brown amorphous solid, m/z (ESI, +ve ion) 458.0 (M+H) + .
  • Step 3 8-(3-Aminophenyl)-2-((2-methoxy-4-(4-methylpiperazin-l- yl)phenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one (lb) (2.17 g, 4.74 mmol) in DCM (30 mL) and THF (30 mL) at 0 °C was treated with DIEA (1.66 mL, 9.49 mmol) and acryloyl chloride (0.46 mL, 5.69 mmol) dropwise over 15 min and stirred at 0 °C. After
  • Step 1 2- ⁇ 6 ⁇ 1 ⁇ -4- ⁇ 1 ⁇ 1 ⁇ 1 ⁇ 6 (Matrix Scientific, Columbia, SC; 135 mg, 0.65 mmol) and bis(teri-butyl (3-(2-(methylsulfonyl)-7-oxopyrido[2,3-d]pyrimidin- 8(7H)-yl)phenyl))carbamate (57) (167 mg, 0.32 mmol) were treated with teri-butanol (2.0 mL) and Et 3 N (0.14 mL, 0.97 mmol) and heated to 110 °C for 75 min.
  • Step 3 8-(3-Aminophenyl)-2-((2-methoxy-4-mo ⁇ holinophenyl)amino)- pyrido[2,3-d]pyrimidin-7(8H)-one 2,2,2-trifluoroacetate (2b, 63 mg, 0.11 mmol) was treated with DCM (5.0 mL), cooled to 0 °C and treated with DIEA (0.06 mL, 0.34 mmol) and acryloyl chloride (9.16 ⁇ L, 0.113 mmol) and stirred at 0 °C for 40 min. The mixture was treated with ice and water and then a saturated solution of NaHCC .
  • Step 1 To a suspension of teri-butyl (3-(5-methyl-2-(methylthio)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)carbamate (54) (2.49 g, 6.25 mmol) in DCM (30 mL) at RT was added TFA (20 mL). The resulting homogeneous solution was stirred for 1 h then the reaction was concentrated under reduced pressure (rotary evaporator). The residue was dissolved in DCM (50 mL), cooled to 0 °C and treated with DIEA (5.43 mL, 31.2 mmol) followed by acryloyl chloride (0.61 mL, 7.50 mmol).
  • Steps 2 and 3 To a suspension of N-(3-(5-methyl-2-(methylthio)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide (5a; 5.15 g, 14.63 mmol) in DCM (100 mL) at 0 °C was added MCPBA (77 wt. %, 3.51 g, 15.65 mmol) in one portion. The resulting suspension was stirred at 0 °C for 1 h. The mixture was diluted with DCM (100 mL) and treated with an ice cold solution of 1.0 M K 2 CO 3 . The aqueous layer was extracted with DCM (2 x 100 mL).
  • Step 4 To a suspension of 2-methoxy-4-(4-methylpiperazin-l -yl)aniline (Green Chempharm; 3.45 g, 15.57 mmol) and N-(3-(5-methyl-2-(methylsulfinyl)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide (5b) (4.59 g, 12.46 mmol) in anhydrous teri-butanol (40 mL) and dioxane (5 mL) at RT was added DIEA (4.33 mL, 24.92 mmol). The mixture was heated at 100 °C for 40 h.
  • 2-methoxy-4-(4-methylpiperazin-l -yl)aniline Green Chempharm; 3.45 g, 15.57 mmol
  • Step 1 At 0 °C, a suspension of teri-butyl (3-(6-ethyl-2-(methylthio)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)carbamate (55) (720 mg, 1.75 mmol) in DCM (15 mL) was treated with mCPBA (70 wt.%, 460 mg, 1.87 mmol) in one portion and stirred at 0 °C for 1 h. The mixture was diluted with DCM (15 mL), and treated with ice and a 10% solution of Na 2 C0 3 (ca. 10 mL).
  • the DCM layer was separated and the aqueous layer was extracted with an additional amount of DCM (2 x 50 mL), dried over Na 2 S0 4 and concentrated to give teri-butyl (3-(6-ethyl-2-(methylsulfinyl)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)carbamate (6a) (682 mg, 1.59 mmol, 91% yield) as a light yellow amorphous solid, m/z (ESI, +ve ion) 451.0 (M+Na) + . The crude material was used in the subsequent step without further purification.
  • reaction mixture was concentrated under reduced presure (rotary evaporator) and purified on silica gel on an ISCO Combiflash RF (40 g Redisep column, 5-20% 2M NH 3 /MeOH in DCM) affording 8-(3-aminophenyl)-6-ethyl-2-((2-methoxy-4-(4-methylpiperazin-l- yl)phenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one (392 mg, 0.81 mmol, 51% yield) as a brown/yellow film, m/z (ESI, +ve ion) 486.0 (M+H) + . !
  • the solution was stirred 0 °C for 15 min. Two additional drops of acryloyl chloride were added and the mixture was stirred an additional 2 h at 0 °C.
  • the mixture was treated with silica gel and concentrated on the rotovap to dryness.
  • the material was purified on an ISCO Combiflash RF (40 g Redisep column, using a gradient of 0-20%o MeOH in DCM) affording enriched product as a yellow powdery solid.
  • tert-butyl (3-(5-methyl-2- (methylsulfonyl)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)carbamate (56) (150 mg, 0.35 mmol), 2-methoxy-4-mo holinoaniline (Matrix Scientific, Columbia, SC, 54 mg, 0.26 mmol) followed by purging with argon.
  • the solids were then treated with tert- butanol (2.0 mL) and DIEA (0.11 mL, 0.65 mmol).
  • the tube was sealed and heated to 85 °C for 20 h.
  • the crude reaction mixture was purified on silica gel on an I SCO
  • Step 1 Preparation of 4-methoxy-6-(4-methylpiperazin-l-yl)pyridin-3-amine (8a).
  • 2-Chloro-4-methoxy-5-nitropyridine (Frontier Scientific, Newark, DE; 1.02 g, 5.40 mmol) and K 2 C0 3 (895 mg, 6.48 mmol) were purged with argon, treated with DMF (10 mL) followed by 1-methylpiperazine (0.66 mL, 5.94 mmol). The reaction was then heated to 60 °C for 3 h.
  • Step 3 N-(3-(2-((4-Methoxy-6-(4-methyl-l-piperazinyl)-3-pyridinyl)amino)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide (8) (14% overall yield for 2 steps) as a yellow crystalline solid was prepared according to the procedures described for Example 6, using teri-butyl (3-(2-((4-methoxy-6-(4-methylpiperazin-l-yl)pyridin-3- yl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)carbamate (8b) as the starting material, m/z (ESI, +ve ion) 512.9 (M+H) + .
  • reaction mixture was removed from the ice bath and stirred at RT for 30 min.
  • the reaction mixture was treated with silica gel, concentrated on the rotovap and purified on an ISCO Combiflash RF (40 g Redisep column, using a gradient of 0-20% MeOH in DCM) affording enriched product as a yellow solid.
  • This sample was repurified on the Gilson preparatory HPLC (Gemini Phenomenex; 30 x 150 mm, 5 u, 10-95%
  • Nl -( 1 -(2-Fluoroethyl)azetidin-3-yl)-3-methoxybenzene-l ,4-diamine (1 lc) was prepared according to the procedures described in WO 2012064706.
  • the reaction was sonicated for 10 min to help dissolve the substrate and another 2 drops of 2-chloroacetyl chloride was added. After 30 min, 2 more drops of 2-chloroacetyl chloride were added and the solution stirred for another 75 min resulting in clean conversion to the desired product.
  • the mixture was concentrated, treated with DMSO (8 mL) and purified on a Gilson preparatory HPLC (Gemini Phenomenex; 30 x 150 mm, 5 ⁇ , 10-95% 0.1%TFA/CH 3 CN in 0.1 %TFA/water).
  • Example 13 3-(dimethylamino)-N-(3-(2-((2-methoxy-4-(4-methylpiperazin-l- yl)phenyl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)propanamide
  • Step 1 8-(3-Aminophenyl)-2-((2-methoxy-4-(4-methylpiperazin-l- yl)phenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one (lb; 200 mg, 0.44 mmol) in DCM (5 mL) at 0 °C was treated with DIEA (0.19 mL, 1.09 mmol) and cooled in an ice bath at 0 °C. The solution was then treated with 3-chloropropionyl chloride (Sigma Aldrich, St.
  • the mixture was purified by chromatography on silica gel on an ISCO Combiflash RF (24 g Redisep HP (Gold), using a gradient of 0-20% 2M NH 3 /MeOH in DCM) affording 3-(dimethylamino)-N-(3-(2-((2-methoxy-4-(4- methylpiperazin-l-yl)phenyl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)- yl)phenyl)propanamide (44.6 mg, 0.066 mmol, 76%o yield) as a yellow-orange amorphous foam, m/z (ESI, +ve ion) 557.0 (M+H) + .
  • Example 17 N-(3-(5-methyl-2-((4-(4-methylpiperazin-l-yl)phenyl)amino)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide
  • a microwave tube was charged with N-(3-(5-methyl-2-(methylsulfmyl)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide (5b; 210 mg, 0.57 mmol), 4-(4- methylpiperazino)aniline (136 mg, 0.71 mmol) and DIEA (0.20 mL, 1.14 mmol) in tert- butanol (5.5 mL). The tube was sealed and the mixture was heated to 100 °C for 3 d. The mixture was concentrated and then the brown solid was suspended in Et 2 0 and collected by filtration. The brown solid was washed with Et 2 0 to afford 270 mg of crude material.
  • the crude material was absorbed onto a plug of silica gel and purified by chromatography through a Redi-Sep pre-packed silica gel column (12 g), eluting with a gradient of 0-20%o MeOH in DCM.
  • This enriched product was repurified on a Gilson preparatory HPLC (Gemini Phenomenex; 30 x 150 mm, 5 ⁇ , 10-95% 0.1 %TFA/CH 3 CN in 0.1%TFA/water).
  • the product containing fractions were combined and concentrated.
  • a saturated solution of aqueous NaHCC was added and the mixture was extracted with 3 : 1 CHCI 3 /IPA (3 x 30 mL).
  • the reaction mixture was concentrated on the rotovap and the crude residue was suspended in Et 2 0 and filtered. The greenish brown amorphous solid was washed with Et 2 0 (3 x 20 mL) and this removed most of the aniline starting material (18a).
  • the crude material contained roughly 19% of the desired product (18b) along with recovered 5b. m/z (ESI, +ve ion) 611.9 (M+H) + .
  • the crude residue was used in the subsequent step without further purification.
  • the solids were purged with argon and treated with 1,4-dioxane (12 mL) and water (4 mL), sealed and heated at 1 10 °C in a heating block for 1 h.
  • the reaction mixture was treated with 1 N NaOH and extracted with EtOAc (3 x 30 mL), dried over MgSO t, filtered and concentrated.
  • the reaction mixture was transferred to a 1-L RBF using water (ca. 50 mL) and concentrated on the rotovap to remove most of the EtOH and treated with water (350 mL) and EtOAc (300 mL). The organic layer was separated and discarded. The aqueous layer was extracted with EtOAc (2 x 300 mL) and discarded. The aqueous layer was treated with NaOAc (ca. 18 g) (pH ca. 5-6) and extracted with CHCl 3 /5% IPA (3 x 300 mL) then treated with 1 N NaOH (10 mL) and extracted with CHC3 ⁇ 4/5% IPA (1 x 300 mL) again.
  • Example B2 N-(3-(2-((4-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)amino)-5- methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide
  • Nl-(2-(Dimethylamino)ethyl)-Nl-methylbenzene-l,4-diamine (335 mg, 1.733 mmol) and N-(3-(5-methyl-2-(methylsulfmyl)-7-oxopyrido[2,3-d]pyrimidin-8(7H)- yl)phenyl)acrylamide (103, 350 mg, 0.950 mmol) was treated with DMAc (4.0 mL) and heated to 100 °C for 3.5 h.
  • the crude mixture was added directly to a silica gel column and the material was purified on the ISCO Combiflash RF (40 g Silicycle column, using a gradient of 0-20% 2M NH 3 /MeOH in DCM) affording enriched product.
  • the material was purified on the Gilson (Gemini Phenomenex; 30 x 150 mm, 5 u, 10-95%o
  • Example B3 N-(3-(2-((3-fluorophenyl)amino)-5-methyl-7-oxopyrido[2,3- d] py rimidin-8(7H)-yl)phenyl)acrylamide
  • Example B4 N-(3-(5-methyl-2-((l-methyl-lH-pyrazol-4-yl)amino)-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide
  • Example B6 8-(((3S)-l-acryloyl-3-pyrrolidinyl)methyl)-2-((2-methoxy-4-(4-methyl- l-piperazinyl)phenyl)amino)-5-methylpyrido[2,3-d]pyrimidin-7(8H)-one
  • Step 1 A solution of l -(2,4-dichloropyrimidin-5-yl)ethanone (800 mg, 4.19 mmol, Princeton Bio) in 3 mL of THF and 18 mL of cyclohexane at RT was treated with ( ?)-tert-butyl 3-(aminomethyl)pyrrolidine-l -carboxylate (923 mg, 4.61 mmol, Astatech Inc.) followed by NaHCC (387 mg, 4.61 mmol). It was stirred at RT for 2 h, and diluted with 150 mL of EtOAc. The mixture was filtered through a pad of Celite. The solid was discarded.
  • Step 2 At -78 °C, EtOAc (329 xL, 3.36 mmol) was added dropwise to a solution of LiHMDS (3.48 mL of 1.0 M solution in THF, 3.48 mmol) in 5 mL of THF. It was stirred at -78 °C for 15 min then treated with a solution of ( ?)-tert-butyl 3-(((5-acetyl-2- chloropyrimidin-4-yl)amino)methyl)pyrrolidine-l-carboxylate (398 mg of B6a that was about 85% pure, 1.12 mmol) in THF (6 mL) dropwise.
  • Step 3 A solution of (R)-tert-butyl 3-((2-chloro-5-methyl-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)methyl)pyrrolidine-l -carboxylate (340 mg of 6b that was about 40% pure, 0.90 mmol) in 3 mL of DCM at RT was treated with TFA (667 xL, 8.97 mmol) and stirred at RT for 45 min. It was concentrated under reduced pressure.
  • Step 4 A mixture of (.S)-8-((l-acryloylpyrrolidin-3-yl)methyl)-2-chloro-5- methylpyrido[2,3-d]pyrimidin-7(8H)-one (B6c, 185 mg, 0.55 mmol), 2-methoxy-4-(4- methylpiperazin-l-yl)aniline (148 mg, 0.66 mmol, GreenchemPharm) and TFA (0.045 mL, 0.61 mmol) in 2-butanol (2 mL, 21.80 mmol) was heated in an oil bath at 100 °C for 3 h.
  • Example B7 N-(3-(2-((l,3-dimethyl-lH-pyrazol-4-yl)amino)-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide
  • Example B8 N-(3-(2-((l-ethyl-lH-pyrazol-5-yl)amino)-5-methyl-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)acrylamide.
  • Example B9 N-(3-(2-((4-(2-(dimethylamino)ethoxy)-2-fluorophenyl)amino)-5- methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide
  • the organic extracts were washed with brine and dried over Na 2 S0 4 .
  • the solution was filtered and concentrated in vacuo to give the crude material as a yellow oil.
  • the crude material was absorbed onto silica gel and purified by chromatography through a Redi-Sep pre-packed silica gel column (40 g), eluting with a gradient of 0-3% 2 M NH 3 MeOH in CH 2 C1 2 , to provide 2-(3-fluoro-4-nitrophenoxy)-A ⁇ ,A ⁇ -dimethylethanamine (B9a, 0.392 g, 21% yield) as yellow oil.
  • Example Bll N-(3-(2-((l,3-dimethyl-lH-pyrazol-4-yl)amino)-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)acrylamide
  • Example B12 N-(3-(5-methyl-2-((l-methyl-3-(trifluoromethyl)-lH-pyrazol-4- yl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide
  • Example B13 N-(3-(5-methyl-2-((4-(l-methylpiperidin-4-yl)phenyl)amino)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide
  • Example B14 N-(3-(2-((4-(2-(dimethylamino)ethoxy)-2-methoxyphenyl)amino)-5- methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide
  • the remaining solid was purified on a silica gel column (5% MeOH in DCM followed by 5-10% of 2 M NH3 in MeOH in DCM) to provide an enriched material (about 580 mg of yellow solid).
  • the yellow solid was stirred in 10 mL of ether for 30 min. The yellow solid was filtered, and washed with 3 x 10 mL of ether. The ether filtrate was discarded.
  • Example B15 A mixture of l,3-dimethyl-lH-pyrazol-5-amine (0.024 g, 0.220 mmol, FSSI), N-
  • Example B16 N-(3-(2-((4-(2-methoxyethoxy)phenyl)amino)-5-methyl-7- oxopyrido [2,3-d] pyrimidin-8(7H)-yl)phenyl)acrylamide.
  • Example B17 N-(3-(2-((4-((2-hydroxyethyl)(methyl)amino)-2- methoxyphenyl)amino)-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)- yl)phenyl)acrylamide
  • Example B17 Preparation of Example B17. To a stirred mixture of 7V-(3-(2-chloro-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7//)-yl)phenyl)acrylamide (510 mg, 1.497 mmol) (100) and crude 2-((4-amino-3-methoxyphenyl)(methyl)amino)ethanol (382 mg, 1.946 mmol) in 2- butanol (5.00 mL) was added TFA (0.15 mL, 1.95 mmol) and the heterogeneous mixture was stirred at 110 °C overnight.
  • TFA 0.15 mL, 1.95 mmol
  • Example B18 N-(3-(5-methyl-7-oxo-2-((4-(piperidin-4-yl)phenyl)amino)pyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)acrylamide
  • reaction mixture was concentrated on the rotovap and chromatographed on the ISCO Combiflash RF (40 g Thompson SingleStep column, using a gradient of 0-10% MeOH in DCM) affording N-(3-(2-((l-isopropyl-lH-pyrazol-4-yl)amino)-5-methyl-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)acrylamide (59 mg, 0.138 mmol, 46% yield) as a yellow crystalline solid, m/z (ESI, +ve ion) 430.0 (M+H) + . !
  • Example B20 N-(3-(2-((2-chloro-4-((2- (dimethylamino)ethyl)(methyl)amino)phenyl)amino)-5-methyl-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide
  • reaction mixture was filtered over Celite, washed with MeOH/THF (2 x 20 mL of 1 : 1 solution). The filtrate was evaporated to dryness to give a viscous blue oil containing a mixture of 3-chloro-Nl-(2- (dimethylamino)ethyl)-Nl -methylbenzene-l,4-diamine (1.15 g, about 80%) and Nl-(2- (dimethylamino)ethyl)-5-fluoro-Nl-methylbenzene-l ,2-diamine (about 20%).
  • a heterogeneous mixture of N-(3-(2-chloro-5-methyl-7-oxopyrido[2,3-d]pyrimidin- 8(7H)-yl)phenyl)acrylamide (100, 194 mg, 0.57 mmol), 3-chloro-Nl -(2- (dimethylamino)ethyl)-Nl-methylbenzene-l,4-diamine hydrochloride (20b, 188 mg, 0.71 mmol, in about 90% pure) contaminated with 10% of N-(3-(2-chloro-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide in 2.5 mL of EtOH was treated with HOAc (32.9 xL, 0.57 mmol) and heated in an oil bath at 100 °C for 30 min.
  • the reaction mixture was heated in a microwave at 120 °C for 1 h.
  • the resulting dark mixture was loaded on a silica gel column and eluted with 2% MeOH in DCM followed by 5-10% of 2 M NH 3 in MeOH in DCM.
  • the residue was stirred in 5 mL of ether for 10 min.
  • the precipitated yellow solid was filtered, rinsed with 2 x 2 mL of ether. The filtrate was discarded.
  • Example B21 N-(3-(5-methyl-2-((3-methyl-l-(l-methylpiperidin-4-yl)-lH-pyrazol-4- yl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide and N-(3-(5- methyl-2-((5-methyl-l-(l-methylpiperidin-4-yl)-lH-pyrazol-4-yl)amino)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide
  • Example 21 The 3-methyl-l-(l-methylpiperidin-4-yl)-lH- pyrazol-4-amine hydrochloride and 5 -methyl- l-(l-methy lpiperidin-4-yl)-lH-pyrazol-4- amine hydrochloride mixture (21b, 0.10 g, 0.43 mmol) was combined with N-(3-(2- chloro-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide (100) (0.137 g, 0.40 mmol) and suspended in EtOH (1 mL) in a microwave vial.
  • the mixture was stirred at 0 °C for 10 min and then at RT for 1 h.
  • the reaction mixture was quenched with water (5 mL) and the resulting fine white precipitate was filtered using a medium porosity sintered glass frit and the filter cake was washed Et20.
  • N-(3-(6-benzyl-2-(methylthio)-7-oxopyrido[2,3-d]pyrimidin- 8(7H)-yl)phenyl)acrylamide (531 mg, 1.24 mmol) was treated with DCM (20 mL), cooled to 0 °C in an ice bath and treated with 3-chloroperoxybenzoic acid (77% max., 278 mg, 1.239 mmol) in one portion. The solution was stirred at 0 °C for 1 h 30 min.
  • Example B23 (5)-N-(3-(2-((2-methoxy-4-((l-methylpyrrolidin-3- yl)oxy)phenyl)amino)-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)- yl)phenyl)acrylamide
  • the first eluent was N-(3-(2-((2-chloro-4-(2-(dimethylamino)ethoxy)- phenyl)amino)-5 -methyl-7-oxopyrido [2,3 -d]pyrimidin-8(7H)-yl)phenyl)acrylamide (Example B25, 50 mg, 15% yield) as a yellow crystalline solid. !
  • Example B27 N-(3-(5-methyl-2-((3-methyl-4-(4-methylpiperazin-l- yl)phenyl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide
  • Reaction mixture was directly purified by Gilson HPLC (Gemini-NX, lOu, Ci 8 , 100x50 mm; 0.1% TFA/water, 0.1% TFA/AcCN). Fractions azeotroped with AcCN. The residue was resolubilized with MeOH and neutralized with Silicycle SiliaPrep Carbonate cartridge.
  • Comparator Example 28 N-(3-(6-methoxy-2-((2-methoxy-4-(4-methylpiperazin-l- yl)phenyl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide.
  • N-(3-(6-methoxy-2-(methylthio)-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)acrylamide (1.02 g, 2.78 mmol) was treated with DCM (50 mL), cooled to 0 °C in an ice bath and treated with 3-chloroperoxybenzoic acid (77% max.; 0.623 g, 2.78 mmol) in one portion. The solution was stirred at 0 °C for 1 h.
  • Example B29 N-(3-(2-((4-(4-(2-hydroxypropan-2-yl)piperidin-l-yl)phenyl)amino)-5- methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide
  • Reaction mixture was directly purified by Gilson HPLC (Gemini-NX, lOu, CI 8, 100x50 mm; 0.1% TFA/water, 0.1% TFA/AcCN). The clean fractions were azeotroped with AcCN. The residue was resolubilized with MeOH and neutralized with Silicycle SiliaPrep Carbonate cartridge to afford N-(3-(2-((4-(4-(2-hydroxypropan-2-yl)piperidin-l -yl)phenyl)amino)-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide (Example B29, 45.3 mg, 0.84 mmol, 29% yield).
  • Example B30 N-(3-(6-Methoxy-2-((2-methoxy-4-(4-methylpiperazin-l- yl)phenyl)amino)-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)- yl)phenyl)acrylamide.
  • LiHMDS (1.0 M in THF, 2.00 mL, 2.00 mmol) was added to THF (10 mL) at -78 °C and treated with methyl methoxyacetate (Sigma Aldrich, 0.145 mL, 1.469 mmol) slowly dropwise. The solution was stirred at -78 °C for 25 min, then tert-butyl (3-((5- acetyl-2-(methylthio)pyrimidin-4-yl)amino)phenyl)carbamate (102, 250 mg, 0.668 mmol) was added in one portion and the solution was removed from the cooling bath, warmed to RT and stirred for 2 h.
  • Martin sulfurane dehydrating agent (Sigma Aldrich, 449 mg, 0.668 mmol) was added in one portion to the reaction mixture and stirred for 3 h. The reaction was quenched with a saturated solution of NH 4 C1 and extracted with EtOAc (2 x 15 mL), dried over MgS0 4 , filtered and concentrated.
  • tert-butyl (3-(6-methoxy-5-methyl-2-(methylthio)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)carbamate (30a; 163 mg, 0.38 mmol) was treated with HC1 (4 M in 1,4-dioxane, 1.90 mL, 7.61 mmol) and heated to 50 °C for 45 min. The volatiles were removed under reduced pressure and the crude material was treated with 1,4-dioxane (4 mL), cooled to 0 °C and treated with NaOH (10 N, 0.84 ml, 8.37 mmol) in an ice bath.
  • N-(3-(6-methoxy-5-methyl-2-(methylthio)-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)acrylamide (30b; 101 mg, 0.26 mmol) was treated with DCM (20 mL), cooled to 0 °C in an ice bath and treated with 3-chloroperoxybenzoic acid (59 mg of 77% max., 0.26 mmol) in one portion. The solution was stirred at 0 °C for 50 min.
  • Example B31 A solution of l -(4-(4-amino-3- chlorophenyl)piperazin-l-yl)ethanone (31b, 0.135 g, 0.53 mmol), N-(3-(2-chloro-5- methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide (0.165 g, 0.484 mmol), TFA (0.036 mL, 0.48 mmol) in 2-butanol (20 mL, 109 mmol) was stirred at 1 10 °C overnight. After cooled to RT, the crude was was concentrated down and
  • Example B32 (R) and (S) N-(3-(2-((4-(3,4-dimethylpiperazin-l-yl)-2- methoxyphenyl)amino)-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)- yl)phenyl)acrylamide
  • Example B33 N-(3-(2-((4-(3-(dimethylamino)propoxy)phenyl)amino)-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide
  • Reaction mixture was directly purified by Gilson HPLC (Gemini-NX, lOu, Ci 8 , 100 x 50 mm column; 0.1% TF A/water, 0.1% TFA/AcCN). The clean fraction was azeotroped with AcCN. The residue was resolubilized with MeOH and neutralized with Silicycle SiliaPrep Carbonate cartridge to afford N-(3-(2-((4-(3-(dimethylamino)propoxy)phenyl)amino)-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide (Example B33, 16.1 mg, 0.032 mmol, 11% yield). !
  • Example B34 N-(3-(2-((2-methoxy-4-(methyl(2-(2-oxopyrrolidin-l- yl)ethyl)amino)phenyl)amino)-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)- yl)phenyl)acrylamide
  • Example B34 Preparation of Example B34. l-(2-((4-Amino-3-methoxyphenyl)(methyl)amino)- ethyl)pyrrolidin-2-one (34c, 0.64 g, 2.430 mmol), N-(3-(2-chloro-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide (100) (0.828 g, 2.43 mmol), HOAc (Sigma-Aldrich; 0.14 mL, 2.43 mmol), and EtOH (5 mL) were combined in a pressure vessel under argon and heated in a 120 °C oil bath.

Abstract

The invention encompasses compounds represented by the following general structures: formula (I) and formula (II), wherein X; R1-R3; R11; R12; and R14 are as defined in the claims and pharmaceutically acceptable salts thereof, pharmaceutical compositions, uses and methods for prophylaxis and treatment of cancer.

Description

SUBSTITUTED 7-OXO-PYRIDO [2, 3-D] PYRIMIDINES AND THEIR USE FOR THE TREATMENT OF EGFR / ERBB2 RELATED DISORDERS
5 Priority
This application claims the benefit of U.S. Provisional Patent Application No. 61/771,582, filed on March 1, 2013, and U.S. Provisional Patent Application No.
61/900,156, filed on November 5, 2013, which specifications are hereby incorporated 10 herein by reference in their entirety.
FIELD OF THE INVENTION
This invention is in the field of pharmaceutical agents and specifically relates to compounds, compositions, uses and methods for treating cancer.
15
Background of the Invention
Protein kinases represent a large family of proteins which play a central role in the regulation of a wide variety of cellular processes, maintaining control over cellular function. A partial list of such kinases includes abl, Atk, bcr-abl, Blk, Brk, Btk, c-kit, c-
20 met, c-src, CDKl, CDK2, CDK3, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDKIO, cRafl, CSF1R, CSK, EGFR, ErbB2, ErbB3, ErbB4, Erk, Fak, fes, FGFR1, FGFR2, FGFR3, FGFR4, FGFR5, Fgr, flt-1, Fps, Frk, Fyn, Hck, IGF-1R, INS-R, Jak, KDR, Lck, Lyn, MEK, p38, PDGFR, PIK, PKC, PYK2, ros, tie, tie2, TRK, Yes, and Zap70.
Inhibition of such kinases has become an important therapeutic target.
25 Initial interest in protein kinases as pharmacological targets was stimulated by the findings that many viral oncogenes encode structurally modified cellular protein kinases with constitutive enzyme activity. These findings pointed to the potential involvement of oncogene related protein kinases in human proliferative disorders. Subsequently, deregulated protein kinase activity, resulting from a variety of more subtle mechanisms,
30 has been implicated in the pathophysiology of a number of important human disorders including, for example, cancer, CNS conditions, and immunologically related diseases. The development of selective protein kinase inhibitors that can block the disease pathologies and/or symptoms resulting from aberrant protein kinase activity has therefore generated much interest.
35 The ErbB receptor family belongs to the subclass I receptor tyrosine kinase superfamily and includes four distinct receptors including epidermal growth factor receptor (EGFR or ErbB 1). ΕΛ132 (HER22 or pl 85neu). Erbl33 (HER3), and Erbl34 (HER4 or rvro2). Over 60% of all solid tumors overexpress at least one of these proteins or their ligands.
EGFR or ErbBl has been implicated in human malignancy. Overexpression of EGFR is commonly found in breast, lung, head and neck, bladder tumors. Monoclonal antibodies directed against the EGFR, or its ligands TGF-alpha and EGF have been evaluated as therapeutic agents in the treatment of such malignancies. The reversible inhibitors Tarceva (erlotinib) and Iressa (gefitinib) currently are first-line therapy for non- small cell lung cancer patients with activating mutations.
Activating mutations in the tyrosine kinase domain of EGFR have been identified in patients with non-small cell lung cancer (Lin, N. U.; Winer, E. P., Breast Cancer Res 6: 204-210, 2004). The most common activating mutations are L858R and delE746-A750. Another mutant, T790M, has been detected in at least half of such clinically resistant patients. Moreover, T790M may also be pre-existing, there may be an independent, oncogenic role for the T790M mutation. In addition, germline EGFR T790M mutations are linked with certain familial lung cancers.
Current drugs in development, including second generation covalent inhibitors, such as BIBW2992, HKI-272 and PF-0299804, are effective against the T790M resistance mutation but exhibit dose-limiting toxicities due to concurrent inhibition of WT EGFR. Accordingly, there remains a need to find mutant-selective EGFR kinase inhibitors useful as therapeutic agents.
The compounds of the current invention have not been described for the treatment of cancer. SUMMARY OF THE INVENTION
The present invention comprises a new class of 7-oxo-pyrido[2,3-d]pyrimidines useful in the treatment of diseases, such as EGFR mutant-mediated diseases, for example cancer. Accordingly, the invention also comprises pharmaceutical compositions comprising the compounds, methods for the treatment of EGFR mutant-mediated diseases and other maladies, such as treatment of solid tumors, for example breast, lung, head and neck, bladder cancers, using the compounds and compositions of the invention, and intermediates and processes useful for the preparation of the compounds of the invention. The compounds of the invention are represented by the following general structure:
and a pharmaceutically acceptable salt thereof; wherein X; R1; R2; and R3 are defined below.
The compounds of the invention are also represented by the following general structure:
and a pharmaceutically acceptable salt thereof; wherein R; Rn; R12; and R14 are defined below.
The foregoing merely summarizes certain aspects of the invention and is not intended, nor should it be construed, as limiting the invention in any way. All patents, patent applications and other publications recited herein are hereby incorporated by reference in their entirety.
DESCRIPTION OF THE INVENTION
One aspect of the current invention relates to compounds having the general structure of formula 1 :
wherein Ring A is 5 membered heteroaryl;
wherein Ring T is phenyl or 6 membered heteroaryl;
wherein R2 is H, F, CI or methyl;
wherein R3 is H, C\-Ce alkyl or C\-Ce dialkylamino- C\-Ce alkyl;
wherein R5 is unsubstituted or substituted 5-6 membered saturated heterocyclyl or substituted 4-7 membered heterocyclylamino;
wherein R6 is H, C\-Ce alkoxy, C\-Ce haloalkoxy or halo; and
wherein X is CH or N;
provided R5 is not 4-morpholinyl;
and pharmaceutically acceptable salts thereof.
In another embodiment, the group X is CH.
In another embodiment, the group R3 is H.
In another embodiment, the group R2 is H or methyl.
In another embodiment, the group R2 is methyl.
In another embodiment, the group R1 is substituted phenyl.
In another embodiment, R1 is substituted pyridyl or substituted pyrimidinyl. In another embodiment, R5 is optionally substituted piperazinyl, optionally substituted piperidinyl, optionally substituted pyrrolidinyl, optionally substituted diazepanyl, or optionally substituted azetidinylamino; wherein the piperazinyl, piperidinyl, pyrrolidinyl, diazepanyl, and azetidinyl rings are optionally substituted with one or more substituents selected from Cu alkyl, Cu haloalkyl, Ci_4 alkoxycarbonyl, Cu alkylamino, optionally substituted 5-6 membered heterocyclyl, C1.4 alkylcarbonyl, C1.4 alkylsulfonyl, aminosulfonyl, C1.4 hydroxyalkylcarbonyl, C1.4 alkylaminocarbonyl, and C1.4 haloalkylcarbonyl.
In another embodiment, the group R1 is
In another embodiment, R5 is l-fluoroethylazetidin-3-ylamino.
In another embodiment, R6 is H, methoxy or chloro.
Another aspect of the current invention relates to compounds having the general structure of Formula II
wherein R2 is H or methyl;
wherein Ra is optionally substituted piperazinyl, optionally substituted piperidinyl,
optionally substituted pyrrolidinyl, optionally substituted diazepanyl, optionally or optionally substituted azetidinylamino; and
wherein Rb is H or methoxy;
and pharmaceutically acceptable salts thereof.
In another embodiment, the group R2 is methyl.
In another embodiment, the group Rb is located at position 3 on the phenyl ring.
In another embodiment, the group Ra is optionally substituted piperazinyl, optionally substituted piperidinyl, optionally substituted pyrrolidinyl, or optionally substituted diazepanyl; wherein the piperazinyl, piperidinyl, pyrrolidinyl and diazepanyl rings are optionally substituted with one or more substituents selected from Cu alkyl, Q_ 3 haloalkyl, C1.4 alkoxycarbonyl, Cu alkylamino, optionally substituted 5-6 membered heterocyclyl, Ci_4 alkylcarbonyl, Ci_4 alkylsulfonyl, aminosulfonyl, C1
hydroxyalkylcarbonyl, C1 alkylaminocarbonyl, and C1.4 haloalkylcarbonyl.
In another embodiment, the group Ra is azetidinylamino; wherein the azetindinyl is optionally substituted with one or more substituents selected from Cu alkyl, Cu haloalkyl, C1.4 alkoxycarbonyl, Cu alkylamino, optionally substituted 5-6 membered heterocyclyl, Ci_4 alkylcarbonyl, Ci_4 alkylsulfonyl, aminosulfonyl, C1
hydroxyalkylcarbonyl, C1 alkylaminocarbonyl, and C1.4 haloalkylcarbonyl.
A family of specific compounds of particular interest within Formula 1 consists of compounds and pharmaceutically-acceptable derivatives thereof as follows:
N-(3-(2-((2-methoxy-4-(4-methyl-l-piperazinyl)phenyl)amino)-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
(2ii)-N-(3-(2-((2-methoxy-4-(4-methyl-l-piperazinyl)phenyl)amino)-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)-2-butenamide; N-(3-(2-((4-(4-methyl-l-piperazinyl)phenyl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)^ yl)phenyl)-2-propenamide;
N-(3-(2-((2-methoxy-4-(4-methyl-l-piperazinyl)phenyl)amino)-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
N-(3-(6-ethyl-2-((2-methoxy-4-(4-methyl-l-piperazinyl)phenyl)amino)-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
N-(3-(2-((4-methoxy-6-(4-methyl-l-piperazinyl)-3-pyridinyl)amino)-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
(2ii)-4-(dimethylamino)-N-(3-(2-((2-methoxy-4-(4-methyl-l-piperazinyl)phenyl)amm 7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-butenamide;
N-(4-fluoro-3-(2-((2-methoxy-4-(4-methyl-l-piperazinyl)phenyl)amino)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
N-(3-(2-((4-((l-(2-fluoroethyl)-3-azetidinyl)amino)-2-methoxyphenyl)amino)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
2-chloro-N-(3-(2-((2-methoxy-4-(4-methyl-l-piperazinyl)phenyl)amino)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acetamide;
3-(dimethylamino)-N-(3-(2-((2-methoxy-4-(4-methylpiperazin-l-yl)phenyl)amino)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)propanamide;
N-(3-(2-((4-((l-acetylazetidin-3-yl)amino)-2-methoxyphenyl)amino)-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)acrylamide;
N-(3-(2-((2-chloro-4-(4-methyl-l-piperazinyl)phenyl)amino)-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
N-(3 -(2-((4-(( 1 -(2-fluoroethyl)-3 -azetidinyl)amino)-2-methoxyphenyl)amino)-5 -methyl-
7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
N-(3-(5-methyl-2-((4-(4-methylpiperazin-l-yl)phenyl)amino)-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)acrylamide;
A^-(3-(2-((2-methoxy-4-(piperazin-l-yl)phenyl)amino)-5-methyl-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)acrylamide
N-(3 -(2-((2-methoxy-4-( 1 -methylpiperidin-4-yl)phenyl)amino)-5 -methyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide; and
N-(3-(2-((4-(4-acetylpiperazin-l-yl)-2-methoxyphenyl)amino)-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide. One aspect of the current invention relates to compounds having the general structure of formula la:
wherein
R is
Rn is unsubstituted or substituted phenyl or unsubstituted or substituted 4-6
membered heterocyclyl;
R12 is H, or methyl;
R14 is H, Ci-C6 alkyl, Ci-C6 alkoxy or phenyl- Ci-C6 alkyl; and
R17 is H or methyl;
and pharmaceutically acceptable salts thereof;
provided Rn is not 3-methoxy-4-methylpiperazin-l -yl-phenyl or phenyl when R is benzacrylamide, R12 is methyl and R14 is H;
further provided Rn is not 3-methoxy-4-methylpiperazin-l -yl-phenyl when R is 3- benzacrylamide, R12 is H and R14 is benzyl;
further provided R14 is not methyl or methoxy when R12 is H.
In another embodiment, R is
; and pharmaceutically acceptable salts thereof.
In another embodiment, R14 is H, benzyl, or methoxy; and pharmaceutically acceptable salts thereof.
In another embodiment, R14 is H; and pharmaceutically acceptable salts thereof.
In another embodiment, R12 is methyl; and pharmaceutically acceptable salts thereof. In another embodiment, Rn is or f V!_/ ; wherein
Ring A is 5 membered heteroaryl; wherein Ring T is phenyl; wherein R15 is unsubstituted or substituted 6-membered nitrogen containing heterocyclyl, C1.4 alkylamino- C1.4 alkylamino, C1.4 hydroxylalkylamino, 5-membered nitrogen containing heterocyclyl-Ci.4 alkylamino, 5-membered nitrogen containing heterocyclyl-oxy, C1.4 alkylamino- C1.4 alkoxy, or C1.4 alkoxy- C1.4 alkoxy; wherein R16 is one or more substituents selected from Ci_4 alkyl, C1.4 alkoxy, chloro, fluoro, H, C^ haloalkoxy and C^ haloalkyl; and wherein R18 is Ci_4 alkyl, Ci_4 alkylamino- Ci_4 alkyl, unsubstituted or substituted 5-membered nitrogen containing heterocyclyl or unsubstituted or substituted 6-membered nitrogen containing heterocyclyl; and pharmaceutically acceptable salts thereof.
In another embodiment, Rn is substituted phenyl; and pharmaceutically acceptable salts thereof.
In another embodiment, Rn is substituted pyrazolyl; and pharmaceutically acceptable salts thereof.
In another embodiment, R15 is optionally substituted piperazinyl, optionally substituted piperidinyl, N-(N',N'-dimethylaminoethyl)-N-methylamino, N-hydroxyethyl- N-methylamino, N-(2-oxo-l -pyrrolidinylethyl)-N-methylamino, N-(l -pyrrolidinylethyl)- N-methylamino, l -methyl-3-pyrrolidinyoxy, Ν,Ν-dimethylaminopropoxy, N,N- dimethylaminoethoxy, or methoxyethoxy; wherein the piperazinyl, and piperidinyl rings are optionally substituted with one or more substituents selected from methyl, trifluoromethyl, 1 -hydroxy- 1-methylethyl and acetyl; and pharmaceutically acceptable salts thereof.
In another embodiment, R16 is methyl, methoxy, chloro, fluoro, H,
trifluoromethyl or difluormethoxy; and pharmaceutically acceptable salts thereof.
In another embodiment, R18 is methyl, ethyl, isopropyl, N,N- dimethylaminoethyl, 1 -methyl-pyrrolidinyl, or 1-methylpiperidinyl; and
pharmaceutically acceptable salts thereof.
In another embodiment, and pharmaceutically acceptable salts thereof, Rn is
Another aspect of the current invention relates to compounds having the general structure of Formula Ila
wherein Ra is unsubstituted or substituted 6-membered nitrogen containing heterocyclyl; and wherein Rbl is one or more substituents selected from C1.4 alkyl, C1.4 alkoxy, chloro, fluoro, H, C^haloalkoxy and C^haloalkyl; and pharmaceutically acceptable salts thereof;
provided Ral is not 1 -methyl-4-piperazinyl when Rbl is 3-methoxy.
In another embodiment, Rbl is located at position 3 on the phenyl ring; and pharmaceutically acceptable salts thereof.
In another embodiment, Ral is piperidinyl or piperazinyl; wherein the piperidinyl or piperazinyl ring is optionally substituted with one or more substituents selected from Ci-3 alkyl, C1.4 alkylcarbonyl, or C1.4 hydroxyalkyl; and pharmaceutically acceptable salts thereof.
In another embodiment, and pharmaceutically acceptable salts thereof, Ral is
In another embodiment, Rbl is methyl, methoxy, chloro, fliioro, H, trifluoromethyl or difluormethoxy; and pharmaceutically acceptable salts thereof.
Another aspect of the current invention relates to compounds having the general structure of Formula Ilia
Ilia wherein
R31 is substituted 5 membered heteroaryl;
R32 is H or methyl;
R34 is H, Ci-C6 alkyl, Ci-C6 alkoxy or phenyl-Ci-C6 alkyl; and
R31 is substituted with one or more substituents selected from C1.4 alkyl, C1.4 alkoxy, chloro, fluoro, C^haloalkoxy, C^haloalkyl, C1.4 alky lamino-C 1.4 alkyl, unsubstituted or substituted 5 -membered nitrogen containing heterocyclyl and unsubstituted or substituted 6-membered nitrogen containing heterocyclyl; and and pharmaceutically acceptable salts thereof.
In another embodiment, R31 is optionally substituted pyrazolyl, optionally substituted isoxazolyl, optionally substituted thiadiazolyl, or optionally substituted imidazolyl; wherein the pyrazolyl, isoxazolyl, thiadiazolyl, or imidazolyl rings are substituted with one or more substituents selected from methyl, ethyl, isopropyl, methoxy, chloro, fluoro, trifluoromethyl, difluoromethoxy, Ν,Ν-dimethylaminoethyl, 1 - methyl-pyrrolidinyl or 1-methylpiperidinyl; and pharmaceutically acceptable salts thereof. In another embodiment, R31 is optionally substituted pyrazolyl; wherein the pyrazolyl ring is substituted with one or more substituents selected from methyl, ethyl, isopropyl, methoxy, chloro, fluoro, trifluoromethyl, difluoromethoxy, N,N- dimethylaminoethyl, 1-methyl-pyrrolidinyl and 1 -methylpiperidinyl; and
pharmaceutically acceptable salts thereof.
In another embodiment, R31 is
and pharmaceutically acceptable salts thereof.
In another embodiment, R34 is H, benzyl, or methoxy; and pharmaceutically acceptable salts thereof.
Another aspect of the current invention relates to compounds having the general structure of Formula IVa
wherein Ra is C1.4 alky lamino-C 1.4 alkylamino, C1.4 hydroxylalkylamino, 5-membered nitrogen containing heterocyclyl-Ci.4 alkylamino, 5-membered nitrogen containing heterocyclyl-oxy, C1.4 alkoxy, or C1.4 alkoxy-Ci.4 alkoxy; and wherein R is one or more substituents selected from Ci_4 alkyl, Ci_4 alkoxy, chloro, fluoro, H, and pharmaceutically acceptable salts thereof.
In another embodiment, Ra4 is N-(N',N'-dimethylaminoethyl)-N-methylamino, N-hydroxyethyl-N-methylamino, N-(2-oxo- 1 -pyrrolidinylethyl)-N-methylamino, N-( 1 - pyrrolidinylethyl)-N-methylamino, l-methyl-3-pyrrolidinyoxy, N,N- dimethylaminopropoxy, Ν,Ν-dimethylaminoethoxy, or methoxyethoxy; and pharmaceutically acceptable salts thereof.
In another embodiment, RM is methyl, methoxy, chloro, fluoro, H,
trifluoromethyl or difluormethoxy; and pharmaceutically acceptable salts thereof.
A family of specific compounds of particular interest within Formula la consists of compounds and pharmaceutically-acceptable derivatives thereof as follows:
N-(3-(2-((4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-5- methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
N-(3-(2-((4-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)amino)-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
N-(3-(2-((3-fluorophenyl)amino)-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)- yl)phenyl)-2-propenamide;
N-(3 -(5 -methyl-2-(( 1 -methyl- 1 H-pyrazol-4-yl)amino)-7-oxopyrido[2,3-d]pyrimidin- 8(7H)-yl)phenyl)-2-propenamide;
N-(3-(2-((l-(2-(dimethylamino)ethyl)-lH-pyrazol-4-yl)amino)-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
8-(((3S)-l-acryloyl-3-pyrrolidinyl)methyl)-2-((2 -methoxy -4-(4-methyl-l- piperazinyl)phenyl)amino)-5-methylpyrido[2,3-d]pyrimidin-7(8H)-one;
N-(3-(2-((l,3-dimethyl-lH-pyrazol-4-yl)amino)-5-methyl-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
N-(3-(2-((l-ethyl-lH-pyrazol-5-yl)amino)-5-methyl-7-oxopyrido[2,3-d]pyrimidin-
8(7H)-yl)phenyl)-2-propenamide;
N-(3-(2-((4-(2-(dimethylamino)ethoxy)-2-fluorophenyl)amino)-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
N-(3-(2-((3-chloro-l-methyl-lH-pyrazol-4-yl)amino)-5-methyl-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
N-(3-(2-((l,3-dimethyl-lH-pyrazol-4-yl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)- yl)phenyl)-2-propenamide; N-(3 -(5-methyl-2-(( 1 -methyl-3-(trifluorom ethyl)- 1 H-pyrazol-4-yl)amino)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
N-(3-(5-methyl-2-((4-(l-methyl-4-piperidinyl)phenyl)amino)-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
N-(3-(2-((4-(2-(dimethylamino)ethoxy)-2-methoxyphenyl)amino)-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
N-(3-(2-((l,3-dimethyl-lH-pyrazol-5-yl)amino)-5-methyl-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
N-(3-(2-((4-(2-methoxyethoxy)phenyl)amino)-5-methyl-7-oxopyrido[2,3-d]pyrimidin- 8(7H)-yl)phenyl)-2-propenamide;
N-(3-(2-((4-((2 -hydroxy ethyl)(methyl)amino)-2-methoxyphenyl)amino)-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
N-(3-(5-methyl-7-oxo-2-((4-(4-piperidinyl)phenyl)amino)pyrido[2,3-d]pyrimidin-
8(7H)-yl)phenyl)-2-propenamide;
N-(3-(5 -methyl-2 -(( 1 -( 1 -methylethyl)- 1 H-pyrazol-4-yl)amino)-7-oxopyrido [2,3- d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
N-(3-(2-((2-chloro-4-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)amino)-5- methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
N-(3 -(5-methyl-2-((3 -methyl- 1 -( 1 -methyl-4-piperidinyl)- 1 H-pyrazol-4-yl)amino)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
N-(3 -(5-methyl-2-((5 -methyl- 1 -( 1 -methyl-4-piperidinyl)- 1 H-pyrazol-4-yl)amino)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
(S)-N-(3-(2-((2-methoxy-4-((l-methylpyrrolidin-3-yl)oxy)phenyl)amino)-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide 2,2,2-trifluoroacetate; N-(3-(2-((3-fluoro-4-(4-methyl-l-piperazinyl)phenyl)amino)-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
N-(3-(2-((2-chloro-4-(2-(dimethylamino)ethoxy)phenyl)amino)-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
N-(3-(2-((4-(2-(dimethylamino)ethoxy)phenyl)amino)-5-methyl-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)acrylamide;
N-(3-(5-methyl-2-((3-methyl-4-(4-methyl-l-piperazinyl)phenyl)amino)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
N-(3-(2-((4-(4-(l -hydro xy-1 -methylethyl)- 1 -piperidinyl)phenyl)amino)-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide; N-(3-(6-methoxy-2-((2-methoxy-4-(4-methyl-l-piperazinyl)phenyl)amino)-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
N-(3-(2-((4-(4-acetyl-l-piperazinyl)-2-chlorophenyl)amino)-5-methyl-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
N-(3-(2-((4-((3R)-3,4-dimethyl-l-piperazinyl)-2-methoxyphenyl)amino)-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
N-(3-(2-((4-((3S)-3,4-dimethyl-l-piperazinyl)-2-methoxyphenyl)amino)-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
N-(3-(2-((4-(3-(dimethylamino)propoxy)phenyl)amino)-5-methyl-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
N-(3-(2-((2-methoxy-4-(methyl(2-(2 -oxo-1 -pyiTolidinyl)ethyl)amino)phenyl)amino)-5- methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
N-(3-(5-methyl-2-((3-methyl-l-((3S)-l-methyl-3-pyrrolidinyl)-lH-pyrazol-4- yl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
N-(3-(2-((2-methoxy-4-(methyl(2-(l-pyiTolidinyl)ethyl)amino)phenyl)amino)-5- methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
N-(3-(2-((4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methylphenyl)amino)-5- methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
(2E)-N-(3-(2-((4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)- 5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-butenamide;
N-(3-(2-((4-(2-(dimethylamino)ethoxy)-2-fluorophenyl)amino)-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide ; and
(2E)-N-(3-(2-((4-(2-(dimethylamino)ethoxy)-2-methoxyphenyl)amino)-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-butenamide.
One aspect of the current invention relates to compounds having the general structure of formula lb:
wherein
R20 is
X is CH or N;
R21 is unsubstituted or substituted phenyl or unsubstituted or substituted 4-6
membered heterocyclyl;
R22 is H, fluoro, chloro or methyl;
R24 is H, Ci-C6 alkyl, Ci-C6 alkoxy or phenyl- Ci-C6 alkyl; and
R27 is H, Ci-C6 alkyl or Ci-C6 dialkylamino- Ci-C6 alkyl;
and pharmaceutically acceptable salts thereof;
In another embodiment, R is or ; wherein Ring A is 5 membered heteroaryl; wherein Ring T is phenyl or 6 membered heteroaryl; wherein R5 is unsubstituted or substituted 5-6 membered saturated heterocyclyl or substituted 4-7 membered heterocyclylamino; and wherein R6 is H, alkoxy, haloalkoxy or halo.
In another embodiment, R21 is unsubstituted or substituted phenyl or unsubstituted or substituted 4-6 membered heterocyclyl.
In another embodiment, R22 is H, or methyl.
In another embodiment, R24 is H. As described in detail herein, infra, provided compounds are selective inhibitors of at least one mutation of EGFR. It has been surprisingly found that provided compounds are selective inhibitors of at least one mutation of EGFR as compared to wild-type ("WT") EGFR. In certain embodiments, the mutation of EGFR is T790M. In certain embodiments, the mutation of EGFR is a deletion mutation. In some
embodiments, the mutation of EGFR is an activating mutation. In certain embodiments, a compound of the invention selectively inhibits at least one resistant mutation and at least one activating mutation as compared to WT EGFR. In some embodiments, a compound of the invention selectively inhibits at least one deletion mutation and/or at least one point mutation, and is sparing as to WT EGFR inhibition.
A mutation of EGFR can be selected from T790M (resistant or oncogenic), L858R (activating), delE746-A750 (activating), G719S (activating), or a combination thereof.
As used herein, the term "selectively inhibits," as used in comparison to inhibition of WT EGFR, means that a provided compound inhibits at least one mutation of EGFR (i.e., at least one deletion mutation, at least one activating mutation, at least one resistant mutation, or a combination of at least one deletion mutation and at least one point mutation) in at least one assay described herein (e.g., biochemical or cellular). In some embodiments, the term "selectively inhibits," as used in comparison to WT EGFR inhibition means that a provided compound is at least 20 times more potent, at least 25 times, at least 30, at least 35, at least 40, at least 45, or at least 50 times more potent as an inhibitor of at least one mutation of EGFR, as defined and described herein, as compared to WT EGFR.
As used herein, the term "sparing as to WT EGFR" means that a selective inhibitor of at least one mutation of EGFR, as defined and described above and herein, inhibits EGFR at the upper limit of detection of at least one assay as described herein (e.g., biochemical or cellular as described in detail below). In some embodiments, the term "sparing as to WT EGFR" means that a provided compound inhibits WT EGFR with an IC50 of at least 1 μΜ, at least 2 μΜ, at least 5 μΜ, or at least 10 μΜ.
In certain embodiments, a provided compound selectively inhibits (a) at least one activating mutation; and (b) T790M; and (c) is sparing as to WT. In some embodiments, the activating mutation is a deletion mutation. In some embodiments, and the activating mutation is a point mutation. In some embodiments, an activating mutation is delE746- A750. In some embodiments, an activating mutation is L858R. In some embodiments, an activating mutation is G719S.
In some embodiments, the at least one mutation of EGFR is L858R and/or
T790M.
Without wishing to be bound by any particular theory, it is believed that administration of a provided compound to a patient having at least one activating mutation may preempt formation of the T790M resistance mutation. Thus, in certain embodiments, the present invention provides a method for inhibiting an activating mutation in a patient comprising administering to the patient a provided compound or composition thereof, as described herein.
One of ordinary skill in the art will appreciate that certain patients have an oncogenic form of the T790M mutation, i.e., the T790M mutation is present prior to administration to the patient any EGFR inhibitor and is therefore oncogenic. Accordingly, in some embodiments, the present invention provides a method for inhibiting oncogenic T790M in a patient comprising administering to the patient a provided compound or composition thereof, as described herein.
Indications
Compounds of the present invention would be useful for, but not limited to, the prevention or treatment of EGFR mutant-mediated diseases. The compounds of the invention have kinase inhibitory activity, such as T790M inhibitory activity.
Compounds of the invention are useful for the treatment of neoplasia including cancer and metastasis, including, but not limited to: carcinoma such as cancer of solid tumors, for example breast, lung, head and neck, bladder cancers.
Besides being useful for human treatment, these compounds are also useful for veterinary treatment of companion animals, exotic animals and farm animals, including mammals, rodents, and the like. More preferred animals include horses, dogs, and cats.
The present invention includes all pharmaceutically acceptable isotopically- labelled compounds of the present invention wherein one or more atoms are replaced by atoms having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number which predominates in nature.
Examples of isotopes suitable for inclusion in the compounds of the invention include, but are not limited to, isotopes of hydrogen, such as 2H and 3H, carbon, such as nC, 13C and 14C, chlorine, such as 38C1, fluorine, such as 18F, iodine, such as 123I and 125I, nitrogen, such as 13N and 15N, oxygen, such as 150, 170 and lsO, phosphorus, such as 32P, and sulphur, such as 35 S.
Certain isotopically-labelled compounds of the present invention, for example, those incorporating a radioactive isotope, are useful in drug and/or substrate tissue distribution studies. The radioactive isotopes tritium, i.e. 3H, and carbon-14, i.e. 14C, are particularly useful for this purpose in view of their ease of incorporation and ready means of detection.
Substitution with heavier isotopes such as deuterium, i.e. 2H, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances.
Substitution with positron emitting isotopes, such as 11 C, 18 F, 15 O and 13 N, can be useful in Positron Emission Topography (PET) studies for examining substrate receptor occupancy.
Isotopically -labeled compounds of the present invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples and Preparations using an appropriate isotopically-labeled reagent in place of the non-labeled reagent previously employed.
As used herein, the compounds of the present invention include the
pharmaceutically acceptable derivatives thereof.
Definitions
The term "treatment" includes therapeutic treatment as well as prophylactic treatment (either preventing the onset of disorders altogether or delaying the onset of a preclinically evident stage of disorders in individuals).
The term "prevention" includes either preventing the onset of
disorders altogether or delaying the onset of a preclinically evident stage of
disorders in individuals. This includes prophylactic treatment of those at risk of developing a disease, such as a cancer, for example. "Prophylaxis" is
another term for prevention.
A "pharmaceutically-acceptable derivative" denotes any salt, ester of a compound of this invention, or any other compound which upon administration to a patient is capable of providing (directly or indirectly) a compound of this invention, or a metabolite or residue thereof, characterized by being therapeutically effective in vivo.
The phrase "therapeutically-effective" is intended to qualify the amount of each agent, which will achieve the goal of improvement in disorder severity and the frequency of incidence over treatment of each agent by itself, while avoiding adverse side effects typically associated with alternative therapies. For example, effective neoplastic therapeutic agents prolong the survivability of the patient, inhibit the rapidly-proliferating cell growth associated with the neoplasm, or effect a regression of the neoplasm.
The term "H" denotes a single hydrogen atom. This radical may be attached, for example, to an oxygen atom to form a hydro xyl radical.
Where the term "alkyl" is used, either alone or within other terms such as "haloalkyl" and "alkylamino", it embraces linear or branched radicals having one to about twelve carbon atoms. More preferred alkyl radicals are "lower alkyl" radicals having one to about six carbon atoms. Examples of such radicals include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, teri-butyl, pentyl, isoamyl, hexyl and the like.
Even more preferred are lower alkyl radicals having one or two carbon atoms. The term "alkylenyl" embraces bridging divalent alkyl radicals such as methylenyl and ethylenyl.
The term "halo" means halogens such as fluorine, chlorine, bromine or iodine atoms.
The term "haloalkyl" embraces radicals wherein any one or more of the alkyl carbon atoms is substituted with halo as defined above. Specifically embraced are monohaloalkyl, dihaloalkyl and polyhaloalkyl radicals. A monohaloalkyl radical, for one example, may have either an iodo, bromo, chloro or fluoro atom within the radical. Dihalo and polyhaloalkyl radicals may have two or more of the same halo atoms or a combination of different halo radicals. "Lower haloalkyl" embraces radicals having 1-6 carbon atoms. Even more preferred are lower haloalkyl radicals having one to three carbon atoms. Examples of haloalkyl radicals include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl and dichloropropyl. "Perfluoroalkyl" means alkyl radicals having all hydrogen atoms replaced with fluoro atoms. Examples include trifluoromethyl and pentafluoroethyl.
The term "hydroxyalkyl" embraces linear or branched alkyl radicals having one to about ten carbon atoms any one of which may be substituted with one or more hydroxyl radicals. More preferred hydroxyalkyl radicals are "lower hydroxyalkyl" radicals having one to six carbon atoms and one or more hydroxyl radicals. Examples of such radicals include hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl and hydroxyhexyl. Even more preferred are lower hydroxyalkyl radicals having one to three carbon atoms.
The term "alkoxy" embrace linear or branched oxy-containing radicals each having alkyl portions of one to about ten carbon atoms. More preferred alkoxy radicals are "lower alkoxy" radicals having one to six carbon atoms. Examples of such radicals include methoxy, ethoxy, propoxy, butoxy and teri-butoxy. Even more preferred are lower alkoxy radicals having one to three carbon atoms. Alkoxy radicals may be further substituted with one or more halo atoms, such as fluoro, chloro or bromo, to provide "haloalkoxy" radicals. Even more preferred are lower haloalkoxy radicals having one to three carbon atoms. Examples of such radicals include fluoromethoxy, chloromethoxy, trifluoromethoxy, trifluoroethoxy, fluoroethoxy and fluoropropoxy.
The term "aryl", alone or in combination, means a carbocyclic aromatic system containing one or two rings wherein such rings may be attached together in a fused manner. The term "aryl" embraces aromatic radicals such as phenyl, naphthyl, indenyl, tetrahydronaphthyl, and indanyl. More preferred aryl is phenyl. Said "aryl" group may have 1 to 3 substituents such as lower alkyl, hydroxyl, halo, haloalkyl, nitro, cyano, alkoxy and lower alkylamino.
The term "heterocyclyl" embraces saturated, partially saturated and unsaturated heteroatom-containing ring-shaped radicals, where the heteroatoms may be selected from nitrogen, sulfur and oxygen. It does not include rings containing -Ο-Ο-,-Ο-S- or -S-S- portions. Said "heterocyclyl" group may have 1 to 3 substituents such as hydroxyl, halo, haloalkyl, cyano, lower alkyl, lower aralkyl, oxo, lower alkoxy, amino and lower alkylamino.
Examples of saturated heterocyclic radicals include saturated 3 to 6-membered heteromonocyclic group containing 1 to 4 nitrogen atoms [e.g. pyrrolidinyl, imidazolidinyl, piperidinyl, pyrrolinyl, piperazinyl]; saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms [e.g. morpholinyl]; saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms [e.g., thiazolidinyl]. Examples of partially saturated heterocyclyl radicals include dihydrothienyl, dihydropyranyl, dihydrofuryl and dihydrothiazolyl. Examples of unsaturated heterocyclic radicals, also termed "heteroaryl" radicals, include unsaturated 5 to 6 membered heteromonocyclyl group containing 1 to 4 nitrogen atoms, for example, pyrrolyl, imidazolyl, pyrazolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazolyl [e.g., 4H-l,2,4-triazolyl, lH-l,2,3-triazolyl, 2H-l,2,3-triazolyl]; unsaturated 5- to 6-membered heteromonocyclic group containing an oxygen atom, for example, pyranyl, 2-furyl, 3-furyl, etc.; unsaturated 5 to 6-membered heteromonocyclic group containing a sulfur atom, for example, 2-thienyl, 3-thienyl, etc.; unsaturated 5- to 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms, for example, oxazolyl, isoxazolyl, oxadiazolyl [e.g., 1,2,4- oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5 -oxadiazolyl]; unsaturated 5 to 6-membered heteromonocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms, for example, thiazolyl, thiadiazolyl [e.g., 1 ,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5- thiadiazolyl].
The term also embraces radicals where heterocyclic radicals are fused/condensed with aryl radicals: unsaturated condensed heterocyclic group containing 1 to 5 nitrogen atoms, for example, indolyl, isoindolyl, indolizinyl, benzimidazolyl, quinolyl, isoquinolyl, indazolyl, benzotriazolyl, tetrazolopyridazinyl [e.g., tetrazolo [1,5- b]pyridazinyl]; unsaturated condensed heterocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms [e.g. benzoxazolyl, benzoxadiazolyl]; unsaturated condensed heterocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms [e.g., benzothiazolyl, benzothiadiazolyl]. Preferred heterocyclic radicals include five to ten membered fused or unfused radicals. More preferred examples of heteroaryl radicals include quinolyl, isoquinolyl, imidazolyl, pyridyl, thienyl, thiazolyl, oxazolyl, furyl, and pyrazinyl. Other preferred heteroaryl radicals are 5- or 6-membered heteroaryl, containing one or two heteroatoms selected from sulfur, nitrogen and oxygen, selected from thienyl, furyl, pyrrolyl, indazolyl, pyrazolyl, oxazolyl, triazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, pyridyl, piperidinyl and pyrazinyl.
"Heterocycle" means a ring comprising at least one carbon atom and at least one other atom selected from N, O and S. Examples of heterocycles that may be found in the claims include, but are not limited to, the following:
The term "sulfonyl", whether used alone or linked to other terms such as alkylsulfonyl, denotes respectively divalent radicals -SO2-.
The terms "carboxy" or "carboxyl", whether used alone or with other terms, such as "carboxyalkyl", denotes -C02H.
The term "carbonyl", whether used alone or with other terms, such as
"aminocarbonyl", denotes -(C=0)-. The term "alkylamino" embraces "N-alkylamino" and "Ν,Ν-dialkylamino" where amino groups are substituted with one alkyl radical and with two alkyl radicals, respectively. More preferred alkylamino radicals are "lower alkylamino" radicals having one or two alkyl radicals of one to six carbon atoms, attached to a nitrogen atom. Even more preferred are lower alkylamino radicals having one to three carbon atoms. Suitable alkylamino radicals may be mono or dialkylamino such as N-methylamino, N- ethylamino, N,N-dimethylamino, Ν,Ν-diethylamino or the like.
The term "heterocyclylamino" embraces amino groups substituted with a heterocyclyl radical.
The term "alkylcarbonyl" denotes a carbonyl radical substituted with an alkyl group. Even more preferred are alkylcarbonyl radicals having alkyl lengths of one to four carbon atoms.
The term "alkoxycarbonyl" denotes an ester group, containing an alkoxy substituted carbonyl. Even more preferred are alkoxycarbonyl radicals having alkoxy lengths of one to four carbon atoms.
The term "haloalkylcarbonyl" denotes a carbonyl radical substituted with a haloalkyl group. Even more preferred are haloalkylcarbonyl radicals having haloalkyl lengths of one to four carbon atoms.
The term "hydroxyalkylcarbonyl" denotes a carbonyl radical substituted with an hydroxyalkyl group. Even more preferred are hydroxyalkylcarbonyl radicals having hydroxyalkyl lengths of one to four carbon atoms.
The term "alkylaminocarbonyl" denotes a carbonyl radical substituted with an alkylamino group. Even more preferred are alkylaminocarbonyl radicals having alkyl lengths of one to four carbon atoms.
The term "alkylsulfonyl" denotes a sulfonyl radical substituted with an alkyl group. Even more preferred are alkylsulfonyl radicals having alkyl lengths of one to four carbon atoms.
The term "aminosulfonyl" denotes a sulfonyl radical substituted with an amino group. This substituent is alternatively named sulfonamidyl or sulfamyl.
The term "sulfinyl", whether used alone or linked to other terms such as alkylsulfinyl, denotes respectively divalent radicals -SO-.
The term "oxo" represents the groups =0 (as in carbonyl).
The term "aralkyl" embraces aryl-substituted alkyl radicals. Preferable aralkyl radicals are "lower aralkyl" radicals having aryl radicals attached to alkyl radicals having one to six carbon atoms. Even more preferred are "phenylalkylenyl" attached to alkyl portions having one to three carbon atoms. Examples of such radicals include benzyl, diphenylmethyl and phenylethyl. The aryl in said aralkyl may be additionally substituted with halo, alkyl, alkoxy, halkoalkyl and haloalkoxy.
The term "heterocyclyloxy" embraces optionally substituted heterocyclyl radicals, as defined above, attached to an oxygen atom.
The term "heterocyclylalkylamino" embraces optionally substituted heterocyclyl radicals, as defined above, attached to an alkylamino group.
The term "alkylaminoalkyl" embraces alkyl radicals substituted with alkylamino radicals. More preferred alkylaminoalkyl radicals are "lower alkylaminoalkyl" radicals having alkyl radicals of one to six carbon atoms. Even more preferred are lower alkylaminoalkyl radicals having alkyl radicals of one to three carbon atoms. Suitable alkylaminoalkyl radicals may be mono or dialkyl substituted, such as N- methylaminomethyl, N,N-dimethyl-aminoethyl, Ν,Ν-diethylaminomethyl and the like.
The term "alkylaminoalkylamino" embraces alkylamino radicals, as defined above, attached to an alkylamino group.
The term "alkylaminoalkoxy" embraces alkylamino radicals, as defined above, attached to an alkoxy group.
The term "hydroxyalkylamino" denotes an amino radical substituted with an hydroxyalkyl group. Even more preferred are hydroxyalkylamino radicals having hydroxyalkyl lengths of one to four carbon atoms.
The term "alkoxyalkoxy" embraces alkoxy radicals attached through an oxygen atom to other alkoxy radicals, as described above. More preferred alkoxyalkoxy radicals are "lower alkoxyalkoxy " radicals having lower alkoxy radicals attached to other lower alkoxy radical.
The term "comprising" is meant to be open ended, including the indicated component but not excluding other elements.
"Saturated, partially-saturated or unsaturated" includes substituents saturated with hydrogens, substituents completely unsaturated with hydrogens and substituents partially saturated with hydrogens.
"Leaving group" generally refers to groups readily displaceable by a nucleophile, such as an amine, a thiol or an alcohol nucleophile. Such leaving groups are well known in the art. Examples of such leaving groups include, but are not limited to, N-hydroxysuccinimide, N-hydroxybenzotriazole, halides, triflates, tosylates and the like. Preferred leaving groups are indicated herein where appropriate.
"Protecting group" generally refers to groups well known in the art which are used to prevent selected reactive groups, such as carboxy, amino, hydroxy, mercapto and the like, from undergoing undesired reactions, such as nucleophilic, electrophilic, oxidation, reduction and the like. Preferred protecting groups are indicated herein where appropriate. Examples of amino protecting groups include, but are not limited to, aralkyl, substituted aralkyl, cycloalkenylalkyl and substituted cycloalkenyl alkyl, allyl, substituted allyl, acyl, alkoxycarbonyl, aralkoxycarbonyl, silyl and the like. Examples of aralkyl include, but are not limited to, benzyl, ortho-methylbenzyl, trityl and benzhydryl, which can be optionally substituted with halogen, alkyl, alkoxy, hydroxy, nitro, acylamino, acyl and the like, and salts, such as phosphonium and ammonium salts. Examples of aryl groups include phenyl, naphthyl, indanyl, anthracenyl, 9-(9-phenylfluorenyl), phenanthrenyl, durenyl and the like. Examples of cycloalkenylalkyl or substituted cycloalkylenylalkyl radicals, preferably have 6-10 carbon atoms, include, but are not limited to, cyclohexenyl methyl and the like. Suitable acyl, alkoxycarbonyl and aralkoxycarbonyl groups include benzyloxycarbonyl, t-butoxycarbonyl, iso- butoxycarbonyl, benzoyl, substituted benzoyl, butyryl, acetyl, trifluoroacetyl, trichloro acetyl, phthaloyl and the like. A mixture of protecting groups can be used to protect the same amino group, such as a primary amino group can be protected by both an aralkyl group and an aralkoxycarbonyl group. Amino protecting groups can also form a heterocyclic ring with the nitrogen to which they are attached, for example,
l,2-bis(methylene)benzene, phthalimidyl, succinimidyl, maleimidyl and the like and where these heterocyclic groups can further include adjoining aryl and cycloalkyl rings. In addition, the heterocyclic groups can be mono-, di- or tri-substituted, such as nitrophthalimidyl. Amino groups may also be protected against undesired reactions, such as oxidation, through the formation of an addition salt, such as hydrochloride, toluenesulfonic acid, trifluoroacetic acid and the like. Many of the amino protecting groups are also suitable for protecting carboxy, hydroxy and mercapto groups. For example, aralkyl groups. Alkyl groups are also suitable groups for protecting hydroxy and mercapto groups, such as tert-butyl.
Silyl protecting groups are silicon atoms optionally substituted by one or more alkyl, aryl and aralkyl groups. Suitable silyl protecting groups include, but are not limited to, trimethylsilyl, triethylsilyl, triisopropylsilyl, tert-butyldimethylsilyl, dimethylphenylsilyl, l,2-bis(dimethylsilyl)benzene, l,2-bis(dimethylsilyl)ethane and diphenylmethylsilyl. Silylation of an amino groups provide mono- or di-silylamino groups. Silylation of aminoalcohol compounds can lead to a Ν,Ν,Ο-trisilyl derivative. Removal of the silyl function from a silyl ether function is readily accomplished by treatment with, for example, a metal hydroxide or ammonium fluoride reagent, either as a discrete reaction step or in situ during a reaction with the alcohol group. Suitable silylating agents are, for example, trimethylsilyl chloride, tert-butyl-dimethylsilyl chloride, phenyldimethylsilyl chloride, diphenylmethyl silyl chloride or their combination products with imidazole or DMF. Methods for silylation of amines and removal of silyl protecting groups are well known to those skilled in the art. Methods of preparation of these amine derivatives from corresponding amino acids, amino acid amides or amino acid esters are also well known to those skilled in the art of organic chemistry including amino acid/amino acid ester or aminoalcohol chemistry.
Protecting groups are removed under conditions which will not affect the remaining portion of the molecule. These methods are well known in the art and include acid hydrolysis, hydrogenolysis and the like. A preferred method involves removal of a protecting group, such as removal of a benzyloxycarbonyl group by hydrogenolysis utilizing palladium on carbon in a suitable solvent system such as an alcohol, acetic acid, and the like or mixtures thereof. A t-butoxycarbonyl protecting group can be removed utilizing an inorganic or organic acid, such as HC1 or trifluoroacetic acid, in a suitable solvent system, such as dioxane or methylene chloride. The resulting amino salt can readily be neutralized to yield the free amine. Carboxy protecting group, such as methyl, ethyl, benzyl, tert-butyl, 4-methoxyphenylmethyl and the like, can be removed under hydrolysis and hydrogenolysis conditions well known to those skilled in the art.
The present invention also comprises the use of a compound of the invention, or pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment either acutely or chronically of an angiogenesis mediated disease state, including those described previously. The compounds of the present invention are useful in the manufacture of an anti-cancer medicament. The compounds of the present invention are also useful in the manufacture of a medicament to attenuate or prevent disorders through inhibition of EGFR mutants.
The present invention comprises a pharmaceutical composition comprising a therapeutically-effective amount of a compound of Formulas I-IVa in association with a least one pharmaceutically -acceptable carrier, adjuvant or diluent. The present invention also comprises a method of treating EGFR mutant related disorders, such as cancer in a subject, the method comprising treating the subject having or susceptible to such disorder with a therapeutically-effective amount of a compound of Formulas I-IVa. This includes first line therapies and second line therapies.
COMBINATIONS
While the compounds of the invention can be administered as the sole active pharmaceutical agent, they can also be used in combination with one or more compounds of the invention or other agents. When administered as a combination, the therapeutic agents can be formulated as separate compositions that are administered at the same time or sequentially at different times, or the therapeutic agents can be given as a single composition.
The phrase "co-therapy" (or "combination-therapy"), in defining use of a compound of the present invention and another pharmaceutical agent, is intended to embrace administration of each agent in a sequential manner in a regimen that will provide beneficial effects of the drug combination, and is intended as well to embrace coadministration of these agents in a substantially simultaneous manner, such as in a single capsule having a fixed ratio of these active agents or in multiple, separate capsules for each agent.
Specifically, the administration of compounds of the present invention may be in conjunction with additional therapies known to those skilled in the art in the prevention or treatment of neoplasia, such as with radiation therapy or with cytostatic or cytotoxic agents.
If formulated as a fixed dose, such combination products employ the compounds of this invention within the accepted dosage ranges. Compounds of Formula I may also be administered sequentially with known anticancer or cytotoxic agents when a combination formulation is inappropriate. The invention is not limited in the sequence of administration; compounds of Formula I may be administered either prior to, at the same time as, or after administration of the known anticancer or cytotoxic agent.
Currently, standard treatment of primary tumors consists of surgical excision followed by either radiation or IV administered chemotherapy. The typical chemotherapy regime consists of either DNA alkylating agents, DNA intercalating agents, CDK inhibitors, or microtubule poisons. The chemotherapy doses used are just below the maximal tolerated dose and therefore dose limiting toxicities typically include, nausea, vomiting, diarrhea, hair loss, neutropenia and the like.
There are large numbers of antineoplastic agents available in commercial use, in clinical evaluation and in pre-clinical development, which would be selected for treatment of neoplasia by combination drug chemotherapy. Such antineoplastic agents fall into several major categories, namely, antibiotic-type agents, alkylating agents, antimetabolite agents, hormonal agents, immunological agents, interferon-type agents and a category of miscellaneous agents.
A first family of antineoplastic agents which may be used in combination with compounds of the present invention consists of antimetabolite-type/thymidilate synthase inhibitor antineoplastic agents. Suitable antimetabolite antineoplastic agents may be selected from but not limited to the group consisting of 5 -FU- fibrinogen, acanthifolic acid, aminothiadiazole, brequinar sodium, carmofur, Ciba-Geigy CGP-30694, cyclopentyl cytosine, cytarabine phosphate stearate, cytarabine conjugates, Lilly DATHF, Merrel Dow DDFC, dezaguanine, dideoxycytidine, dideoxyguanosine, didox, Yoshitomi DMDC, doxifluridine, Wellcome EHNA, Merck & Co. EX-015, fazarabine, floxuridine, fludarabine phosphate, 5-fluorouracil, N-(2'-furanidyl)-5-fluorouracil, Daiichi Seiyaku FO-152, isopropyl pyrrolizine, Lilly LY-188011, Lilly LY-264618, methobenzaprim, methotrexate, Wellcome MZPES, norspermidine, NCI NSC-127716, NCI NSC-264880, NCI NSC-39661, NCI NSC-612567, Warner-Lambert PALA, pentostatin, piritrexim, plicamycin, Asahi Chemical PL-AC, Takeda TAC-788, thioguanine, tiazofurin, Erbamont TIF, trimetrexate, tyrosine kinase inhibitors, tyrosine protein kinase inhibitors, Taiho UFT and uricytin.
A second family of antineoplastic agents which may be used in combination with compounds of the present invention consists of alkylating-type antineoplastic agents. Suitable alkylating-type antineoplastic agents may be selected from but not limited to the group consisting of Shionogi 254-S, aldo-phosphamide analogues, altretamine, anaxirone, Boehringer Mannheim BBR-2207, bestrabucil, budotitane, Wakunaga CA-102, carboplatin, carmustine, Chinoin-139, Chinoin-153, chlorambucil, cisplatin,
cyclophosphamide, American Cyanamid CL-286558, Sanofi CY-233, cyplatate, Degussa D-19-384, Sumimoto DACHP(Myr)2, diphenylspiromustine, diplatinum cytostatic, Erba distamycin derivatives, Chugai DWA-2114R, ITI E09, elmustine, Erbamont FCE-24517, estramustine phosphate sodium, fotemustine, Unimed G-6-M, Chinoin GYKI-17230, hepsul-fam, ifosfamide, iproplatin, lomustine, mafosfamide, mitolactol, Nippon Kayaku NK-121, NCI NSC-264395, NCI NSC-342215, oxaliplatin, Upjohn PCNU,
prednimustine, Proter PTT-119, ranimustine, semustine, SmithKline SK&F-101772, Yakult Honsha SN-22, spiromus-tine, Tanabe Seiyaku TA-077, tauromustine, temozolomide, teroxirone, tetraplatin and trimelamol.
A third family of antineoplastic agents which may be used in combination with compounds of the present invention consists of antibiotic-type antineoplastic agents. Suitable antibiotic-type antineoplastic agents may be selected from but not limited to the group consisting of Taiho 4181-A, aclarubicin, actinomycin D, actinoplanone, Erbamont ADR-456, aeroplysinin derivative, Ajinomoto AN-201-II, Ajinomoto AN-3, Nippon Soda anisomycins, anthracycline, azino-mycin-A, bisucaberin, Bristol-Myers BL-6859, Bristol-Myers BMY-25067, Bristol-Myers BMY-25551, Bristol-Myers BMY-26605, Bristol-Myers BMY-27557, Bristol-Myers BMY-28438, bleomycin sulfate, bryostatin-1, Taiho C-1027, calichemycin, chromoximycin, dactinomycin, daunorubicin, Kyowa Hakko DC-102, Kyowa Hakko DC-79, Kyowa Hakko DC-88A, Kyowa Hakko DC89- Al, Kyowa Hakko DC92-B, ditrisarubicin B, Shionogi DOB-41, doxorubicin, doxorubicin-fibrinogen, elsamicin-A, epirubicin, erbstatin, esorubicin, esperamicin-Al, esperamicin-Alb, Erbamont FCE-21954, Fujisawa FK-973, fostriecin, Fujisawa FR- 900482, glidobactin, gregatin-A, grincamycin, herbimycin, idarubicin, illudins, kazusamycin, kesarirhodins, Kyowa Hakko KM-5539, Kirin Brewery KRN-8602, Kyowa Hakko KT-5432, Kyowa Hakko KT-5594, Kyowa Hakko KT-6149, American Cyanamid LL-D49194, Meiji Seika ME 2303, menogaril, mitomycin, mitoxantrone, SmithKline M- TAG, neoenactin, Nippon Kayaku NK-313, Nippon Kayaku NKT-01 , SRI International NSC-357704, oxalysine, oxaunomycin, peplomycin, pilatin, pirarubicin, porothramycin, pyrindanycin A, Tobishi RA-I, rapamycin, rhizoxin, rodorubicin, sibanomicin, siwenmycin, Sumitomo SM-5887, Snow Brand SN-706, Snow Brand SN-07, sorangicin- A, sparsomycin, SS Pharmaceutical SS-21020, SS Pharmaceutical SS-7313B, SS Pharmaceutical SS-9816B, steffimycin B, Taiho 4181-2, talisomycin, Takeda TAN- 868A, terpentecin, thrazine, tricrozarin A, Upjohn U-73975, Kyowa Hakko UCN- 10028A, Fujisawa WF-3405, Yoshitomi Y-25024 and zorubicin.
A fourth family of antineoplastic agents which may be used in combination with compounds of the present invention consists of a miscellaneous family of antineoplastic agents, including tubulin interacting agents, topoisomerase II inhibitors, topoisomerase I inhibitors and hormonal agents, selected from but not limited to the group consisting of a-carotene, a-difluoromethyl-arginine, acitretin, Biotec AD-5, Kyorin AHC-52, alstonine, amonafide, amphethinile, amsacrine, Angiostat, ankinomycin, anti-neoplaston A10, antineoplaston A2, antineoplaston A3, antineoplaston A5, antineoplaston AS2-1, Henkel APD, aphidicolin glycinate, asparaginase, Avarol, baccharin, batracylin, benfluron, benzotript, Ipsen-Beaufour BIM-23015, bisantrene, Bristo-Myers BMY- 40481, Vestar boron-10, bromofosfamide, Wellcome BW-502, Wellcome BW-773, caracemide, carmethizole hydrochloride, Ajinomoto CDAF, chlorsulfaquinoxalone, Chemes CHX-2053, Chemex CHX-100, Warner-Lambert CI-921, Warner-Lambert CI- 937, Warner-Lambert CI-941, Warner-Lambert CI-958, clanfenur, claviridenone, ICN compound 1259, ICN compound 4711, Contracan, Yakult Honsha CPT-11, crisnatol, curaderm, cytochalasin B. cytarabine, cytocytin, Merz D-609, DABIS maleate, dacarbazine, datelliptinium, didemnin-B, dihaematopo hyrin ether, dihydrolenperone, dinaline, distamycin, Toyo Pharmar DM-341, Toyo Pharmar DM-75, Daiichi Seiyaku DN-9693, docetaxel elliprabin, elliptinium acetate, Tsumura EPMTC, the epothilones,_ ergotamine, etoposide, etretinate, fenretinide, Fujisawa FR-57704, gallium nitrate, genkwadaphnin, Chugai GLA-43, Glaxo GR-63178, grifolan NMF-5N,
hexadecylphosphocholine, Green Cross HO-221, homoharringtonine, hydroxyurea, BTG ICRF-187, ilmofosine, isoglutamine, isotretinoin, Otsuka JI-36, Ramot K-477, Otsuak K- 76COONa, Kureha Chemical K-AM, MECT Corp KI-8110, American Cyanamid L-623, leukoregulin, lonidamine, Lundbeck LU-23-112, Lilly LY-186641, NCI (US) MAP, marycin, Merrel Dow MDL-27048, Medco MEDR-340, merbarone, merocyanlne derivatives, methylanilinoacridine, Molecular Genetics MGI-136, minactivin, mitonafide, mitoquidone mopidamol, motretinide, Zenyaku Kogyo MST-16, N-(retinoyl)amino acids, Nisshin Flour Milling N-021, N-acylated-dehydroalanines, nafazatrom, Taisho NCU-190, nocodazole derivative, Normosang, NCI NSC-145813, NCI NSC-361456, NCI NSC- 604782, NCI NSC-95580, ocreotide, Ono ONO-112, oquizanocine, Akzo Org-10172, paclitaxel, pancratistatin, pazelliptine, Warner-Lambert PD-111707, Warner-Lambert PD-115934, Warner-Lambert PD-131141, Pierre Fabre PE-1001, ICRT peptide D, piroxantrone, polyhaematoporphyrin, polypreic acid, Efamol porphyrin, probimane, procarbazine, proglumide, Invitron protease nexin I, Tobishi RA-700, razoxane, Sapporo Breweries RBS, restrictin-P, retelliptine, retinoic acid, Rhone-Poulenc RP-49532, Rhone- Poulenc RP-56976, SmithKline SK&F-104864, Sumitomo SM-108, Kuraray SMANCS, SeaPharm SP-10094, spatol, spirocyclopropane derivatives, spirogermanium, Unimed, SS Pharmaceutical SS-554, strypoldinone, Stypoldione, Suntory SUN 0237, Suntory SUN 2071, superoxide dismutase, Toyama T-506, Toyama T-680, taxol, Teijin TEI-0303, teniposide, thaliblastine, Eastman Kodak TJB-29, tocotrienol, topotecan, Topostin, Teijin TT-82, Kyowa Hakko UCN-01, Kyowa Hakko UCN-1028, ukrain, Eastman Kodak USB- 006, vinblastine sulfate, vincristine, vindesine, vinestramide, vinorelbine, vintriptol, vinzolidine, withanolides and Yamanouchi YM-534.
Alternatively, the present compounds may also be used in co-therapies with other anti-neoplastic agents, such as acemannan, aclarubicin, aldesleukin, alemtuzumab, alitretinoin, altretamine, amifostine, aminolevulinic acid, amrubicin, amsacrine, anagrelide, anastrozole, ANCER, ancestim, ARGLABIN, arsenic trioxide, BAM 002 (Novelos), bexarotene, bicalutamide, broxuridine, capecitabine, celmoleukin, cetrorelix, cladribine, clotrimazole, cytarabine ocfosfate, DA 3030 (Dong-A), daclizumab, denileukin diftitox, deslorelin, dexrazoxane, dilazep, docetaxel, docosanol,
doxercalciferol, doxifluridine, doxorubicin, bromocriptine, carmustine, cytarabine, fluorouracil, HIT diclofenac, interferon alfa, daunorubicin, doxorubicin, tretinoin, edelfosine, edrecolomab, eflornithine, emitefur, epirubicin, epoetin beta, etoposide phosphate, exemestane, exisulind, fadrozole, filgrastim, finasteride, fludarabine phosphate, formestane, fotemustine, gallium nitrate, gemcitabine, gemtuzumab zogamicin, gimeracil/oteracil/tegafur combination, glycopine, goserelin, heptaplatin, human chorionic gonadotropin, human fetal alpha fetoprotein, ibandronic acid, idarubicin, (imiquimod, interferon alfa, interferon alfa, natural, interferon alfa-2, interferon alfa-2a, interferon alfa-2b, interferon alfa-Nl, interferon alfa-n3, interferon alfacon-1, interferon alpha, natural, interferon beta, interferon beta-la, interferon beta-lb, interferon gamma, natural interferon gamma-la, interferon gamma-lb, interleukin-1 beta, iobenguane, irinotecan, irsogladine, lanreotide, LC 9018 (Yakult), leflunomide, lenograstim, lentinan sulfate, letrozole, leukocyte alpha interferon, leuprorelin, levamisole + fluorouracil, liarozole, lobaplatin, lonidamine, lovastatin, masoprocol, melarsoprol, metoclopramide, mifepristone, miltefosine, mirimostim, mismatched double stranded RNA, mitoguazone, mitolactol, mitoxantrone, molgramostim, nafarelin, naloxone + pentazocine, nartograstim, nedaplatin, nilutamide, noscapine, novel erythropoiesis stimulating protein, NSC 631570 octreotide, oprelvekin, osaterone, oxaliplatin, paclitaxel, pamidronic acid, pegaspargase, peginterferon alfa-2b, pentosan polysulfate sodium, pentostatin, picibanil, pirarubicin, rabbit antithymocyte polyclonal antibody, polyethylene glycol interferon alfa-2a, porfimer sodium, raloxifene, raltitrexed, rasburicase, rhenium Re 186 etidronate, RII retinamide, rituximab, romurtide, samarium (153 Sm) lexidronam, sargramostim, sizofiran, sobuzoxane, sonermin, strontium-89 chloride, suramin, tasonermin, tazarotene, tegafur, temoporfin, temozolomide, teniposide, tetrachlorodecaoxide, thalidomide, thymalfasin, thyrotropin alfa, topotecan, toremifene, tositumomab-iodine 131, trastuzumab, treosulfan, tretinoin, trilostane, trimetrexate, triptorelin, tumor necrosis factor alpha, natural, ubenimex, bladder cancer vaccine, Maruyama vaccine, melanoma lysate vaccine, valrubicin, verteporfin, vinorelbine, VIRULIZIN, zinostatin stimalamer, or zoledronic acid; abarelix; AE 941 (Aeterna), ambamustine, antisense oligonucleotide, bcl-2 (Genta), APC 8015 (Dendreon), cetuximab, decitabine, dexaminoglutethimide, diaziquone, EL 532 (Elan), EM 800 (Endorecherche), eniluracil, etanidazole, fenretinide, filgrastim SD01 (Amgen), fulvestrant, galocitabine, gastrin 17 immunogen, HLA-B7 gene therapy (Vical), granulocyte macrophage colony stimulating factor, histamine dihydrochloride, ibritumomab tiuxetan, ilomastat, IM 862 (Cytran), interleukin-2, iproxifene, LDI 200 (Milkhaus), leridistim, lintuzumab, CA 125 MAb (Biomira), cancer MAb (Japan Pharmaceutical Development), HER-2 and Fc MAb (Medarex), idiotypic 105 AD7 MAb (CRC Technology), idiotypic CEA MAb (Trilex), LYM- 1 -iodine 131 MAb
(Techniclone), polymorphic epithelial mucin-yttrium 90 MAb (Antisoma), marimastat, menogaril, mitumomab, motexafm gadolinium, MX 6 (Galderma), nelarabine, nolatrexed, P 30 protein, pegvisomant, pemetrexed, porfiromycin, prinomastat, RL 0903 (Shire), rubitecan, satraplatin, sodium phenylacetate, sparfosic acid, SRL 172 (SR Pharma), SU 5416 (SUGEN), TA 077 (Tanabe), tetrathiomolybdate, thaliblastine, thrombopoietin, tin ethyl etiopurpurin, tirapazamine, cancer vaccine (Biomira), melanoma vaccine (New York University), melanoma vaccine (Sloan Kettering
Institute), melanoma oncolysate vaccine (New York Medical College), viral melanoma cell lysates vaccine (Royal Newcastle Hospital), or valspodar.
Alternatively, the present compounds may also be used in co-therapies with other anti-neoplastic agents, such as other kinase inhibitors, TNF inhibitors, metallomatrix proteases inhibitors (MMP) and VEGFR inhibitors.
When the compositions of this invention comprise a combination of a kinase inhibitor of the Formulas described herein and one or more additional therapeutic or prophylactic agents, both the kinase inhibitor and the additional agent should be present at dosage levels of between about 10 to 100%, and more preferably between about 10 to 80% of the dosage normally administered in a monotherapy regimen. Such additional kinase inhibitory agents were those which may modulate, regulate or otherwise affect kinase enzyme activity. Such effects may lead to modulation of disease pathology and/or symptoms. Kinase inhibitory agents include, for example, small molecules, polypeptides, antibodies (including for example, monoclonals, chimeric, humanized, single chain, immunokines, etc.), and the like. Examples of additional kinase inhibitory small molecule agents include, but were not limited to, CDK inhibitors and p38 inhibitors, including SU- 6668, SU-5416, ZD-4190, ZD-1839, STI-571, CP-358774, LY-333531 and the like.
The pharmaceutical compositions of this invention comprise an additional immunosuppression agent. Examples of additional immunosuppression agents include, but were not limited to, cyclosporin A, FK506, rapamycin, leflunomide, deoxyspergualin, prednisone, azathioprine, mycophenolate mofetil, OKT3, ATAG, interferon and mizoribine.
The pharmaceutical compositions of this invention may additionally comprise antibodies (including for example, monoclonals, chimeric, humanized, single chain, immunokines, etc.), cytotoxic or hormonal anti-cancer agents or combinations thereof.
The present invention comprises a process for the preparation of a compound of Formulas I-IVa.
Compounds of the present invention can possess, in general, one or more asymmetric carbon atoms and are thus capable of existing in the form of optical isomers as well as in the form of racemic or non-racemic mixtures thereof. The optical isomers can be obtained by resolution of the racemic mixtures according to conventional processes, e.g., by formation of diastereoisomeric salts, by treatment with an optically active acid or base. Examples of appropriate acids are tartaric, diacetyltartaric, dibenzoyltartaric, ditoluoyltartaric, and camphorsulfonic acid and then separation of the mixture of diastereoisomers by crystallization followed by liberation of the optically active bases from these salts. A different process for separation of optical isomers involves the use of a chiral chromatography column optimally chosen to maximize the separation of the enantiomers. Still another available method involves synthesis of covalent diastereoisomeric molecules by reacting compounds of the invention with an optically pure acid in an activated form or an optically pure isocyanate. The synthesized diastereoisomers can be separated by conventional means such as chromatography, distillation, crystallization or sublimation, and then hydro lyzed to deliver the enantiomerically pure compound. The optically active compounds of the invention can likewise be obtained by using active starting materials. These isomers may be in the form of a free acid, a free base, an ester or a salt. Also included in the family of compounds of Formulas I-IVa are the pharmaceutically-acceptable salts thereof. The term "pharmaceutically-acceptable salts" embraces salts commonly used to form alkali metal salts and to form addition salts of free acids or free bases. The nature of the salt is not critical, provided that it is
pharmaceutically-acceptable. Suitable pharmaceutically-acceptable acid addition salts of compounds of Formulas I-IVa may be prepared from an inorganic acid or from an organic acid. Examples of such inorganic acids are hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuric and phosphoric acid. Appropriate organic acids may be selected from aliphatic, cycloaliphatic, aromatic, arylaliphatic, heterocyclic, carboxylic and sulfonic classes of organic acids, example of which are acetic, adipic, algenic, anthranilic, ascorbic, aspartic, benzoic, benzenesulfonic, butyric, camphoric, camphorsulfonic, citric, cyclopentanepropionic, cyclohexylaminosulfonic, digluconic, dodecylsulfonic, ethanesulfonic, formic, fumaric, galactaric, galacturonic, glycolic, gluconic, glucuronic, glucoheptanoic, glutamic, glycerophosphonic, heptanoic, hexanoic, 4-hydroxybenzoic, 2 -hydroxy ethanesulfonic, β-hydroxybutyric, lactic, malic, maleic, mandelic, mesylic, methanesulfonic, nicotinic, 2-naphthalenesulfonic, oxalic, palmoic, pectinic, pivalic, persulfuric, 2-phenylpropionic, picric, pyruvic, propionic, phenylacetic, embonic (pamoic), cyclopentane proprionic, pantothenic, toluenesulfonic, salicylic, sulfanilic, stearic, succinic, tartaric, thiocyanic, and undecanoic.
Suitable pharmaceutically-acceptable base addition salts of compounds of
Formulas I-IVa include metallic salts, such as salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc, or salts made from organic bases including primary, secondary and tertiary amines, substituted amines including cyclic amines, such as caffeine, arginine, diethylamine, N-ethyl piperidine, histidine, glucamine, isopropylamine, lysine, morpholine, N-ethyl morpholine, piperazine, piperidine, triethylamine, trimethylamine. All of these salts may be prepared by conventional means from the corresponding compound of the invention by reacting, for example, the appropriate acid or base with the compound of Formulas I-IVa.
Also, the basic nitrogen-containing groups can be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl, and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides, and others. Water or oil-soluble or dispersible products are thereby obtained. Additional examples of such salts can be found in Berge et al., J. Pharm. Sci., 66, 1 (1977).
The invention also relates to a method of making a compound of the formulas described herein, comprising synthesizing any one or more intermediates illustrated in the synthetic schemes herein and then converting that intermediate(s) to a compound of the formulas described herein. The invention also relates to a method of making a compound of the formulas described herein, comprising synthesizing any one or more intermediates illustrated in the examples herein and then converting that intermediate(s) to a compound of the formulas described herein.
GENERAL SYNTHETIC PROCEDURES
The compounds of the invention can be synthesized according to the following procedures of Schemes l-3a, wherein the substituents are as defined for Formulas I-IVa, above, except where further noted.
The following abbreviations are used:
RT room temperature
MCPBA 3-chloroperoxybenzoic acid
DCM, CH2C12 dichloromethane
DIEA, EtNiPr2 diisopropylethylamine, Hunig's base
DMF dimethylformamide
DMSO dimethylsulfoxide
K2CO3 potassium carbonate
AcCN, ACN acetonitrile
TFA trifluoroacetic acid
HC1 hydrochloric acid
HOAc, AcOH acetic acid
LiAlFLt lithium aluminum hydride
THF tetrahydrofuran
CHC13 Chloroform
CDCI3 Deuterated chloroform
EtOAc ethyl acetate
Na2S04 sodium sulfate
LiHMDS Lithium bis(trimethylsilyl)amide mg milligram g gram
ml milliliter h hour
min minutes
Et20 ethyl ether
MgS04 magnesium sulfate
NH4C1 ammonium chloride
H20 water
NaHC03 sodium bicarbonate
Na2C03 sodium carbonate
Na2S04 sodium sulfate
MeOH methanol
Boc feri-butyloxycarbonyl
NaOH sodium hydroxide
NaH sodium hydride
Cul copper iodide
NH3 ammonia
EtOH ethanol
Et3N triethylamine
Pd/C- palladium on carbon
NMP N-methylpyrrolidinyl
Cs2C03 cesium carbonate
H2 hydrogen
Mn02 manganese oxide iPOH isopropanol
Scheme 1
Acrylamide substituted 7-oxo-pyrido[2,3-d]pyrimidines can be prepared according to the methods set out in Scheme 1. 2-(Methylthio)-7-oxopyrido[2,3- djpyrimidines (I) is treated with an oxidizing agent such as MCPBA, in an appropriate solvent such as in DCM, to furnish 2-(methylsulfonyl)-7-oxopyrido[2,3-d]pyrimidines (II). The 2-(methylsulfonyl)-7-oxopyrido[2,3-d]pyrimidines (II) is treated with a base, such as with DIEA, and heated at a temperature above RT, preferably above about 50 °C, more preferably at about 80 °C to yield the amino substituted 7-oxopyrido[2,3- d]pyrimidines (III). Deprotection, such as with treatment with acid, followed by treatment with an unsaturated acid chloride, such as acryloyl chloride yields the desired product (IV).
Alternatively, the acrylamide (V) is formed from the starting material (I) by a method similar to that described above. The 2-(methylthio)-7-oxopyrido[2,3- djpyrimidinyl acrylamides (V) can be oxidized, by a method similar to that described above followed by amination to yield the desired product (IV). Scheme 2
Acrylamide substituted 7-oxo-pyrido[2,3-d]pyrimidines can be prepared from the di-Boc protected compound, according to the method set out in Scheme 2. The 2- (methylsulfonyl)-7-oxopyrido[2,3-d]pyrimidines (57) is treated with a base, such as with DIEA, and heated at a temperature above RT, preferably above about 50 °C, more preferably at about 80 °C to yield the amino substituted 7-oxopyrido[2,3-d]pyrimidines (VII). Deprotection, such as with treatment with acid, followed by treatment with an unsaturated acid chloride, such as acryloyl chloride yields the desired product (IV).
Scheme la
Acrylamide substituted 7-oxo-pyrido[2,3-d]pyrimidines can be prepared according to the methods set out in Scheme la. The protected (3-(-2-(methylthio)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)amine (Ix) was deprotected, such as by treatment with acid, such as TFA, to form the free amine. Treatment with base, such as with DIPEA, followed by addition of an acyl chloride, such as acryloyl chloride, provides the desired acrylamide. Oxidation of the sulfide, such as with MCPBA, yields the sulfinyl derivative (IIx). Treatment of sulfinyl IIx with a substituted amine, in the presence of acid, such as TFA, or DMAc, at a temperature above RT, preferably above about 50 °C and more preferably at about 90-110 °C provides the desired 7- oxopyrido [2,3 -d]pyrimidines (IIIx). Scheme 2 a
Acrylamide substituted 7-oxo-pyrido[2,3-d]pyrimidines can be prepared according to the methods set out in Scheme 2a. The protected (3-(-2-(methylthio)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)amine (Ix) was deprotected, such as by treatment with acid, such as HC1, to form the free amine. Treatment with base, such as with NaOH, followed by addition of an acyl chloride, such as acryloyl chloride, provides the desired acrylamide Vx. Treatment of acrylamide Vx with a substituted amine, in the presence of acid, such as AcOH, at a temperature above RT, preferably above about 70 °C and more preferably at about 125 °C. provides the desired 7-oxopyrido[2,3- d]pyrimidines (IIIx).
Scheme 3 a
A solution of protected (R)- 3-((2-chloro-5-methyl-7-oxopyrido[2,3-d]pyrimidin- 8(7H)-yl)methyl)pyrrolidine is treated with deprotected, such as with acid, for example TFA, yields the free amine. Treated with base, such as DIPEA and an acyl chloride at a temperature below RT, preferably at about 0 °C affords the acrylamide derivative VIIx. The desired compounds of the invention VIIIx are prepared by coupling of the acrylamide derivative VIIx with a substituted amine. One example of such coupling involves heating the reactants in the presence of acid, such as TFA, at a temperature above RT, preferably above about 50 °C and more preferably at about 100 °C.
The starting compounds defined in Schemes l-3a may also be present with functional groups in protected form if necessary and/or in the form of salts, provided a salt- forming group is present and the reaction in salt form is possible. If so desired, one compound of formula I can be converted into another compound of formula I or a N- oxide thereof; a compound of formula I can be converted into a salt; a salt of a compound of formula I can be converted into the free compound or another salt; and/or a mixture of isomeric compounds of formula I can be separated into the individual isomers.
N-Oxides can be obtained in a known manner by reacting a compound of formula I with hydrogen peroxide or a peracid, e.g. 3-chloroperoxy-benzoic acid, in an inert solvent, e.g. CH2C12, at a temperature between about -10 to about 35°C, such as about 0°C to about RT.
If one or more other functional groups, for example carboxy, hydroxy, amino, or mercapto, are or need to be protected in a compound of Formulas I-IVa, because they should not take part in the reaction, these are such groups as are usually used in the synthesis of peptide compounds, and also of cephalosporins and penicillins, as well as nucleic acid derivatives and sugars.
The protecting groups may already be present in precursors and should protect the functional groups concerned against unwanted secondary reactions, such as acylations, etherifications, esterifications, oxidations, solvolysis, and similar reactions. It is a characteristic of protecting groups that they lend themselves readily, i.e. without undesired secondary reactions, to removal, typically by solvolysis, reduction, photolysis or also by enzyme activity, for example under conditions analogous to physiological conditions, and that they are not present in the end-products. The specialist knows, or can easily establish, which protecting groups are suitable with the reactions mentioned above and hereinafter.
The protection of such functional groups by such protecting groups, the protecting groups themselves, and their removal reactions are described for example in standard reference works, such as J. F. W. McOmie, "Protective Groups in Organic Chemistry", Plenum Press, London and New York 1973, in T. W. Greene, "Protective Groups in Organic Synthesis", Wiley, New York 1981, in "The Peptides"; Volume 3 (editors: E. Gross and J. Meienhofer), Academic Press, London and New York 1981, in "Methoden der organischen Chemie" (Methods of organic chemistry), Houben Weyl, 4th edition, Volume 15/1, Georg Thieme Verlag, Stuttgart 1974, in H.-D. Jakubke and H. Jescheit, "Aminosauren, Peptide, Proteine" (Amino acids, peptides, proteins), Verlag Chemie, Weinheim, Deerfield Beach, and Basel 1982, and in Jochen Lehmann, "Chemie der Kohlenhydrate: Monosaccharide und Derivate" (Chemistry of carbohydrates:
monosaccharides and derivatives), Georg Thieme Verlag, Stuttgart 1974.
In the additional process steps, carried out as desired, functional groups of the starting compounds which should not take part in the reaction may be present in unprotected form or may be protected for example by one or more of the protecting groups mentioned above under "protecting groups". The protecting groups are then wholly or partly removed according to one of the methods described there.
Salts of a compound of formula I with a salt-forming group may be prepared in a manner known per se. Acid addition salts of compounds of formula I may thus be obtained by treatment with an acid or with a suitable anion exchange reagent. A salt with two acid molecules (for example a dihalogenide of a compound of formula I) may also be converted into a salt with one acid molecule per compound (for example a
monohalogenide); this may be done by heating to a melt, or for example by heating as a solid under a high vacuum at elevated temperature, for example from about 130°C to about 170°C, one molecule of the acid being expelled per molecule of a compound of formula I.
Salts can usually be converted to free compounds, e.g. by treating with suitable basic agents, for example with alkali metal carbonates, alkali metal hydrogen carbonates, or alkali metal hydroxides, typically K2CO3 or NaOH.
All process steps described here can be carried out under known reaction conditions, preferably under those specifically mentioned, in the absence of or usually in the presence of solvents or diluents, preferably such as are inert to the reagents used and able to dissolve these, in the absence or presence of catalysts, condensing agents or neutralizing agents, for example ion exchangers, typically cation exchangers, for example in the H+ form, depending on the type of reaction and/or reactants at reduced, normal, or elevated temperature, for example in the range from about -100°C to about 190°C, preferably from about -80°C to about 150°C, for example at about -80°C to about 60°C, at RT, at about -20°C to about 40°C or at the boiling point of the solvent used, under atmospheric pressure or in a closed vessel, where appropriate under pressure, and/or in an inert atmosphere, for example under argon or nitrogen. Salts may be present in all starting compounds and transients, if these contain salt-forming groups. Salts may also be present during the reaction of such compounds, provided the reaction is not thereby disturbed.
The solvents from which those can be selected which are suitable for the reaction in question include for example water, esters, e.g EtOAc, ethers, typically aliphatic ethers, e.g. Et20, or cyclic ethers, e.g. THF, liquid aromatic hydrocarbons, typically benzene or toluene, alcohols, typically MeOH, EtOH, iPOH or 1-propanol, nitriles, typically AcCN, halogenated hydrocarbons, typically CH2C12, amides, e.g. DMF, bases, typically heterocyclic nitrogen bases, e.g. pyridine, carboxylic acids, typically lower alkanecarboxylic acids, e.g. HO Ac, carboxylic acid anhydrides, typically lower alkane acid anhydrides, e.g. acetic anhydride, cyclic, linear, or branched hydrocarbons, typically cyclohexane, hexane, or isopentane, or mixtures of these solvents, e.g. aqueous solutions, unless otherwise stated in the description of the process.
The invention relates also to those forms of the process in which one starts from a compound obtainable at any stage as a transient and carries out the missing steps, or breaks off the process at any stage, or forms a starting material under the reaction conditions, or uses said starting material in the form of a reactive derivative or salt, or produces a compound obtainable by means of the process according to the invention and processes the said compound in situ. In the preferred embodiment, one starts from those starting materials which lead to the compounds described above as preferred.
A compound of any of the formulas delineated herein may be synthesized according to any of the processes delineated herein. In the processes delineated herein, the steps may be performed in an alternate order and may be preceded, or followed, by additional protection/deprotection steps as necessary. The processes may further comprise use of appropriate reaction conditions including inert solvents, additional reagents, such as bases (e.g., LDA, DIEA, pyridine, K2C03, and the like), catalysts, and salt forms of the above. The intermediates may be isolated or carried on in situ, with or without purification. Purification methods are known in the art and include, for example, crystallization, chromatography (liquid and gas phase, simulated moving bed ("SMB")), extraction, distillation, trituration, reverse phase HPLC and the like. Reactions conditions such as temperature, duration, pressure, and atmosphere (inert gas, ambient) are known in the art and may be adjusted as appropriate for the reaction.
Additionally, the various synthetic steps described above may be performed in an alternate sequence or order to give the desired compounds. Synthetic chemistry transformations and protecting group methodologies (protection and deprotection) useful in synthesizing the inhibitor compounds described herein are known in the art and include, for example, those such as described in R. Larock, Comprehensive Organic Transformations, VCH Publishers (1989); T.W. Greene and P.G.M. Wuts, Protective Groups in Organic Synthesis, 3rd. Ed., John Wiley and Sons (1999); L. Fieser and M. Fieser, Fieser and Fieser's Reagents for Organic Synthesis, John Wiley and Sons (1994); and L. Paquette, ed., Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons (1995).
The compounds of formula I-IVa, including their salts, are also obtainable in the form of hydrates, or their crystals can include for example the solvent used for crystallization (present as solvates).
New starting materials and/or intermediates, as well as processes for the preparation thereof, are likewise the subject of this invention. In the preferred embodiment, such starting materials are used and reaction conditions so selected as to enable the preferred compounds to be obtained.
Starting materials of the invention are known, are commercially available, or can be synthesized in analogy to or according to methods that are known in the art.
In the preparation of starting materials, existing functional groups which do not participate in the reaction should, if necessary, be protected. Preferred protecting groups, their introduction and their removal are described above or in the examples.
The following examples contain detailed descriptions of the methods of preparation of compounds of Formulas I-IVa. These detailed descriptions fall within the scope, and serve to exemplify, the above described General Synthetic Procedures which form part of the invention. These detailed descriptions are presented for illustrative purposes only and are not intended as a restriction on the scope of the invention.
The compounds of this invention may contain one or more asymmetric centers and thus occur as racemates and racemic mixtures, scalemic mixtures, single enantiomers, individual diastereomers and diastereomeric mixtures. All such isomeric forms of these compounds are expressly included in the present invention.
The invention expressly includes all tautomeric forms of the compounds described herein.
The compounds may also occur in cis- or trans- or E- or Z- double bond isomeric forms. All such isomeric forms of such compounds are expressly included in the present invention. All crystal forms of the compounds described herein are expressly included in the present invention.
Substituents on ring moieties (e.g., phenyl, thienyl, etc.) may be attached to specific atoms, whereby they are intended to be fixed to that atom, or they may be drawn unattached to a specific atom (see below), whereby they are intended to be attached at any available atom that is not already substituted by an atom other than H.
Such heterocyclic ring systems may be attached through a carbon atom or a heteroatom in the ring system. In instances wherein a heterocyclic or heteroaryl ring system is stated to be attached at a heteroatom (e.g., nitrogen atom), this refers to the heterocyclic or heteroaryl ring system being attached to the designated functional group at said nitrogen heteroatom. Unless otherwise noted, all materials were obtained from commercial suppliers and used without further purification. All parts are by weight and temperatures are in Degrees centigrade unless otherwise indicated. All compounds showed NMR spectra consistent with their assigned structures.
In order that the invention described herein may be more readily understood, the following examples are set forth. It should be understood that these examples are for illustrative purposes only and are not to be construed as limiting this invention in any manner.
Analytical methods:
Unless otherwise indicated all HPLC analyses were run on a HP- 1050 system with an HP Zorbax SB-Cis (5μ) reverse phase column (4.6 x 150mm) run at 30°C with a flow rate of 1.00 mL/min. The mobile phase used solvent A (H2O/0.1 % TFA) and solvent B (AcCN/0.1% TFA) with a 20 min gradient from 10% to 90% AcCN. The gradient was followed by a 2 min return to 10% AcCN and a 3 min flush.
LC-MS method for:
Method A:
1. Samples were run on a HP-1 100 MSD system with a HP Zorbax SB-C8 (5μ) reverse phase column (4.6 x 50mm) run at 30°C with a flow rate of 0.75 ml/min. 2. The mobile phase used solvent A (H2O/0.1 % HOAc) and solvent B (AcCN/0.1 % HO Ac) with a 10 min gradient from 10% to 90% AcCN. The gradient was followed by a 1 min return to 10% AcCN and a 2 min flush. Method B:
1. Samples were run on an HP- 1100 system with an HP Zorbax SB-Cs (5 μ) reverse phase column (4.6 x 50mm) run at 30°C with a flow rate of 1.5 ml/min.
2. The mobile phase used solvent A (H2O/0.1 % HOAc) and solvent B (AcCN/0.1 % HOAc) with a 5 min gradient from 10% to 90% AcCN. The gradient was followed by a 0.5 min return to 10% AcCN and a 1.5 min flush.
Preparative HPLC: Where indicated, compounds of interest were purified via preparative HPLC using a Gilson workstation with a 20 x 50 mm column at 45 ml/min. The mobile phase used solvent A (H2O/0.1% TFA) and solvent B (AcCN/0.1% TFA) with a 10 min gradient from 10% to 95% AcCN. The gradient was followed by a 2 min return to 20% AcCN.
Proton NMR Spectra: Unless otherwise indicated, all !H NMR spectra were run on a Bruker Advance 400 MHz instrument. All observed protons were reported as parts-per- million (ppm) downfield from tetramethylsilane (TMS) or other internal reference in the appropriate solvent indicated.
Intermediates
Preparation of teri-butyl (3-((5-formyl-2-(methylthio)pyrimidin-4- yl)amino)phenyl)carbamate (50).
Step 1. A mixture of N-Boc-m-phenylenediamine (50a, prepared according to the procedures reported in: Duceppe, J.-S. et al. Org. Process. Res. Dev. 2009, 13, 1156- 1160) (280 g, 1.35 mol) and ethyl 4-chloro-2-(methylthio)pyrimidine-5-carboxylate (Sigma-Aldrich; 303.7 g, 1.32 mol) in DMF (200 mL) at RT was treated with K2C03
(361 g, 2.6 mol). The mixture was stirred at 80 °C in an oil bath overnight. It was cooled to RT and treated with ice water. The resulting white suspension was filtered and washed with water. The white solid was collected and dried to afford crude ethyl 4-((3 -((tert- butoxycarbonyl)amino)phenyl)amino)-2-(methylthio)pyrimidine-5-carboxylate (50c) (450 g, 84% yield). !H NMR (400 MHz, DMSO-d6) δ 10.22 (s, 1 H), 9.44 (s, 1 H), 8.72 (s, 1 H), 7.90 (s, 1 H), 7.35-7.33 (m, 1 H), 7.28-7.24 (m, 1 H), 7.14-7.12 (m, 1 H), 4.38- 4.33 (q, 2 H), 2.51 (s, 3 H), 1.48 (s, 9 H), 1.35 (t, 3 H). m/z (ESI, +ve ion) 405.0 (M+l)+.
Step 2. To a suspension of ethyl 4-((3-((tert- butoxycarbonyl)amino)phenyl)amino)-2-(methylthio)pyrimidine-5-carboxylate (50c) (340 g, 0.84 mol) in THF (200 mL) at -40 °C was added LiAlH4 (2.57 L of 1.0 M solution in THF, 2.57 mol) dropwise. The reaction mixture was stirred at 0 °C for 13 h, then cooled to -20 °C and carefully quenched with solid Na2S04* 10H2O. The reaction mixture was filtered and rinsed with 2 X 150 mL of EtOAc. The filtrate was concentrated affording crude teri-butyl (3-((5-(hydroxymethyl)-2-(methylthio)pyrimidin-4- yl)amino)phenyl)carbamate (50d) (280 g, 92% yield), m/z (ESI, +ve ion) 363.0 (M+l)+.
Step 3. At RT, manganese (IV) oxide (358 g, 4.1 mol) was added to a solution of teri-butyl (3-((5-(hydroxymethyl)-2-(methylthio)pyrimidin-4-yl)amino)phenyl)carbamate (50d) (140 g, 386.8 mmol) in CHCI3. After 18 h, the reaction mixture was filtered through a pad of Celite washing with 3 x 100 mL of CHCI3. The filtrate was concentrated and the residue was purified on a silica gel column (eluted with 15-65%o EtOAc in hexanes) to give teri-butyl (3-((5-formyl-2-(methylthio)pyrimidin-4- yl)amino)phenyl)carbamate (60 g, 43% yield) as a yellow solid. !H NMR (400 MHz, CDCh) δ ppm 10.61 (1 H, br. s.), 9.77 (1 H, s), 8.44 (1 H, s), 7.99 (1 H, br. s.), 7.33 - 7.39 (1 H, m), 7.27 - 7.30 (1 H, m), 7.00 - 7.06 (1 H, m), 6.41 - 6.55 (1 H, m), 2.59 (3 H, s), 1.53 (9 H, s). m/z (ESI, +ve ion) 361.1 (M+l)+.
Preparation of teri-butyl (3-(2-(methylthio)-7-oxopyrido[2,3-d]pyrimidin-8(7H)- yl)phenyl)carbamate (51).
50 51
LiHMDS (41.6 mL of 1.0 M in THF solution, 41.6 mmol) was added to 2- MeTHF (70 mL) at -78 °C and treated with EtOAc (4.34 mL, 44.4 mmol). The solution was stirred at -78 °C for 10 min, then solid teri-butyl (3-((5-formyl-2- (methylthio)pyrimidin-4-yl)amino)phenyl)carbamate (50) (5.00 g, 13.87 mmol) was added in one portion and the solution was stirred at -78 °C for 10 min then removed from the cooling bath warmed to RT for 3 h. The reaction was cooled in an ice bath and quenched with a saturated solution of NH4C1 and extracted with EtOAc (2 x 100 mL), dried over MgS04, filtered and concentrated. The crude solid was suspended in Et20 (50 mL) and collected by filtration, washed with Et20 (2 x 15 mL) and dried under vacuum affording teri-butyl (3-(2-(methylthio)-7-oxopyrido[2,3-d]pyrimidin-8(7H)- yl)phenyl)carbamate (51) (4.24 g, 11.03 mmol, 80% yield) as a pale yellow solid. !H NMR (400 MHz, CDCh) δ ppm 8.60 - 8.65 (1 H, m), 7.64 - 7.71 (1 H, m), 7.52 (1 H, s), 7.39 - 7.47 (1 H, m), 7.29 (2 H, dd, J=8.3, 1.3 Hz), 6.89 - 6.95 (1 H, m), 6.71 (1 H, d, J=9.6 Hz), 6.56 (1 H, s), 2.19 (3 H, s), 1.50 (9 H, s). m/z (ESI, +ve ion) 385.0 (M+l)+.
Preparation of teri-butyl (3-(2-(methylsulfinyl)-7-oxopyrido[2,3-d]pyrimidin-8(7H)- yl)phenyl)carbamate (52).
51 52
At 0 °C, a suspension of tert-butyl (3-(2-(methylthio)-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)carbamate (51) (3.57 g, 9.29 mmol) in DCM (80 mL) was treated with peracetic acid (32 wt% in AcOH, 1.95 mL, 9.29 mmol) slowly dropwise. After 5-10 min, the reaction mixture became a homogeneous yellow solution, and after
20 min, it became a suspension again. After 1 h, the reaction mixture was treated with
DCM (50 mL) followed by a solution of aqueous sodium thiosulfate and stirred at 0 °C for 5 min. It was then treated with a saturated solution of NaHC03, extracted with DCM
(6 x 50 mL), dried over MgS04, filtered and concentrated affording teri-butyl (3-(2- (methylsulfmyl)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)carbamate (52) (2.50 g,
9.70 mmol, 67% yield) as a light yellow crystalline solid. The crude material was used without further purification. !H NMR (400 MHz, DMSO-d6) δ ppm 9.58 (1 H, s), 9.28 (1 H, s), 8.18 (1 H, d, J=9.6 Hz), 7.53 (1 H, s), 7.37 - 7.47 (2 H, m), 6.89 - 6.95 (2 H, m),
2.71 (3 H, s), 1.46 (9 H, s). m/z (ESI, +ve ion) 422.9 (M+Na)+.
Preparation of tert-butyl (3-((5-acetyl-2-(methylthio)pyrimidin-4- yl)amino)phenyl)carbamate (53).
Step 1. A 3-necked 2 L RBF equipped with an addition funnel, temperature probe and nitrogen inlet was charged with teri-butyl (3-((5-formyl-2-(methylthio)pyrimidin-4- yl)amino)phenyl)carbamate (50) (25.0 g, 69.4 mmol) and THF (400 mL). The mixture was cooled to 0.5 °C using an ice water bath. Methylmagnesium bromide (3.0 M in Et20, 74.0 mL, 222 mmol) was added dropwise via an addition funnel over 35 min. The temperature was kept below 8 °C during the addition. The reaction mixture was stirred for 90 min at 0.5 °C and then saturated NH4C1 (aq.) was added slowly via an addition funnel while cooling in ice. The mixture was stirred for 1 h then extracted with EtOAc (2 x 300 rriL). The combined organic layers were washed with brine, dried over anhydrous MgS04, filtered and concentrated furnishing a yellow solid. The yellow solid was suspended in Et20 (ca. 200 mL), filtered, washed with additional Et20 (2 x 50 mL), and dried under vacuum overnight affording tert-butyl (3-((5-(l-hydroxyethyl)-2- (methylthio)pyrimidin-4-yl)amino)phenyl)carbamate (23.17 g, 61.5 mmol, 89% yield) as a light yellow solid, m/z (ESI, +ve ion) 377.0 (M+H)+. !H NMR (400 MHz, DMSO-d6) δ ppm 9.34 (1 H, s), 8.86 (1 H, s), 8.07 (1 H, s), 7.80 (1 H, s), 7.32 (1 H, dd, J=8.1, 1.1 Hz), 7.19 (1 H, t, J=8.1 Hz), 6.95 - 7.07 (1 H, m), 5.87 (1 H, d, J=4.1 Hz), 4.93 (1 H, dd, J=6.5, 4.3 Hz), 2.43 (3 H, s), 1.47 (9 H, s), 1.40 (3 H, d, J=6.5 Hz).
Step 2. Tetrapropylammonium perruthenate (1.05 g, 2.99 mmol) was added to a heterogenous mixture of tert-butyl (3-((5-(l-hydroxyethyl)-2-(methylthio)pyrimidin-4- yl)amino)phenyl)carbamate (22.5 g, 59.8 mmol) and 4-methylmorpholine N-oxide (8.75 g, 74.7 mmol) in DCM (460 mL) at RT. The mixture was stirred at RT for 3 h and concentrated under reduced pressure. The dark solid was dissolved in 10%> MeOH in DCM and the material was adsorbed on to silica gel. The material was purified by silica gel pad (2-L sintered medium frit filled halfway with silica gel) eluted with 10% EtOAc in DCM (2 L) followed by 20% EtOAc in DCM (2 L). The fractions containing the desired product was concentrated to afford a white solid. 1.2 L of 1/1 MeOH/EtOAc was added to the solid and the mixture was heated to reflux and cooled to RT slowly. The mixture sat at RT overnight. The white fluffy needles were collected by filtration and washed with EtOAc to afford tert-butyl (3-((5-acetyl-2-(methylthio)pyrimidin-4- yl)amino)phenyl)carbamate (53) (12.66 g, 33.8 mmol, 56% yield). The filtrate was concentrated and the residue was absorbed on to silica gel and the material was purified by silica gel pad (2 L sintered medium frit filled halfway with silica gel) eluted with 10% EtOAc in DCM (2 L) followed by 15% EtOAc in DCM (2 L) followed by 20% EtOAc in DCM. The fractions containing the desired product was concentrated to afford a white solid. 600 mL of 1/1 MeOH/EtOAc was added to the solid and the mixture was heated to reflux and cooled to RT slowly. The mixture was seeded with a small amount of the desired product when the mixture was at 60 °C. The mixture sat at RT overnight. The white fluffy needles were collected by filtration and washed with EtOAc to afford tert- butyl (3-((5-acetyl-2-(methylthio)pyrimidin-4-yl)amino)phenyl)carbamate (53) (4.20 g, 11.22 mmol, 18% yield), m/z (ESI, +ve ion) 374.9 (M+H)+. !H NMR (400 MHz, CDCl3) δ ppm 1 1.30 (1 H, s), 8.68 - 8.73 (1 H, m), 7.91 (1 H, s), 7.30 - 7.35 (1 H, m), 7.05 (1 H, dd, J=8.0, 1.0 Hz), 6.46 (1 H, br. s.), 2.59 (3 H, s), 2.56 (3 H, s), 1.52 (9 H, s).
Preparation of teri-butyl (3-(5-methyl-2-(methylthio)-7-oxopyrido[2,3-d]pyrimidin- 8(7H)-yl)phenyl)carbamate (54).
LiHMDS (1.0 M in THF, 27.3 mL, 27.3 mmol) was added to THF (100 mL) at - 78 °C and treated with EtOAc (2.50 mL, 25.6 mmol) and stirred 15 min. teri-Butyl (3- ((5-acetyl-2-(methylthio)pyrimidin-4-yl)amino)phenyl)carbamate (53) (3.19 g, 8.52 mmol) was added in one portion at -78 °C and the solution warmed to RT and stirred for 3 h. The reaction mixture was quenched with a saturated solution of NH4CI and extracted with EtOAc (150 mL), washed with brine and dried over MgS04, filtered and concentrated. Purification of the crude residue on silica gel column (10-90% EtOAc in hexanes) afforded the title compound (54) (2.49 g, 6.25 mmol, 73% yield) as a light yellow amorphous solid, m/z (ESI, +ve ion) 398.9 (M+H)+. !H NMR (400 MHz, CDCl3) δ ppm 8.72 (1 H, s), 7.46 (1 H, br. s.), 7.42 (1 H, t, J=8.0 Hz), 7.31 (1 H, dd, J=8.2, 1.4 Hz), 6.87 - 6.94 (1 H, m), 6.50 - 6.59 (2 H, m), 2.50 (3 H, d, J=1.0 Hz), 2.17 (3 H, s), 1.50 (9 H, s). Preparation of teri-butyl (3-(6-ethyl-2-(methylthio)-7-oxopyrido[2,3-d]pyrimidin- 8(7H)-yl)phenyl)carbamate (55).
This compound (720 mg, 1.75 mmol, 31% yield) obtained as an off-white solid was prepared according to procedure described for Intermediate 51, using methyl butanoate (1.89 mL, 16.65 mmol) and teri-butyl (3-((5-formyl-2-(methylthio)pyrimidin- 4-yl)amino)phenyl)carbamate (50) (2.00 g, 5.55 mmol) as the starting materials, m/z (ESI, +ve ion) 413.0 (M+l)+. !H NMR (400 MHz, CDCl3) δ ppm 8.62 (1 H, s), 7.47 - 7.55 (2 H, m), 7.39 - 7.46 (1 H, m), 7.29 (1 H, d, J=I A Hz), 6.92 (1 H, dd, J=7.8, 1.0 Hz), 6.57 (1 H, br. s.), 2.66 (2 H, q, J=7.4 Hz), 2.19 (3 H, s), 1.50 (9 H, s), 1.23 - 1.31 (3 H, m).
Preparation of tert-butyl (3-(5-methyl-2-(methylsulfonyl)-7-oxopyrido[2,3- d] pyrimidin-8(7H)-yl)phenyl)carbamate (56).
54 56
At RT, tert-butyl (3-(5-methyl-2-(methylthio)-7-oxopyrido[2,3-d]pyrimidin- 8(7H)-yl)phenyl)carbamate (54) (440 mg, 1.10 mmol) in DCM (10 mL) was treated with MCPBA (75 wt. %, 681 mg, 2.76 mmol) and stirred for 90 min. The reaction mixture was diluted with DCM (25 mL), treated with ice and 1 N NaOH (30 mL). The DCM layer was separated and the aqueous layer was extracted with an additional amount of DCM (2 x 20 mL), dried over Na2S04 and concentrated to furnish tert-butyl (3-(5- methyl-2-(methylsulfonyl)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)carbamate (451 mg, 1.05 mmol, 95% yield) as an off-white foam. The crude material was used without purification, m/z (ESI, +ve ion) 453.0 (M+Na)+. !H NMR (400 MHz, CDCl3) δ ppm 9.11 (1 H, s), 7.60 (1 H, br. s.), 7.45 (1 H, t, J=8.0 Hz), 7.23 (1 H, dt, J=8.2, 1.0 Hz), 6.91 (1 H, ddd, J=7.9, 1.9, 0.8 Hz), 6.80 (1 H, d, J=1.4 Hz), 6.60 (1 H, s), 3.04 (3 H, s), 2.60 (3 H, d, J=1.2 Hz), 1.49 (9 H, s).
Preparation of Intermediate 57.
NaH
Boc20
Step 1. In a 20 mL glass microwave tube, 2-(methylthio)pyrido[2,3-d]pyrimidin- 7(8H)-one (57a, Matrix Scientific; 500 mg, 2.59 mmol) was treated with K2C03 (715 mg, 5.18 mmol), Cul (99 mg, 0.52 mmol) and 4,7-dimethoxy-l,10-phenanthroline (Sigma Aldrich, 187 mg, 0.77 mmol) followed by purging with argon for 3 min. The solids were then treated with DMSO (6.0 mL) and 3-iodoaniline (0.31 mL, 2.59 mmol). The tube was sealed and heated to 110 °C for 20 h. The reaction mixture was treated with water and extracted with EtOAc (3 x 50 mL) and the suspension filtered through a pad of Celite. The crude material was purified on a silica gel column (1-20% MeOH in DCM) affording enriched product. It was then repurified on a Gilson preparatory HPLC
(Silicycle Silichrome XT Ci8 column; 30 x 150 mm, 5 μ, 5-95% 0.1%TFA/CH3CN in 0.1 %TF A/water) affording 8-(3-aminophenyl)-2-(methylthio)pyrido[2,3-d]pyrimidin- 7(8H)-one 2,2,2 -trifluoroacetate (57b) (150 mg, 0.38 mmol, 14% yield) as a light yellow crystalline solid, m/z (ESI, +ve ion) 285.0 (M+l)+.
Step 2. At 0 °C, 8-(3-aminophenyl)-2-(methylthio)pyrido[2,3-d]pyrimidin-7(8H)- one 2,2,2-trifluoroacetate (57b) (150 mg, 0.38 mmol) in THF (5.0 mL), and treated with NaH (60 wt. % dispersion in mineral oil, 60 mg, 1.51 mmol) in one portion. It was stirred at this temperature for 30 min then treated with di-t-butyldicarbonate (205 mg, 0.94 mmol) and heated to 70 °C for 6 h. The reaction mixture was cooled to RT, quenched with ice water and extracted with EtOAc (2 x 30 mL), dried over MgS04, concentrated and purified on silica gel column (10-90% EtOAc in hexanes) affording bis(teri-butyl (3-(2-(methylthio)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)) carbamate (57c) (158 mg, 0.33 mmol, 87%o yield) as a yellow film, m/z (ESI, +ve ion) 485.1 (M+l)+. ¾ NMR (400 MHz, CDCl3) δ ppm 8.65 (1 H, s), 7.69 (1 H, d, J=9.6 Hz), 7.52 (1 H, t, J=8.0 Hz), 7.24 - 7.29 (1 H, m), 7.20 (1 H, d, J=7.8 Hz), 7.07 (1 H, t, =1.8 Hz), 6.71 (1 H, d, J=9.4 Hz), 2.22 (3 H, s), 1.43 (18 H, s).
Step 3. Bis(teri-butyl (3-(2-(methylthio)-7-oxopyrido[2,3-d]pyrimidin-8(7H)- yl)phenyl)) carbamate (57c, 157 mg, 0.32 mmol) was treated with DCM (5.0 mL) followed by MCPBA, 75% max., 200 mg, 0.81 mmol) and stirred at RT for 1 h. The reaction mixture was diluted with 100 mL of DCM, washed with 10 mL of sat. NaHCC followed by 10 mL of brine. The organic solution was dried over Na2S04, filtered and concentrated to give Intermediate 57 as an off white solid. The crude material was used without purification.
Preparation of teri-butyl (4-fluoro-3-((5-formyl-2-(methylthio)pyrimidin-4- yl)amino)phenyl)carbamate (58).
The title compound was prepared according to the procedures described for Intermediate 50, starting from teri-butyl (3-amino-4-fluorophenyl)carbamate (58a; prepared according to the reported protocol in Kuramoto, Y. et al. J. Med. Chem. 2003, 46, 1905-1917).
Ethyl 4-((5-((?er?-butoxycarbonyl)amino)-2-fluorophenyl)amino)-2- (methylthio)pyrimidine-5-carboxylate (58b): m/z (ESI, +ve ion) 422.9 (M+l)+. !H NMR (400 MHz, DMSO-de) δ ppm 10.36 (1 H, s), 9.48 (1 H, s), 8.76 (1 H, s), 8.48 (1 H, d,
J=5.3 Hz), 7.19 - 7.28 (1 H, m), 7.07 - 7.15 (1 H, m), 4.37 (2 H, q, J=7.2 Hz), 2.49 ( 3 H, s), 1.45 - 1.51 (9 H, s), 1.35 (3 H, t, J=7.0 Hz). 19F NMR (376 MHz, DMSO-d6) δ ppm - 134.43 (1 F, s).
teri-Butyl (4-fluoro-3-((5-(hydroxymethyl)-2-(methylthio)pyrimidin-4- yl)amino)phenyl)carbamatecarbamate (58c): m/z (ESI, +ve ion) 380.0 (M+l)+. ¾ NMR (400 MHz, CDCh) δ ppm 8.33 (1 H, d, J=5.7 Hz), 7.75 - 7.81 (1 H, m), 6.84 - 6.94 (2 H, m), 4.50 (2 H, s), 2.40 - 2.44 (3 H, m), 1.39 - 1.43 (9 H, s).
teri-Butyl (4-fluoro-3-((5-formyl-2-(methylthio)pyrimidin-4- yl)amino)phenyl)carbamate (58): mix (ESI, +ve ion) 379.0 (M+l)+. !H NMR (400 MHz, CDCl3) δ ppm 10.78 (1 H, br. s.), 9.81 (1 H, s), 8.60 (1 H, d, J=4.7 Hz), 8.48 (1 H, s), 7.04 - 7.1 1 (1 H, m), 6.97 - 7.03 (1 H, m), 6.43 (1 H, br. s.), 2.61 (3 H, s), 1.52 (9 H, s). 19F NMR (377 MHz, CDC13) δ ppm -133.41 (1 F, s).
Preparation of teri-butyl (4-fluoro-3-(2-(methylthio)-7-oxopyrido[2,3-d]pyrimidin- 8(7H)-yl)phenyl)carbamate (59).
This compound (270 mg, 59% yield) as a light yellow crystalline solid was prepared according to the procedures described for Intermediate 51, using teri-butyl (4- fluoro-3-((5-formyl-2-(methylthio)pyrimidin-4-yl)amino)phenyl)carbamate (58) (430 mg, 1.14 mmol) as the starting material, m/z (ESI, +ve ion) 403.0 (M+l)+. !H NMR (400 MHz, CDCl3) δ ppm 8.64 (1 H, s), 7.70 (1 H, d, J=9.6 Hz), 7.55 (1 H, br. s.), 7.28 - 7.35 (1 H, m), 7.17 (1 H, t, J=9.0 Hz), 6.72 (1 H, d, J=9.6 Hz), 6.56 (1 H, br. s.), 2.22 (3 H, s), 1.49 (9 H, s). 19F NMR (376 MHz, DMSO-d6) δ ppm -126.87 (1 F, s). Preparation of teri-butyl (4-fluoro-3-(2-(methylsulfinyl)-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)carbamate (60).
59 60
At 0 °C, a suspension of teri-butyl (4-fluoro-3-(2-(methylthio)-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)carbamate (59) (270 mg, 0.67 mmol) in DCM (10 mL) was treated with MCPBA (77 wt. %, 161 mg, 0.72 mmol) in one portion and stirred at 0 °C for 1 h. The reaction mixture was diluted with DCM (50 mL), and treated with ice and water (30 mL) followed by 10% Na2C03 (ca. 10 mL). The DCM layer was separated and the aqueous layer was extracted with an additional amount of DCM (2 x 50 mL), dried over Na2S04 and concentrated to give crude tert-butyl (4-fluoro-3-(2-(methylsulfinyl)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)carbamate (60) (369 mg) as a light yellow solid, m/z (ESI, +ve ion) 440.9 (M+Na)+. !H NMR (400 MHz, DMSO-d6) δ ppm 9.63 (1 H, br. s.), 8.24 (1 H, d, J=9.6 Hz), 7.68 (1 H, d, J=3.5 Hz), 7.44 - 7.52 (1 H, m), 7.33 - 7.41 (1 H, m), 6.95 - 7.01 (1 H, m), 5.76 (1 H, s), 2.72 - 2.78 (3 H, m), 1.47 (9 H, s). 19F NMR (376 MHz, DMSO-d6) δ ppm -129.58 (1 F, s). Preparation of N-(3-(2-chloro-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)- yl)phenyl)acrylamide (100).
Step 1. A mixture of 5-bromo-2,4-dichloro-pyrimidine (180 g, 0.79 mol, Matrix Scientific), A-Boc-m-phenylenediamine (170 g, 0.82 mol, Synchem Inc), and Na2C03 (90 g, 0.85 mol) in THF (620 mL) and DMF (310 mL) was stirred at RT for 18 h under nitrogen. It was treated with water (6 L) and EtOAc (6 L). The insoluble solid containing the desired product [m/z (ESI, +ve ion) 400.9/422.9 (M+l)+] was filtered and washed with EtOAc (2 x 1 L) and collected. The filtrate was transferred to a separatory funnel. The aqueous layer was discarded and the organic layer was combined with the above filtered solid. The slurry was evaporated to dryness under reduced pressure and the crude residue was further dried under high vacuum. It was stirred in Et20 (1 L) and filtered through a sintered glass frit. The off-white solid was dried in a vacuum oven at 40 °C for 18 h to give tert-butyl (3-((5-bromo-2-chloropyrimidin-4- yl)amino)phenyl)carbamate (100a, 150 g, 22.17 mmol, 53% yield). !H-NMR (400 MHz, DMSO-D6) δ ppm 9.42 (1 H, s), 9.27 (1 H, s), 8.44 (1 H, s), 7.65 (1 H, s), 7.19 - 7.29 (2 H, m), 7.07 - 7.17 (1 H, m), 1.48 (9 H, s). m/z (ESI, +ve ion) 400.9/422.9 (M+l)+.
Step 2. To a 3 -L 3 -neck round-bottomed flask armed with a mechanical stirrer was added teri-butyl (3-((5-bromo-2-chloropyrimidin-4-yl)amino)phenyl)carbamate (100a, 92 g, 230 mmol), crotonic acid (78.95 g, 920 mmol), bis(benzonitrile)palladium(ii) chloride (4.41 g, 11.51 mmol, Sigma-Aldrich), tri(o-toly)lphosphine (3.50 g, 11.51 mmol, Sigma- Aldrich), THF (319 mL), DIPEA (400 mL, 2302 mmol). The suspension was purged with argon for 5 min. It was stirred at 68 °C in an oil bath overnight. The reaction mixture was cooled to RT, and treated in one portion with acetic anhydride (58.6 mL, 622 mmol). The reaction mixture was stirred at 68 °C in an oil bath for 1 h. It was cooled to RT, diluted with 2.1 L of EtOAc. The mixture was washed with 1.12 L of 1 N HC1 followed by 1.12 L of saturated NaHCC>3 solution. The organic layer was dried over
MgS04, filtered and concentrated in vacuo. To the brown oil residue was slowly added 1 L of diethyl ether. The resulting suspension was let stand in the hood overnight at RT.
The solid was filtered, collected and treated with 500 mL EtOAc and stirred at 45 °C for 30 min. The insoluble tan solid was filtered and dried to give the desired tert-butyl (3-(2- chloro-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)carbamate (100b) (45 g). !H NMR (400 MHz, CDC13) δ ppm 8.81 (1 H, s), 7.48 (2 H, m), 7.30 (1 H, d, J=8.4 Hz), 6.88 (1 H, d, J=8.0 Hz), 6.67 (1 H, s), 6.60 (1 H, br.), 2.54 (3 H, s), 1.50 (9 H, s). m/z (ESI, +ve ion) 387.1 (M+l)+. The filtrate was concentrated and purified on a silica gel column (10-50% EtOAc in hexanes) to give the desired tert-butyl (3-(2-chloro-5-methyl- 7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)carbamate (20 g) as a tan crystalline solid. m/z (ESI, +ve ion) 387.1 (M+l)+.
Step 3. In a 3-L three-neck RBF equipped with a thermometer, a suspension of tert-butyl (3-(2-chloro-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)- yl)phenyl)carbamate (100b, 31 g, 80 mmol) in 4.0 M hydrochloric acid in dioxane (200 mL, 801 mmol) was stirred at 50 °C for 2.5 h. LCMS indicated the completed removal of N-Boc protecting group. After the reaction was completed, the overall mixture was cooled in an ice bath, and treated with NaOH 10.0 N solution (88 mL, 882 mmol) in a rate that the internal temperature did not exceed 15 °C. The resulting mixture was treated with acryloyl chloride (8.46 mL, 104 mmol) at 0 °C and the mixture was stirred at 0 °C for 1 h. The resulting brown precipitate was filtered, washed with water (2 x 25 mL), collected and dried in a vacuum oven at 40 °C for 48 h to give N-(3-(2-chloro-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide (100) (27 g, 98% yield). The crude brown solid was used in the next step without further purification. 1H NMR (400 MHz, DMSO-D6) δ 10.69 (br., 1 H), 9.1 1 (s, 1 H), 7.78 (d, J = 8.22 Hz, 1 H), 7.71 (br., 1 H), 7.49 (t, J = 7.92 Hz, 1 H), 7.00 (d, J = 7.63 Hz, 1 H), 6.74 (s, 1 H), 6.56 (dd, J = 10.27, 16.92 Hz, 1 H), 6.26 (d, J = 16.82 Hz, 1 H), 5.76 (d, J = 10.17 Hz, 1 H), 2.55 (s, 3 H). m/z (ESI, +ve ion) 341.0 (M+l)+.
Preparation of teri-butyl (3-((5-formyl-2-(methylthio)pyrimidin-4- yl)amino)phenyl)carbamate (101).
Step 1. A mixture of N-Boc-m-phenylenediamine (280 g, 1.35 mol) and ethyl 4- chloro-2-(methylthio)pyrimidine-5-carboxylate ( Sigma -Aldrich; 303.7 g, 1.32 mol) in DMF (200 mL) at RT was treated with potassium carbonate (361 g, 2.6 mol). The mixture was stirred at 80 °C in an oil bath overnight. It was cooled to RT and treated with ice water. The resulting white suspension was filtered and washed with water. The white solid was collected and dried to afford crude ethyl 4-((3-((tert- butoxycarbonyl)amino)phenyl)amino)-2-(methylthio)pyrimidine-5-carboxylate (101a)
(450 g, 84% yield). !H NMR (400 MHz, DMSO-d6) δ 10.22 (s, 1 H), 9.44 (s, 1 H), 8.72 (s, 1 H), 7.90 (s, 1 H), 7.35-7.33 (m, 1 H), 7.28-7.24 (m, 1 H), 7.14-7.12 (m, 1 H), 4.38- 4.33 (q, 2 H), 2.51 (s, 3 H), 1.48 (s, 9 H), 1.35 (t, 3 H). m/z (ESI, +ve ion) 405.0 (M+l)+. Step 2. To a suspension of ethyl 4-((3-((tert- butoxycarbonyl)amino)phenyl)amino)-2-(methylthio)pyrimidine-5-carboxylate (101a) (340 g, 0.84 mol) in THF (200 mL) at -40 °C was added LiAlH4 (2.57 L of 1.0 M solution in THF, 2.57 mol) dropwise. The reaction mixture was stirred at 0 °C for 13 h, then cooled to -20 °C and carefully quenched with solid Na2S04* 10H2O. The reaction mixture was filtered and rinsed with 2 x 150 mL of EtOAc. The filtrate was concentrated affording crude tert-butyl (3-((5-(hydroxymethyl)-2-(methylthio)pyrimidin-4- yl)amino)phenyl)carbamate (280 g, 92% yield), m/z (ESI, +ve ion) 363.0 (M+l)+.
Step 3. At RT, manganese (IV) oxide (358 g, 4.1 mol) was added to a solution of tert-butyl (3-((5-(hydroxymethyl)-2-(methylthio)pyrimidin-4-yl)amino)phenyl)carbamate (101c) (140 g, 386.8 mmol) in CHCI3. After 18 h, the reaction mixture was filtered through a pad of celite washing with 3 x 100 mL of CHCI3. The filtrate was concentrated and the residue was purified on a silica gel column (eluted with 15-65% EtOAc in hexanes) to give teri-butyl (3-((5-formyl-2-(methylthio)pyrimidin-4- yl)amino)phenyl)carbamate (101) (60 g, 43% yield) as a yellow solid. 1H NMR (400 MHz, CDCl3) δ ppm 10.61 (1 H, br. s.), 9.77 (1 H, s), 8.44 (1 H, s), 7.99 (1 H, br. s.), 7.33 - 7.39 (1 H, m), 7.27 - 7.30 (1 H, m), 7.00 - 7.06 (1 H, m), 6.41 - 6.55 (1 H, m), 2.59 (3 H, s), 1.53 (9 H, s). m/z (ESI, +ve ion) 361.1 (M+l)+.
Preparation of teri-butyl (3-((5-acetyl-2-(methylthio)pyrimidin-4- yl)amino)phenyl)carbamate (102).
Step 1. A 3-necked 2-L RBF equipped with an addition funnel, temperature probe and nitrogen inlet was charged with teri-butyl (3-((5-formyl-2-(methylthio)pyrimidin-4- yl)amino)phenyl)carbamate (25.0 g, 69.4 mmol) and THF (400 mL). The mixture was cooled to 0.5 °C using an ice water bath. Methylmagnesium bromide (3.0 M in Et20, 74.0 mL, 222 mmol) was added dropwise via an addition funnel over 35 min. The temperature was kept below 8 °C during the addition. The reaction mixture was stirred for 90 min at 0.5 °C and then saturated NH4C1 (aq.) was added slowly via an addition funnel while cooling with an ice bath. The mixture was stirred for 1 h then extracted with EtOAc (2 x 300 mL). The combined organic layers were washed with brine, dried over anhydrous magnesium sulfate, filtered and concentrated furnishing a yellow solid. The yellow solid was suspended in Et20 (ca. 200 mL), filtered, washed with additional Et20 (2 x 50 mL), and dried under vacuum overnight to afford tert-butyl (3-((5-(l - hydroxyethyl)-2-(methylthio)pyrimidin-4-yl)amino)phenyl)carbamate (23.17 g, 61.5 mmol, 89% yield) as a light yellow solid, m/z (ESI, +ve ion) 377.0 (M+H)+. !H NMR (400 MHz, DMSO-de) δ ppm 9.34 (1 H, s), 8.86 (1 H, s), 8.07 (1 H, s), 7.80 (1 H, s), 7.32 (1 H, dd, J=8.1, 1.1 Hz), 7.19 (1 H, t, .7=8.1 Hz), 6.95 - 7.07 (1 H, m), 5.87 (1 H, d, J=4.1 Hz), 4.93 (1 H, dd, J=6.5, 4.3 Hz), 2.43 (3 H, s), 1.47 (9 H, s), 1.40 (3 H, d, J=6.5 Hz).
Step 2. Tetrapropylammonium perruthenate (1.05 g, 2.99 mmol) was added to a heterogeneous mixture of tert-butyl (3-((5-(l-hydroxyethyl)-2-(methylthio)pyrimidin-4- yl)amino)phenyl)carbamate (22.5 g, 59.8 mmol) and 4-methylmorpholine N-oxide (8.75 g, 74.7 mmol) in DCM (460 mL) at RT. The mixture was stirred at RT for 3 h and concentrated under reduced pressure. The dark solid was dissolved in 10% MeOH in DCM and the material was adsorbed on to silica gel. The material was purified by silica gel pad (2-L sintered medium frit filled halfway with silica gel) eluted with 10% EtOAc in DCM (2 L) followed by 20% EtOAc in DCM (2 L). The fractions containing the desired product were concentrated to afford a white solid with black stripes. 1.2 L of 1/1 MeOH/EtOAc was added to the solid and the mixture was heated to reflux and cooled to RT slowly. The mixture was kept at RT overnight. The white fluffy needles were collected by filtration and washed with EtOAc to afford tert-butyl (3-((5-acetyl-2- (methylthio)pyrimidin-4-yl)amino)phenyl)carbamate (102) (12.66 g, 33.8 mmol, 56% yield). The filtrate was concentrated and the residue was absorbed on to silica gel and the material was purified by silica gel pad (2000 mL sintered medium frit filled halfway with silica gel) eluted with 10% EtOAc in DCM (2 L) followed by 15% EtOAc in DCM (2 L) followed by 20% EtOAc in DCM. The fractions containing the desired product were concentrated to afford a white solid with black stripes. 600 mL of 1/1 MeOH/EtOAc was added to the solid and the mixture was heated to reflux and cooled to RT slowly. The mixture was seeded with a small amount of the desired product when the mixture was at 60 °C. The mixture was kept at RT overnight. The white fluffy needles were collected by filtration and washed with EtOAc to afford additional tert-butyl (3-((5-acetyl-2- (methylthio)pyrimidin-4-yl)amino)phenyl)carbamate (102) (4.20 g, 11.22 mmol, 18% yield), m/z (ESI, +ve ion) 374.9 (M+H)+. !H NMR (400 MHz, CDCh) δ ppm 11.30 (1 H, s), 8.68 - 8.73 (1 H, m), 7.91 (1 H, s), 7.30 - 7.35 (1 H, m), 7.05 (1 H, dd, J=8.0, 1.0 Hz), 6.46 (1 H, br. s.), 2.59 (3 H, s), 2.56 (3 H, s), 1.52 (9 H, s). Preparation of N-(3-(5-methyl-2-(methylsulfinyl)-7-oxopyrido[2,3-d]pyrimidin- 8(7H)-yl)phenyl)acrylamide (103).
Step 1. In a RBF equipped a with magnetic stirrer was charged with tert-butyl (3- ((5-acetyl-2-(methylthio)pyrimidin-4-yl)amino)phenyl)carbamate (102) (49.5 g, 132 mmol) and THF (1300 mL). The mixture was stirred for 30 min at RT and filtered through a fritted funnel. The resulting filtrate containing 102 was charged to an addition funnel, degassed and purged with nitrogen. In a separate 5 L 3-necked RBF equipped with an overhead stirrer, a thermocouple and a nitrogen inlet was charged with THF (325 mL). The solvent was degassed and purged with nitrogen. It was cool to -78 °C, treated with LiHMDS (463 mL of 1 M in THF solution, 463 mmol, Aldrich). The mixture was stirred at -78 °C for 5 min, and treated with EtOAc (45.3 mL, 463 mmol) dropwise via a syringe. The resulting enolate was stirred for 30 min at -78°C, and treat with the solution of the starting material (102) in THF dropwise via the addition funnel mentioned above while maintaining the reaction temperature <-70 °C. The reaction mixture was stirred at - 78°C and warmed to RT overnight. The reaction mixture was poured into a biphasic mixture of EtOAc (1000 mL) and saturated NH4C1 solution (200 mL) cooled with an ice bath. The mixture was stirred for 30 min. The layers were separated. The organic layer was washed with brine (950 mL), dried over Na2S04 and concentrated to dryness upon which the desired product crystallized out of solution. MTBE was flushed in several times. The off-white solid was filtered, washed with MTBE and dried under vacuum with nitrogen sweep to afford tert-butyl (3-(5-methyl-2-(methylthio)-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)carbamate (103a, 46.7 g, 89%). m/z (ESI, +ve ion) 398.9 (M+H)+. !H NMR (400 MHz, CDCh) δ ppm 8.72 (1 H, s), 7.46 (1 H, br. s.), 7.42 (1 H, t, J=8.0 Hz), 7.31 (1 H, dd, J=8.2, 1.4 Hz), 6.87 - 6.94 (1 H, m), 6.50 - 6.59 (2 H, m), 2.50 (3 H, d, J=1.0 Hz), 2.17 (3 H, s), 1.50 (9 H, s).
Step 2. To a suspension of tert-butyl (3-(5-methyl-2-(methylthio)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)carbamate (103a, 6.52 g, 16.36 mmol) in DCM (50 mL) was added TFA (30 mL). The resulting homogeneous solution was stirred at RT for 30 min. The reaction mixture was concentrated under reduced pressure (rotary evaporator) and then under high vacuum for 20 min to give 103b as a viscous brown oil. m/z (ESI, +ve ion) 299.1 (M+H)+.
Step 3. The crude residue of 103b was taken up in DCM (75 mL), cooled to 0 °C and treated with DIEA (14.23 mL, 82 mmol) followed by acryloyl chloride (1.60 mL, 19.63 mmol). The resulting yellow suspension was kept at 0 °C for 50 min. The reaction mixture was quenched by the addition of an aqueous solution of ca. 1.0 M K2CO3 (50 mL) and the resulting light yellow suspension was filtered through a medium porosity sintered glass frit washing with water and then with Et20 affording N-(3-(5-methyl-2-
(methylthio)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide (103c, 5.46 g, 15.49 mmol, 95% yield) as a light yellow amorphous solid after drying under high vacuum for 2 h. m/z (ESI, +ve ion) 353.1 (M+H)+. !H NMR (400 MHz, DMSO-d6) δ ppm 10.31 (1 H, s), 8.98 (1 H, s), 7.64 - 7.71 (2 H, m), 7.48 (1 H, t, J=8.0 Hz), 7.01 (1 H, d, J=8.2 Hz), 6.59 (1 H, d, J=1.2 Hz), 6.44 (1 H, dd, J=17.0, 10.2 Hz), 6.26 (1 H, dd, J=16.8, 2.0 Hz), 5.71 - 5.81 (1 H, m), 2.51 (3 H, s), 2.20 (3 H, s).
Step 4. To a suspension of N-(3-(5-methyl-2-(methylthio)-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)acrylamide (103c, 5.46 g, 15.49 mmol) in DCM (100 mL) at 0 °C was treated with 3-chlorobenzoperoxoic acid (77% max. wt. from Aldrich) (3.72 g, 16.58 mmol) in 1 portion and stirred at 0 °C for 1 h. The reaction mixture was diluted with DCM (150 mL) and treated with an ice cold solution of ca. 1.0 M K2CO3 (25 mL).
The organic layer was separated, washed with brine (15 mL), dried over Na2SOzL, filtered and concentrated affording crude N-(3-(5-methyl-2-(methylsulfmyl)-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)acrylamide (103) (5.62 g, 15.25 mmol, 98%o yield, about 90% pure, m/z (ESI, +ve ion) 369.1 (M+H)+) as a light yellow foam, contaminated with about 10%o of N-(3-(5-methyl-2-(methylsulfonyl)-7-oxopyrido[2,3-d]pyrimidin-8(7H)- yl)phenyl)acrylamide (m/z (ESI, +ve ion) 385.1 (M+H)+). The crude material was used without further purification
Preparation of N-(3-(2-(methylsulfinyl)-7-oxopyrido[2,3-d]pyrimidin-8(7H)- yl)phenyl)acrylamide (104).
Step 1. LiHMDS (41.6 mL of 1.0 M in THF solution, 41.6 mmol) was added to 2-MeTHF (70 mL) at -78 °C and treated with EtOAc (4.34 mL, 44.4 mmol). The solution was stirred at -78 °C for 10 min, then solid tert-butyl (3-((5-formyl-2- (methylthio)pyrimidin-4-yl)amino)phenyl)carbamate (101) (5.00 g, 13.87 mmol) was added in one portion and the solution was stirred at -78 °C for 10 min then removed from the cooling bath and warmed to RT for 3 h. The reaction was cooled in an ice bath and quenched with a saturated solution of NH4C1 and extracted with EtOAc (2 x 100 mL), dried over MgS04, filtered and concentrated. The crude solid was suspended in Et20 (50 mL) and collected by filtration, washed with Et20 (2 x 15 mL) and dried under vacuum affording tert-butyl (3-(2-(methylthio)-7-oxopyrido[2,3-d]pyrimidin-8(7H)- yl)phenyl)carbamate (104a) (4.24 g, 11.03 mmol, 80% yield) as a pale yellow solid. !H NMR (400 MHz, CDCl3) δ ppm 8.60 - 8.65 (1 H, m), 7.64 - 7.71 (1 H, m), 7.52 (1 H, s), 7.39 - 7.47 (1 H, m), 7.29 (2 H, dd, J=8.3, 1.3 Hz), 6.89 - 6.95 (1 H, m), 6.71 (1 H, d, J=9.6 Hz), 6.56 (1 H, s), 2.19 (3 H, s), 1.50 (9 H, s). m/z (ESI, +ve ion) 385.0 (M+l)+.
Step 2. To a suspension of tert-butyl (3-(2-(methylthio)-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)carbamate (104a, 3.30 g, 8.58 mmol) in DCM (30 mL) was added 20 mL of TFA. The resulting homogeneous solution was stirred at RT for 30 min, and concentrated under reduced pressure to afford 104b as a viscous orange oil. Step 3. The crude residue of 104b was taken up in DCM (70 mL), cooled to 0 °C and treated with DIEA (7.47 mL, 42.9 mmol) followed by acryloyl chloride (0.84 mL, 10.30 mmol) slowly. The resulting orange suspension was stirred at 0 °C for 15 min, and quenched by saturated K2C03 solution (15 mL). The suspension was filtered through a medium porosity sintered glass frit and washed with water (2 x 5 mL) and Et20 (2 x 5 mL). The light yellow amorphous solid was collected and dried under high vacuum affording N-(3-(2-(methylthio)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide (104c) (2.25 g). !H NMR (400 MHz, DMSO-d6) δ ppm 10.31 (1 H, s), 8.94 (1 H, s), 8.04 (1 H, d, J=9.6 Hz), 7.64 - 7.72 (2 H, m), 7.49 (1 H, t, J=8.2 Hz), 7.03 (1 H, dt, J=1A, 1.2 Hz), 6.71 (1 H, d, J=9.6 Hz), 6.44 (1 H, dd, J=17.0, 10.2 Hz), 6.25 (1 H, dd, J=16.8, 2.0 Hz), 5.72 - 5.81 (1 H, m), 2.19 (3 H, s). m/z (ESI, +ve ion) 338.9 (M+l)+. The aqueous filtrate was extracted with DCM (2 x 150 mL), dried over MgSC^, filtered and concentrated affording a yellow amorphous solid. It was suspended in Et20 (50 mL), filtered and washed with Et20 (2 x 10 mL) give N-(3-(2-(methylthio)-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)acrylamide (104c) (400 mg). m/z (ESI, +ve ion) 338.9 (M+l)+.
Step 4. To a suspension of N-(3-(2-(methylthio)-7-oxopyrido[2,3-d]pyrimidin- 8(7H)-yl)phenyl)acrylamide (104c, 2.20 g, 6.50 mmol) in DCM (100 mL) at 0 °C was treated with MCPBA (1.559 g, 6.96 mmol, 77% max. wt. from Aldrich) and stirred at 0 °C for 75 min. The reaction mixture was treated with crushed ice followed by saturated K2CO3 solution (15 mL). The aqueous layer was extracted with DCM (2 x 75 mL), dried over Na2S04, filtered and concentrated affording N-(3-(2-(methylsulfinyl)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide (104) (2.38 g) as a light yellow amorphous solid. !H NMR (400 MHz, DMSO-d6) δ ppm 10.34 (1 H, s), 9.29 (1 H, s), 8.20 (1 H, d, J=9.6 Hz), 7.75 (1 H, br. s.), 7.67 (1 H, br.), 7.50 (1 H, t, J=8.0 Hz), 7.03 - 7.08 (1 H, m), 6.94 (1 H, d, J=9.6 Hz), 6.44 (1 H, dd, J=17.0, 10.2 Hz), 6.25 (1 H, dd, J=17.0, 2.0 Hz), 5.75 - 5.79 (1 H, m), 5.75 (1 H, s), 2.71 (3 H, s). m/z (ESI, +ve ion) 354.9 (M+l)+. The crude material was used without further purification. Preparation of (£)-N-(3-(2-chloro-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)- yl)phenyl)but-2-enamide (105).
To a 500 mL RBF was added tert-butyl (3-(2-chloro-5-methyl-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)carbamate (100b, 2.00 g, 5.17 mmol), HC1 (4.0 M in 1,4- dioxane, 19.4 mL, 78 mmol) and 1,4-dioxane (10 mL). The mixture was stirred at 50 °C with a reflux condenser and progress was followed with LC/MS. After 90 min all starting material was consumed. The mixture was cooled to 0 °C using an ice/brine bath and treated slowly dropwise via addition funnel with 10 N NaOH (8.79 mL, 88 mmol), keeping the temperature below 15 °C. After the addition was completed, the pH was checked to ensure basic. The mixture was stirred at 0 °C and treated dropwise via a syringe with (is)-crotonoyl chloride (Sigma Aldrich, 0.64 mL, 6.72 mmol) and progress was followed with LC/MS. After 1 h, the reaction was quenched with water (50 mL) and the precipitate was filtered through a 600-mL fine porosity sintered glass frit and the filter cake was washed with water and dried in a vacuum oven overnight at 50 °C affording (ii)-A^-(3-(2-chloro-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)but-2- enamide (1.83 g, 5.40 mmol, 100% yield) as an off-white crumbly solid, m/z (ESI, +ve ion) 355.1 (M+H)+. !H NMR (400 MHz, DMSO-d6) δ ppm 10.15 (1 H, s), 9.10 (1 H, s), 7.63 - 7.71 (2 H, m), 7.41 - 7.53 (1 H, m), 6.93 - 7.02 (1 H, m), 6.74 - 6.86 (1 H, m), 6.73 (1 H, d, J=1.2 Hz), 6.13 (1 H, dd, J=15.2, 1.7 Hz), 2.53 - 2.57 (3 H, m), 1.87 (3 H, dd, J=6.8, 1.6 Hz). e 1 : N-(3-(2-((2-methoxy-4-(4-methyl-l-piperazinyl)phenyl)amino) oxopyrido [2,3-d] pyrimidin-8(7H)-yl)phenyl)-2-pr openamide
Step 1. To a mixture of 2-methoxy-4-(4-methylpiperazin-l-yl)aniline (Combi-Blocks Inc; 342 mg, 1.55 mmol) and tert-butyl (3-(2-(methylsulfmyl)-7-oxopyrido[2,3-d]pyrimidin- 8(7H)-yl)phenyl)carbamate (52) (521 mg, 1.30 mmol) in teri-butanol (10 mL, 105 mmol) was added DIEA (0.57 mL, 3.25 mmol). The reaction mixture was heated at 80 °C in an oil bath for 21 h. The resulting brown suspension was concentrated under reduced pressure and the crude solid was suspended in Et20 (ca. 20 mL) and filtered affording the crude material of tert-butyl (3-(2-((2-methoxy-4-(4-methylpiperazin-l-yl)phenyl)amino)- 7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)carbamate (la) as a green solid, m/z (ESI, +ve ion) 558.0 (M+H)+. !H NMR (400 MHz, DMSO-d6) δ ppm 9.57 (1 H, s), 8.73 (1 H, s), 8.14 (1 H, s), 7.89 (1 H, d, J=9.4 Hz), 7.57 (1 H, d, J=8.4 Hz), 7.42 (3 H, t, J=8.0 Hz), 7.28 (1 H, d, J=8.8 Hz), 6.87 (1 H, d, J=8.6 Hz), 6.53 (1 H, d, J=2.3 Hz), 6.43 (1 H, d, J=9.4 Hz), 6.05 (1 H, br. s.), 3.73 - 3.82 (3 H, m), 3.06 (4 H, br. s.), 2.36 - 2.47 (4 H, m), 2.15 - 2.26 (3 H, s), 1.45 (9 H, s).
Step 2. The crude la from above was treated with DCM (20 mL) and TFA (20 mL) and stirred at RT for 30 min. The reaction mixture was concentrated under reduced pressure (rotary evaporator) and purified on a silica gel column (1-20% 2M NH3/MeOH in DCM) affording 8-(3-aminophenyl)-2-((2-methoxy-4-(4-methylpiperazin-l- yl)phenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one (lb) (470 mg, 1.03 mmol, 79% yield) as a brown amorphous solid, m/z (ESI, +ve ion) 458.0 (M+H)+. !H NMR (400 MHz, MeOH-d4) δ ppm 8.67 (1 H, s), 7.88 (1 H, d, J=9.4 Hz), 7.63 (1 H, d, J=8.2 Hz), 7.32 (1 H, t, J=8.0 Hz), 6.91 (1 H, dd, J=8.1, 1.5 Hz), 6.59 - 6.65 (2 H, m), 6.53 - 6.59 (1 H, m), 6.46 - 6.52 (1 H, m), 6.24 (1 H, br. s.), 3.88 (3 H, s), 3.21 (4 H, br. s.), 2.84 (4 H, br. s.), 2.53 (3 H, s).
Step 3. 8-(3-Aminophenyl)-2-((2-methoxy-4-(4-methylpiperazin-l- yl)phenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one (lb) (2.17 g, 4.74 mmol) in DCM (30 mL) and THF (30 mL) at 0 °C was treated with DIEA (1.66 mL, 9.49 mmol) and acryloyl chloride (0.46 mL, 5.69 mmol) dropwise over 15 min and stirred at 0 °C. After
I .5 h, more acryloyl chloride (0.20 mL) was added slowly over 10 min then the suspension was stirred at 0 °C for another 20 min. More acryloyl chloride (0.1 mL) was added and the reaction was stirred for another 15 min. The mixture was treated with a saturated solution of NaHCC , extracted with DCM (5 x 100 mL), dried over Na2S04, filtered and concentrated. Purification of the crude residue on a silica gel column (1 -20% MeOH in DCM) afforded the desired product as a yellow solid. This material was treated with 20 mL of EtOH and the slurry was filtered through a medium porosity sintered glass frit and washed with additional EtOH (10 mL) and Et20 (3 x 10 mL) affording N-(3-(2- ((2-methoxy-4-(4-methylpiperazin- 1 -yl)phenyl)amino)-7-oxopyrido [2,3 -djpyrimidin- 8(7H)-yl)phenyl)acrylamide (1) (680 mg, 1.33 mmol, 28%o yield) as a yellow solid after drying overnight at 36 °C in a vacuum oven, m/z (ESI, +ve ion) 512.0 (M+H)+. !H NMR (400 MHz, DMSO-de) δ ppm 10.35 (1 H, s), 8.75 (1 H, br. s.), 8.17 (1 H, br. s.), 7.92 (2 H, d, J=9.4 Hz), 7.59 (1 H, br. s.), 7.52 (1 H, t, J=8.1 Hz), 7.29 (1 H, d, J=9.0 Hz), 7.01 (1 H, d, J=8.0 Hz), 6.54 (1 H, br. s.), 6.37 - 6.50 (2 H, m), 6.20 - 6.33 (1 H, m), 6.03 (1 H, br. s.), 5.77 (1 H, d, J=10.0 Hz), 3.78 (3 H, s), 3.07 (4 H, br. s.), 2.43 (3 H, s), 2.34 (4 H, br. s.).
Example 2 : N-(3-(2-((2-methoxy-4-(4-morpholinyl)phenyl)amino)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide
Step 1. 2-Μ6ί1ιοχγ-4-ηιο 1ιο1ίηοαηί1ίη6 (Matrix Scientific, Columbia, SC; 135 mg, 0.65 mmol) and bis(teri-butyl (3-(2-(methylsulfonyl)-7-oxopyrido[2,3-d]pyrimidin- 8(7H)-yl)phenyl))carbamate (57) (167 mg, 0.32 mmol) were treated with teri-butanol (2.0 mL) and Et3N (0.14 mL, 0.97 mmol) and heated to 110 °C for 75 min. The mixture was concentrated and the crude bis(teri-butyl (3-(2-((2-methoxy-4-moφholinophenyl)amino)- 7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl))carbamate (2a) was used in the next step without further purification, m/z (ESI, +ve ion) 668.1 (M+Na)+.
Step 2. Crude bis(teri-butyl (3-(2-((2-methoxy-4-moφholinophenyl)amino)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl))carbamate (2a) was treated with DCM (5 mL) and TFA (3 mL) and stirred at RT for 15 min. The mixture was concentrated and purified on a Gilson preparatory HPLC (Silicycle Silichrome XT d8 column; 30 x 150 mm, 5 u, 5-95% 0.1 %TFA/CH3CN in 0.1 %TF A/water) affording 8-(3-aminophenyl)-2- ((2-methoxy-4-mo holinophenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one 2,2,2- trifluoroacetate (2b, 74 mg, 0.13 mmol, 41% yield) as a brown anK^hous solid after drying in a genevac overnig ht. m/z (ESI, +ve ion) 446.1 (M+Na)+. !H NMR (400 MHz, MeOH-d4) δ ppm 8.86 (1 H, s), 8.05 (1 H, d, J=9.6 Hz), 7.51 - 7.58 (1 H, m), 7.32 (1 H, dt, J=7.6, 1.3 Hz), 7.15 - 7.21 (2 H, m), 6.90 (1 H, d, J=8.6 Hz), 6.71 (1 H, d, J=9.6 Hz), 6.67 (1 H, d, J=2.5 Hz), 6.53 (1 H, dd, J=8.7, 2.6 Hz), 3.87 - 3.93 (5 H, m), 3.68 (3 H, s), 3.18 - 3.24 (4 H, m).
Step 3. 8-(3-Aminophenyl)-2-((2-methoxy-4-moφholinophenyl)amino)- pyrido[2,3-d]pyrimidin-7(8H)-one 2,2,2-trifluoroacetate (2b, 63 mg, 0.11 mmol) was treated with DCM (5.0 mL), cooled to 0 °C and treated with DIEA (0.06 mL, 0.34 mmol) and acryloyl chloride (9.16 \L, 0.113 mmol) and stirred at 0 °C for 40 min. The mixture was treated with ice and water and then a saturated solution of NaHCC . It was extracted with DCM (3 x 25 mL), dried over Na2S04, filtered and concentrated. The crude residue was purified on a Gilson prepatory HPLC (Silicycle Silichrome XT d8 column; 30 x 150 mm, 5 μ, 20-95% 0.1 %TFA/CH3CN in 0.1 %TF A/water) affording N-(3-(2-((2-methoxy- 4-mo holinophenyl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide (2) (26 mg, 0.054 mmol, 47% yield) as a light orange amorphous solid after concentration of the sample containing fractions, treatment with a saturated solution of NaHCC , extraction with DCM (3 x 25 mL), drying over Na2S04, filtration and drying under vacuum, m/z (ESI, +ve ion) 500.1 (M+H)+. !H NMR (400 MHz, DMSO-d6) δ ppm 10.33 (1 H, s), 8.88 (1 H, s), 8.04 (1 H, d, J=9.6 Hz), 7.66 - 7.70 (1 H, m), 7.64 (1 H, d, J=8.2 Hz), 7.45 (1 H, t, J=8.0 Hz), 6.94 - 7.00 (1 H, m), 6.90 (1 H, d, J=8.6 Hz), 6.67 (1 H, d, J=9.6 Hz), 6.59 (1 H, d, J=2.5 Hz), 6.42 - 6.51 (1 H, m), 6.40 (1 H, dd, J=8.8, 2.5 Hz), 6.22 - 6.32 (1 H, m), 5.77 - 5.82 (1 H, m), 3.71 - 3.80 (4 H, m), 3.63 (3 H, s), 3.04 - 3.14 (4 H, m).
Example 3: (2£')-N-(3-(2-((2-methoxy-4-(4-methyl-l-piperazinyl)phenyl)amino)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-butenamide
This compound (10 mg, 14% yield) as a yellow amorphous solid was prepared according to the procedures described for Example 1, using 8-(3-aminophenyl)-2-((2- methoxy-4-(4-methylpiperazin-l-yl)phenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one 2,2,2-trifluoroacetate (lb, 78 mg, 0.14 mmol) and (is)-crotonoyl chloride (Sigma Aldrich, 0.013 mL, 0.14 mmol) as the starting materials, m/z (ESI, +ve ion) 526.3 (M+H)+. !H
NMR (400 MHz, DMSO-d6) δ ppm 10.17 (1 H, s), 8.76 (1 H, s), 8.17 (1 H, br. s.), 7.92 (1 H, d, J=9.4 Hz), 7.84 (1 H, br. s.), 7.61 (1 H, s), 7.50 (1 H, t, J=8.0 Hz), 7.29 (1 H, d, J=8.8 Hz), 6.99 (1 H, d, J=7.6 Hz), 6.76 - 6.86 (1 H, m), 6.54 (1 H, s), 6.46 (1 H, d, J=9.4 Hz), 6.14 (1 H, d, J=15.1 Hz), 6.05 (1 H, d, J=16.0 Hz), 3.79 (3 H, s), 3.05 (4 H, br. s.), 2.45 (4 H, d, J=4.5 Hz), 2.24 (3 H, s), 1.85 - 1.91 (3 H, m).
Example 4: N-(3-(2-((4-(4-methyl-l-piperazinyl)phenyl)amino)-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide
This compound was isolated as an orange amorphous solid according to the procedures described for Example 2, using 8-(3-aminophenyl)-2-((2-methoxy-4-(4- methylpiperazin-l-yl)phenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one 2,2,2- trifluoroacetate (57) and 4-(4-methylpiperazino)aniline (Maybridge, Cambridge, as the starting materials, m/z (ESI, +ve ion) 482.1 (M+H)+. !H NMR (400 MHz, DMSO-d6) δ ppm 10.40 (1 H, s), 9.88 (1 H, br. s.), 8.78 (1 H, s), 7.92 (2 H, d, J=9.4 Hz), 7.62 (1 H, s), 7.56 (1 H, t, .7=8.1 Hz), 7.15 - 7.27 (2 H, m), 7.00 - 7.07 (1 H, m), 6.57 (2 H, br. s.), 6.40 - 6.50 (2 H, m), 6.22 - 6.31 (1 H, m), 5.75 - 5.83 (1 H, m), 2.98 (4 H, m), 2.43 (4 H, m), 2.23 (3 H, s).
Example 5: N-(3-(2-((2-methoxy-4-(4-methyl-l-piperazinyl)phenyl)amino)-5-methyl-
7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide
Step 1. To a suspension of teri-butyl (3-(5-methyl-2-(methylthio)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)carbamate (54) (2.49 g, 6.25 mmol) in DCM (30 mL) at RT was added TFA (20 mL). The resulting homogeneous solution was stirred for 1 h then the reaction was concentrated under reduced pressure (rotary evaporator). The residue was dissolved in DCM (50 mL), cooled to 0 °C and treated with DIEA (5.43 mL, 31.2 mmol) followed by acryloyl chloride (0.61 mL, 7.50 mmol). This resulted in a yellow suspension after stirring 25 min. The reaction was quenched by the addition of an aqueous solution of 1.0 M K2C03 and the resulting light yellow suspension was filtered through a medium porosity sintered glass frit washing with water and Et20 affording N- (3-(5-methyl-2-(methylthio)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide (5a; 2.17 g, 6.15 mmol, 98% yield) as a light yellow solid after drying under high vacuum, m/z (ESI, +ve ion) 353.1 (M+H)+. !H NMR (400 MHz, DMSO-d6) δ ppm 10.31 (1 H, s), 8.98 (1 H, s), 7.64 - 7.71 (2 H, m), 7.48 (1 H, t, J=8.0 Hz), 7.01 (1 H, d, J=8.2 Hz), 6.59 (1 H, d, J=1.2 Hz), 6.44 (1 H, dd, J=17.0, 10.2 Hz), 6.26 (1 H, dd, J= 16.8, 2.0 Hz), 5.71 - 5.81 (1 H, m), 2.51 (3 H, s), 2.20 (3 H, s).
Steps 2 and 3. To a suspension of N-(3-(5-methyl-2-(methylthio)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide (5a; 5.15 g, 14.63 mmol) in DCM (100 mL) at 0 °C was added MCPBA (77 wt. %, 3.51 g, 15.65 mmol) in one portion. The resulting suspension was stirred at 0 °C for 1 h. The mixture was diluted with DCM (100 mL) and treated with an ice cold solution of 1.0 M K2CO3. The aqueous layer was extracted with DCM (2 x 100 mL). The organic extracts were dried over Na2S04, filtered and concentrated affording crude N-(3-(5-methyl-2-(methylsulfinyl)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide (5b; 1.09 g, 2.96 mmol, 20% yield) as a light yellow foam. The aqueous layer with suspended material was filtered through a medium porosity sintered glass frit and washed with water and Et20 affording additional N-(3-(5-methyl-2-(methylsulfmyl)-7-oxopyrido[2,3-d]pyrimidin-8(7H)- yl)phenyl)acrylamide (5b; 4.59 g, 12.46 mmol, 85% yield) as a light yellow free-flowing solid after drying under vacuum, m/z (ESI, +ve ion) 369.1 (M+H)+. !H NMR (400 MHz, DMSO-de) δ ppm 10.33 (1 H, s), 9.33 (1 H, s), 7.69 - 7.76 (1 H, m), 7.66 (1 H, d, J=1.8 Hz), 7.43 - 7.52 (1 H, m), 6.97 - 7.07 (1 H, m), 6.81 (1 H, d, J=1.4 Hz), 6.44 (1 H, dd, J=16.9, 10.1 Hz), 6.25 (1 H, dd, J=16.9, 1.9 Hz), 5.69 - 5.81 (1 H, m), 2.71 (3 H, s), 2.59 (3 H, d, J=1.2 Hz).
Step 4. To a suspension of 2-methoxy-4-(4-methylpiperazin-l -yl)aniline (Green Chempharm; 3.45 g, 15.57 mmol) and N-(3-(5-methyl-2-(methylsulfinyl)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide (5b) (4.59 g, 12.46 mmol) in anhydrous teri-butanol (40 mL) and dioxane (5 mL) at RT was added DIEA (4.33 mL, 24.92 mmol). The mixture was heated at 100 °C for 40 h. The mixture was concentrated under reduced pressure (rotary evaporator) and the resulting crude residue was suspended in Et20 and filtered. The greenish-brown amorphous solid was washed with Et20 (3 x 50 mL). The crude material was dry -packed on silica gel and purified on a silica gel column (1-20% MeOH in DCM) affording N-(3-(2-((2-methoxy-4-(4-methylpiperazin-l - yl)phenyl)amino)-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide (5) (2.03 g, 3.86 mmol, 31 %o yield) as a yellow amorphous solid, m/z (ESI, +ve ion) 526.2 (M+H)+. !H NMR (400 MHz, DMSO-d6) δ ppm 10.33 (1 H, s), 8.80 (1 H, s), 8.09 (1 H, s), 7.88 (1 H, d, J=8.2 Hz), 7.56 (1 H, t, =1.9 Hz), 7.50 (1 H, t, J=8.1 Hz), 7.27 (1 H, d, J=8.8 Hz), 6.97 (1 H, dt, J=6.9, 1.0 Hz), 6.52 (1 H, d, J=2.5 Hz), 6.37 - 6.48 (1 H, m), 6.29 - 6.35 (1 H, m), 6.19 - 6.29 (1 H, m), 6.01 (1 H, br. s.), 5.71 - 5.80 (1 H, m), 3.78 (3 H, s), 3.02 (4 H, br. s.), 2.46 (3 H, s), 2.43 (4 H, t, J=4.9 Hz), 2.22 (3 H, s).
Example 6: N-(3-(6-ethyl-2-((2-methoxy-4-(4-methyl-l-piperazinyl)phenyl)
oxopyrido [2,3-d] pyrimidin-8(7H)-yl)phenyl)-2-pr openamide
Step 1. At 0 °C, a suspension of teri-butyl (3-(6-ethyl-2-(methylthio)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)carbamate (55) (720 mg, 1.75 mmol) in DCM (15 mL) was treated with mCPBA (70 wt.%, 460 mg, 1.87 mmol) in one portion and stirred at 0 °C for 1 h. The mixture was diluted with DCM (15 mL), and treated with ice and a 10% solution of Na2C03 (ca. 10 mL). The DCM layer was separated and the aqueous layer was extracted with an additional amount of DCM (2 x 50 mL), dried over Na2S04 and concentrated to give teri-butyl (3-(6-ethyl-2-(methylsulfinyl)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)carbamate (6a) (682 mg, 1.59 mmol, 91% yield) as a light yellow amorphous solid, m/z (ESI, +ve ion) 451.0 (M+Na)+. The crude material was used in the subsequent step without further purification.
Step 2. 2-Methoxy-4-(4-methylpiperazin-l-yl)aniline (Combi-Blocks Inc, San Diego, CA; 386 mg, 1.75 mmol), teri-butyl (3-(6-ethyl-2-(methylsulfinyl)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)carbamate (6a) (680 mg, 1.59 mmol) were treated with tert-butanol (10 mL) and DIEA (0.69 mL, 3.97 mmol) and heated to 85 °C for 14 h in a 250 mL round-bottomed flask with a reflux condenser. The reaction mixture was concentrated under reduced pressure (rotary evaporator) and the crude solid was purified by chromatography on a silica gel column (1-20% MeOH in DCM) affording teri-butyl (3-(6-ethyl-2-((2-methoxy-4-(4-methylpiperazin- 1 -yl)phenyl)amino)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)carbamate (6b; 717 mg, 1.23 mmol, 77 %> yield) as a light brown film, m/z (ESI, +ve ion) 585.9 (M+H)+. Steps 3 and 4. teri-Butyl (3-(6-ethyl-2-((2-methoxy-4-(4-methylpiperazin-l- yl)phenyl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)carbamate from above was treated with DCM (10 mL) and TFA (10 mL) and stirred at RT for 30 min. The reaction mixture was concentrated under reduced presure (rotary evaporator) and purified on silica gel on an ISCO Combiflash RF (40 g Redisep column, 5-20% 2M NH3/MeOH in DCM) affording 8-(3-aminophenyl)-6-ethyl-2-((2-methoxy-4-(4-methylpiperazin-l- yl)phenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one (392 mg, 0.81 mmol, 51% yield) as a brown/yellow film, m/z (ESI, +ve ion) 486.0 (M+H)+. !H NMR (400 MHz, MeOH-d4) δ ppm 8.67 (1 H, s), 7.74 (1 H, s), 7.68 (1 H, d, J=8.6 Hz), 7.34 (1 H, t, J=7.9 Hz), 6.92 (1 H, dd, J=8.1, 1.5 Hz), 6.61 - 6.67 (2 H, m), 6.58 (1 H, dd, J=7.6, 1.0 Hz), 6.26 (1 H, d, J=7.2 Hz), 5.51 (2 H, s), 3.90 (3 H, s), 3.30 (4 H, br. s), 3.18 (4 H, br. s), 2.79 (3 H, s), 2.63 (2 H, q, J=7.4 Hz), 1.28 (3 H, t, J=7.5 Hz). 8-(3-Aminophenyl)-6-ethyl-2-((2- methoxy-4-(4-methylpiperazin-l-yl)phenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one (390 mg, 0.80 mmol) in a mixture of DCM (7 mL) and THF (7 mL) at 0 °C was treated with DIEA (0.35 mL, 2.01 mmol) followed by the slow dropwise addition of acryloyl chloride (0.078 mL, 0.964 mmol) over 5 min. The solution was stirred 0 °C for 15 min. Two additional drops of acryloyl chloride were added and the mixture was stirred an additional 2 h at 0 °C. The mixture was treated with silica gel and concentrated on the rotovap to dryness. The material was purified on an ISCO Combiflash RF (40 g Redisep column, using a gradient of 0-20%o MeOH in DCM) affording enriched product as a yellow powdery solid. It was repurified on a Gilson preparatory HPLC (Gemini Phenomenex; 30 x 150 mm, 5 u, 10-95% 0.1 %TFA/CH3CN in 0.1%TFA/water), concentrated on the rotovap and treated with IN NaOH and extracted with CHCI3 (3 x 50 mL), dried over Na2S04, filtered and concentrated affording N-(3-(6-ethyl-2-((2- methoxy-4-(4-methylpiperazin-l-yl)phenyl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)- yl)phenyl)acrylamide (6) (154 mg, 0.29 mmol, 35%o yield) as a bright yellow solid, m/z (ESI, +ve ion) 540.0 (M+H)+. !H NMR (400 MHz, MeOH-d4) δ ppm 8.68 (1 H, s), 8.04 (1 H, d, J=7.2 Hz), 7.77 (1 H, s), 7.58 - 7.65 (2 H, m), 7.49 (1 H, d, J=8.4 Hz), 7.08 (1 H, d, J=8.0 Hz), 6.58 (1 H, d, J=2.5 Hz), 6.34 - 6.51 (2 H, m), 6.14 (1 H, d, J=7.0 Hz), 5.80 (1 H, dd, J=9.6, 2.2 Hz), 3.88 (3 H, s), 3.13 (4 H, d, J=3.9 Hz), 2.58 - 2.69 (6 H, m), 2.38 (3 H, s), 1.30 (3 H, t, J=7.4 Hz). Example 7: N-(3-(2-((2-methoxy-4-(4-morpholinyl)phenyl)amino)-5-methyl-7- oxopyrido [2,3-d] pyrimidin-8(7H)-yl)phenyl)-2-pr openamide
In a 5 mL glass microwave tube was weighed tert-butyl (3-(5-methyl-2- (methylsulfonyl)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)carbamate (56) (150 mg, 0.35 mmol), 2-methoxy-4-mo holinoaniline (Matrix Scientific, Columbia, SC, 54 mg, 0.26 mmol) followed by purging with argon. The solids were then treated with tert- butanol (2.0 mL) and DIEA (0.11 mL, 0.65 mmol). The tube was sealed and heated to 85 °C for 20 h. The crude reaction mixture was purified on silica gel on an I SCO
Combiflash RF (40 g Thomson SingleStep column, using a gradient of 0-15% MeOH in DCM) affording teri-butyl (3-(5-methyl-2-(methylsulfonyl)-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)carbamate (7a; 150 mg, 0.35 mmol) as a brownish film, m/z (ESI, +ve ion) 560.0 (M+H)+.
N-(3-(2-((2-Methoxy-4-(4-mo holinyl)phenyl)amino)-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide (7) (11 mg, 9% overall yield for 2 steps) as a yellow solid was prepared according to the procedures described for Example 6, using (3-(5-methyl-2-(methylsulfonyl)-7-oxopyrido[2,3-d]pyrimidin-8(7H)- yl)phenyl)carbamate (7a; 150 mg, 0.35 mmol) as the starting material, m/z (ESI, +ve ion) 514.0 (M+H)+. !H NMR (400 MHz, MeOH-d4) δ ppm 9.01 (1 H, s), 7.66 (1 H, d, J=7.6 Hz), 7.47 - 7.53 (1 H, m), 7.33 (1 H, t, J=8.0 Hz), 6.77 - 6.85 (2 H, m), 6.56 (1 H, s), 6.40 - 6.47 (3 H, m), 6.36 (1 H, dd, J=8.7, 2.4 Hz), 5.82 (1 H, dd, J=9.6, 2.2 Hz), 3.82 - 3.92 (4 H, m), 3.61 (3 H, s), 3.05 - 3.14 (4 H, m), 2.62 (3 H, s).
Example 8: N-(3-(2-((4-methoxy-6-(4-methyl-l-piperazinyl)-3-pyridinyl)amino)-7- oxopyrido [2,3-d] pyrimidin-8(7H)-yl)phenyl)-2-pr openamide
Step 1. Preparation of 4-methoxy-6-(4-methylpiperazin-l-yl)pyridin-3-amine (8a). 2-Chloro-4-methoxy-5-nitropyridine (Frontier Scientific, Newark, DE; 1.02 g, 5.40 mmol) and K2C03 (895 mg, 6.48 mmol) were purged with argon, treated with DMF (10 mL) followed by 1-methylpiperazine (0.66 mL, 5.94 mmol). The reaction was then heated to 60 °C for 3 h. The mixture was cooled to RT and treated with water, extracted with EtOAc (2 x 100 mL), washed with brine (2 x 25 mL) and dried over MgSOt, filtered and concentrated affording crude l-(4-methoxy-5-nitropyridin-2-yl)-4-methylpiperazine (1.36 g, 5.39 mmol, 99% yield), m/z (ESI, +ve ion) 252.9 (M+H)+. !H NMR (400 MHz, CDCl3) δ ppm 8.88 (1 H, s), 5.97 (1 H, s), 3.97 (3 H, s), 3.70 - 3.78 (4 H, m), 2.47 - 2.55 (4 H, m), 2.36 (3 H, s). Pd/C (10 wt. %, 586 mg, 0.55 mmol) and l-(4-methoxy-5- nitropyridin-2-yl)-4-methylpiperazine (1.36 g, 5.39 mmol) were treated with EtOH (20 mL) and EtOAc (20 mL) and stirred at RT overnight (18 h) under an atmosphere of H2 (balloon). The reaction mixture was filtered through a pad of Celite, washed with MeOH, and concentrated to dryness affording 4-methoxy-6-(4-methylpiperazin-l-yl)pyridin-3- amine (8a) (1.22 g, 5.77 mmol, 99% yield) as a purple viscous oil. m/z (ESI, +ve ion) 223.1 (M+H)+. !H NMR (400 MHz, CDCl3) δ ppm 7.67 (1 H, s), 6.17 (1 H, s), 3.87 (3 H, s), 3.37 - 3.45 (4 H, m), 3.32 (2 H, br. s.), 2.51 - 2.60 (4 H, m), 2.36 (3 H, s).
Step 2. Preparation of teri-butyl (3-(2-((4-methoxy-6-(4-methylpiperazin-l- yl)pyridin-3-yl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)carbamate (8b). 4- Methoxy-6-(4-methylpiperazin-l-yl)pyridin-3 -amine (8a; 1.22 g, 5.49 mmol), ieri-butyl (3-(2-(methylsulfmyl)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)carbamate (52; 1.40 g, 3.50 mmol) were treated with teri-butanol (20 mL) and DIEA (1.53 mL, 8.74 mmol) and heated to 85 °C overnight (20 h) in a 250 mL round-bottomed flask with a reflux condenser. The mixture was concentrated on the rotovap and the crude solid was suspended in Et20 and filtered affording the crude teri-butyl (3-(2-((4-methoxy-6-(4- methylpiperazin-l-yl)pyridin-3-yl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)- yl)phenyl)carbamate (8b; 1.50 g, 2.69 mmol, 77% yield) as a brownish-yellow amorphous solid, m/z (ESI, +ve ion) 559.0 (M+H)+. !H NMR (400 MHz, DMSO-d6) δ ppm 9.48 (1 H, br. s.), 8.65 (1 H, br. s.), 8.54 (1 H, s), 7.86 (1 H, d, J=9.4 Hz), 7.82 (1 H, s), 7.43 (1 H, d, J=8.0 Hz), 7.37 (2 H, br. s.), 6.81 (1 H, br. s.), 6.38 (1 H, d, J=9.4 Hz), 6.29 (1 H, br. s.), 3.73 (3 H, s), 3.45 (4 H, br. s.), 2.40 (4 H, br. s.), 2.24 (3 H, s), 1.47 (9 H, s).
Step 3. N-(3-(2-((4-Methoxy-6-(4-methyl-l-piperazinyl)-3-pyridinyl)amino)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide (8) (14% overall yield for 2 steps) as a yellow crystalline solid was prepared according to the procedures described for Example 6, using teri-butyl (3-(2-((4-methoxy-6-(4-methylpiperazin-l-yl)pyridin-3- yl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)carbamate (8b) as the starting material, m/z (ESI, +ve ion) 512.9 (M+H)+. !H NMR (400 MHz, DMSO-d6) δ ppm 10.26 (1 H, br. s.), 8.67 (1 H, br. s.), 8.55 (1 H, s), 7.87 (1 H, d, J=9.4 Hz), 7.82 (1 H, s), 7.70 (1 H, d, J=7.8 Hz), 7.57 (1 H, br. s.), 7.34 - 7.48 (1 H, m), 6.94 (1 H, br. s.), 6.37 - 6.49 (2 H, m), 6.20 - 6.32 (2 H, m), 5.72 - 5.80 (1 H, m), 3.72 (3 H, s), 3.43 (4 H, br. s.), 2.38 (4 H, t, J=4.9 Hz), 2.22 (3 H, s).
Example 9: (2£)-4-(dimethylamino)-N-(3-(2-((2-methoxy-4-(4-methyl-l- piperazinyl)phenyl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2- butenamide
8-(3-Aminophenyl)-2-((2-methoxy-4-(4-methylpiperazin-l- yl)phenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one (lb, 255 mg, 0.56 mmol) was added in one portion as a solid to a suspension of (7s)-4-(dimethylamino)but-2-enoyl chloride hydrochloride (283 mg, 1.538 mmol) in THF (10 mL) at 0 °C. The resulting orange suspension was treated with DIEA (0.39 mL, 2.23 mmol) slowly and stirred for 30 min at 0 °C. The reaction mixture was removed from the ice bath and stirred at RT for 30 min. The reaction mixture was treated with silica gel, concentrated on the rotovap and purified on an ISCO Combiflash RF (40 g Redisep column, using a gradient of 0-20% MeOH in DCM) affording enriched product as a yellow solid. This sample was repurified on the Gilson preparatory HPLC (Gemini Phenomenex; 30 x 150 mm, 5 u, 10-95%
0.1%TFA/CH3CN in 0.1 %TF A/water). The product containing fractions were concentrated in the genevac overnight and the resulting orange solid was then passed through a Silicycle SPE-R66030B-20X SiliaSep OT, 5g/25 mL carbonate column using 10% MeOH/DCM then concentrated and dried again in the genevac for 3 h affording (ii)- 4-(dimethylamino)-N-(3-(2-((2-methoxy-4-(4-methylpiperazin-l-yl)phenyl)amino)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)but-2-enamide (35 mg, 0.062 mmol, 11% yield) as an orange solid, m/z (ESI, +ve ion) 569.0 (M+H)+. !H NMR (400 MHz, DMSO- d6) δ ppm 10.25 (1 H, s), 8.74 (1 H, s), 8.14 (1 H, s), 7.90 (1 H, d, J=9.4 Hz), 7.79 - 7.88 (1 H, m), 7.59 (1 H, s), 7.49 (1 H, t, J=8.0 Hz), 7.27 (1 H, d, J=9.0 Hz), 6.98 (1 H, d, J=8.6 Hz), 6.73 (1 H, dt, .7=15.4, 5.8 Hz), 6.51 (1 H, d, J=2.3 Hz), 6.44 (1 H, d, J=9.4 Hz), 6.27 (1 H, d, J=15.3 Hz), 6.02 (1 H, br. s.), 3.77 (3 H, s), 3.04 (6 H, d, J=5.7 Hz), 2.36 - 2.46 (4 H, m), 2.22 (3 H, s), 2.16 (6 H, s).
Example 10: N-(4-fluoro-3-(2-((2-methoxy-4-(4-methyl-l- piperazinyl)phenyl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2- propenamide
The title compound was prepared according to the procedures described for Example 1, starting from tert-butyl (4-fluoro-3-(2-(methylsulfmyl)-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)carbamate (60). teri-Butyl (4-fluoro-3-(2-((2-methoxy-4- (4-methylpiperazin-l-yl)phenyl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)- yl)phenyl)carbamate (10a): m/z (ESI, +ve ion) 575.9 (M+H)+. 19F NMR (376 MHz, CZX¾) δ ρρι -127.13 (1 F, s).
8-(5 -Amino-2-fluorophenyl)-2-((2-methoxy-4-(4-methylpiperazin- 1 - yl)phenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one (10b): m/z (ESI, +ve ion) 476.0
(M+H)+. !H NMR (400 MHz, DMSO-d6) δ ppm 8.73 (1 H, s), 8.25 (1 H, br. s.), 7.90 (1 H, d, J=9.4 Hz), 7.39 (1 H, d, J=8.6 Hz), 7.08 (1 H, t, J=9.3 Hz), 6.67 - 6.73 (1 H, m), 6.56 (1 H, d, J=2.3 Hz), 6.50 (1 H, dd, J=6.5, 2.7 Hz), 6.42 (1 H, d, J=9.4 Hz), 6.20 (1 H, br. s.), 5.14 (2 H, s), 3.75 - 3.83 (3 H, m), 3.12 (4 H, br. s.), 2.58 (3 H, br. s.), 2.21 - 2.40 (4 H, m). 19F NMR (376 MHz, DMSO-d6) δ ppm -139.03 (1 F, s).
N-(4-Fluoro-3-(2-((2-methoxy-4-(4-methylpiperazin-l-yl)phenyl)amino)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide (10). m/z (ESI, +ve ion) 529.9 (M+H)+. !H NMR (400 MHz, DMSO-d6) δ ppm 10.42 (1 H, s), 8.78 (1 H, br. s.), 8.35 (1 H, br. s.), 7.95 (1 H, d, J=9.4 Hz), 7.88 (1 H, br. s.), 7.74 (1 H, dd, J=6.7, 2.5 Hz), 7.44 (1 H, t, J=9.3 Hz), 7.24 (1 H, d, J=8.8 Hz), 6.50 - 6.56 (1 H, m), 6.38 - 6.50 (2 H, m), 6.22 - 6.31 (1 H, m), 6.03 (1 H, br. s.), 5.74 - 5.83 (1 H, m), 3.77 (3 H, s), 3.05 (4 H, br. s.), 2.44 (4 H, t, J=4.8 Hz), 2.23 (3 H, s). 19F NMR (376 MHz, DMSO-d6) δ ppm -127.45 (1 F, s). Example 11 : N-(3-(2-((4-((l-(2-fluoroethyl)-3-azetidinyl)amino)-2- methoxyphenyl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2- propenamide
Preparation of N-(3-(2-(methylthio)-7-oxopyrido[2,3-d]pyrimidin-8(7H)- yl)phenyl)acrylamide (11a). To a suspension of teri-butyl (3-(2-(methylthio)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)carbamate (51) (651 mg, 1.69 mmol) in 10 mL of DCM at RT was added 3 mL of TFA. The resulting homogeneous solution was stirred at RT for 1 h. It was concentrated under reduced pressure. The residue was in dissolved in 20 mL of DCM and cooled with an ice bath, then treated with DEIA (1.47 mL, 8.47 mmol) followed by acryloyl chloride (0.16 mL, 2.03 mmol). After 20 min at 0 °C, additional acryloyl chloride (80 μί) was added in. The resulting mixture was stirred for 5 min, then quenched with 0.5 N NaOH (10 mL). The layers were separated and the water layer was extracted with 50 mL of DCM. The combined DCM extracts were washed with 2 x 5 mL of brine, dried over Na2S04 and concentrated. The residue was stirred in 25 mL of EtOAc. The insoluble solid was filtered and dried to give 310 mg of N-(3-(2-(methylthio)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide (11a). The filtrate was concentrated and purified on a silica gel column (35-100% EtOAc in hexanes) to give 140 mg of N-(3-(2-(methylthio)-7-oxopyrido[2,3-d]pyrimidin-8(7H)- yl)phenyl)acrylamide (11a). m/z (ESI, +ve ion) 338.9 (M+H)+. !H NMR (400 MHz, DMSO-de) δ ppm 10.40 (1 H, s), 8.95 (1 H, s), 8.05 (1 H, d, J=9.6 Hz), 7.68 (2 H, m), 7.49 (1 H, t, J=7.8 Hz), 7.04 (1 H, d, J=8.2 Hz), 6.72 (1 H, d, J=9.6 Hz), 6.46 (1 H, dd, J=17.0, 10.2 Hz), 6.26 (1 H, d, J=16.8 Hz), 5.78 (1 H, d, J=9.6 Hz), 2.20 (3 H, s).
Preparation of N-(3-(2-(methylsulfmyl)-7-oxopyrido[2,3-d]pyrimidin-8(7H)- yl)phenyl)acrylamide (lib). At 0 °C, to a suspension of N-(3-(2-(methylthio)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide (11a) (450 mg, 1.33 mmol) in 25 mL of DCM was added MCPBA (319 mg of 77% max. from Aldrich, 1.42 mmol). After the reaction mixture was stirred at 0 °C for 35 min, it was diluted with 100 mL of DCM, washed with 20 mL of ice cold sat Na2C03 solution. The DCM layer was dried over Na2S04 and concentrated to give N-(3-(2-(methylsulfmyl)-7-oxopyrido[2,3-d]pyrimidin- 8(7H)-yl)phenyl)acrylamide (lib) (398 mg, 84% yield) as an off white crystalline solid. The crude material was used in next step without further purification, m/z (ESI, +ve ion) 355.0 (M+H)+. !H NMR (400 MHz, DMSO-d6) δ ppm 10.36 (1 H, s), 9.30 (1 H, s), 8.20 (1 H, d, J=9.6 Hz), 7.76 (1 H, m), 7.69 (1 H, m), 7.51 (1 H, t, J=8.0 Hz), 7.06 (1 H, d, J=7.6 Hz), 6.94 (1 H, m), 6.45 (1 H, dd, J=16.9, 10.1 Hz), 6.26 (1 H, d, J=16.8 Hz), 5.79 (1 H, m), 2.72 (3 H, s)
Nl -( 1 -(2-Fluoroethyl)azetidin-3-yl)-3-methoxybenzene-l ,4-diamine (1 lc) was prepared according to the procedures described in WO 2012064706.
Preparation of N-(3-(2-((4-((l-(2-fluoroethyl)azetidin-3-yl)amino)-2- methoxyphenyl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide (11). To a suspension of Nl-(l-(2-fluoroethyl)azetidin-3-yl)-3-methoxybenzene-l,4-diamine (11c) (135 mg, 0.56 mmol) and N-(3-(2-(methylsulfmyl)-7-oxopyrido[2,3-d]pyrimidin- 8(7H)-yl)phenyl)acrylamide (lib) (230 mg, 0.65 mmol) in 1 mL of dioxane and 1 mL of iBuOH at RT was added DIEA (0.29 mL, 1.69 mmol). The mixture was heated in an oil bath at 85 °C for 3 h. It was concentrated under reduced pressure. The residue was purified on a silica gel column (5% MeOH in DCM followed by 2-6% of 2 M NH3 in
MeOH in DCM) to give a material that was about 95% pure. The material was dissolved in 10 mL of DMSO and purified on a reverse phase HPLC, using a gradient of 10-90%o of (0.1% TFA in CH3CN) in (0.1% TFA in water). Desired fractions were collected, lyophilized and the powdery residue was dissolved in 2 mL of MeOH, passed through a Silicycle (5 G) carbonate cartridge, rinsed with MeOH (20 mL). The fractions were collected and concentrated to give the title compound (95 mg, 31 %> yield) as a brown crystalline solid, m/z (ESI, +ve ion) 530.0 (M+H)+. !H NMR (400 MHz, DMSO-d6) δ ppm 10.40 (1 H, br.), 8.73 (1 H, br.), 8.10 (1 H, br.), 7.90 (1 H, d, J=9.4 Hz), 7.83 (1 H, br.), 7.64 (1 H, s), 7.51 (1 H, t, J=8.0 Hz), 7.15 (1 H, br.), 7.02 (1 H, d, J=8.6 Hz), 6.44 (2 H, m), 6.29 (1 H, m), 6.16 (1 H, d, J=2.0 Hz), 5.86 (1 H, br.), 5.78 (1 H, m), 5.57 (1 H, br.), 4.49 (1 H, t, J=4.8 Hz), 4.37 (1 H, t, J=4.9 Hz), 3.90 (1 H, br.), 3.72 (3 H, s), 3.70 (2 H, m), 2.83 (2 H, m), 2.74 (1 H, t, J=4.8 Hz), 2.67 (1 H, t, J=4.8 Hz). Example 12: 2-chloro-N-(3-(2-((2-methoxy-4-(4-methyl-l- piperazinyl)phenyl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acetamide
8-(3-Aminophenyl)-2-((2-methoxy-4-(4-methylpiperazin-l-yl)phenyl)amino)- pyrido[2,3-d]pyrimidin-7(8H)-one (lb, 131 mg, 0.29 mmol) in DCM (5 mL) at 0 °C was treated with DIEA (0.13 mL, 0.72 mmol) and cooled in an ice bath at 0 °C. The solution was then treated with 2-chloroacetyl chloride (Sigma Aldrich; 0.027 mL, 0.344 mmol) slowly dropwise over 10 min and stirred at 0 °C for 30 min. The reaction was sonicated for 10 min to help dissolve the substrate and another 2 drops of 2-chloroacetyl chloride was added. After 30 min, 2 more drops of 2-chloroacetyl chloride were added and the solution stirred for another 75 min resulting in clean conversion to the desired product. The mixture was concentrated, treated with DMSO (8 mL) and purified on a Gilson preparatory HPLC (Gemini Phenomenex; 30 x 150 mm, 5 μ, 10-95% 0.1%TFA/CH3CN in 0.1 %TFA/water). The product containing fractions were concentrated under reduced pressure (rotary evaporator) and the resulting aqueous solution treated with a 10% aqueous solution of Na2C03 and extracted with DCM (4 x 30 mL), dried over Na2S04 and dried under vacuum overnight affording 2-chloro-N-(3-(2-((2-methoxy-4-(4- methylpiperazin-l-yl)phenyl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)- yl)phenyl)acetamide (53.4 mg, 0.100 mmol, 35 % yield) as a yellow solid, m/z (ESI, +ve ion) 533.9 (M+H)+. !H NMR (400 MHz, DMSO-d6) δ ppm 10.50 (1 H, s), 8.75 (1 H, s), 8.17 (1 H, s), 7.91 (1 H, d, J=9.4 Hz), 7.75 (1 H, d, J=8.2 Hz), 7.49 - 7.57 (2 H, m), 7.25 (1 H, d, J=9.0 Hz), 7.04 (1 H, d, J=7.8 Hz), 6.53 (1 H, d, J=2.2 Hz), 6.44 (1 H, d, J=9.4 Hz), 6.04 (1 H, br. s.), 4.25 (2 H, s), 3.78 (3 H, s), 3.06 (4 H, br. s.), 2.40 - 2.48 (4 H, m), 2.23 (3 H, s).
Example 13 : 3-(dimethylamino)-N-(3-(2-((2-methoxy-4-(4-methylpiperazin-l- yl)phenyl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)propanamide
Step 1. 8-(3-Aminophenyl)-2-((2-methoxy-4-(4-methylpiperazin-l- yl)phenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one (lb; 200 mg, 0.44 mmol) in DCM (5 mL) at 0 °C was treated with DIEA (0.19 mL, 1.09 mmol) and cooled in an ice bath at 0 °C. The solution was then treated with 3-chloropropionyl chloride (Sigma Aldrich, St. Louis, MO; 0.042 mL, 0.44 mmol) dropwise over 10 min and stirred at 0 °C for 30 min then stirred at RT for 2 h. 3 more drops of 3-chloropropionyl chloride was added and the reaction stirred at RT overnight. The reaction mixture was then concentrated, treated with DMSO (8 mL) and purified on a Gilson preparatory HPLC (Gemini Phenomenex; 30 x 150 mm, 5 μ, 10-95% 0.1%TFA/CH3CN in 0.1%TF A/water). The product containing fractions were concentrated under reduced pressure (rotary evaporator) and the resulting aqueous solution treated with a 10% solution of Na2C03 and extracted with DCM (4 x 30 mL), dried over Na2S04 and concentrated under vacuum overnight affording 3-chloro-N-(3-(2-((2-methoxy-4-(4-methylpiperazin-l-yl)phenyl)amino)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)propanamide (57 mg, 0.10 mmol, 23%o yield) as a yellow solid, m/z (ESI, +ve ion) 548.0 (M+H)+ in about 65%o purity with the mass balance corresponding to the acrylamide. The material was used in the subsequent step without further purification.
Step 2. 3-Chloro-N-(3-(2-((2-methoxy-4-(4-methylpiperazin-l-yl)phenyl)amino)- 7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)propanamide (57 mg, 0.086 mmol) was treated with dimethylamine (2.0 M in THF, 2.00 mL, 4.00 mmol) and stirred at 50 °C for 90 min then stirred at RT for 72 h. The mixture was purified by chromatography on silica gel on an ISCO Combiflash RF (24 g Redisep HP (Gold), using a gradient of 0-20% 2M NH3/MeOH in DCM) affording 3-(dimethylamino)-N-(3-(2-((2-methoxy-4-(4- methylpiperazin-l-yl)phenyl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)- yl)phenyl)propanamide (44.6 mg, 0.066 mmol, 76%o yield) as a yellow-orange amorphous foam, m/z (ESI, +ve ion) 557.0 (M+H)+. !H NMR (400 MHz, MeOH-d4) δ ppm 8.71 (1 H, s), 7.92 (1 H, d, J=9.4 Hz), 7.57 - 7.61 (1 H, m), 7.56 (1 H, s), 7.44 (1 H, d, J=7.8 Hz), 7.06 (1 H, d, J=8.0 Hz), 6.58 (1 H, d, J=2.5 Hz), 6.53 (1 H, d, J=9.4 Hz), 6.12 (1 H, br. s.), 3.88 (3 H, s), 3.10 - 3.19 (4 H, m), 2.77 (2 H, q, J=6.7 Hz), 2.63 - 2.68 (4 H, m), 2.57 - 2.62 (2 H, m), 2.39 (3 H, s), 2.33 (6 H, s).
Example 14: N-(3-(2-((4-((l-acetylazetidin-3-yl)amino)-2-methoxyphenyl)
oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide
To a suspension of l-(3-((4-amino-3-methoxyphenyl)amino)azetidin-l- yl)ethanone (14a, prepared according to the procedures described in WO 2012064706 (120 mg, 0.51 mmol) and N-(3-(2-(methylsulfmyl)-7-oxopyrido[2,3-d]pyrimidin-8(7H)- yl)phenyl)acrylamide (51) (150 mg, 0.42 mmol) in 1 mL of dioxane and 1 mL of iBuOH at RT was added DIEA (0.22 mL, 1.27 mmol). The mixture was heated in an oil bath at
85 °C for 1 h. NMP (0.5 mL) was added to the reaction mixture and heating was continued for 3 h. It was concentrated under reduced pressure. The residue was purified on a silica gel column (5% MeOH in DCM followed by 2-6% of 2 M NH3 in MeOH in DCM) to give a material that was about 90% pure. This material was dissolved in 10 mL of DMSO and purified on a reverse phase HPLC, using a gradient of 10-90%o of (0.1% TFA in CH3CN) in (0.1% TFA in water). Desired fractions were collected, lyophilized and the powdery residue was dissolved in MeOH, passed through a Silicycle (5 G) carbonate cartridge, rinsed with MeOH (20 mL). The fractions were collected and concentrated to give N-(3-(2-((4-((l-acetylazetidin-3-yl)amino)-2- methoxyphenyl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide (14) (135 mg , 0.257 mmol, 60.7 % yield) as a yellow crystalline solid, m/z (ESI, +ve ion) 526.0 (M+H)+. 1H NMR (400 MHz, DMSO-d6) δ ppm 10.42 (1 H, br.), 8.74 (1 H, s), 8.15 (1 H, s), 7.91 (2 H, d, J=9.4 Hz), 7.61 (1 H, br.), 7.51 (1 H, t, J=8.0 Hz), 7.18 (1 H, br.), 7.02 (1 H, d, J=8.0 Hz), 6.36 - 6.56 (2 H, m), 6.23 - 6.36 (1 H, m), 6.15 (2 H, m), 5.71 - 5.87 (1 H, m), 4.44 (1 H, m), 4.18 (1 H, m), 4.10 (1 H, m), 3.75 (1 H, m), 3.73 (3 H, s), 3.58 (1 H, m), 3.03 (1 H, m), 1.80 (3 H, s).
Example 15: N-(3-(2-((2-chloro-4-(4-methyl-l-piperazinyl)phenyl)amino)-7- oxopyrido [2,3-d] pyrimidin-8(7H)-yl)phenyl)-2-pr openamide
The title compound was prepared according to the procedures described for Example 1, starting from 2-chloro-4-(4-methylpiperazin-l-yl)aniline (Aurum
Pharmatech LLC). teri-Butyl (3-(2-((2-chloro-4-(4-methylpiperazin-l-yl)phenyl)amino)- 7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)carbamate (15a): m/z (ESI, +ve ion) 562.0 (M+H)+. 8-(3-Aminophenyl)-2-((2-chloro-4-(4-methylpiperazin-l -yl)phenyl)amino)- pyrido[2,3-d]pyrimidin-7(8H)-one (15b) : m/z (ESI, +ve ion) 461.9 (M+H)+.
N-(3-(2-((2-Chloro-4-(4-methylpiperazin-l-yl)phenyl)amino)-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)acrylamide (15): m/z (ESI, +ve ion) 515.9 (M+H)+. !H NMR (400 MHz, DMSO-d6) δ ppm 10.35 (1 H, s), 10.03 (1 H, br. s.), 8.83 (1 H, s), 7.94 (1 H, d, J=9.4 Hz), 7.83 (1 H, d, J=8.4 Hz), 7.69 (1 H, s), 7.53 (1 H, t, J=8.0 Hz), 7.41 (1 H, br. s.), 7.28 (1 H, d, J=7.2 Hz), 7.02 (1 H, d, J=7.8 Hz), 6.78 (1 H, br. s.), 6.50 (1 H, d, J=9.4 Hz), 6.44 (1 H, dd, J=17.0, 10.2 Hz), 6.25 (1 H, dd, J=17.0, 2.0 Hz), 5.76 (1 H, dd, J=10.2, 2.0 Hz), 2.83 (4 H, br. s.), 2.44 (4 H, br. s.), 2.23 (3 H, s).
Example 16: N-(3-(2-((4-((l-(2-fluoroethyl)-3-azetidinyl)amino)-2- methoxyphenyl)amino)-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2- propenamide
To a suspension of Nl-(l-(2-fluoroethyl)azetidin-3-yl)-3-methoxybenzene-l,4- diamine (11c; 373 mg, 1.56 mmol) and N-(3-(5-methyl-2-(methylsulfinyl)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide (5b; 440 mg, 1.194 mmol) in teri-butanol (10 mL) was added DIEA (0.62 mL, 3.58 mmol). The mixture was heated in an oil bath at 80 °C for 1 h. The reaction mixture was concentrated to dryness under reduced pressure (rotary evaporator) and the crude residue was purified on silica gel on an ISCO Combiflash RF (40 g Redisep column, using a gradient of 5-10% 2M
NH3/MeOH in DCM) affording enriched product. It was then repurified on a Gilson preparatory HPLC (Gemini Phenomenex; 30 x 150 mm, 5 μ, 10-95% 0.1%TFA/CH3CN in 0.1%TF A/water). The desired fractions were collected, and concentrated to dryness in a genevac overnight. The resulting solid was dissolved in 9: 1 = DCM:MeOH and was then passed through a Silicycle SPE-R66030B-20X SiliaSep OT, 5g/25 mL carbonate column using 10% MeOH/DCM then concentrated and dried under vacuum affording N- (3-(2-((4-((l-(2-fluoroethyl)azetidin-3-yl)amino)-2-methoxyphenyl)amino)-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide (317 mg, 0.58 mmol, 49% yield) as a yellow solid, m/z (ESI, +ve ion) 544.0 (M+H)+. !H NMR (400 MHz, DMSO-d6) δ ppm 10.37 (1 H, s), 8.78 (1 H, br. s.), 8.05 (1 H, br. s.), 7.84 (1 H, d, J=7.0 Hz), 7.60 (1 H, s), 7.50 (1 H, t, J=8.0 Hz), 7.15 (1 H, d, J=9.0 Hz), 6.99 (1 H, d, J=9.0 Hz), 6.41 - 6.51 (1 H, m), 6.23 - 6.34 (2 H, m), 6.16 (1 H, d, J=2.2 Hz), 5.85 (1 H, br. s.), 5.73 - 5.81 (1 H, m), 5.57 (1 H, br. s.), 4.49 (1 H, t, J=4.8 Hz), 4.37 (1 H, t, J=4.8 Hz), 3.90 (1 H, br. s.), 3.73 (5 H, br. s.), 2.76 - 2.88 (2 H, m), 2.74 (1 H, t, J=4.9 Hz), 2.63 - 2.71 (1 H, m), 2.46 (3 H, s).
Example 17: N-(3-(5-methyl-2-((4-(4-methylpiperazin-l-yl)phenyl)amino)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide
A microwave tube was charged with N-(3-(5-methyl-2-(methylsulfmyl)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide (5b; 210 mg, 0.57 mmol), 4-(4- methylpiperazino)aniline (136 mg, 0.71 mmol) and DIEA (0.20 mL, 1.14 mmol) in tert- butanol (5.5 mL). The tube was sealed and the mixture was heated to 100 °C for 3 d. The mixture was concentrated and then the brown solid was suspended in Et20 and collected by filtration. The brown solid was washed with Et20 to afford 270 mg of crude material. The crude material was absorbed onto a plug of silica gel and purified by chromatography through a Redi-Sep pre-packed silica gel column (12 g), eluting with a gradient of 0-20%o MeOH in DCM. This enriched product was repurified on a Gilson preparatory HPLC (Gemini Phenomenex; 30 x 150 mm, 5 μ, 10-95% 0.1 %TFA/CH3CN in 0.1%TFA/water). The product containing fractions were combined and concentrated. A saturated solution of aqueous NaHCC was added and the mixture was extracted with 3 : 1 CHCI3/IPA (3 x 30 mL). The combined organic layers were dried over anhydrous Na2S04, filtered and concentrated to provide N-(3-(5-methyl-2-((4-(4-methylpiperazin-l-yl)phenyl)amino)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide (52 mg, 0.11 mmol, 18% yield) as a yellow solid, m/z (ESI, +ve ion) 496.1 (M+H)+. !H NMR (400 MHz, DMSO-i¾) δ ppm 10.35 (1 H, s), 8.82 (1 H, s), 7.93 (1 H, d, J=8.61 Hz), 7.57 - 7.56 (1 H, m), 7.53 (1 H, t, .7=8.12 Hz), 7.17 - 7.19 (2 H, m), 6.95 - 7.02 (1 H, m), 6.53 - 6.56 (1 H, m), 6.37 - 6.48 (1 H, m), 6.31 (1 H, d, J=0.39 Hz), 6.21 - 6.28 (1 H, m), 5.72 - 5.80 (1 H, m), 2.91 - 3.02 (4 H, m), 2.46 (3 H, s), 2.39 - 2.44 (4 H, m), 2.21 (3 H, s).
Example 18: N-(3-(2-((2-methoxy-4-(piperazin-l-yl)phenyl)amino)-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide
Preparation of teri-butyl 4-(4-amino-3-methoxyphenyl)piperazine-l-carboxylate (18a): A solution of 1-teri-butyl 1-piperazinecarboxylate (Sigma Aldrich, 3.37 g, 18.12 mmol), 5-fluoro-2-nitroanisole (Oakwood Products, 3.10 g, 18.12 mmol) and N-ethyl-N- isopropylpropan-2 -amine (6.31 mL, 36.2 mmol) in DMSO (11 mL) in a 20 mL glass microwave tube was sealed and heated in a heating block at 95 °C overnight (20 h). Upon cooling, the mixture crystallized to a yellow solid. It was diluted with 150 mL of EtOAc, washed sequentially with 20 mL of water, 20 mL of NaHC03 and brine (20 mL). The organic solution was dried over MgS04 and concentrated affording teri-butyl 4-(3- methoxy-4-nitrophenyl)piperazine-l-carboxylate (6.14 g, 18.20 mmol, 99% yield) as a yellow crystalline solid, m/z (ESI, +ve ion) 359.9 (M+Na)+. !H NMR (400 MHz, MeOH-d4) δ ppm 7.96 (1 H, d, J=9.2 Hz), 6.59 (1 H, dd, J=9A, 2.5 Hz), 6.55 (1 H, d, J=2.3 Hz), 3.97 (3 H, s), 3.56 - 3.65 (4 H, m), 3.45 - 3.52 (4 H, m), 1.51 (9 H, s). Pd/C (10 wt. %, dry basis, wet activated, 284 mm, 0.267 mmol) and tert-butyl 4-(3-methoxy-4- nitrophenyl)piperazine-l-carboxylate (600 mg, 1.78 mmol) were treated with EtOH (30 mL) and allowed to stir under an atmosphere of H2 (balloon) for 23 h. The reaction mixture was filtered through an acrodisc (0.20 um), the resulting purple solution was then concentrated on the rotovap and then under vacuum overnight affording tert-butyl 4-(4- amino-3-methoxyphenyl)piperazine-l-carboxylate (539 mg, 1.76 mmol, 99% yield) as a purple film, m/z (ESI, +ve ion) 307.0/309.0 (M+H)+. !H NMR (400 MHz, MeOH-d4) δ ppm 6.71 (1 H, d, J=8.4 Hz), 6.62 (1 H, d, J=2.3 Hz), 6.46 (1 H, dd, J=8.3, 2.4 Hz), 3.85 (3 H, s), 3.51 - 3.61 (4 H, m), 2.92 - 3.02 (4 H, m), 1.47 - 1.52 (9 H, s).
Preparation of N-(3-(2-((2-methoxy-4-(piperazin-l-yl)phenyl)amino)-5-methyl- 7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide (18). To a suspension of tert- butyl 4-(4-amino-3-methoxyphenyl)piperazine-l-carboxylate (18a, 539 mg, 1.753 mmol) and N-(3-(5-methyl-2-(methylsulfmyl)-7-oxopyrido[2,3-d]pyrimidin-8(7H)- yl)phenyl)acrylamide (5b, 432 mg, 1.173 mmol) in teri-butanol (15 mL) at RT was added DIEA (0.61 mL, 3.52 mmol) followed by dioxane (6 mL). The reaction mixture was heated in a heating block at 90 °C for 20 h. The reaction mixture was concentrated on the rotovap and the crude residue was suspended in Et20 and filtered. The greenish brown amorphous solid was washed with Et20 (3 x 20 mL) and this removed most of the aniline starting material (18a). The crude material contained roughly 19% of the desired product (18b) along with recovered 5b. m/z (ESI, +ve ion) 611.9 (M+H)+. The crude residue was used in the subsequent step without further purification.
Crude teri-butyl 4-(4-((8-(3-acrylamidophenyl)-5-methyl-7-oxo-7,8- dihydropyrido[2,3-d]pyrimidin-2-yl)amino)-3-methoxyphenyl)piperazine-l-carboxylate (18b) from the previous step was treated with DCM (5 mL) and TFA (5.0 mL, 64.9 mmol) and allowed to stir at RT for 30 min. The reaction mixture was concentrated and purified on the on an ISCO Combiflash RF (24 g Redisep Gold column, using a gradient of 5-20% 2 M NH3/MeOH in DCM) affording enriched product. It was repurifed on a Gilson (Gemini Phenomenex; 30 x 150 mm, 5 u, 10-95% 0.1%TFA/CH3CN in
0.1 %TF A/water), concentrated in the genevac overnight and then passed through a Silicycle SPE-R66030B-20X SiliaSep OT, 5g/25 mL carbonate column using 20% MeOH/DCM to remove any residual salt then dried under vacuum affording N-(3-(2-((2- methoxy-4-(piperazin-l-yl)phenyl)amino)-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)- yl)phenyl)acrylamide (18) (20.6 mg, 0.040 mmol) as a bright yellow amorphous solid. m/z (ESI, +ve ion) 512.0 (M+H)+. !H NMR (400 MHz, DMSO-d6) δ ppm 10.33 (1 H, s), 8.80 (1 H, s), 8.08 (1 H, s), 7.87 (1 H, d, J=8.2 Hz), 7.57 (1 H, s), 7.50 (1 H, t, J=8.0 Hz), 7.27 (1 H, d, J=8.8 Hz), 6.97 (1 H, d, J=8.6 Hz), 6.50 (1 H, d, J=2.3 Hz), 6.38 - 6.48 (1 H, m), 6.20 - 6.35 (2 H, m), 5.99 (1 H, br. s.), 5.76 (1 H, dd, J=10.1, 1.9 Hz), 3.77 (3 H, s), 2.87 - 2.99 (4 H, m), 2.74 - 2.85 (4 H, m), 2.46 (3 H, s).
Example 19: N-(3-(2-((2-methoxy-4-(l-methylpiperidin-4-yl)phenyl)amino) methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide
Preparation of 2-methoxy-4-(l-methylpiperidin-4-yl)aniline (19b): A 25 mL glass microwave tube was charged with potassium phosphate tribasic (3.00 g, 13.05 mmol), 2-(dicyclohexylphosphino)-2',4',6',-tri-isopropyl-l , -biphenyl (Strem Chemicals, Newburyport, MA, 83 mg, 0.174 mmol), tris (dibenzylideneacetone) dipalladium (0) (Strem Chemicals, 80 mg, 0.087 mmol), 1 -methyl- l,2,3,6-tetrahydropyridine-4-boronic acid pinacol ester (Acros Organics, New Jersey, 971 mg, 4.35 mmol) followed by 5- chloro-2-nitroanisole (Sigma Aldrich, 816 mg, 4.35 mmol). The solids were purged with argon and treated with 1,4-dioxane (12 mL) and water (4 mL), sealed and heated at 1 10 °C in a heating block for 1 h. The reaction mixture was treated with 1 N NaOH and extracted with EtOAc (3 x 30 mL), dried over MgSO t, filtered and concentrated. The crude residue was purified on the ISCO Combiflash RF (80 g Thomson SingleStep column, using a gradient of 0-20% MeOH in DCM) affording 4-(3-methoxy-4- nitrophenyl)-l-methyl-l,2,3,6-tetrahydropyridine (19a; 970 mg, 3.91 mmol, 90% yield) as a rust-brown solid which crystallized upon standing, m/z (ESI, +ve ion) 249.1 (M+H)+. !H NMR (400 MHz, CDCl3) δ ppm 7.86 (1 H, d, J=8.4 Hz), 6.99 - 7.08 (2 H, m), 6.17 - 6.24 (1 H, m), 3.97 (3 H, s), 3.15 (2 H, q, J=2.8 Hz), 2.65 - 2.74 (2 H, m), 2.53 - 2.62 (2 H, m), 2.38 - 2.46 (3 H, m). In a 50 mL glass reactor, 4-(3-methoxy-4- nitrophenyl)-l -methyl- 1, 2,3, 6-tetrahydropyridine (940 mg, 3.79 mmol) was treated with palladium hydroxide (20 wt%> Pd, dry basis, on wet carbon, degussa type el 01 ne/w, 266 mg, 0.38 mmol) and anhydrous EtOH (20 mL). The reactor was purged with H2 (5 x) and stirred under 50 psi H2 at RT for 4 h. The mixture was filtered through a 0.45 um acrodisc, washing with MeOH and concentrated to dryness under high vacuum affording 2-methoxy-4-(l-methylpiperidin-4-yl)aniline (19b; 830 mg, 3.77 mmol, 99%o yield) as a yellow crystalline solid, m/z (ESI, +ve ion) 221.0 (M+H)+. !H NMR (400 MHz, CDCl3) δ ppm 6.56 - 6.74 (3 H, m), 3.76 - 3.89 (3 H, m), 3.54 - 3.76 (2 H, m), 2.97 (2 H, d,
J=\ \ 2 Hz), 2.34 - 2.47 (1 H, m), 2.23 - 2.34 (3 H, m), 1.95 - 2.12 (2 H, m), 1.70 - 1.90 (4 H, m).
Preparation of N-(3-(2-((2-methoxy-4-( 1 -methylpiperidin-4-yl)phenyl)amino)-5- methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide (19): To a suspension of 2-methoxy-4-(l-methylpiperidin-4-yl)aniline (19b, 363 mg, 1.65 mmol) and /V-(3-(5- methyl-2-(methylsulfmyl)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide (5b, 300 mg, 0.81 mmol) in teri-butanol (15 mL) at RT was added EtNiPr2 (0.43 mL, 2.443 mmol). The mixture was heated at 100 °C for 48 h. The reaction mixture was concentrated on the rotovap and the crude residue was suspended in Et20 and filtered. The resulting light yellow amorphous solid was washed with Et20 (3 x 50 mL) and chromatographed on an ISCO Combiflash RF (40 g Thomson SingleStep column, using a gradient of 0-15% MeOH in DCM) affording enriched product. It was repurifed on a Gilson (Gemini Phenomenex; 30 x 150 mm, 5 u, 10-95% 0.1%TFA/CH3CN in
0.1 %TF A/water), concentrated in the genevac overnight and then passed through a Silicycle SPE-R66030B-20X SiliaSep OT, 5g/25 mL carbonate column using 20%
MeOH/DCM to remove any residual salt then dried under vacuum affording N-(3-(2-((2- methoxy-4-(l-methylpiperidin-4-yl)phenyl)amino)-5-methyl-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)acrylamide (22 mg) as a light yellow solid, m/z (ESI, +ve ion) 525.0 (M+H)+. !H NMR (400 MHz, DMSO-d6) δ ppm 10.34 (1 H, s), 8.85 (1 H, s), 8.16 (1 H, s), 7.85 (1 H, d, J=9.2 Hz), 7.63 (1 H, s), 7.48 - 7.56 (1 H, m), 7.36 (1 H, d, J=8.4 Hz), 7.00 (1 H, d, J=7.8 Hz), 6.80 (1 H, d, J=1.4 Hz), 6.38 - 6.47 (1 H, m), 6.30 - 6.38 (2 H, m), 6.19 - 6.29 (1 H, m), 5.70 - 5.78 (1 H, m), 3.80 (3 H, s), 2.84 (2 H, d, J=11.2 Hz), 2.47 (3 H, s), 2.25 - 2.36 (1 H, m), 2.19 (3 H, s), 1.92 (2 H, td, J=l l . l, 3.7 Hz), 1.52 - 1.69 (4 H, m).
Example 20: N-(3-(2-((4-(4-acetylpiperazin-l-yl)-2-methoxyphenyl)amino)-5-methyl- 7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide
Preparation of l-(4-(3-methoxy-4-nitrophenyl)piperazin-l-yl)ethanone (20a). To a solution of tert-butyl 4-(3-methoxy-4-nitrophenyl)piperazine-l -carboxylate (18a; 1.66 g, 4.92 mmol) in 5 mL of DCM at RT was added TFA (3.65 mL, 49.2 mmol) and the resulting mixture was stirred at RT for 2 h. It was concentrated under reduced pressure. The yellow residue was partitioned between 200 mL of EtOAc and 25 mL of 1 N NaOH. The layers were separated and the organic solution was washed with 25 mL of brine, dried over Na2S04 and concentrated to give 1 -(3-methoxy-4-nitrophenyl)piperazine, m/z (ESI, +ve ion) 238.1 (M+H)+. THe yellow residue was dissolved in 100 mL of DCM, cooled with and ice bath, treated with triethylamine (1.37 mL, 9.84 mmol) followed by acetyl chloride (0.38 mL, 5.41 mmol). After 1 h at 0 °C, it was treated with 25 mL of 0.5 N NaOH. The layers were separated and the aqueous was extracted with 50 mL of DCM. The combined DCM solution was washed with 25 mL of brine, dried over Na2S04 and concentrated to give l-(4-(3-methoxy-4-nitrophenyl)piperazin-l-yl)ethanone (20a) as a yellow crystalline solid. Crude material was used in the next step. !H NMR (400 MHz, DMSO-de) δ ppm 7.91 (1 H, d, J=9.4 Hz), 6.59 (1 H, dd, J=9A, 2.3 Hz), 6.54 (1 H, d, J=2.3 Hz), 3.92 (3 H, s), 3.59 (4 H, d, J=2.7 Hz), 3.51 - 3.56 (2 H, m), 3.43 - 3.50 (2 H, m), 2.05 (3 H, s).
Preparation of l-(4-(4-amino-3-methoxyphenyl)piperazin-l-yl)ethanone (20b). A solution of l-(4-(3-methoxy-4-nitrophenyl)piperazin-l-yl)ethanone (20a) in 10 mL of EtOH was hydrogenated with a balloon filled with H2 in the presence of Pd/C (10 wt. %, 0.61 g, 0.57 mmol) for 18 h at RT. It was filtered through a pad of Celite and rinsed with EtOAc (2 x 20 mL). The filtrate was concentrated. The brown residue was triturated with 10 mL of hexanes. The liquid was decanted. The solid was dried in a vacuum oven at 40 °C for 1 h to give l-(4-(4-amino-3-methoxyphenyl)piperazin-l-yl)ethanone (20b; 1.42 g, 5.70 mmol, 99% yield) as a brown solid. Crude material used in the next step. !H NMR (400 MHz, DMSO-d6) δ ppm 6.54 (2 H, m), 6.32 (1 H, dd, J=8.3, 2.4 Hz), 4.63 (2 H, br.), 3.76 (3 H, s), 3.54 (4 H, m), 2.95 (2 H, m), 2.89 (2 H, m), 2.02 (3 H, s). m/z (ESI, +ve ion) 250.1 (M+H)+.
Preparation of N-(3-(2-((4-(4-acetylpiperazin-l-yl)-2-methoxyphenyl)amino)-5- methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide (20). A suspension of l-(4-(4-amino-3-methoxyphenyl)piperazin-l-yl)ethanone (20b; 351 mg, 1.40 mmol), EtNiPr2 (0.41 mL, 2.34 mmol) and N-(3-(5-methyl-2-(methylsulfmyl)-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)acrylamide (5b; 288 mg, 0.78 mmol) in teri-butanol (2 mL) and dioxane (1 mL) in a sealed glass tube was heated in an oil bath at 110 °C for 72 h. It was concentrated under reduced pressure. The brown residue was stirred in 5 mL of ether for 10 min. The liquid was decanted; the remaining solid was loaded on a silica gel column and eluted with 2- 10% MeOH in DCM followed by 5% 2 M NH3 in MeOH in DCM to give the title compound (20) (150 mg, 34% yield) as a yellow crystalline solid. !H NMR (400 MHz, DMSO-d6) δ ppm 10.33 (1 H, s), 8.81 (1 H, s), 8.12 (1 H, s), 7.88 (1 H, d, J=8.0 Hz), 7.42 - 7.61 (2 H, m), 7.28 (1 H, d, J=9.0 Hz), 6.98 (1 H, d, J=7.8 Hz), 6.56 (1 H, m), 6.44 (1 H, m), 6.33 (1 H, s), 6.24 (1 H, m), 6.04 (1 H, br. s.), 5.75 (1 H, m), 3.78 (3 H, s), 3.56 (4 H, m), 3.04 (2 H, m), 2.97 (2 H, m), 2.46 (3 H, s), 2.03 (3 H, s). m/z (ESI, +ve ion) 554.3 (M+H)+. Example Bl N-(3-(2-((4-((2-(dimethylamino)ethyl)(methyl)amino)-2- methoxyphenyl)amino)-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7//)- yl)phenyl)acrylamide
Preparation of N 1 -(2-(dimethylamino)ethyl)-3 -methoxy-N 1 -methylbenzene- 1 ,4- diamine hydrochloride (Bib). A mixture of 5-fluoro-2-nitroanisole (TCI America, 25.20 g, 147 mmol) in THF (100 mL) and DMF (50.0 mL) at RT was treated with Ν,Ν,Ν'- trimethylethylenediamine (Sigma Aldrich, 22.46 mL, 177 mmol) followed by Na2C03 (46.8 g, 442 mmol). The resulting mixture was heated at 85 °C for 22 h. The crude reaction mixture was cooled to RT and filtered and rinsed with EtOAc (2 x 50 mL). The filtrate was diluted with EtOAc (300 mL), washed with water (2 x 100 mL) followed by brine (50 mL) and dried over anhydrous Na2S04, filtered and concentrated affording crude Nl-(3-methoxy-4-nitrophenyl)-Nl,N2,N2-trimethylethane-l,2-diamine (Bla, 34.68 g, 137 mmol, 93% yield) as a viscous yellow oil after drying under high vacuum overnight. !H NMR (400 MHz, DMSO-d6) δ ppm 7.90 (1 H, d, J=9.4 Hz), 6.38 (1 H, d, J=9.4 Hz), 6.25 (1 H, s), 3.91 (3 H, s), 3.57 (2 H, t, J=6.7 Hz), 3.08 (3 H, s), 2.43 (2 H, t, J=6.7 Hz), 2.20 (6 H, s). m/z (ESI, +ve ion) 254.0 (M+H)+.
In a 500-mL RBF fitted with an air cooled reflux condenser was added Nl-(3- methoxy-4-nitrophenyl)-Nl,N2,N2-trimethylethane-l,2-diamine (Bla, 34.68 g, 137 mmol) followed by EtOH (100 mL) and 5 N HC1 (54.8 mL, 274 mmol). To this stirring solution was added zinc dust (<10 micron, 44.8 g, 685 mmol) in about 20 small portions over 20 min and the reaction was (suspension) stirred vigorously for 30 min warming to 50 °C. The mixture was briefly cooled and the suspension was filtered through a pad of celite. The solids were washed with MeOH (ca. 200 mL) and the filtrate concentrated under reduced pressure to remove the MeOH and EtOH. 5 N NaOH (60 mL) was added followed by CHC13 (300 mL) and the phases mixed and separated. The aqueous was extracted with additional CHCI3 (50 mL) and the combined organic layers dried with anhydrous Na2S04 and evaporated to dryness under reduced pressure. The free base was taken up in Et20 (150 mL) and cooled to 0 °C in an ice bath under argon. It was then treated with HC1 (4.0M solution in 1,4-dioxane, 31.7 mL, 127 mmol) and let stand for 5 min. The lumpy suspension was then stirred on the rotovap and slowly concentrated to remove the volatiles. The resulting greyish solid was then dried under high vacuum overnight affording Nl-(2-(dimethylamino)ethyl)-3-methoxy-Nl -methylbenzene-l,4- diamine hydrochloride (Bib, 32.17 g, 124 mmol, 90% yield). !H NMR (400 MHz, DMSO-de) δ ppm 6.75 (1 H, d, J=6.7 Hz), 6.49 (1 H, br. s.), 6.32 (1 H, d, J=7.4 Hz), 3.83 (3 H, br. s.), 3.58 (2 H, br. s.), 3.16 (2 H, br. s.), 2.70 - 2.89 (8 H, m). m/z (ESI, +ve ion) 224.0 (M+H)+.
Preparation of N-(3-(2-((4-((2-(dimethylamino)ethyl)(methyl)amino)-2- methoxyphenyl)amino)-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)- yl)phenyl)acrylamide (1). A 350-mL glass reaction vessel was charged with Nl-(2- (dimethylamino)ethyl)-3-methoxy-Nl-methylbenzene-l,4-diamine hydrochloride (8.77 g, 33.7 mmol) and N-(3-(2-chloro-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)- yl)phenyl)acrylamide (100, 10.00 g, 29.3 mmol) followed by purging with argon and addition of EtOH (55 mL) and glacial HOAc (1.85 mL, 32.3 mmol). The reaction mixture was sealed and heated to 125 °C in an oil bath for 1.5 h. The reaction mixture was transferred to a 1-L RBF using water (ca. 50 mL) and concentrated on the rotovap to remove most of the EtOH and treated with water (350 mL) and EtOAc (300 mL). The organic layer was separated and discarded. The aqueous layer was extracted with EtOAc (2 x 300 mL) and discarded. The aqueous layer was treated with NaOAc (ca. 18 g) (pH ca. 5-6) and extracted with CHCl3/5% IPA (3 x 300 mL) then treated with 1 N NaOH (10 mL) and extracted with CHC¾/5% IPA (1 x 300 mL) again. It was treated with 1 N NaOH (10 mL) and extracted with CHCl3/5% IPA (300 mL) again. The combined organic extracts were treated with a saturated solution of NaHC03 and separated. The organic extracts were dried over anhydrous MgS04, filtered and concentrated affording crude title compound as a brown-yellow solid. This material was recrystallized from a 4: 1 mixture of EtOH:water (ca. 80 mL) by briefly heating to reflux with a heat gun until the solution was homogeneous then gradually allowing to cool overnight and then filtering through a medium porosity sintered glass frit washing with water affording N-(3- (2-((4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide (Example Bl, 4.85 g, 9.19 mmol, 31% yield) as a fine yellow crystalline solid after drying. !H NMR (400 MHz, DMSO-de) δ ppm 10.31 (1 H, s), 8.77 (1 H, s), 8.06 (1 H, br. s.), 7.84 (1 H, br. s.), 7.55 (1 H, s), 7.48 (1 H, t, J=8.0 Hz), 7.20 (1 H, d, J=8.8 Hz), 6.97 (1 H, d, J=7.8 Hz), 6.37 - 6.49 (1 H, m), 6.18 - 6.34 (3 H, m), 5.64 - 5.91 (2 H, m), 3.66 - 3.84 (3 H, m), 2.75 - 2.89 (3 H, m), 2.45 (3 H, s), 2.33 (2 H, br. s.), 2.19 (6 H, s). m/z (ESI, +ve ion) 527.9 (M+H)+. Example B2: N-(3-(2-((4-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)amino)-5- methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide
A mixture of 4-fluoronitrobenzene (Sigma Aldrich; 6.14 mL, 57.9 mmol), Ν,Ν,Ν''-trimethylethylenediamine (Sigma Aldrich, 7.36 mL, 57.9 mmol) and potassium carbonate (16.00 g, 116 mmol) in DMSO (50 mL) was heated at 70 °C for 4 h. The reaction mixture was cooled to RT and treated with water. The yellow mixture was extracted with EtOAc (3 x 150 mL), washed with brine, dried over MgS04, filtered and concentrated affording crude Nl,Nl,N2-trimethyl-N2-(4-nitrophenyl)ethane-l,2-diamine (2a, 12.90 g, 57.8 mmol, 100% yield) as a viscous yellow oil. m/z (ESI, +ve ion) 224.0 (M+H)+. !H NMR (400 MHz, CDCl3) δ ppm 8.07 - 8.15 (2 H, m), 6.56 - 6.66 (2 H, m), 3.51 - 3.60 (2 H, m), 3.10 (3 H, s), 2.48 - 2.55 (2 H, m), 2.30 (6 H, s). In a 250 mL RBF, Nl ,Nl,N2-trimethyl-N2-(4-nitrophenyl)ethane-l ,2-diamine (B2a, 406 mg, 1.818 mmol) was treated with Pd/C (10 wt. % (dry basis) 194 mg, 0.18 mmol) in anhydrous EtOH (15 mL) and the atmosphere of the flask was subjected to vacuum/ H2 backfill cycles (x 5) and stirred under an atmosphere of H2 using a balloon for 16 h. The reaction mixture was filtered through a 0.45 um acrodisc washing with MeOH and concentrated to dryness affording Nl -(2-(dimethylamino)ethyl)-Nl - methylbenzene-l,4-diamine (B2b, 337 mg, 1.74 mmol, 96% yield) as a light yellow viscous oil. m/z (ESI, +ve ion) 194.1 (M+H)+. !H NMR (400 MHz, CDC13) δ ppm 6.55 - 6.74 (4 H, m), 3.34 (2 H, t, .7=7.1 Hz), 2.75 - 2.87 (3 H, m), 2.48 (2 H, t, J=7.0 Hz), 2.30 (6 H, s).
Nl-(2-(Dimethylamino)ethyl)-Nl-methylbenzene-l,4-diamine (335 mg, 1.733 mmol) and N-(3-(5-methyl-2-(methylsulfmyl)-7-oxopyrido[2,3-d]pyrimidin-8(7H)- yl)phenyl)acrylamide (103, 350 mg, 0.950 mmol) was treated with DMAc (4.0 mL) and heated to 100 °C for 3.5 h. The crude mixture was added directly to a silica gel column and the material was purified on the ISCO Combiflash RF (40 g Silicycle column, using a gradient of 0-20% 2M NH3/MeOH in DCM) affording enriched product. The material was purified on the Gilson (Gemini Phenomenex; 30 x 150 mm, 5 u, 10-95%o
0.1%TFA CH3CN in 0.1 %TF A/water), concentrated in a Genevac overnight and then passed through a Silicycle SPE-R66030B-20X SiliaSep OT, 5g/25 mL carbonate column using 20% MeOH/DCM then dried under vacuum affording N-(3-(2-((4-((2-
(dimethylamino)ethyl)(methyl)amino)phenyl)amino)-5-methyl-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)acrylamide TFA salt (Example B2; 290 mg, 0.47 mmol, 50% yield) as a bright yellow amorphous solid, m/z (ESI, +ve ion) 498.0 (M+H)+. !H NMR (400 MHz, DMSO-d6) δ ppm 10.33 (1 H, s), 9.73 (1 H, br. s.), 8.79 (1 H, s), 7.89 (1 H, d, J=7.2 Hz), 7.43 - 7.61 (2 H, m), 7.14 (2 H, d, J=6.5 Hz), 6.98 (1 H, dd, J=7.8, 1.0 Hz), 6.37 - 6.49 (1 H, m), 6.17 - 6.37 (4 H, m), 5.67 - 5.83 (1 H, m), 3.21 - 3.29 (2 H, m), 2.72 - 2.84 (3 H, s), 2.45 (3 H, s), 2.28 (2 H, t, .7=7.1 Hz), 2.09 - 2.21 (6 H, s).
Example B3: N-(3-(2-((3-fluorophenyl)amino)-5-methyl-7-oxopyrido[2,3- d] py rimidin-8(7H)-yl)phenyl)acrylamide
3-Fluoroaniline (Alfa Aesar, Ward Hill, MA, 0.112 mL, 1.166 mmol) and N-(3-
(5-methyl-2-(methylsulfinyl)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide (103, 358 mg, 0.972 mmol) was treated with anhydrous 2-butanol (5 mL, 54.5 mmol) and TFA (0.075 mL, 0.97 mmol), fitted with a reflux condenser and heated to 110 °C for 15 h. The crude reaction mixture was added directly to a silica gel column and the material was purified on the ISCO Combiflash RF (40 g Thomson SingleStep column, using a gradient of 0-20% 2 M NH3/MeOH in DCM) affording N-(3-(2-((3-fluorophenyl)amino)- 5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide (283 mg, 0.68 mmol, 70%o yield) as a light yellow solid after washing with Et20 and drying in a vacuum oven. m/z (ESI, +ve ion) 415.9 (M+H)+. !H NMR (400 MHz, DMSO-d6) δ ppm 10.33 (1 H, s), 10.20 (1 H, br. s.), 8.93 (1 H, s), 7.68 - 7.81 (2 H, m), 7.52 (1 H, t, J=8.0 Hz), 7.22 (1 H, d, J=12.3 Hz), 7.16 (1 H, d, J=8.0 Hz), 6.92 - 7.09 (2 H, m), 6.64 (1 H, t, J=8.4 Hz), 6.35 - 6.50 (2 H, m), 6.15 - 6.31 (1 H, m), 5.66 - 5.82 (1 H, m). 19F NMR (376 MHz, DMSO- d6) δ ppm -11 1.67.
Example B4: N-(3-(5-methyl-2-((l-methyl-lH-pyrazol-4-yl)amino)-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide
A mixture of 1 -methyl- 1 -H-pyrazol-4-ylamine (63.0 mg, 0.65 mmol, Astatech, Inc.) and N-(3-(5-methyl-2-(methylsulfmyl)-7-oxopyrido[2,3-d]pyrimidin-8(7H)- yl)phenyl)acrylamide (103) (199 mg, 0.54 mmol) in N,N-dimethylacetamide (0.51 mL, 5.40 mmol) was heated in an oil bath at 90 °C for 90 min. The reaction mixture was loaded on a silica gel column and eluted with 3-10% MeOH in DCM to give N-(3-(5- methyl-2-(( 1 -methyl- 1 H-pyrazol-4-yl)amino)-7-oxopyrido [2,3 -d]pyrimidin-8(7H)- yl)phenyl)acrylamide (Example B4, 168 mg, 0.419 mmol, 77%o yield), as a brown crystalline solid. !H NMR (400 MHz, DMSO-d6) δ ppm 10.39 (1 H, br.), 10.03 (1 H, s), 8.81 (1 H, s), 7.86 (1 H, d, J=8.6 Hz), 7.66 (1 H, s), 7.60 (1 H, t, J=8.0 Hz), 7.11 (1 H, s), 7.04 (1 H, d, J=8.4 Hz), 6.75 (1 H, s), 6.35 - 6.51 (1 H, m), 6.07 - 6.32 (2 H, m), 5.74 - 5.81 (1 H, m), 3.51 (3 H, s), 2.46 (3 H, s). m/z (ESI, +ve ion) 402.2 (M+H)+. Example 5: N-(3-(2-((l-(2-(dimethylamino)ethyl)-lH-pyrazol-4-yl)amino)-5-methyl- 7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide
A mixture of l-(2-(dimethylamino)ethyl)-lH-pyrazol-4-amine (103 mg, 0.671 mmol, Enamine Ltd.) and N-(3-(5-methyl-2-(methylsulfinyl)-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)acrylamide (103) (206 mg, 0.559 mmol) in N,N- dimethylacetamide (0.53 mL, 5.59 mmol) was heated in an oil bath at 90 °C for 2 h. The mixture was loaded on a silica gel column and eluted with 3-10% MeOH in DCM to give N-(3-(2-((l-(2-(dimethylamino)ethyl)-lH-pyrazol-4-yl)amino)-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide (Example B5, 178 mg, 0.388 mmol, 69% yield), as a brown crystalline solid. !H NMR (400 MHz, DMSO-d6) δ ppm 10.38 (1 H, br.), 10.04 (1 H, s), 8.81 (1 H, s), 7.86 (1 H, d, J=8.6 Hz), 7.64 (1 H, s), 7.59 (1 H, t, J=8.0 Hz), 7.14 (1 H, s), 7.05 (1 H, d, J=7.6 Hz), 6.78 (1 H, s), 6.40 (1 H, m), 6.34 (1 H, s), 6.25 (1 H, m), 5.76 (1 H, dd, J=10.2, 1.8 Hz), 3.80 (2 H, q, J=6.3 Hz), 2.46 (3 H, s), 2.42 (2 H, m), 2.09 (6 H, s). m/z (ESI, +ve ion) 459.2 (M+H)+
Example B6: 8-(((3S)-l-acryloyl-3-pyrrolidinyl)methyl)-2-((2-methoxy-4-(4-methyl- l-piperazinyl)phenyl)amino)-5-methylpyrido[2,3-d]pyrimidin-7(8H)-one
Step 1. A solution of l -(2,4-dichloropyrimidin-5-yl)ethanone (800 mg, 4.19 mmol, Princeton Bio) in 3 mL of THF and 18 mL of cyclohexane at RT was treated with ( ?)-tert-butyl 3-(aminomethyl)pyrrolidine-l -carboxylate (923 mg, 4.61 mmol, Astatech Inc.) followed by NaHCC (387 mg, 4.61 mmol). It was stirred at RT for 2 h, and diluted with 150 mL of EtOAc. The mixture was filtered through a pad of Celite. The solid was discarded. The filtrate was concentrated and the residue was purified on a silica gel column (25-55% EtOAc in hexanes) to afford ( ?)-tert-butyl 3-(((5-acetyl-2- chloropyrimidin-4-yl)amino)methyl)pyrrolidine-l-carboxylate (B6a, 398 mg, 1.12 mmol, 26% yield, about 85%o pure) as an off white amorphous solid, m/z (ESI, +ve ion) 376.9 (M+23)+.
Step 2. At -78 °C, EtOAc (329 xL, 3.36 mmol) was added dropwise to a solution of LiHMDS (3.48 mL of 1.0 M solution in THF, 3.48 mmol) in 5 mL of THF. It was stirred at -78 °C for 15 min then treated with a solution of ( ?)-tert-butyl 3-(((5-acetyl-2- chloropyrimidin-4-yl)amino)methyl)pyrrolidine-l-carboxylate (398 mg of B6a that was about 85% pure, 1.12 mmol) in THF (6 mL) dropwise. After stirring at -78 °C for 10 min, the cold bath was removed, and the mixture was stirred for 90 min. It was quenched with 25 mL of sat NH4C1 and extracted with 2 x 50 mL of EtOAc. The organic solution was dried over Na2S04 and concentrated. The residue was purified on a silica gel column (35-55% EtOAc in hexanes) to give ( ?)-tert-butyl 3-((2-chloro-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)methyl)pyrrolidine-l-carboxylate (B6b, 340 mg, 0.897 mmol, 80% yield, about 40% pure) as a brown amorphous solid, m/z (ESI, +ve ion) 401 (M+23)+.
Step 3. A solution of (R)-tert-butyl 3-((2-chloro-5-methyl-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)methyl)pyrrolidine-l -carboxylate (340 mg of 6b that was about 40% pure, 0.90 mmol) in 3 mL of DCM at RT was treated with TFA (667 xL, 8.97 mmol) and stirred at RT for 45 min. It was concentrated under reduced pressure. The brown residue was dissolved in 10 mL of DCM, cooled with an ice bath and treated with EtNiPr2 (0.62 mL, 3.59 mmol) followed by acryloyl chloride (87 xL, 1.07 mmol). The mixture was stirred at 0 °C for 30 min. It was diluted with 50 mL of DCM, washed with 10 mL of sat NaHCC followed by 5 mL of brine. The DCM solution was dried over Na2S04 and concentrated. The residue was purified on a silica gel column (65-100%o EtOAc in DCM) to afford (,S)-8-((l-acryloylpyrrolidin-3-yl)methyl)-2-chloro-5- methylpyrido[2,3-d]pyrimidin-7(8H)-one (B6c, 187 mg, 0.562 mmol, 63 % yield) as a yellow amorphous solid, m/z (ESI, +ve ion) 333.0 (M+H)+.
Step 4. A mixture of (.S)-8-((l-acryloylpyrrolidin-3-yl)methyl)-2-chloro-5- methylpyrido[2,3-d]pyrimidin-7(8H)-one (B6c, 185 mg, 0.55 mmol), 2-methoxy-4-(4- methylpiperazin-l-yl)aniline (148 mg, 0.66 mmol, GreenchemPharm) and TFA (0.045 mL, 0.61 mmol) in 2-butanol (2 mL, 21.80 mmol) was heated in an oil bath at 100 °C for 3 h. The reaction mixture was diluted with 50 mL of EtOAc, washed with 5 mL of 0.5 N NaOH followed by 5 mL of brine. The organic solution was concentrated and purified on a silica gel column twice (5% MeOH in DCM followed by 5-8% of 2 M NH3 in MeOH in DCM) to give (S)-8-((l-acryloylpyrrolidin-3-yl)methyl)-2-((2-methoxy-4-(4- methylpiperazin-l-yl)phenyl)amino)-5-methylpyrido[2,3-d]pyrimidin-7(8H)-one
(Example B6) (41 mg, 0.079 mmol, 14% yield) as a yellow amorphous solid. !H NMR (400 MHz, DMSO-de) δ ppm 8.73 (1 H, s), 8.58 - 8.70 (1 H, m), 7.53 (1 H, t, J=9.0 Hz), 6.63 (1 H, d, J=2.3 Hz), 6.48 - 6.57 (1 H, m), 6.36 - 6.48 (1 H, m), 6.19 (1 H, s), 6.03 - 6.14 (1 H, m), 5.62 (1 H, ddd, J=10.3, 8.0, 2.4 Hz), 4.13 (2 H, m), 3.77 (3 H, s), 3.45 (2 H, m), 3.24 (2 H, m), 3.14 (4 H, br.), 2.67 (1 H, m), 2.46 (4 H, m), 2.38 (3 H, s), 2.23 (3 H, s), 1.82 (1 H, m), 1.63 (1 H, m). m/z (ESI, +ve ion) 518.2 (M+H)+.
Example B7: N-(3-(2-((l,3-dimethyl-lH-pyrazol-4-yl)amino)-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide
A mixture of l ,3-dimethyl-lH-pyrazol-4-amine dihydrochloride (85 mg, 0.462 mmol, ChemBridge) and N-(3-(5-methyl-2-(methylsulfmyl)-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)acrylamide (103) (148 mg, 0.402 mmol) in N,N- dimethylacetamide (0.37 mL, 4.02 mmol) was heated in an oil bath at 100 °C for 90 min. It was loaded on a silica gel column and eluted with 3-10% MeOH in DCM to give N-(3- (2-((l,3-dimethyl-lH-pyrazol-4-yl)amino)-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)- yl)phenyl)acrylamide (Example B7, 126 mg, 0.303 mmol, 75% yield) as a yellow crystalline solid. !H NMR (400 MHz, DMSO-d6) δ ppm 10.38 (1 H, br.), 9.52 (1 H, s), 8.82 (1 H, s), 7.85 (1 H, m), 7.59 (2 H, m), 7.03 (1 H, d, J=7.8 Hz), 6.69 (1 H, s), 6.48 (1 H, m), 6.25 (2 H, m), 5.77 (1 H, m), 3.41 (3 H, m), 2.47 (3 H, s), 2.10 (3 H, s). m/z (ESI, +ve ion) 416.1 (M+l)+. Example B8: N-(3-(2-((l-ethyl-lH-pyrazol-5-yl)amino)-5-methyl-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)acrylamide.
A mixture of 5-amino-l-ethylpyrazole (Sigma Aldrich, 48 mg, 0.432 mmol) and
N-(3-(5-methyl-2-(methylsulfmyl)-7-oxopyrido[2,3-d]pyrimidin-8(7H)- yl)phenyl)acrylamide (103) (100 mg, 0.27 mmol) in 2-butanol (2 mL) was treated with TFA (0.025 mL, 0.33 mmol) and heated at 110 °C for 15 h. The crude mixture was purified on the Gilson (Gemini Phenomenex; 30 x 150 mm, 5 u, 10-95%o 0.1 %>
TFA/CH3CN in 0.1% TF A/water) affording enriched product. It was repurified on the ISCO Combiflash RF (12 g Thomson SingleStep column, using a gradient of 0-10% MeOH in DCM) affording N-(3-(2-((l-ethyl-lH-pyrazol-5-yl)amino)-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide (23.8 mg, 0.057 mmol, 21% yield) as a yellow amorphous solid after drying in the vacuum oven at 45 °C for 1.5 h. m/z (ESI, +ve ion) 416.0 (M+H)+. !H NMR (400 MHz, DMSO-d6) δ ppm 10.30 (1 H, s), 9.83 (1 H, br. s.), 8.89 (1 H, s), 7.69 (1 H, d, J=7.8 Hz), 7.63 (1 H, s), 7.47 (1 H, t, J=7.9 Hz), 7.06 (1 H, d, J=8.0 Hz), 6.98 (1 H, d, J=8.2 Hz), 6.34 - 6.53 (3 H, m), 6.18 - 6.32 (1
H, m), 5.92 (1 H, br. s.), 5.60 - 5.84 (2 H, m), 3.92 - 4.08 (2 H, m), 3.79 - 3.91 (1 H, m),
I .10 - 1.29 (3 H, m) ca. a 1 :0.3 ratio of two conformers (data for the major conformer shown).
Example B9: N-(3-(2-((4-(2-(dimethylamino)ethoxy)-2-fluorophenyl)amino)-5- methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide
Example B9 I
Preparation of 4-(2-(dimethylamino)ethoxy)-2-fluoroaniline hydrochloride (9b). To a stirred solution of 3-fluoro-4-nitrophenol (Sigma Aldrich, 1.30 g, 8.26 mmol) in DMF (12 mL) was added Cs2C03 (6.72 g, 20.64 mmol) and 2-(dimethylamino)ethyl chloride hydrochloride (Sigma Aldrich, 1.55 g, 10.73 mmol) and the bright yellow suspension was stirred at 50 °C overnight. After the mixture was cooled to RT, the reaction mixture was diluted with H20 (30 mL) and extracted with DCM (3 x 40 mL). The organic extracts were washed with brine and dried over Na2S04. The solution was filtered and concentrated in vacuo to give the crude material as a yellow oil. The crude material was absorbed onto silica gel and purified by chromatography through a Redi-Sep pre-packed silica gel column (40 g), eluting with a gradient of 0-3% 2 M NH3 MeOH in CH2C12, to provide 2-(3-fluoro-4-nitrophenoxy)-A^,A^-dimethylethanamine (B9a, 0.392 g, 21% yield) as yellow oil. MS (ESI positive ion): m/z calcd for CioHi3FN203 228; found 229 (M + H); ¾ MR (400 MHz, CDC13) δ 8.00-8.13 (m, 1H), 6.69-6.85 (m, 2H), 4.15 (t, J= 5.58 Hz, 2H), 2.78 (t, J= 5.48 Hz, 2H), 2.36 (s, 6H). The material of B9a isolated above was redissolved in EtOH (5.00 mL) and wet 10% Pd on carbon (0.39 g, 0.36 mmol) was added and the suspension was stirred under 1 atm H2 for 3 h. The mixture was passed through a short path of Celite. The filter cake was washed with MeOH (3 x 5 mL) and the combined organic phases were concentrated to give the crude 2-(3-fluoro-4- nitrophenoxy)-A^,A^-dimethylethanamine as a colorless oil. MS (ESI positive ion): m/z calcd for Ci0Hi5FN2O 198; found 199 (M + H). A colorless solution of crude material isolated above in EtOAc (5 mL) was added HCl (4.0 N solution in 1,4-dioxane, 0.45 mL, 1.80 mmol) and stirred for 5 min. The resulting white suspension was concentrated to give 4-(2-(dimethylamino)ethoxy)-2-fluoroaniline hydrochloride (B9b, 0.40 g, 21% overall yield from 3-fluoro-4-nitrophenol) as a white solid which was used directly for the next reaction without further purification.
Preparation of N-(3-(2-((4-(2-(dimethylamino)ethoxy)-2-fluorophenyl)amino)-5- methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide (Example B9). To a stirred mixture of A^-(3-(2-chloro-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)- yl)phenyl)acrylamide (100) (202 mg, 0.59 mmol) and 4-(2-(dimethylamino)ethoxy)-2- fluoroaniline hydrochloride (B9b, 167 mg, 0.71 mmol) was added EtOH (2.00 mL) and AcOH (0.051 mL, 0.89 mmol) and the suspension was heated at 125 °C for 2 h. After the reaction was cooled to RT, the mixture was concentrated and treated with saturated aqueous NaHC03 solution and the resulting precipitate was collected and dried under a reduced pressure. The crude material was absorbed onto silica gel and purified by chromatography through a Redi-Sep pre-packed silica gel column (40 g), eluting with a gradient of 0-7% of 2 M NH3 MeOH in CH2C12, followed by two preparative TLC purifications (7% of 2 M NH3 MeOH in EtOAc), to provide N-(3-(2-((4-(2-
(dimethylamino)ethoxy)-2-fluorophenyl)amino)-5-methyl-7-oxopyrido[2,3-d]pyrimidin- 8(7H)-yl)phenyl)acrylamide (17 mg, 6%> yield) as an off-white solid. MS (ESI positive ion): m/z calcd for C27H27FN603 502; found 503 (M + H); !H NMR (400 MHz, DMSO- d6) δ 10.31 (s, 1H), 9.23 (br. s., 1H), 8.83 (br. s., 1H), 7.75 (d, J= 8.22 Hz, 1H), 7.57 (s, 1H), 7.47 (t, J= 8.12 Hz, 1H), 7.27 (t, J= 8.80 Hz, 1H), 6.96 (d, J= 7.63 Hz, 1H), 6.75 (d, J= 12.52 Hz, 1H), 6.22-6.49 (m, 4H), 5.77 (d, J= 9.98 Hz, 1H), 3.91-4.01 (m, 2H), 2.60 (t, J= 4.89 Hz, 2H), 2.47 (s, 3H), 2.22 (s, 6H). Example BIO: N-(3-(2-((3-chloro-l-methyl-lH-pyrazol-4-yl)amino)-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide
3-Chloro-l-methyl-lH-pyrazol-4-amine (BlOb) was prepared according to the procedures reported in WO 201039731. !H NMR (400 MHz, DMSO-d6) δ ppm 7.10 (1 H, s), 4.02 (2 H, br.), 3.64 (3 H, s). m/z (ESI, +ve ion) 132.1 (M+l)+.
A mixture of 3 -chloro-1 -methyl- lH-pyrazol-4-amine (BlOb, 52 mg, 0.39 mmol) and N-(3-(2-chloro-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide (100) (123 mg, 0.361 mmol) in 2-butanol (2.5 mL) was treated with TFA (29.5 xL, 0.39 mmol) and the mixture was heated in an oil bath at 100 °C for 20 h. The mixture was loaded on a silica gel column and eluted with 35-75% EtOAc in DCM to give a material that was enriched with the desired product, m/z (ESI, +ve ion) 436.1 (M+l)+. The material was purified again on a silica gel column (50% EtOAc in DCM) to provide N- (3-(2-((3-chloro-l-methyl-lH-pyrazol-4-yl)amino)-5-methyl-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)acrylamide (Example B10, 101 mg, 0.232 mmol, 64% yield), as a yellow crystalline solid. !H NMR (400 MHz, DMSO-d6) δ ppm 10.43 (1 H, br.), 9.57 (1 H, br.), 8.87 (1 H, s), 7.83 (1 H, m), 7.53 - 7.68 (2 H, m), 7.05 (1 H, m), 6.78 (1 H, s), 6.45 (1 H, m), 6.35 (1 H, s), 6.28 (1 H, m), 5.78 (1 H, d, J=10.2 Hz), 3.48 (3 H, s), 2.47 (3 H, s). m/z (ESI, +ve ion) 436.1 (M+l)+.
Example Bll: N-(3-(2-((l,3-dimethyl-lH-pyrazol-4-yl)amino)-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)acrylamide
A mixture of 1,3 -dimethyl- lH-pyrazol-4-amine dihydro chloride (Frontier Scientific, Newark, DE, 55.0 mg, 0.299 mmol) and N-(3-(2-(methylsulfinyl)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide (104, 92 mg, 0.260 mmol) in DMAc (1 mL) was treated with DIPEA (0.14 mL, 0.779 mmol) and heated at 100 °C for 2 h. The crude reaction mixture was purified on the I SCO Combiflash RF (24 g Redisep column, using a gradient of 0-10% MeOH in DCM) affording N-(3-(2-((l,3-dimethyl- lH-pyrazol-4-yl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide (17 mg, 0.043 mmol, 16% yield) as a yellow amorphous solid after washing with Et20 and drying in the vacuum oven at 42 °C overnight, m/z (ESI, +ve ion) 401.9 (M+H)+. !H NMR (400 MHz, DMSO-d6) δ ppm 10.38 (1 H, s), 9.54 (1 H, s), 8.77 (1 H, s), 7.91 (1 H, d, J=9.6 Hz), 7.85 (1 H, d, J=8.4 Hz), 7.66 (1 H, s), 7.59 (1 H, t, J=8.0 Hz), 7.06 (1 H, d, J=7.2 Hz), 6.72 (1 H, s), 6.37 - 6.49 (2 H, m), 6.20 - 6.30 (1 H, m), 5.71 - 5.82 (1 H, m), 3.41 (3 H, s), 2.10 (3 H, s).
Example B12: N-(3-(5-methyl-2-((l-methyl-3-(trifluoromethyl)-lH-pyrazol-4- yl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide
A mixture of l-methyl-3-(trifluoromethyl)-lH-pyrazol-4-amine hydrochloride (67.0 mg, 0.33 mmol, Princeton Bio) and N-(3-(2-chloro-5-methyl-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)acrylamide (100) (103 mg, 0.30 mmol) in 2-butanol (2 mL) was was heated in an oil bath at 100 °C for 18 h. It was diluted with 50 mL of EtOAc, washed with 1 N NaOH (5 mL) followed by brine (5 mL). The organic solution was concentrated and the resude was loaded on a silica gel column and eluted with 35-75% EtOAc in DCM to give N-(3-(5-methyl-2-((l-methyl-3-(trifluoromethyl)-lH-pyrazol-4- yl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide (66 mg, 46 % yield) as an off white crystalline solid. !H NMR (400 MHz, DMSO-d6) δ ppm 10.40 (1 H, br.), 9.43 (1 H, br.), 8.88 (1 H, s), 7.81 (1 H, d, J=7.8 Hz), 7.48 - 7.66 (2 H, m), 7.04 (2 H, m), 6.32 - 6.48 (2 H, m), 6.22 (1 H, m), 5.78 (1 H, d, J=10.0 Hz), 3.60 (3 H, s), 2.48 (3 H, s). 19F NMR (376 MHz, DMSO-d6) δ ppm -58.66 (s). m/z (ESI, +ve ion) 470.0.
Example B13 : N-(3-(5-methyl-2-((4-(l-methylpiperidin-4-yl)phenyl)amino)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide
A mixture of 4-bromoaniline (0.80 g,4.65 mmol), l-methyl-4-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)-l,2,3,6-tetrahydropyridine (1.04 g, 4.65 mmol), dicyclohexyl(2',4',6'-triisopropyl-[l,l'-biphenyl]-2-yl)phosphine (0.089 g, 0.186 mmol), potassium phosphate (2.96 g, 13.95 mmol), and Pd2(dba)3 (0.085 g, 0.093 mmol) in p- dioxane/H20 (4:1, 15 mL) was heated at 100 °C for 2 h. The reaction was cooled, treated with water, and extracted with EtOAc (3 x). The extracts were dried over MgSOt, concentrated and purified by silica gel column (0-10% MeOH/DCM) to give 4-(l- methyl-l,2,3,6-tetrahydropyridin-4-yl)aniline (B13a, 0.567g, 65%). m/z (ESI, +ve ion) 189.1 (M+H)+.
A mixture of 4-(l-methyl-l,2,3,6-tetrahydropyridin-4-yl)aniline (0.567 g, 3.01 mmol) and 10% Pd/C (50 mg) in EtOH (10 mL) was hydrogenated under H2 balloon overnight. The catalyst was filtered off, the filtrate was concentrated to dryness and the resulting 4-(l-methylpiperidin-4-yl)aniline (B13b) was used in the next step (0.515g, 90%). m/z (ESI, +ve ion) 191.1 (M+H)+.
A mixture of N-(3-(5-methyl-2-(methylsulfinyl)-7-oxopyrido[2,3-d]pyrimidin- 8(7H)-yl)phenyl)acrylamide (0.100 g, 0.271 mmol) and 4-(l-methylpiperidin-4-yl)aniline
(0.077 g, 0.407 mmol) in DMA (2 mL) was heated at 100 °C for 14 h. The reaction mixture was cooled, and treated with water. The solid was collected, washed with H20, dried and purified by reverse phase HPLC. The pure fractions were concentrated to dryness and dissolved in MeOH and passed through Stratophere SPE PL-HCO3 MP SPE (200mg, 0.36 mmol) to give N-(3-(5-methyl-2-((4-(l-methylpiperidin-4- yl)phenyl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide (Example B13; 16 mg, 12%). !H NMR (400 MHz, DMSO-d6) δ ppm 10.37 (1 H, s), 9.93 (1 H, br. s.), 8.86 (1 H, s), 7.88 (1 H, d, J=8.8 Hz), 7.64 (1 H, s), 7.54 (1 H, t, .7=8.1 Hz), 7.15 - 7.32 (2 H, m), 6.96 - 7.06 (1 H, m), 6.83 (2 H, m, J=8.0 Hz), 6.38 - 6.48 (1 H, m), 6.34 (1 H, d, J=1.2 Hz), 6.19 - 6.29 (1 H, m), 5.71 - 5.80 (1 H, m), 2.82 (2 H, d, J=11.3 Hz), 2.45 (3 H, s), 2.20 - 2.31 (1 H, m), 2.18 (3 H, s), 1.83 - 1.95 (2 H, m), 1.47 - 1.64 (4 H, m). m/z (ESI, +ve ion) 495.2 (M+H)+.
Example B14: N-(3-(2-((4-(2-(dimethylamino)ethoxy)-2-methoxyphenyl)amino)-5- methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide
A mixture of 4-fluoro-2-methoxy-l -nitrobenzene (5.94 g, 34.7 mmol), 2- (dimethylamino)ethanol (4.64 g, 52.1 mmol) and Cs2C03 (22.62 g, 69.4 mmol) in DMF
(20 mL) was heated at 80 °C in an oil bath for 4 h. The mixture was diluted with 250 mL of EtOAc and filtered. The filtrate was washed with water (2 x 20 mL) followed by brine (20 mL) and concentrated. The residue was purified on a silica gel column (1-5% of 2 M NH3 in MeOH in DCM) to give 2-(3-methoxy-4-nitrophenoxy)-N,N-dimethylethanamine
(B14a, 6.3 g, 75% yield) as a yellow viscous oil. !H NMR (400 MHz, DMSO-d6) δ ppm 7.97 (1 H, s), 6.82 (1 H, d, J=2.5 Hz), 6.69 (1 H, dd, J=9.2, 2.3 Hz), 4.21 (2 H, t, J=5.8 Hz), 3.94 (3 H, s), 2.66 (2 H, t, J=5.7 Hz), 2.24 (6 H, s).
A solution of 2-(3-methoxy-4-nitrophenoxy)-N,N-dimethylethanamine (B14a,
6.3 g, 26.2 mmol) in 50 mL of EtOH and 70 mL of EtOAc was hydrogenated with a balloon filled with H2 in the presence of Pd/C (10% 2.23 g, 2.09 mmol) for 18 h at RT. It was filtered through a pad of Celite and rinsed with 2 x 30 mL of EtOAc. The filtrate was concentrated to give 4-(2-(dimethylamino)ethoxy)-2-methoxyaniline (5.39 g, 25.6 mmol, 98% yield) as a brown viscous oil. !H NMR (400 MHz, DMSO-d6) δ ppm 6.54 (1 H, d, J=8.4 Hz), 6.45 (1 H, s), 6.30 (1 H, d, J=8.4 Hz), 4.22 (2 H, br.), 3.92 (2 H, t, J=5.8 Hz), 3.75 (3 H, s), 2.57 (2 H, t, J=5.8 Hz), 2.21 (6 H, s). The brown viscous oil was dissolved in 3 mL of dioxane and treated with a solution of 4 N HC1 in dioxane (6.5 mL, 26 mmol) and stirred at RT for 10 min. The heterogeneous mixture was concentrated to dryness to give 4-(2-(dimethylamino)ethoxy)-2-methoxyaniline hydrochloride (B14b, 6.30 g, 25.5 mmol, 97% yield) as a brown solid. !H NMR (400 MHz, DMSO-d6) δ ppm 6.59 (1 H, m), 6.55 (1 H, s), 6.39 (1 H, d, J=7.8 Hz), 5.40 (3 H, br.), 4.22 (2 H, m), 3.75 (3 H, s), 3.42 (2 H, m), 2.82 (6 H, s). m/z (ESI, +ve ion) 211.2
A heterogeneous mixture of N-(3-(2-chloro-5-methyl-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)acrylamide (630 mg, 1.849 mmol), 4-(2-
(dimethylamino)ethoxy)-2-methoxyaniline hydrochloride (B14b, 525 mg, 2.12 mmol) and HOAc (0.11 mL, 1.85 mmol) in 5 mL of EtOH was heated in a microwave at 120 °C for 75 min. It was diluted with 100 mL of CHCI3 and washed with 10 mL of 1 N NaOH followed by 5 mL of brine. The organic solution was concentrated. The brown residue was washed with 2 x 15 mL of ether. The remaining solid was purified on a silica gel column (5% MeOH in DCM followed by 5-10% of 2 M NH3 in MeOH in DCM) to provide an enriched material (about 580 mg of yellow solid). The yellow solid was stirred in 10 mL of ether for 30 min. The yellow solid was filtered, and washed with 3 x 10 mL of ether. The ether filtrate was discarded. The yellow solid was collected and dried to give N-(3-(2-((4-(2-(dimethylarnino)ethoxy)-2-rnethoxyphenyl)amino)-5-rnethyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide (Example B14, 440 mg, 46% yield). !H NMR (400 MHz, DMSO-d6) δ ppm 10.34 (1 H, br.), 8.82 (1 H, s), 8.16 (1 H, s), 7.84 (1 H, d, J=7.8 Hz), 7.60 (1 H, s), 7.52 (1 H, t, J=8.0 Hz), 7.32 (1 H, d, J=8.6 Hz), 6.99 (1 H, d, J=7.4 Hz), 6.54 (1 H, s), 6.36 - 6.49 (1 H, m), 6.34 (1 H, s), 6.18 - 6.31 (1 H, m), 6.05 (1 H, br. s.), 5.77 (1 H, d, J=10.0 Hz), 3.96 (2 H, m), 3.80 (3 H, s), 2.59 (2 H, m), 2.47 (3 H, s), 2.23 (6 H, s). m/z (ESI, +ve ion) 515.3 Example B15: N-(3-(2-((l,3-dimethyl-lH-pyrazol-5-yl)amino)-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide
100 Example B15 A mixture of l,3-dimethyl-lH-pyrazol-5-amine (0.024 g, 0.220 mmol, FSSI), N-
(3-(2-chloro-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide (0.050 g, 0.147 mmol), and, Cs2C03 (0.072 g, 0.220 mmol) in DMSO (2 mL) was stirred at 100 °C for 4 h. The reaction mixture was cooled, and H20 was added. The solid was filtered, dried then purified by reverse phase HPLC to give the title compound as mono TFA salt (3.5 mg, 6%). !H NMR (400 MHz, DMSO-d6) δ ppm 10.35 (1 H, s), 10.01 (1 H, br. s.), 8.92 (1 H, s), 7.79 (1 H, d, J=8.2 Hz), 7.66 (1 H, s), 7.51 (1 H, t, J=8.0 Hz), 6.88 - 7.04 (1 H, m), 6.36 - 6.56 (2 H, m), 6.19 - 6.32 (1 H, m), 5.78 (1 H, dd, J=10.0, 2.0 Hz), 5.43 (1 H, br. s.), 3.58 (6 H, s), 1.90 (3 H, s). m/z (ESI, +ve ion) 416.2 (M+H)+. Example B16: N-(3-(2-((4-(2-methoxyethoxy)phenyl)amino)-5-methyl-7- oxopyrido [2,3-d] pyrimidin-8(7H)-yl)phenyl)acrylamide.
- I l l -
A mixture of 4-(2-methoxyethoxy)aniline (0.074 g, 0.440 mmol, Matrix), sodium carbonate (0.156 g, 1.467 mmol), and N-(3-(2-chloro-5-methyl-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)acrylamide (0.100 g, 0.293 mmol) in DMF (3 mL) was heated at 80 °C for 4 h. The reaction mixture was cooled, and ¾0 was added. The solid was filtered, washed with ether, dried to give the title compound (0.083 g, 83%). !H NMR (400 MHz, DMSO-d6) δ ppm 10.37 (1 H, br. s.), 9.90 (1 H, br. s.), 8.85 (1 H, s), 7.84 (1 H, d, J=7.8 Hz), 7.65 (1 H, br. s.), 7.54 (1 H, t, J=7.8 Hz), 7.15 - 7.35 (2 H, m), 7.01 (1 H, d, J=7.6 Hz), 6.57 (2 H, br. s.), 6.44 (1 H, dd, J=16.7, 10.3 Hz), 6.33 (1 H, s), 6.17 - 6.30 (1 H, m), 5.76 (1 H, d, J=10.0 Hz), 3.96 (2 H, br. s.), 3.62 (2 H, br. s.), 3.35 (3 h, s), 2.48 (3 H, br. s.). m/z (ESI, +ve ion) 472.2 (M+H)+.
Example B17: N-(3-(2-((4-((2-hydroxyethyl)(methyl)amino)-2- methoxyphenyl)amino)-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)- yl)phenyl)acrylamide
Preparation of 2-((4-amino-3-methoxyphenyl)(methyl)amino)ethanol (17b). A yellow solution of 5-fluoro-2-nitroanisole (Oakwood Products, Inc., 7.0 g, 40.9 mmol) and DIPEA (12.15 mL, 69.5 mmol) in NMP (70 mL) was added -methylethanolamine (Sigma Aldrich, 4.92 mL, 61.4 mmol) and the bright yellow solution was heated at 80 °C for overnight. After the reaction was cooled to RT, the reaction mixture was diluted with H20 (80 mL) and extracted with EtOAc (3 x 60 mL). The organic extract was washed with brine and dried over Na2SC>4. The solution was filtered and concentrated in vacuo to give the crude material as a brown oil. The crude residue was absorbed onto silica gel and purified by chromatography through a Redi-Sep pre-packed silica gel column (120 g), eluting with a gradient of 0-5% 2 M NH3 MeOH in CH2C12, to provide 2-((3- methoxy-4-nitrophenyl)(methyl)amino)ethanol (B17a) as yellow oil, which became a yellow semi-solid upon dried under vacuum. MS (ESI positive ion): m/z calcd for CioH14N204 226; found 227 (M + H).
The material isolated above was added EtOH (70.0 mL) and EtOAc (10 mL) was added Pd/C (4.6 g, 10 wt% on wet carbon) and the black suspension was stirred under 1 atm H2 overnight. The mixture was passed through a short path of Celite. The filtrated cake was washed with EtOAc (3 x 50 mL). The combined organic phases were concentrated to give the crude 2-((4-amino-3-methoxyphenyl)(methyl)amino)ethanol (B17b, 6.24 g, 78% in two steps) as a dark purple oil. MS (ESI positive ion): m/z calcd for CioH16N202 196; found 197 (M + H).
Preparation of Example B17. To a stirred mixture of 7V-(3-(2-chloro-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7//)-yl)phenyl)acrylamide (510 mg, 1.497 mmol) (100) and crude 2-((4-amino-3-methoxyphenyl)(methyl)amino)ethanol (382 mg, 1.946 mmol) in 2- butanol (5.00 mL) was added TFA (0.15 mL, 1.95 mmol) and the heterogeneous mixture was stirred at 110 °C overnight. The reaction was not finished so another equivalent of crude 2-((4-amino-3-methoxyphenyl)(methyl)amino)ethanol in 2-butanol (2.5 mL) was added and the entire mixture was heated at 110 °C for additional 12 h. The reaction mixture was diluted with H20 (20 mL) and extracted with CH2C12 (3 x 60mL). The organic extracts were washed with H20 and dried over Na2SC>4. The solution was filtered and concentrated in vacuo to give a black solid. The crude material was absorbed onto silica gel and purified by chromatography through a Redi-Sep pre-packed silica gel column (40 g), eluting with a gradient of 0-7% of 2 M NH3 MeOH in CH2C12, to provideV-(3-(2-((4-((2 -hydro xyethyl)(methyl)amino)-2-methoxyphenyl)amino)-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide (Example B17, 0.43 g, 57%o yield) as a yellow solid. MS (ESI positive ion): m/z calcd for C27H28 6O4 500; found 501 (M + H); !H NMR (400 MHz, DMSO-dg) δ 10.32 (s, 1H), 8.76 (s, 1H), 8.07 (br s, 1H), 7.83 (d, J= 7.63 Hz, 1H), 7.58 (s, 1H), 7.48 (t, J= 8.02 Hz, 1H), 7.19 (d, J= 8.80 Hz, 1H), 6.96 (d, J= 7.82 Hz, 1H), 6.38-6.56 (m, 1H), 6.16-6.32 (m, 3H), 5.82 (br s, 1H), 5.76 (dd, J= 1.86, 10.07 Hz, 1H), 4.60 (t, J= 5.38 Hz, 1H), 3.75 (s, 3H), 3.51 (q, J= 5.87 Hz, 2H), 3.33-3.42 (m, 2H), 2.86 (s, 3H), 2.45 (s, 3H).
Example B18: N-(3-(5-methyl-7-oxo-2-((4-(piperidin-4-yl)phenyl)amino)pyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)acrylamide
A mixture of N-(3-(2-chloro-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)- yl)phenyl)acrylamide (0.10 g, 0.293 mmol), tert-butyl 4-(4-aminophenyl)piperidine-l- carboxylate (0.097 g, 0.352 mmol), and HOAc (0.017 mL, 0.293 mmol) in «-BuOH (4 mL) was heated at 100 °C for 16 h. The reaction mixture was cooled, concentrated to dryness, purified by silica gel column (25% acetone/DCM) to give the boc protected piperidine intermediate which was dissolved in DCM (5 mL) and added TFA (2 mL) and stirred at RT overnight. The mixture was concentrated to dryness and purified by reverse phase HPLC. The pure fractions were concentrated to minimal amount of H20, neutralized by saturated aqueous NaHC03. The tan solid was collected, dried to give the title compound (16.5 mg, 9.5%) as mono TFA salt. !H NMR (400 MHz, DMSO-d6) δ ppm 10.33 (1 H, s), 9.98 (1 H, br. s.), 8.87 (1 H, s), 8.52 (1 H, d, J=11.0 Hz), 8.25 (1 H, d, J=10.0 Hz), 7.97 (1 H, d, J=7.8 Hz), 7.54 (1 H, t, J=8.0 Hz), 7.49 (1 H, s), 7.29 (2 H, m, J=7.8 Hz), 7.00 - 7.09 (1 H, m), 6.83 (2 H, m, J=7.8 Hz), 6.38 - 6.48 (1 H, m), 6.36 (1 H, d, J=1.2 Hz), 6.20 - 6.32 (1 H, m), 5.70 - 5.82 (1 H, m), 3.24 - 3.40 (3 H, m), 2.88 - 3.05 (2 H, m), 2.60 - 2.74 (1 H, m), 2.48 (2 H, br. s.), 1.83 (2 H, d, J=13.5 Hz), 1.53 - 1.74 (2 H, m). m/z (ESI, +ve ion) 595.2 (M+H)+. Example B19: N-(3-(2-((l-isopropyl-lH-pyrazol-4-yl)amino)-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide
In a 20-mL glass reaction vessel was weighed l-(propan-2-yl)-lH-pyrazol-4- amine (Astatech Inc., Bristol, PA, 37.5 mg, 0.299 mmol) and N-(3-(2-chloro-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide (100, 102 mg, 0.30 mmol) followed by purging with argon and addition of 2-butanol (2.0 mL, 21.80 mmol). The reaction mixture was sealed and heated to 125 °C in a heating block for 2 h. The reaction mixture was concentrated on the rotovap and chromatographed on the ISCO Combiflash RF (40 g Thompson SingleStep column, using a gradient of 0-10% MeOH in DCM) affording N-(3-(2-((l-isopropyl-lH-pyrazol-4-yl)amino)-5-methyl-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)acrylamide (59 mg, 0.138 mmol, 46% yield) as a yellow crystalline solid, m/z (ESI, +ve ion) 430.0 (M+H)+. !H NMR (400 MHz, DMSO-d6) δ ppm 10.39 (1 H, br. s.), 10.03 (1 H, s), 8.82 (1 H, s), 7.90 (1 H, d, J=8.4 Hz), 7.67 (1 H, br. s.), 7.59 (1 H, t, J=8.0 Hz), 7.16 (1 H, s), 7.04 (1 H, d, J=7.0 Hz), 6.84 (1 H, s), 6.36 - 6.50 (1 H, m), 6.18 - 6.34 (2 H, m), 5.77 (1 H, d, J=9.6 Hz), 3.95 - 4.14 (1 H, m), 2.47 (3 H, s), 1.20 (6 H, dd, J=15.6, 6.6 Hz).
Example B20: N-(3-(2-((2-chloro-4-((2- (dimethylamino)ethyl)(methyl)amino)phenyl)amino)-5-methyl-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide
Preparation of 2-(3-chloro-4-nitrophenoxy)-N,N-dimethylethanamine (20a). A solution of Ν,Ν,Ν''-trimethylethylenediamine (2.21 mL, 17.43 mmol) and 2-chloro-4- fluoronitrobenzene (2.66 g, 15.15 mmol, Oakwood Products Inc.) in 50 mL of THF at RT was treated with N-ethyl-N-isopropylpropan-2 -amine (3.17 mL, 18.18 mmol) and stirred for 18 h. It was diluted with 50 mL of EtOAc and washed with 2 x 5 mL of water. The Organic solution was concentrated and purified on a silica gel column (50% EtOAc in DCM followed by 5% 2 M NH3 in MeOH in DCM) to give Nl-(3-chloro-4-nitrophenyl)- Nl ,N2,N2-trimethylethane-l ,2-diamine (B20a, 3.40 g, 13.19 mmol, 87% yield) as a yellow sticky oil in about 80%o purity [m/z (ESI, +ve ion) 258.0], contaminated with 20%o of Nl -(5-fluoro-2-nitrophenyl)-Nl ,N2,N2-trimethylethane-l,2-diamine [m/z (ESI, +ve ion) 242.0]. This material was used in the next step without further purification.
Preparation of 3-chloro-Nl -(2-(dimethylamino)ethyl)-Nl -methylbenzene- 1 ,4- diamine hydrochloride (B20b). A solution of Nl -(3-chloro-4-nitrophenyl)-Nl ,N2,N2- trimethylethane- 1 ,2 -diamine (B20a, 1.46 g, 5.67 mmol) contaminated with 20% ofNl- (5-fluoro-2-nitrophenyl)-Nl,N2,N2-trimethylethane-l,2-diamine in MeOH/THF (1/1 , 62 mL) was hydrogenated with a balloon filled with H2 in the presence of Raney nickel (0.85 g of 50% slurry in water, active catalyst, 5.67 mmol). The reaction mixture was filtered over Celite, washed with MeOH/THF (2 x 20 mL of 1 : 1 solution). The filtrate was evaporated to dryness to give a viscous blue oil containing a mixture of 3-chloro-Nl-(2- (dimethylamino)ethyl)-Nl -methylbenzene-l,4-diamine (1.15 g, about 80%) and Nl-(2- (dimethylamino)ethyl)-5-fluoro-Nl-methylbenzene-l ,2-diamine (about 20%). To a solution of 740 mg of the viscous blue oil in 10 mL of ether at RT was added 4 M HCl in dioxane (0.82 mL, 3.25 mmol) dropwise. It was stirred at RT for 15 min. The heterogeneous mixture was concentrated to dryness. The resulting purple solid was stirred in 3 mL of ether and 3 mL of hexanes for 5 min. The purple solid was filtered, rinsed with 2 x 15 mL of hexanes, collected and dried to give 3-chloro-Nl-(2- (dimethylamino)ethyl)-Nl-methylbenzene-l,4-diamine hydrochloride (B20b, 803 mg in about 90% pure, m/z (ESI, +ve ion) 228.0), contaminated with Nl-(5-fluoro-2- nitrophenyl)-Nl ,N2,N2-trimethylethane-l ,2-diamine (in about 10%, m/z (ESI, +ve ion) 212.0).
Preparation of N-(3-(2-((2-chloro-4-((2-(dimethylamino)ethyl)(methyl)amino)p- henyl)amino)-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide (B20). A heterogeneous mixture of N-(3-(2-chloro-5-methyl-7-oxopyrido[2,3-d]pyrimidin- 8(7H)-yl)phenyl)acrylamide (100, 194 mg, 0.57 mmol), 3-chloro-Nl -(2- (dimethylamino)ethyl)-Nl-methylbenzene-l,4-diamine hydrochloride (20b, 188 mg, 0.71 mmol, in about 90% pure) contaminated with 10% of N-(3-(2-chloro-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide in 2.5 mL of EtOH was treated with HOAc (32.9 xL, 0.57 mmol) and heated in an oil bath at 100 °C for 30 min. The reaction mixture was heated in a microwave at 120 °C for 1 h. The resulting dark mixture was loaded on a silica gel column and eluted with 2% MeOH in DCM followed by 5-10% of 2 M NH3 in MeOH in DCM. Fractions containing the desired mass, m/z (ESI, +ve ion) 532.0, were concentrated. The residue was stirred in 5 mL of ether for 10 min. The precipitated yellow solid was filtered, rinsed with 2 x 2 mL of ether. The filtrate was discarded. The yellow solid was collected and dried to give N-(3-(2-((2-chloro-4-((2- (dimethylamino)ethyl)(methyl)amino)phenyl)amino)-5-methyl-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)acrylamide (155 mg, 0.291 mmol, 51 %o yield) in about 90%o pure. For further purification, 100 mg of the 90%o pure yellow solid was stirred in EtOH/H20 (5 mL, 4/1) at 75 °C in an oil bath for 5 min. It was cooled to RT and let stand in the hood for 18 h. The yellow solid was filtered and dried to give N-(3-(2-((2- chloro-4-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)amino)-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide (Example B20, 58 mg). The mother liquor was concentrated and purified on a silica gel column (5-10% of 2 M NH3 in MeOH in DCM) to give N-(3-(2-((2-chloro-4-((2-(dimethylamino)ethyl)(methyl)amino)- phenyl)amino)-5 -methyl-7-oxopyrido [2,3 -d]pyrimidin-8(7H)-yl)phenyl)acrylamide (Example B20, 30 mg). !H NMR (400 MHz, DMSO-d6) δ ppm 10.30 (1 H, br. ), 8.78 (2 H, br.), 7.77 (1 H, d, J=8.0 Hz), 7.55 (1 H, s), 7.44 (1 H, m), 7.19 (1 H, m), 6.96 (1 H, m), 6.59 (1 H, m), 6.45 (1 H, m), 6.31 (2 H, m), 6.26 (1 H, m), 5.75 (1 H, m), 3.41 (2 H, m), 2.86 (3 H, s), 2.46 (3 H, s), 2.34 (2 H, m), 2.19 (6 H, s). m/z (ESI, +ve ion) 532.0.
Example B21: N-(3-(5-methyl-2-((3-methyl-l-(l-methylpiperidin-4-yl)-lH-pyrazol-4- yl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide and N-(3-(5- methyl-2-((5-methyl-l-(l-methylpiperidin-4-yl)-lH-pyrazol-4-yl)amino)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide
Preparation of 3-methyl- 1 -( 1 -methylpiperidin-4-yl)- 1 H-pyrazol-4-amine hydrochloride and 5-methyl- 1 -( 1 -methylpiperidin-4-yl)- 1 H-pyrazol-4-amine hydrochloride (21b). To a stirred mixture of 4-hydroxy-N-methylpiperidine (Acros; 1.156 g, 10.04 mmol), 3-methyl-4-nitro-lH-pyrazole (Alfa Aesar; 0.813 mL, 9.13 mmol), and triphenylphosphine (Sigma Aldrich; 3.11 g, 11.86 mmol) in dry THF (15 mL) at 0 °C was added diisopropyl azodicarboxylate (Sigma Aldrich; 2.307 mL, 11.86 mmol) dropwise. After the addition, the reaction mixture was gradually warmed to RT and stirred overnight. The mixture was then concentrated and purified by silica chromatography (0- 25% acetone in DCM) to give 21a (1.0 g, 4.46 mmol) as an inseparable mixture of two regio-isomers, l-methyl-4-(5-methyl-4-nitro-lH-pyrazol-l-yl)piperidine and l-methyl-4- (3-methyl-4-nitro-lH-pyrazol-l-yl)piperidine. m/z (ESI, +ve ion) 225.2 (M+l)+
A mixture of 21a (1.000 g, 4.46 mmol), NH4C1 (Sigma Aldrich; 0.06 g, 1.11 mmol), and iron (Sigma Aldrich; 1.245 g, 22.30 mmol) in a mixture of EtOH and water (5:1, 35 mL) was heated at reflux for 2 h. The heat was removed, and the mixture was filtered hot through a pad of celite. The filtrate was concentrate to dryness then partitioned between 1 N NaOH (10 mL) and CHCI3 (10 mL). The aqueous was extracted with additional CHCI3 (10 mL) and the combined organic dried with MgS04 before evaporating to dryness under reduced pressure to give the free amine as a dark oil. It was dissolved in EtOAc (5 mL) and treated with 1 N HC1 in Et20 (0.5 mL). A white precipitate formed and the mixture was evaporated to dryness under reduced pressure. The crude salt 21b was used without purification, m/z (ESI, +ve ion) 195.1 (M+l)+.
Preparation of Example 21. The 3-methyl-l-(l-methylpiperidin-4-yl)-lH- pyrazol-4-amine hydrochloride and 5 -methyl- l-(l-methy lpiperidin-4-yl)-lH-pyrazol-4- amine hydrochloride mixture (21b, 0.10 g, 0.43 mmol) was combined with N-(3-(2- chloro-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide (100) (0.137 g, 0.40 mmol) and suspended in EtOH (1 mL) in a microwave vial. HO Ac (Sigma Aldrich; 0.023 mL, 0.40 mmol) was added and the vial sealed. It was heated in a 115 °C oil bath for 90 min. The crude was evaporated to dryness under reduced pressure and partitioned between DCM (75 mL) and 50% saturated NaHCC (50 mL). The organic was dried with MgS04 and evaporated to dryness under reduced pressure. Purification using silica chromatography (0-10% 2 N NH3 in MeOH) in DCM gradient) gave a mixture of N-(3-(5-methyl-2-((3-methyl-l -( 1 -methylpiperidin-4-yl)-l H-pyrazol-4- yl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide (51 mg, 0.102 mmol, 25% yield) and N-(3-(5-methyl-2-((5-methyl-l-(l-methylpiperidin-4-yl)-lH- pyrazol-4-yl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide as an orange solid, m/z (ESI, +ve ion) 195.1 (M+l)+. !H NMR (400 MHz, CDCl3) δ ppm 8.97 (br. s., 1H), 8.68 (br. s., 1H), 7.89-8.39 (m, 2H), 7.27-7.55 (m, 2H), 6.63-6.94 (m, 1H), 6.25-6.50 (m, 1H), 5.99-6.21 (m, 1H), 5.62 (d, J=10.2 Hz, 1H), 3.66-4.16 (m, 1H), 2.93- 3.04 (m, 1H), 2.46 (s, 3H), 2.32 (s, 3H), 1.81-2.23 (12 H).
Comparator Example 22: N-(3-(6-benzyl-2-((2-methoxy-4-(4-methylpiperazin-l- yl)phenyl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide
In a 250-mL RBF was added THF (55.5 mL) followed by cooling to -78 °C in a dry ice/acetone and the addition of LiHMDS (1.0 M in THF, 16.65 mL, 16.65 mmol) followed by the slow dropwise addition of methyl 3-phenylpropionate (TCI America, Portland, OR, 1.93 ml, 12.21 mmol). The solution was stirred at this temperature for 30 min. teri-Butyl (3-((5-formyl-2-(methylthio)pyrimidin-4-yl)amino)phenyl)carbamate (101, 2.00 g, 5.55 mmol) was then added in one portion and the solution removed from the cooling bath and warmed to RT and stirred for 3.5 h. The reaction was quenched with a saturated solution of NH4CI and the reaction mixture was extracted with EtOAc (2 x 70 mL), washed with brine and dried over MgS04, filtered and concentrated. The crude residue was then chromatographed on the ISCO Combiflash RF (80 g Thomson SingleStep column, using a gradient of 0-10% EtOAc in DCM (eluted with ca. 3-5%o EtOAc)) affording a mixture of starting material and desired product. The solid was suspended in Et20 and collected by filtration and washed with EX2O and dried in the vacuum oven at 40 °C for 4 h affording teri-butyl (3-(6-benzyl-2-(methylthio)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)carbamate (22a; 824 mg, 1.738 mmol, 31% yield) as a white solid, m/z (ESI, +ve ion) 475.2 (M+H)+. !H NMR (400 MHz, MeOH- d4/CDCl3 mixture) δ ppm 8.52 (1 H, s), 7.48 (1 H, br. s.), 7.30 - 7.42 (6 H, m), 7.22 -
7.30 (3 H, m), 6.82 - 6.90 (1 H, m), 3.91 (2 H, s), 2.14 (3 H, s), 1.41 - 1.54 (9 H, s).
In a 250 mL round-bottomed flask was added teri-butyl (3-(6-benzyl-2-
(methylthio)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)carbamate (653 mg, 1.37 mmol) and HC1, 4 M in 1 ,4-dioxane (3.44 mL, 13.76 mmol). The mixture was stirred at 50 °C and progress was followed with LC/MS. After 1 h, the mixture cooled to 0 °C using ice/NaCl and treated dropwise with NaOH 10.0 N (3.03 mL, 30.3 mmol). After addition was complete the mixture was stirred at 0 °C and treated dropwise via syringe with acryloyl chloride (145 μΐ, 1.789 mmol). The mixture was stirred at 0 °C for 10 min and then at RT for 1 h. The reaction mixture was quenched with water (5 mL) and the resulting fine white precipitate was filtered using a medium porosity sintered glass frit and the filter cake was washed Et20. The resulting solid was dried in a vacuum oven at 40 °C overnight affording N-(3-(6-benzyl-2-(methylthio)-7-oxopyrido[2,3-d]pyrimidin- 8(7H)-yl)phenyl)acrylamide (22b; 554 mg, 1.29 mmol, 94% yield) as an off-white amorphous solid, m/z (ESI, +ve ion) 429.2 (M+H)+. !H NMR (400 MHz, DMSO-d6) δ ppm 10.32 (1 H, br. s.), 8.89 (1 H, s), 7.76 (1 H, s), 7.62 - 7.74 (2 H, m), 7.49 (1 H, t, J=7.8 Hz), 7.33 (4 H, br. s.), 7.25 (1 H, br. s.), 7.03 (1 H, d, J=7.8 Hz), 6.44 (1 H, dd, J=16.9, 10.1 Hz), 6.26 (1 H, d, J=16.8 Hz), 5.77 (1 H, d, J=10.2 Hz), 3.89 (2 H, s), 2.20 (3 H, s).
In a 250 mL RBF, N-(3-(6-benzyl-2-(methylthio)-7-oxopyrido[2,3-d]pyrimidin- 8(7H)-yl)phenyl)acrylamide (531 mg, 1.24 mmol) was treated with DCM (20 mL), cooled to 0 °C in an ice bath and treated with 3-chloroperoxybenzoic acid (77% max., 278 mg, 1.239 mmol) in one portion. The solution was stirred at 0 °C for 1 h 30 min. The reaction mixture was treated with a 10% solution of Na2C03, extracted with DCM (2 x 50 mL), dried over anhydrous Na2S04, filtered and concentrated affording crude N-(3- (6-benzyl-2-(methylsulfmyl)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide (22c; 545 mg, 1.22 mmol, 99% yield) as an off white foam, m/z (ESI, +ve ion) 445.1
(M+H)+. !H NMR (400 MHz, DMSO-d6) δ ppm 10.34 (1 H, s), 9.24 (1 H, s), 7.91 (1 H, s), 7.62 - 7.79 (2 H, m), 7.49 (1 H, t, J=8.0 Hz), 7.31 - 7.39 (3 H, m), 7.26 (1 H, dq, J=8.8, 4.1 Hz), 6.98 - 7.08 (1 H, m), 6.44 (1 H, dd, J=16.9, 10.1 Hz), 6.24 (1 H, dd, J=17.0, 1.8 Hz), 5.75 - 5.80 (2 H, m), 3.89 - 4.00 (2 H, m), 2.63 - 2.75 (3 H, m) product contained ca. 7%> of the corresponding sulfone as well.
2-Methoxy-4-(4-methylpiperazin-l-yl)aniline (GreenChemPharm, Bardonia, NY, 96 mg, 0.432 mmol) and N-(3-(6-benzyl-2-(methylsulfinyl)-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)acrylamide (22c; 160 mg, 0.360 mmol) were treated with DMAc (2.0 mL) under N2 and heated to 90 °C for 6.5 h. The reaction mixture was treated with IN NaOH and extracted first with EtOAc (20 mL) and DCM (3 x 20 mL), dried over MgS04, filtered and concentrated. The crude residue was purified on the ISCO (40 g Thomson column, using a gradient of 0-10% MeOH in DCM) affording N-(3-(6-benzyl- 2-((2-methoxy-4-(4-methylpiperazin-l-yl)phenyl)amino)-7-oxopyrido[2,3-d]pyrimidin- 8(7H)-yl)phenyl)acrylamide (Example 22; 37 mg, 0.062 mmol, 17% yield) as a bright yellow-orange solid after washing with Et20 and drying under high vacuum, m/z (ESI, +ve ion) 602.3 (M+H)+. !H NMR (400 MHz, DMSO-d6) δ ppm 10.33 (1 H, s), 8.70 (1 H, s), 8.06 (1 H, br. s.), 7.87 (1 H, d, J=8.2 Hz), 7.66 (1 H, s), 7.59 (1 H, s), 7.52 (1 H, t, J=7.8 Hz), 7.18 - 7.38 (6 H, m), 7.01 (1 H, d, J=7.4 Hz), 6.52 (1 H, br. s.), 6.43 (1 H, dd, J=17.0, 9.8 Hz), 6.25 (1 H, d, J=17.0 Hz), 6.03 (1 H, br. s.), 5.77 (1 H, d, J=9.8 Hz), 3.84 (2 H, s), 3.69 - 3.81 (3 H, m), 3.03 (4 H, br. s.), 2.44 (4 H, br. s.), 2.23 (3 H, br. s.).
Example B23. (5)-N-(3-(2-((2-methoxy-4-((l-methylpyrrolidin-3- yl)oxy)phenyl)amino)-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)- yl)phenyl)acrylamide
A mixture of Cs2C03 (4.96 g, 15.21 mmol), (S)-(+)-l -methyl-3-pyrrolidinol (1 g, 9.89 mmol, Acros Organics), 5-fluoro-2-nitroanisole (1.3 g, 7.61 mmol, Oakwood Products) and DMF (15.21 mL) was heated to 100 °C overnight. Reaction mixture was diluted with DCM and washed with water and brine to give (S)-3-(3-methoxy-4- nitrophenoxy)-l -methylpyrrolidine (23a, 1.58 g, 6.26 mmol, about 82% yield). The oil residue was advanced to the next step before further purification.
A mixture of (S)-3-(3-methoxy-4-nitrophenoxy)-l -methylpyrrolidine (23a, 1.58 g, 6.26 mmol), iron (1.749 g, 31.3 mmol), NH4C1 (0.335 g, 6.26 mmol) in water (2.75 mL) and EtOH (13.74 mL) was heated to 100 °C for ~ 2 h. Reaction mixture was filtered over Celite and rinsed with copious amount of water. The filtrate was rotovapped to remove volatile solvents and then basified to pH >9 using 5 N NaOH solution. The filtrate was then back extracted with CHCI3 (2 x). The organic layer was dried over Mg2S04 and then rotovapped to give (S)-2-methoxy-4-((l -methylpyrrolidin-3- yl)oxy)aniline (816 mg, 3.67 mmol, about 58% yield). The dark oil residue was advanced to next step directly, m/z (ESI, +ve ion) 223.1 (M+H)+.
A mixture of N-(3-(2-chloro-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)- yl)phenyl)acrylamide (0.171 g, 0.502 mmol), HOAc (0.035 ml, 0.602 mmol), (S)-2- methoxy-4-((l -methylpyrrolidin-3-yl)oxy)aniline (23b, 0.145 g, 0.652 mmol), TFA
(0.043 mL, 0.552 mmol) in EtOH (1.673 mL) was heated to 1 10 °C overnight. Reaction mixture was directly purified by Gilson HPLC (Gemini-NX, l Ou, Ci8, 100x50 mm; 0.1% TF A/water, 0.1 % TFA/AcCN). The clean fractions were azeotroped with AcCN to afford (S)-N-(3-(2-((2-methoxy-4-((l-methylpyrrolidin-3-yl)oxy)phenyl)amino)-5- methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide 2,2,2-trifluoroacetate (Example B23, 31.9 mg, 0.050 mmol, 10% yield).1H NMR (300 MHz, MeOH-d4) δ 8.69-8.87 (m, 1H), 8.10 (br. s., 1H), 7.33-7.62 (m, 3H), 7.01 (d, J=7.75 Hz, 1H), 6.28- 6.60 (m, 4H), 6.08 (br. s., 1H), 5.78 (dd, J=2.78, 8.92 Hz, 1H), 5.09 (br. s., 1H), 3.83 (s, 5H), 3.16-3.46 (m, 5H), 3.02 (br. s., 3H), 2.65 (br. s., 1H), 2.11 -2.40 (m, 1H), 2.08-2.37 (m, 1H), 2.46 (s, 5H). m/z (ESI, +ve ion) 527.0 (M+H)+.
Example B24: N-(3-(2-((3-fluoro-4-(4-methyl-l-piperazinyl)phenyl)amino)
7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide
A mixture of N-(3-(2-chloro-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)- yl)phenyl)acrylamide (0.15 g, 0.440 mmol), AcOH (0.031 ml, 0.528 mmol), 3-fluoro-4- (4-methylpiperazino)aniline (0.079 ml, 0.440 mmol, Advanced ChemBlocks), HCl (0.088 mL of 5 N in iPrOH, 0.440 mmol) and TFA (0.037 mL, 0.484 mmol) in EtOH (1.467 ml) was heated to 1 10 °C overnight (~14 h). Reaction mixture was directly purified by Gilson HPLC (Gemini-NX, l Ou, d8, 100x50 mm; 0.1 % TFA/water, 0.1 % TFA/AcCN).
Fractions were rotovapped to remove volatile solvents. The residual oil was resolubilized in MeOH and neutralized using Silicycle SiliaPrep Carbonate cartridge. The filtrate was concentrated to afford N-(3-(2-((3-fluoro-4-(4-methyl-l-piperazinyl)phenyl)amino)-5- methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide (Example B24, 24.5 mg, 0.048 mmol, 11% yield). !H NMR (300 MHz, MeOH-d4) δ 8.83 (s, IH), 7.86 (d, J=8.48 Hz, IH), 7.71 (s, IH), 7.55 (t, J=8.04 Hz, IH), 7.15 (d, J=12.86 Hz, IH), 6.91- 7.07 (m, 2H), 6.72 (t, .7=9.13 Hz, IH), 6.24-6.51 (m, 3H), 5.75 (dd, J=2.05, 9.50 Hz, IH), 2.99 (br. s., 4H), 2.61 (br. s., 4H), 2.53 (s, 3H), 2.35 (s, 3H), 1.88-1.95 (m, IH). m/z (ESI, +ve ion) 514.0 (M+H)+.
Examples B25 and B26: N-(3-(2-((2-chloro-4-(2- (dimethylamino)ethoxy)phenyl)amino)-5-methyl-7-oxopyrido [2,3-d] pyrimidin-
8(7H)-yl)phenyl)acrylamide and N-(3-(2-((4-(2- (dimethylamino)ethoxy)phenyl)amino)-5-methyl-7-oxopyrido[2,3-d]pyrimidin-
8(7H)-yl)phenyl)acrylamide
Preparation of 2-(3-chloro-4-nitrophenoxy)-N,N-dimethylethanamine (25a). A mixture of 2-chloro-4-fluoronitrobenzene (2.15 g, 12.25 mmol, Oakwood Products, Inc.), 2-(dimethylamino)ethanol (1.42 g, 15.92 mmol, Aldrich) and Cs2C03 (11.97 g, 36.7 mmol) in DMF (10 mL) was stirred at RT for 36 h. The reaction mixture was treated with ¾0 (25 mL) and extracted with DCM (3 x 50 mL). The extracts were combined, washed with brine (15 mL), and concentrated. The residue was purified by silica gel chromatography (50% EtOAc in DCM followed by 5% of 2 M NH3 in MeOH in DCM) to provide 2-(3-chloro-4-nitrophenoxy)-N,N-dimethylethanamine (25a, 2.60 g, 10.63 mmol, 87% yield) as a yellow viscous oil. !H NMR (400 MHz, DMSO-d6) δ ppm 8.10 (1 H, d, J=9.0 Hz), 7.96 (1 H, s), 7.14 (1 H, d, J=9.0 Hz), 4.22 (2 H, t, J=5.6 Hz), 2.64 (2 H, t, J=5.5 Hz), 2.22 (6 H, s). m/z (ESI, +ve ion) 245.0 (M+H)+.
Preparation of N-(3-(2-((2-chloro-4-(2-(dimethylamino)ethoxy)phenyl)amino)-5- methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide (Example 25) and N- (3-(2-((4-(2-(dimethylamino)ethoxy)phenyl)amino)-5-methyl-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)acrylamide (Example 26). A solution of 2-(3-chloro-4- nitrophenoxy)-N,N-dimethylethanamine (25a, 2.60 g, 10.63 mmol) in MeOH/THF (62 mL of 1/1) was hydrogenated with a balloon filled with H2 in the presence of Raney nickel (1.1 g of active catalyst 50% slurry in water, Aldrich) for 18 h at RT. The reaction mixture was filtered over a bed of Celite, washed with MeOH/THF (2 x 20 mL, 1/1). The filtrate was evaporated to dryness to give a tan solid as a mixture of 2-chloro-4-(2- (dimethylamino)ethoxy)aniline [m/z (ESI, +ve ion) 250.1 (M+H)+] and 4-(2-
(dimethylamino)ethoxy)aniline [m/z (ESI, +ve ion) 181.1 (M+H)+] in about 60% : 40% ratio. The tan solid was suspended in 5 mL of dioxane and treated with HC1 (2.5 mL of 4.0 M in dioxane, 10 mmol, Aldrich). The mixture was stirred at RT for 5 min, and concentrated under reduced pressure to give a tan solid. The tan solid was stirred in 25 mL of heptane for 5 min. The solid was filtered and dried to give 2-chloro-4-(2-
(dimethylamino)ethoxy)aniline hydrochloride (25b, 2.51 g, 9.99 mmol, 94% yield) in a mixture with 4-(2-(dimethylamino)ethoxy)aniline hydrochloride in about 60% : 40% ratio, m/z (ESI, +ve ion) 250.1 (M+H)+ and m/z (ESI, +ve ion) 181.1 (M+H)+.
A heterogeneous mixture of 2-chloro-4-(2-(dimethylamino)ethoxy)aniline hydrochloride (25b, 178 mg, 0.71 mmol) in a mixture with 4-(2-
(dimethylamino)ethoxy)aniline hydrochloride, N-(3-(2-chloro-5-methyl-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)acrylamide (100, 210 mg, 0.61 mmol) and HOAc (35 xL,
0.61 mmol) in 5 mL of EtOH was heated in a microwave at 120 °C for 75 min. The reaction mixture was stirred in 15 mL of ether for 15 min. The liquid was decanted. The remaining solid was adsorbed onto 5 g of silica gel and purified on a silica gel column (5% MeOH in DCM followed by 2-6% 2 M NH3 in MeOH in DCM) to provide two compounds. The first eluent was N-(3-(2-((2-chloro-4-(2-(dimethylamino)ethoxy)- phenyl)amino)-5 -methyl-7-oxopyrido [2,3 -d]pyrimidin-8(7H)-yl)phenyl)acrylamide (Example B25, 50 mg, 15% yield) as a yellow crystalline solid. !H NMR (400 MHz, DMSO-de) δ ppm 10.31 (1 H, br.), 8.90 (1 H, s), 8.83 (1 H, s), 7.74 (1 H, d, J=8.4 Hz), 7.58 (1 H, s), 7.46 (1 H, t, .7=8.1 Hz), 7.34 (1 H, d, J=8.8 Hz), 6.97 (2 H, m), 6.58 (1 H, br.), 6.48 (1 H, m), 6.35 (1 H, s), 6.26 (1 H, m), 5.78 (1 H, m), 4.01 (2 H, m), 2.61 (2 H, t, J=5.7 Hz), 2.47 (3 H, s), 2.23 (6 H, s). m/z (ESI, +ve ion) 519.2 (M+H)+. The second eluent was N-(3-(2-((4-(2-(dimethylamino)ethoxy)phenyl)amino)-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide (Example B26) (35 mg, 11% yield) as a yellow crystalline solid. !H NMR (400 MHz, DMSO-d6) δ ppm 10.36 (1 H, s), 9.90 (1 H, br.), 8.85 (1 H, s), 7.86 (1 H, d, J=8.2 Hz), 7.63 (1 H, br.), 7.54 (1 H, t, J=7.9 Hz), 7.24 (2 H, d, J=5.5 Hz), 7.01 (1 H, d, J=7.4 Hz), 6.56 (2 H, br.), 6.38 - 6.50 (1 H, m), 6.33 (1 H, s), 6.16 - 6.30 (1 H, m), 5.76 (1 H, d, J=10.0 Hz), 3.91 (2 H, m), 2.57 (2 H, m), 2.48 (3 H, s), 2.21 (6 H, s). m/z (ESI, +ve ion) 485.3 (M+H)+.
Example B27 : N-(3-(5-methyl-2-((3-methyl-4-(4-methylpiperazin-l- yl)phenyl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide
A mixture of N-(3-(2-chloro-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)- yl)phenyl)acrylamide (0.1 g, 0.293 mmol), HOAc (0.020 mL, 0.352 mmol), 3-methyl-4- (4-methylpiperazin-l-yl)aniline (0.060 g, 0.293 mmol, FSSI), TFA (0.025 mL, 0.323 mmol) in EtOH (0.978 mL) was heated to 110 °C overnight. Reaction mixture was directly purified by Gilson HPLC (Gemini-NX, lOu, Ci8, 100x50 mm; 0.1% TFA/water, 0.1% TFA/AcCN). Fractions azeotroped with AcCN. The residue was resolubilized with MeOH and neutralized with Silicycle SiliaPrep Carbonate cartridge. The filtrate was concentrated to afford N-(3-(5-methyl-2-((3-methyl-4-(4-methylpiperazin-l - yl)phenyl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide (Example B27, 31.6 mg, 0.062 mmol, 21% yield). !H NMR (300 MHz, MeOH-d4) δ 8.79 (s, 1H), 8.75-8.83 (m, 1H), 7.93 (d, J=8.18 Hz, 1H), 7.47-7.70 (m, 4H), 6.96-7.15 (m, 3H), 6.71 (d, J=8.04 Hz, 1H), 6.26-6.50 (m, 3H), 5.76 (dd, J=2.05, 9.35 Hz, 1H), 2.74-2.93 (m, 8H), 2.44-2.57 (m, 7H), 2.09 (s, 3H). m/z (ESI, +ve ion) 510.0 (M+H)+.
Comparator Example 28: N-(3-(6-methoxy-2-((2-methoxy-4-(4-methylpiperazin-l- yl)phenyl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide.
In a 500-mL RBF under nitrogen, THF (55.5 mL) was cooled to -78 °C in a dry ice/acetone and treated with LiHMDS (l .OM in THF, 16.65 ml, 16.65 mmol) followed by the slow dropwise addition of methyl methoxyacetate (Sigma Aldrich, 1.21 mL, 12.21 mmol). The solution was then stirred at this temperature for 20 min. teri-Butyl (3-((5- formyl-2-(methylthio)pyrimidin-4-yl)amino)phenyl)carbamate (101, 2.00 g, 5.55 mmol) was then added in one portion and the solution removed from the cooling bath and warmed to RT for 2 h. The reaction mixture was a suspension. It was treated with a saturated solution of NH4C1 and the resulting suspension was filtered using a fine porosity sintered glass frit washing with water and Et20 affording ieri-butyl (3-(6-methoxy-2- (methylthio)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)carbamate (28a; 1.70 g, 4.10 mmol, 74% yield) as a white crystalline solid after drying in the vacuum oven at 40 °C overnight, m/z (ESI, +ve ion) 415.0 (M+H)+. !H NMR (400 MHz, DMSO-d6) δ ppm 9.57 (1 H, s), 8.87 (1 H, s), 7.33 - 7.54 (4 H, m), 6.93 (1 H, d, J=7.4 Hz), 3.90 (3 H, s), 2.21 (3 H, s), 1.48 (9 H, s).
In a 250 mL RBF was added teri-butyl (3-(6-methoxy-2-(methylthio)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)carbamate (1.66 g, 4.01 mmol), HC1 (4 M in 1,4-dioxane, 10.01 mL, 40.4 mmol). The mixture was stirred at 50 °C for 1 h. The mixture was cooled to RT and was stirred at 0 °C using ice/NaCl and treated dropwise with NaOH 10.0 N (8.81 ml, 88 mmol). After addition was complete checked pH to ensure basic and the mixture was stirred at 0 °C and treated dropwise via syringe with acryloyl chloride (0.42 mL, 5.21 mmol). The mixture was stirred at 0 °C for 15 min and then at RT for 1 h. The reaction was quenched with water (5 mL) and the resulting precipitate was filtered on a medium porosity sintered glass frit and the filter cake was washed with water and dried in a vacuum oven at 40 °C for 3 h affording N-(3-(6- methoxy-2-(methylthio)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide (28b; 1.38 g, 3.75 mmol, 94% yield) as a white crystalline solid, m/z (ESI, +ve ion) 368.9 (M+H)+. !H NMR (400 MHz, DMSO-d6) δ ppm 10.33 (1 H, s), 8.87 (1 H, s), 7.70 (2 H, br. s.), 7.50 (1 H, t, J=7.5 Hz), 7.38 (1 H, s), 7.05 (1 H, d, J=7.8 Hz), 6.45 (1 H, dd,
J=17.0, 9.8 Hz), 6.26 (1 H, d, J= 17.0 Hz), 5.78 (1 H, d, J=10.4 Hz), 3.90 (3 H, s), 2.19 (3 H, s).
In a 250 mL RBF, N-(3-(6-methoxy-2-(methylthio)-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)acrylamide (1.02 g, 2.78 mmol) was treated with DCM (50 mL), cooled to 0 °C in an ice bath and treated with 3-chloroperoxybenzoic acid (77% max.; 0.623 g, 2.78 mmol) in one portion. The solution was stirred at 0 °C for 1 h. The reaction mixture was treated with a 10% solution of Na2C03, extracted with DCM (2 x 50 mL), dried over anhydrous Na2S04, filtered and concentrated affording crude N-(3-(6- methoxy-2 -(methylsulfinyl)-7-oxopyrido [2 ,3 -d]pyrimidin-8 (7H)-yl)pheny l)acrylamide (28c; 1.07 g, 2.89 mmol, 100%o yield) as a light yellow crystalline solid, m/z (ESI, +ve ion) 385.1 (M+H)+. !H NMR (400 MHz, DMSO-d6) δ ppm 10.36 (1 H, br. s.), 9.19 (1 H, s), 7.74 - 7.81 (1 H, m), 7.63 - 7.74 (1 H, m), 7.45 - 7.59 (2 H, m), 7.00 - 7.13 (1 H, m), 6.45 (1 H, dd, J=17.0, 10.2 Hz), 6.26 (1 H, d, J=17.0 Hz), 5.79 (1 H, s), 3.92 - 4.01 (3 H, s), 2.70 (3 H, s) 84:16 mixture of the desired sulfoxide and the corresponding sulfone. The crude material was used in the next step without further purification.
A suspension of N-(3-(6-methoxy-2-(methylsulfmyl)-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)acrylamide (0.134 g, 0.349 mmol), l-(4-amino-3- methoxyphenyl)-4-methyl-piperazine (0.085 g, 0.383 mmol), TFA (0.026 ml, 0.349 mmol), in 2-butanol (20 ml, 54.5 mmol) was stirred at 110°C overnight. After cooled to RT the crude was concentrated down and purified by chromatography through a Redi- Sep pre-packed silica gel column (40 g), eluting with a gradient of 0%> to 10%o 2M NH3 MeOH in DCM. The product was repurified with reverse-phase preparative HPLC using phenomenex C\% 30 x 150mm column with a gradient of AcCN/Water 10-100% over 16 minute to provide N-(3-(6-methoxy-2-((2-methoxy-4-(4-methylpiperazin-l- yl)phenyl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamid^ (Example 28; 35 mg, 0.065 mmol, 19%) as a light yellow solid. ). m/z (ESI, +ve ion) 542.2. !H NMR (400 MHz, DMSO-d6) δ 10.36 (br. s., 1H), 8.69 (s, 1H), 7.90 (br. s., 1H), 7.84 (br. s., 1H), 7.62 (br. s., 1H), 7.54 (br. s., 1H), 7.31 (br. s., 2H), 7.03 (d, J= 7.24 Hz, 1H), 6.53 (br. s., 1H), 6.38 - 6.50 (m, 1H), 6.28 (br. s., 1H), 5.98 - 6.08 (m, 1H), 5.76 (s, 1H), 3.85 (br. s., 3H), 3.79 (br. s., 3H), 3.02 (br. s., 4H), 2.44 (br. s., 4H), 2.23 (br. s., 3H).
Example B29: N-(3-(2-((4-(4-(2-hydroxypropan-2-yl)piperidin-l-yl)phenyl)amino)-5- methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide
A mixture of N-(3-(2-chloro-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)- yl)phenyl)acrylamide (0.1 g, 0.293 mmol), HOAc (0.020 mL, 0.352 mmol), 2-(l-(4- aminophenyl)piperidin-4-yl)propan-2-ol (0.069 g, 0.293 mmol, FSSI), TFA (0.025 mL, 0.323 mmol) in EtOH (0.978 mL) was heated to 110 °C overnight. Reaction mixture was directly purified by Gilson HPLC (Gemini-NX, lOu, CI 8, 100x50 mm; 0.1% TFA/water, 0.1% TFA/AcCN). The clean fractions were azeotroped with AcCN. The residue was resolubilized with MeOH and neutralized with Silicycle SiliaPrep Carbonate cartridge to afford N-(3-(2-((4-(4-(2-hydroxypropan-2-yl)piperidin-l -yl)phenyl)amino)-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide (Example B29, 45.3 mg, 0.84 mmol, 29% yield). !H NMR (300 MHz, MeOH-d4) δ 8.89 (s, 1H), 7.96-8.12 (m, 1H), 7.60 (t, J=8.11 Hz, 2H), 7.49 (br. s., 1H), 7.42-7.47 (m, 2H), 7.29 (d, J=9.35 Hz, 2H), 7.07 (dd, J=0.95, 8.84 Hz, 1H), 6.37-6.49 (m, 3H), 5.79 (dd, J=3.14, 8.84 Hz, 1H), 3.48- 3.65 (m, 4H), 3.18-3.33 (m, 4H), 2.53 (s, 3H), 2.07-2.21 (m, 2H), 1.72-1.97 (m, 3H), 1.25 (s, 7H). m/z (ESI, +ve ion) 539.1 (M+H)+.
Example B30: N-(3-(6-Methoxy-2-((2-methoxy-4-(4-methylpiperazin-l- yl)phenyl)amino)-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)- yl)phenyl)acrylamide.
LiHMDS (1.0 M in THF, 2.00 mL, 2.00 mmol) was added to THF (10 mL) at -78 °C and treated with methyl methoxyacetate (Sigma Aldrich, 0.145 mL, 1.469 mmol) slowly dropwise. The solution was stirred at -78 °C for 25 min, then tert-butyl (3-((5- acetyl-2-(methylthio)pyrimidin-4-yl)amino)phenyl)carbamate (102, 250 mg, 0.668 mmol) was added in one portion and the solution was removed from the cooling bath, warmed to RT and stirred for 2 h. Martin sulfurane dehydrating agent (Sigma Aldrich, 449 mg, 0.668 mmol) was added in one portion to the reaction mixture and stirred for 3 h. The reaction was quenched with a saturated solution of NH4C1 and extracted with EtOAc (2 x 15 mL), dried over MgS04, filtered and concentrated. The reaction was purified on the ISCO Combiflash RF (25 g Thomson column, using a gradient of 0-60% EtOAc in hexanes) affording tert-butyl (3-(6-methoxy-5-methyl-2-(methylthio)-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)carbamate (30a; 142 mg, 0.33 mmol, 49% yield) as a pale yellow crystalline solid, m/z (ESI, +ve ion) 428.9 (M+H)+. !H NMR (400 MHz, DMSO- d6) δ ppm 9.55 (1 H, br. s.), 8.98 (1 H, s), 7.31 - 7.60 (3 H, m), 6.91 (1 H, d, J=7.4 Hz), 3.32 (2 H, s), 2.43 (3 H, s), 2.20 (3 H, s), 1.47 (9 H, s).
In a 250-mL RBF, tert-butyl (3-(6-methoxy-5-methyl-2-(methylthio)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)carbamate (30a; 163 mg, 0.38 mmol) was treated with HC1 (4 M in 1,4-dioxane, 1.90 mL, 7.61 mmol) and heated to 50 °C for 45 min. The volatiles were removed under reduced pressure and the crude material was treated with 1,4-dioxane (4 mL), cooled to 0 °C and treated with NaOH (10 N, 0.84 ml, 8.37 mmol) in an ice bath. The solution was stirred for 30 min then treated with acryloyl chloride (40.2 μί, 0.495 mmol) and stirred warming to RT for 1 h. The reaction mixture was quenched with water (15 mL) and extracted with EtOAc and DCM, dried over MgS04, filtered and concentrated and dried under high vacuum overnight, m/z (ESI, +ve ion) 383.1 (M+H)+. !H NMR (400 MHz, DMSO-d6) δ ppm 10.34 (1 H, s), 8.98 (1 H, s), 7.65 - 7.74 (2 H, m), 7.49 (1 H, t, J=8.0 Hz), 7.00 - 7.08 (1 H, m), 6.45 (1 H, dd, J=16.9, 10.1 Hz), 6.25 (1 H, dd, J=17.0, 2.0 Hz), 5.71 - 5.81 (1 H, m), 3.83 (3 H, s), 2.43 (3 H, s), 2.13 - 2.22 (3 H, s).
In a 250 mL RBF, N-(3-(6-methoxy-5-methyl-2-(methylthio)-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)acrylamide (30b; 101 mg, 0.26 mmol) was treated with DCM (20 mL), cooled to 0 °C in an ice bath and treated with 3-chloroperoxybenzoic acid (59 mg of 77% max., 0.26 mmol) in one portion. The solution was stirred at 0 °C for 50 min. The reaction mixture was treated with a 10% solution of Na2C03, extracted with DCM (2 x 20 mL), dried over anhydrous Na2S04, filtered and concentrated affording crude N-(3-(6-methoxy-5-methyl-2-(methylsulfmyl)-7-oxopyrido[2,3-d]pyrimidin-8(7H)- yl)phenyl)acrylamide (105 mg, 0.28 mmol, 100%o yield) as a light yellow foam, m/z (ESI, +ve ion) 399.0 (M+H)+. !H NMR (400 MHz, DMSO-d6) δ ppm 10.36 (1 H, br. s.), 9.34 (1 H, s), 7.63 - 7.81 (2 H, m), 7.51 (1 H, t, J=8.0 Hz), 7.06 (1 H, d, J=7.6 Hz), 6.46 (1 H, dd, J=16.7, 10.3 Hz), 6.26 (1 H, d, J=16.8 Hz), 5.78 (1 H, d, J=10.6 Hz), 3.89 (3 H, s), 2.70 (3 H, s) the sample also contained ca. 7%> of the corresponding sulfone.
In a 250 mL RBF, 2-methoxy-4-(4-methylpiperazin-l-yl)aniline
(GreenChemPharm, Bardonia, NY, 70.0 mg, 0.316 mmol) and N-(3-(6-methoxy-5- methyl-2-(methylsulfmyl)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide (30c; 105 mg, 0.264 mmol) were treated with DMAc (2.0 mL) under nitrogen and heated to 90 °C for 24 h. The crude reaction mixture was transferred to a silica gel column with DCM and purified on an ISCO Combiflash RF (40 g Thomson SingleStep column, using a gradient of 0-20% MeOH in DCM (eluted with ca. 15- 18% MeOH)) affording enriched product. The material was repurified on the Gilson (Gemini Phenomenex; 30 x 150 mm, 5 u, 10-95% 0.1%TFA/CH3CN in 0.1 %TF A/water), concentrated in the genevac overnight and then passed through a Silicycle SPE-R66030B-20X SiliaSep OT, 5g/25 mL carbonate column using 20% MeOH/DCM then dried under vacuum affording N-(3-(6- methoxy-2-((2-methoxy-4-(4-methylpiperazin-l-yl)phenyl)amino)-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide (Example B30; 8.8 mg, 0.016 mmol, 6% yield) as a bright yellow solid after drying in a vacuum oven at 40 °C for 3 h. m/z (ESI, +ve ion) 556.3 (M+H)+. !H NMR (400 MHz, DMSO-d6) δ ppm 10.35 (1 H, s), 8.80 (1 H, s), 7.97 (1 H, s), 7.90 (1 H, d, J=8.0 Hz), 7.59 (1 H, br. s.), 7.52 (1 H, t, J=7.9 Hz), 7.27 (1 H, d, J=7.8 Hz), 7.01 (1 H, d, J=7.8 Hz), 6.52 (1 H, br. s.), 6.43 (1 H, dd, J=17.4, 10.6 Hz), 6.25 (1 H, d, J=17.0 Hz), 6.01 (1 H, br. s.), 5.76 (1 H, d, J=10.2 Hz), 3.78 (6 H, br. s.), 3.02 (4 H, br. s.), 2.36 - 2.46 (7 H, m), 2.22 (3 H, s). Example 31: N-(3-(2-((4-(4-acetylpiperazin-l-yl)-2-chlorophenyl)amino)-5-methyl- 7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide
Preparation of l-(4-(4-amino-3-chlorophenyl)piperazin-l-yl)ethanone (31b). A solution of 2-chloro-4-fluoronitrobenzene (3.45 g, 19.68 mmol), 1-acetylpiperazine (2.52 g, 19.68 mmol), in DMSO (25 mL, 352 mmol) was stirred at 90 °C for 3 h. After the reaction mixture was cooled to RT, water (25 mL) was added and the compound was extracted with EtOAc (3 x 100 mL). The organic extracts were washed with water (3 x 50 mL), brine (10 mL) and dried over Na2S04, filtered and concentrated in vacuum to give l-(4-(3-chloro-4-nitrophenyl)piperazin-l-yl)ethanone (31a, 3.56 g, 64% yield) as a yellow sticky oil. m/z (ESI, +ve ion) 284.2.
A solution of l-(4-(3-chloro-4-nitrophenyl)piperazin-l-yl)ethanone (31a, 5.36 g, 18.89 mmol), and HC1 (7.56 mL of 5 N solution, 37.8 mmol) in EtOH (15 mL, 258 mmol) was stirred at RT and treated in portions with zinc dust (3.71 g, 56.7 mmol). The mixture was stirred at 50 °C for 1 h. The mixture was briefly cooled and the suspension was filtered through a bed of celite and the celite cake was washed with MeOH. The filtrate was concentrated under reduced pressure and 5 N NaOH (10 mL) was added followed by CHCI3 (100 mL) and the phase was mixed and separated. The aqueous layer was extracted with additional CHCI3 (20 mL). The combined organic layer was dried over Na2S04, filtered and concentrated in vacuum to give l-(4-(4-amino-3- chlorophenyl)piperazin-l-yl)ethanone (31b, 2.65 g, 10.44 mmol, 55% yield) as a dark sticky oil, [m/z (ESI, +ve ion) 254.1.
Preparation of Example B31. A solution of l -(4-(4-amino-3- chlorophenyl)piperazin-l-yl)ethanone (31b, 0.135 g, 0.53 mmol), N-(3-(2-chloro-5- methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide (0.165 g, 0.484 mmol), TFA (0.036 mL, 0.48 mmol) in 2-butanol (20 mL, 109 mmol) was stirred at 1 10 °C overnight. After cooled to RT, the crude was was concentrated down and
chromatographed through a Redi-Sep pre-packed silica gel column (40 g), eluting with a gradient of 0-10% of 2 M NH3 MeOH in CH2C12. The product was purified by reverse- phase preparative HPLC using a Phenomenex Luna column, 5 micron, Ci8(2), 100 A , 150 x 30 mm, 0.1 % TFA in CH3CN/H20, gradient 15% to 100% over 16 minute to provide N-(3-(2-((4-(4-acetylpiperazin- 1 -yl)-2-chlorophenyl)amino)-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide (Example B31, 47 mg, 0.084 mmol, 22% yield) as yellow solid, [m/z (ESI, +ve ion) 558.2. !H NMR (400 MHz, DMSO-d6) δ 10.31 (s, 1H), 8.84 (d, J = 10.37 Hz, 2H), 7.79 (d, J = 9.00 Hz, 1H), 7.54 (s, 1H), 7.46 (t, J = 8.02 Hz, 1H), 7.28 (d, J = 9.00 Hz, 1H), 6.87 - 7.00 (m, 2H), 6.40 - 6.63 (m, 2H), 6.23 - 6.37 (m, 2H), 5.75 - 5.83 (m, 2H), 3.57 (q, J = 5.48 Hz, 4H), 2.98 - 3.15 (m, 4H), 2.47 (s, 3H), 2.04 - 2.09 (m, 2H).
Example B32: (R) and (S) N-(3-(2-((4-(3,4-dimethylpiperazin-l-yl)-2- methoxyphenyl)amino)-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)- yl)phenyl)acrylamide
A mixture of 5-fluoro-2-nitroanisole (2.498 g, 14.60 mmol, Oakwood Products), K2C03 (6.05 g, 43.8 mmol), 1 ,2-dimethylpiperazine (2 g, 17.51 mmol, FSSI) in DMSO (29.2 mL) was heated to 70 °C for ~4 h. Reaction mixture was diluted with DCM and washed with water and brine. The organic layer was rotovapped and dried on high vac to afford 4-(3-methoxy-4-nitrophenyl)-l,2-dimethylpiperazine as orange colored semi-solid (32a, 3.97g, 14.96 mmol). The material was advanced to next step before further purification, m/z (ESI, +ve ion) 266.1 (M+H)+.
A mixture of 4-(3-methoxy-4-nitrophenyl)-l,2-dimethylpiperazine (32a, 3.87 g, 14.60 mmol), iron (4.08 g, 73.0 mmol), NH4C1 (0.781 g, 14.60 mmol) in EtOH (32.0 mL) and water (6.40 mL) was heated to 100 °C for 2 h. Reaction mixture was filtered over Celite and rinsed with copious amount of water. The filtrate was rotovapped to remove volatile solvents and then basified to pH >9 using 5 N NaOH solution. The filtrate was then back extracted with CHCI3 (2 x). The organic layer was dried over Mg2S04 and then rotovapped. The oil residue (32b) was advanced to next step directly, m/z (ESI, +ve ion) 236.1 (M+H)+.
A mixture of N-(3-(2-chloro-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)- yl)phenyl)acrylamide (0.2 g, 0.587 mmol), HOAc (0.041 mL, 0.704 mmol), 4-(3,4- dimethylpiperazin-l -yl)-2-methoxyaniline (0.180 g, 0.763 mmol), TFA (0.050 mL, 0.646 mmol) in EtOH (1.956 mL) was heated to 1 10 °C overnight. Reaction mixture formed a suspension of solids which was washed with copious amounts of DMSO, MeOH, and AcCN to afford (R) and (S) N-(3-(2-((4-(3,4-dimethylpiperazin-l -yl)-2- methoxyphenyl)amino)-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)- yl)phenyl)acrylamide 2,2,2-trifluoroacetate (Example B32, 277.3 mg, 0.424 mmol, 72% yield). ¾ NMR (300 MHz, DMSO-d6) δ 10.44 (s, 1H), 10.16-10.33 (m, 1H), 8.81 (s, 1H), 8.17 (s, 1H), 7.94 (d, J=7.89 Hz, 1H), 7.44-7.57 (m, 2H), 7.30 (d, J=8.92 Hz, 1H), 6.98 (d, J=7.60 Hz, 1H), 6.60 (br. s., 1H), 6.39-6.55 (m, 1H), 6.37-6.37 (m, 1H), 6.33 (s, 2H), 6.06 (br. s., 1H), 5.77 (d, J=10.82 Hz, 1H), 3.64-3.87 (m, 5H), 3.53 (d, J=1 1.98 Hz, 1H), 3.18 (br. s., 1H), 2.62-3.04 (m, 6H), 2.46 (s, 3H), 1.37 (d, J=5.41 Hz, 3H). m/z (ESI, +ve ion) 540.2 (M+H)+.
Example B33: N-(3-(2-((4-(3-(dimethylamino)propoxy)phenyl)amino)-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide
A mixture of N-(3-(2-chloro-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)- yl)phenyl)acrylamide (0.1 g, 0.293 mmol), HOAc (0.020 ml, 0.352 mmol), 4-(3- (dimethylamino)propoxy)aniline (0.057 g, 0.293 mmol, FSSI), TFA (0.025 mL, 0.323 mmol) in EtOH (0.978 mL) was heated to 110 °C overnight. Reaction mixture was directly purified by Gilson HPLC (Gemini-NX, lOu, Ci8, 100 x 50 mm column; 0.1% TF A/water, 0.1% TFA/AcCN). The clean fraction was azeotroped with AcCN. The residue was resolubilized with MeOH and neutralized with Silicycle SiliaPrep Carbonate cartridge to afford N-(3-(2-((4-(3-(dimethylamino)propoxy)phenyl)amino)-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide (Example B33, 16.1 mg, 0.032 mmol, 11% yield). !H NMR (300 MHz, MeOH-d4) δ 8.80 (s, IH), 7.95 (d, J=8.62 Hz, IH), 7.47-7.70 (m, 3H), 7.19 (d, J=8.18 Hz, 2H), 7.03 (d, J=7.60 Hz, IH), 6.58 (d, J=8.18 Hz, 2H), 6.31-6.49 (m, 3H), 5.77 (dd, J=2.34, 9.50 Hz, IH), 3.92 (t, J=6.07 Hz, 2H), 2.46-2.62 (m, 6H), 2.33 (s, 6H), 1.87-2.01 (m, 2H), 1.25 (d, J=6.28 Hz, IH). m/z (ESI, +ve ion) 499.1 (M+H)+.
Example B34: N-(3-(2-((2-methoxy-4-(methyl(2-(2-oxopyrrolidin-l- yl)ethyl)amino)phenyl)amino)-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)- yl)phenyl)acrylamide
Preparation of 1 -(2-((4-amino-3-methoxyphenyl)(methyl)amino)ethyl)pyrrolidin- 2-one (34c). 2-((3-Methoxy-4-nitrophenyl)(methyl)amino)ethanol (B17a, 1.7 g, 7.51 mmol) and DIPEA (Sigma-Aldrich; 2.0 mL, 11.50 mmol) were dissolved in DCM (45 mL) under N2. The yellow solution was cooled in an ice bath and a solution of methanesulfonyl chloride (Alfa-Aesar; 0.6 mL, 7.75 mmol) in DCM (5 mL) was added dropwise. The reaction was warmed to RT. After another 45 min additional DIPEA (2.0 mL, 11.50 mmol) was added followed by methanesulfonyl chloride (0.6 mL, 7.75 mmol). The mixture was stirred for 5 min after which water (75 mL) was added. The phases mixed and separated. The organic layer was dried with MgS04 and evaporated to dryness under reduced pressure. Purification using silica chromatography (DCM to EtOAc gradient) gave the desired 2-((3-methoxy-4-nitrophenyl)(methyl)amino)ethyl methanesulfonate (34a, 1.75 g, 5.75 mmol, 77% yield) as a light yellow solid, m/z (ESI, +ve ion) 326.9 (M+l)+ !H NMR (400 MHz, CDC13) δ ppm 7.97 (d, J=9.4 Hz, 1H), 6.26 (d, J=9.4 Hz, 1H), 6.20 (s, 1H), 4.40 (t, J=5.8 Hz, 2H), 3.95 (s, 3H), 3.81 (t, J=5.8 Hz, 2H), 3.14 (s, 3H), 3.00 (s, 3H).
NaH (Sigma-Aldrich; 60% dispersion in mineral oil, 0.17 g, 4.19 mmol) was suspended in dry THF (10 mL) under nitrogen and cooled in an ice bath. 2-Pyrrolidone (Sigma-Aldrich; 0.50 ml, 6.58 mmol) was added dropwise and the mixture stirred for 15 min. 2-((3-Methoxy-4-nitrophenyl)(methyl)amino)ethyl methanesulfonate (34a, 0.85 g, 2.79 mmol) was added in one portion and the suspension stirred under nitrogen for 60 h. Dry DMSO (1 mL) was added and the mixture heated in a 60 °C oil bath for 90 min. The reaction was cooled to RT. Water (75 mL) and EtOAc (100 mL) were added and the phases mixed and separated. The aqueous was extracted with CHCI3 (100 mL) and the two organic layers combined, dried with MgS04 and evaporated to dryness under reduced pressure. Purification using silica chromatography (0-5% MeOH in DCM gradient) gave the desired l-(2-((3-methoxy-4-nitrophenyl)(methyl)amino)ethyl)pyrrolidin-2-one (34b, 0.74 g, 2.52 mmol, 90% yield) as a yellow solid, m/z (ESI, +ve ion) 294.0 (M+l)+ !H NMR (400 MHz, CDC13) δ ppm 8.00 (d, J=9.2 Hz, 1H), 6.21-6.35 (m, 2H), 3.99 (s, 3H), 3.62 (t, J=6.6 Hz, 2H), 3.47 (t, J=6.6 Hz, 2H), 3.39 (t, J=6.9 Hz, 2H), 3.09 (s, 3H), 2.30 (t, J=8.0 Hz, 2H), 1.95 (quin, J=7.5 Hz, 2H).
l-(2-((3-Methoxy-4-nitrophenyl)(methyl)amino)ethyl)pyrrolidin-2-one (0.740 g, 2.52 mmol) was suspended in dry EtOH (15 mL) under argon. Pd/C (Sigma-Aldrich; 10 wt%>, 0.25 g, 0.23 mmol) was added and the resulting suspension stirred under a balloon of H2 overnight. The mixture was filtered through a pad of Celite and the solids washed with DCM (50 mL). The filtrate was evaporated to dryness under reduced pressure. The initial filtrate was clear and colorless, but it slowly turned dark green during the removal of the solvent. It was further dried under high vacuum to afford l-(2-((4-amino-3- methoxyphenyl)(methyl)amino)ethyl)pyrrolidin-2-one (34c) which was used without purification, m/z (ESI, +ve ion) 264.0 (M+l)+
Preparation of Example B34. l-(2-((4-Amino-3-methoxyphenyl)(methyl)amino)- ethyl)pyrrolidin-2-one (34c, 0.64 g, 2.430 mmol), N-(3-(2-chloro-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide (100) (0.828 g, 2.43 mmol), HOAc (Sigma-Aldrich; 0.14 mL, 2.43 mmol), and EtOH (5 mL) were combined in a pressure vessel under argon and heated in a 120 °C oil bath. After 105 min the reaction was cooled to RT. The reaction mixture was evaporated to dryness under reduced pressure and the crude partitioned between water (50 mL), 1 N HC1 (5 mL) and EtOAc (75 mL). The aqueous was carefully basified with saturated NaHCC (20 mL) and extracted with DCM (3 x 40 mL). The combined DCM layers were dried with MgS04 and evaporated to dryness under reduced pressure to give a yellow solid. It was triturated with t butyl methyl ether (50 mL) and the suspension heated in a 50 °C water bath. After 5 min the mixture was filtered through a sintered glass frit and the solids dried under high vac. The crude was suspended in EtOH (10 mL) and heated to gentle reflux. The mixture was cooled and the solids were filtered off. They were dried under high vacuum to give N-(3-(2-((2-methoxy-4-(methyl(2-(2-oxopyrrolidin-l-yl)ethyl)amino)- phenyl)amino)-5 -methyl-7-oxopyrido [2,3 -d]pyrimidin-8(7H)-yl)phenyl)acrylamide (Example B34, 0.59 g, 1.04 mmol, 42% yield) as an orange solid, m/z (ESI, +ve ion) 568.0 (M+l)+ !H NMR (400 MHz, CDCI3) δ ρριη 9.55 (br. s., IH), 8.60 (s, IH), 8.19 (br. s., IH), 7.71 (br. s., IH), 7.53 (d, J=7.0 Hz, IH), 7.35-7.47 (m, 2H), 6.97 (d, J=7.6 Hz, IH), 6.10-6.42 (m, 4H), 6.02 (d, J=8.2 Hz, IH), 5.61 (dd, J=9.6, 1.8 Hz, IH), 3.82 (s, 3H), 3.24-3.62 (m, 6H), 2.91 (s, 3H), 2.41 (d, J=8.2 Hz, 5H), 1.92-2.10 (m, 2H).
Example B35: (^-N-iS-iS-meth l- -iiS-meth l-l-il-meth lp rrolidin-S- -lH- pyrazol-4-yl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide
A solution of triphenylphosphine (3.37 g, 12.85 mmol), 3 -methyl -4-nitro-lH- pyrazole (0.881 ml, 9.89 mmol, Ark Pharm), (r)-(-)-l-methyl-3-pyrrolidinol (1 g, 9.89 mmol, Alfa Aesar) in THF (19.77 mL) was precooled to 0 °C before addition of diisopropyl azodicarboxylate (2.53 ml, 12.85 mmol). The reaction mixture was gradually warmed to RT and stirred overnight. The mixture was directly loaded onto silica gel. Purification by Biotage (0-10% MeOH/DCM) produced (S)-3-methyl-l-(l- methylpyrrolidin-3-yl)-4-nitro-lH-pyrazole (35a, 0.96 g, 4.57 mmol, 46% yield), m/z (ESI, +ve ion) 211.1 (M+H)+.
A mixture of (S)-3-methyl-l-(l-methylpyrrolidin-3-yl)-4-nitro-lH-pyrazole (0.96 g, 4.57 mmol), iron (1.275 g, 22.83 mmol), NH4C1 (0.244 g, 4.57 mmol) in EtOH (10.01 ml) and water (2.003 mL) was heated to 100 °C under nitrogen for ~2 h. Reaction mixture was cooled to RT and filtered over a cake of Celite. The filtrate was rotovapped to remove as much residual EtOH as possible. The solution was then basified to pH >9 using 5 M NaOH solution. The aqueous solution was then back extracted to (S)-3- methyl-l-(l-methylpyrrolidin-3-yl)-lH-pyrazol-4-amine (35b, 541 mg, 3.00 mmol, 65% yield) that solidified after rotovap drying, m/z (ESI, +ve ion) 181.1 (M+H)+.
A mixture of N-(3-(2-chloro-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)- yl)phenyl)acrylamide (0.213 g, 0.624 mmol), AcOH (0.043 mL, 0.749 mmol), (S)-3- methyl- l-(l-methylpyrrolidin-3-yl)-lH-pyrazol-4-amine (0.180 g, 0.999 mmol), TFA (0.053 mL, 0.687 mmol) in EtOH (2.080 mL) was heated to 110 °C overnight. Reaction mixture was directly purified by Gilson HPLC (Gemini-NX, lOu, Ci8, 100 x 50 mm column; 0.1% TF A/water, 0.1% TFA/AcCN). Fractions were azeotroped with AcCN. The residue was resolubilized with MeOH and purified a second time with prep plate TLC (2% MeOH/DCM) to afford (S)-N-(3 -(5 -methyl-2-((3 -methyl- 1-(1 - methylpyrrolidin-3-yl)-lH-pyrazol-4-yl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)- yl)phenyl)acrylamide 2,2,2-trifluoroacetate (Example B35, 38.6 mg, 0.064 mmol, 10% yield). !H NMR (300 MHz, MeOH-d4) δ 8.82 (s, 1H), 8.15 (br. s., 1H), 8.07-8.27 (m, 1H), 7.64 (t, J=7.67 Hz, 1H), 7.39 (d, J=19.15 Hz, 1H), 7.08 (br. s., 1H), 6.88 (d, J=5.12 Hz, 1H), 6.24-6.51 (m, 3H), 5.80 (d, J=8.62 Hz, 1H), 4.59-4.78 (m, 2H), 3.33-4.03 (m, 4H), 3.05 (br. s., 3H), 2.52 (s, 4H), 2.19 (s, 4H). m/z (ESI, +ve ion) 485.1 (M+H)+.
Exmple B36: N-(3-(2-((2-methoxy-4-(methyl(2-(pyrrolidin-l- :thyl)amino)phenyl)amino)-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)- yl)phenyl)acrylamide
2- ((3-Methoxy-4-nitrophenyl)(methyl)amino)ethyl methanesulfonate (34a, 0.775 g, 2.55 mmol) was added to a mixture of pyrrolidine (Sigma-Aldrich; 2.0 ml, 23.90 mmol) in dry THF (10 mL) under nitrogen. The reaction was heated in a 60 °C oil bath for 2½ h. The reaction mixture was concentrated under reduced pressure and the crude was partitioned between water (75 mL) and DCM (150 mL). The organic layer was dried with MgS04 before evaporating to dryness under reduced pressure. The crude was dried under high vacuum to give 3-methoxy-N-methyl-4-nitro-N-(2-(pyrrolidin-l- yl)ethyl)aniline (36a, 0.694 g, 2.48 mmol, 98% yield) as a yellow oil. m/z (ESI, +ve ion) 280.1 (M+l)+ !H NMR (400 MHz, CDC13) δ ppm 8.00 (d, J=9.4 Hz, IH), 6.25 (d, J=9.5 Hz, IH), 6.12 (s, IH), 3.94 (s, 3H), 3.57 (t, J=7.5 Hz, 2H), 3.09 (s, 3H), 2.69 (t, J=7.5 Hz, 2H), 2.55-2.65 (m, 4H), 1.75-1.90 (m, 4H).
3- Methoxy-N-methyl-4-nitro-N-(2-(pyrrolidin-l-yl)ethyl)aniline (36a, 0.694 g, 2.48 mmol) was suspended in dry EtOH (15 mL) under argon. Pd/C (10 wt%, Sigma- Aldrich; 0.25 g, 0.23 mmol) was added and the resulting suspension stirred under a balloon of H2. After 2 h the suspension was filtered through a pad of Celite and the solids washed with DCM (30 mL). The filtrate was evaporated to dryness under reduced pressure to give a light yellow oil. It was further dried under high vacuum for 30 min. The crude was dissolved in EtOAc (20 mL) and MeOH (5 mL) and treated with 1 N HC1 in diethyl ether (Sigma-Aldrich; 2.5 mL). The mixture was evaporated to dryness under reduced pressure and the crude solid containing 36b was used without further purification, m/z (ESI, +ve ion) 250.1 (M+l)+.
3-Methoxy-N 1 -methyl-N 1 -(2-(pyrrolidin- 1 -yl)ethyl)benzene- 1 ,4-diamine hydrochloride (36b, 0.70 g, 2.45 mmol), N-(3-(2-chloro-5-methyl-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)acrylamide (0.835 g, 2.45 mmol), AcOH (Sigma-Aldrich; 0.14 mL, 2.45 mmol), and EtOH (5 mL) were combined in a pressure vessel under argon and heated in a 120 °C oil bath. After 75 min the reaction was cooled to RT. Water (50 mL) and EtOAc (75 mL) were added and the mixture stirred. The phases were separated and the organic discarded. The aqueous was basified with 1 N NaOH and extracted with DCM (3 x 30 mL). The combined DCM layers were dried with MgS04 and evaporated to dryness under reduced pressure. The solid was suspended in EtOAc (75 mL) and heated in a 60 °C oil bath for 10 min. The suspension was cooled to RT and was filtered through a sintered glass frit. The solids were suspended in EtOH (10 mL) and heated to gentle reflux. The mixture was cooled to RT over night. The suspension was filtered through a sintered glass frit to give the crude product as a yellow solid. Purification using silica gel chromatography (2-10% MeOH in DCM gradient) gave N-(3-(2-((2-methoxy-4- (methyl(2-(pyrrolidin-l -yl)ethyl)amino)phenyl)amino)-5-methyl-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)acrylamide (Example 3B6) (297 mg, 0.54 mmol, 22% yield), m/z (ESI, +ve ion) 554.0 (M+l)+. !H NMR (400 MHz, CDC13) δ ppm 8.62 (s, 1H), 7.90 (br. s., 1H), 7.69 (br. s., 1H), 7.48 (t, J=8.2 Hz, 1H), 7.39 (br. s., 1H), 6.99 (d, J=8.5 Hz, 1H), 6.29-6.47 (m, 3H), 6.19 (br. s., 1H), 5.92 (br. s., 1H), 5.68 (d, J=10.5 Hz, 1H), 3.83 (s, 3H), 3.44 (t, J=7.5 Hz, 2H), 2.83-3.03 (m, 5H), 2.63-2.74 (m., 6H), 2.47 (s, 3H), 2.10-2.20 (m, 4H).
Example B37: N-(3-(2-((4-((2-(dimethylamino)ethyl)(methyl)amino)-2- methylphenyl)amino)-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)- yl)phenyl)acrylamide
A solution of 5-fluoro-2-nitrotoluene (1.93 mL, 15.86 mmol), Ν,Ν,Ν'- trimethylethylenediamine (2.01 mL, 15.86 mmol), and DIEA (2.76 mL, 15.86 mmol) in DMSO (25 mL, 352 mmol), was stirred at 90 °C for 3 h. After cooling to RT water (25 mL) was added and the compound was extracted with EtOAc (3 x 100 mL). The organic layer was washed with water (3 x 50 mL), brine and dried over Na2S04, filtered and concentrated in vacuum to give Nl,Nl ,N2-trimethyl-N2-(3-methyl-4- nitrophenyl)ethane-l ,2-diamine (37a, 3.4 g, 14.33 mmol, 90%o yield) as a yellow sticky oil. m/z (ESI, +ve ion) 238.2.
A solution of Nl,Nl,N2-trimethyl-N2-(3-methyl-4-nitrophenyl)ethane-l,2- diamine (37a, 3.58 g, 15.09 mmol), HCl (12.07 mL of 5 N solution, 60.3 mmol) in EtOH (25 mL, 429 mmol) was stirred at RT and treated in portions with zinc powder (4.93 g, 75 mmol). The mixture was stirred at 50 °C for 1 h. The mixture was briefly cooled and the suspension was filtered through bed of Celite and the Celite cake was washed with MeOH. The filtrate was concentrated under reduced pressure and 5 N NaOH (10 mL) was added followed by CHC13 (100 mL) and the phase was mixed and separated. The aqueous layer was extracted with additional CHCI3 (20 mL). The combined organic layer was dried over Na2S04, filtered and concentrated in vacuum to give Nl -(2- (dimethylamino)ethyl)-Nl,3-dimethylbenzene-l,4-diamine (37b, 2.35 g, 11.34 mmol, 75% yield) as a dark sticky oil. m/z (ESI, +ve ion) 208.2.
A suspension of N-(3-(2-chloro-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)- yl)phenyl)acrylamide (100) (110 mg, 0.32 mmol), Nl-(2-(dimethylamino)ethyl)-Nl,3- dimethylbenzene-l ,4-diamine (37b, 67 mg, 0.32 mmol), TFA (0.024 mL, 0.32 mmol) in 2-butanol (25 mL, 273 mmol) was stirred at 1 10 °C overnight. After cooled to RT, the crude product was concentrated and purified by chromatography through a Redi-Sep prepacked silica gel column (40 g), eluting with a gradient of 0-10% 2 M NH3 MeOH in DCM. The crude material was repurified by reverse-phase preparative HPLC using a
Phenomenex Luna column, 5 micron, Cis(2), 100 A , 150 x 30 mm column, 0.1% TFA in AcCN/H20, gradient 10% to 100% over 16 min to provide N-(3-(2-((4-((2- (dimethylamino)ethyl)(methyl)amino)-2-methylphenyl)amino)-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide (80 mg, 0.156 mmol, 48%o yield) as a yellow solid. !H NMR (400 MHz, DMSO-d6) δ 10.29 (br. s., 1H), 8.77 (d, J = 9.00 Hz, 2H), 7.74 (d, J= 7.82 Hz, 1H), 7.56 (br. s., 1H), 7.39 - 7.46 (m, 1H), 7.01 - 7.10 (m, 1H), 6.94 (br. s., 1H), 6.44 (d, J= 10.17 Hz, 2H), 6.20 - 6.34 (m, 3H), 5.78 (d, J = 9.78 Hz, 1H), 3.33 (br. s., 3H), 2.83 (br. s., 3H), 2.45 (br. s., 3H), 2.35 (br. s., 2H), 2.20 (s, 6H), 2.08 (br. s., 3H). m/z (ESI, +ve ion) 517.3.
Example B38: ¾ -N-(3-(2-((4-((2-(dimethylamino)ethyl)(methyl)amino)-2- methoxyphenyl)amino)-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)but-
2-enamide
In a 20-mL glass microwave tube was weighed Nl -(2-(dimethylamino)ethyl)-3- methoxy-Nl -methylbenzene-l,4-diamine hydrochloride (269 mg, 1.037 mmol) and (E)- A^-(3-(2-chloro-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)but-2-enamide (105) (320 mg, 0.90 mmol) followed by purging with argon and addition of EtOH (1.8 mL) and glacial AcOH (56.8 μΐ,, 0.99 mmol). The reaction mixture was sealed and heated to 125 °C in heating block for 90 min. The reaction mixture was concentrated to dryness and the crude residue was purified by chromatography on an ISCO Combiflash RF (40 g Thomson SingleStep column, using a gradient of 0-20% 2 M NH3/MeOH in DCM) affording (E)-N-(3 -(2-((4-((2-(dimethylamino)ethyl)(methyl)amino)-2- methoxyphenyl)amino)-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)but-2- enamide (256 mg, 0.474 mmol, 52% yield) as a bright yellow solid, m/z (ESI, +ve ion) 542.3 (M+H)+. !H NMR (400 MHz, DMSO-d6) δ ppm 10.13 (1 H, s), 8.79 (1 H, s), 8.08 (1 H, br. s.), 7.83 (1 H, d, J=7.4 Hz), 7.56 (1 H, t, =1.8 Hz), 7.47 (1 H, t, J=8.0 Hz), 7.23 (1 H, d, J=9.0 Hz), 6.95 (1 H, dd, J=7.8, 1.0 Hz), 6.74 - 6.87 (1 H, m), 6.22 - 6.35 (2 H, m), 6.13 (1 H, dd, J=15.3, 1.8 Hz), 5.67 - 5.96 (1 H, m), 3.78 (3 H, s), 2.85 (3 H, s), 2.46 (3 H, s), 2.34 (2 H, t, J=6.8 Hz), 2.21 (6 H, s), 1.87 (3 H, dd, J=7.0, 1.4 Hz).
Example B39: N-(3-(2-((2-(difluoromethoxy)-4-((2- (dimethylamino)ethyl)(methyl)amino)phenyl)amino)-5-methyl-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)acrylamide
Preparation of 2-(difluoromethoxy)-4-fluoro-l -nitrobenzene (39a). To a stirred bright yellow suspension of 5-fluoro-2-nitrophenol (Sigma- Aldrich, 3.1 g, 19.73 mmol) and K2C03 (4.23 g, 30.6 mmol) in DMF (40 mL) was added methyl 2-chloro-2,2- difluoroacetate (Fluka, 3.26 mL, 30.6 mmol) and the mixture was stirred at 100 °C for 2 h. The reaction mixture was cooled to RT and carefully diluted with ¾0 (50 mL) and extracted with EtOAc (3 x 70 mL). The organic extract was washed with brine and dried over Na2S04. The solution was filtered and concentrated in vacuo to give a residue as a brown oil. The crude material was absorbed onto silica gel and purified by
chromatography through a Redi-Sep pre-packed silica gel column (80 g), eluting with a gradient of 0-20% EtOAc in hexanes, to provide the title compound (39a, 3.01 g, 74% yield) as yellow oil. !H NMR (400 MHz, CDC13) δ 8.03 (dd, J= 5.67, 9.00 Hz, 1H), 7.06-7.21 (m, 2H), 6.64 (s, 1H).
Preparation of 3-(difluoromethoxy)-N1-(2-(dimethylamino)ethyl)-N1- methylbenzene-l,4-diamine hydrochloride (39c). To a solution of 2-(difluoromethoxy)- 4-fluoro-l -nitrobenzene (39a, 3.01 g, 14.53 mmol), DIPEA (3.30 mL, 18.89 mmol) in DMSO (20 mL) was added AyV^'-trimethylethylenediamine (2.21 mL, 17.44 mmol) and the yellow solution was stirred at 80 °C for 4.5 h and cooled to RT. The reaction mixture was diluted with saturated aqueous NH4C1 (50 mL) and extracted with EtOAc (3 x 70 mL). The combined organic extracts were washed with water, brine, and dried over Na2S04. The solution was filtered and concentrated in vacuo to give Λ^!-(3- (difluoromethoxy)-4-nitrophenyl)- ,A^2,A^2-trimethylethane- 1,2 -diamine (39b) as a yellow oil, which became a dark yellow solid upon under vacuum. MS (ESI positive ion): m/z calcd for C12H17F2N3O3 289; found 290 (M + H). This material was used directly for the next reaction without further purification. To a stirred yellow solution of (2.81 g, 9.71 mmol) in EtOH (8.00 mL) was added wet 10% Pd/C (1.03 g) and the suspension was stirred under a 1 atm H2 for 3 h. The mixture was passed through a short path of Celite. The filtrated cake was washed with MeOH (3 x 10 mL). The combined organic phases were concentrated to give the crude dark purple residue. It was redissolved in ether (10 mL) and 4 Ν HC1 in 1,4-dioxane (2.42 mL, 9.71 mmol) was added dropwise. The pale purple-brown mixture was concentrated and dried under vacuum to give the title compound (39c, 2.66 g, 93% yield) as a pale-purple solid. MS (ESI positive ion): m/z calcd for C12H19F2N3O 259; found 260 (M + H). This material was used directly for the next reaction without further purification.
Preparation of A^-(3-(2-((2-(difluoromethoxy)-4-((2- (dimethylamino)ethyl)(methyl)amino)phenyl)amino)-5-methyl-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)acrylamide (B39). To a stirred suspension of N-(3-(2- chloro-5-methyl-7-oxopyrido[2,3-i/]pyrimidin-8(7//)-yl)phenyl)acrylamide (100) (189 mg, 0.55 mmol) in EtOH (1.50 mL) was added 3-(difluoromethoxy)-M -(2- (dimethylamino)ethyl)-M -methylbenzene-l ,4-diamine hydrochloride (39c, 180 mg, 0.61 mmol) and then AcOH (0.048 mL, 0.83 mmol). The mixture was heated at 125 °C for 2 h and cooled to RT. The mixture was concentrated and the residue was washed with saturated aqueous NaHCC>3 and the resulting brown precipitate was collected and dried under a reduced pressure. The crude solid material was absorbed onto silica gel and purified by chromatography through a Redi-Sep pre-packed silica gel column (24 g), eluting with a gradient of 0- 10% 2 M NH3 MeOH in CH2C12, followed by washing with EtOAc to provide Example 39 (61 mg, 20% yield) as a bright yellow solid. MS (ESI positive ion): m/z calcd for C29H3iF2N703 563; found 564 (M + H); ¾-NMR (DMSO-dg, 400 MHz) δ 10.31 (s, 1H), 8.79 (br., 1H), 8.59 (br., 1H), 7.81 (d, J= 7.82 Hz, 1H), 7.54 (br., 1H), 7.45 (t, J= 8.02 Hz, 1H), 7.21 (br s, 1H), 6.86-7.13 (m, 2H), 6.16-6.52 (m, 5H), 5.77 (d, J = 9.98 Hz, 1H), 3.37 (br., 2H), 2.85 (s, 3H), 2.46 (br., 5H), 2.25 (br., 6H). Example B40: ¾)-N-(3-(2-((4-(2-(dimethylamino)ethoxy)-2-methoxyphenyl)amino)- 5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)but-2-enamide
A heterogeneous mixture of (iT)-N-(3-(2-chloro-5-methyl-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)but-2-enamide (105) (190 mg, 0.53 mmol), 4-(2- (dimethylamino)ethoxy)-2-methoxyaniline hydrochloride (152 mg, 0.61 mmol) and
AcOH (31 μΐ,, 0.53 mmol) in 3 mL of EtOH was heated in a microwave at 120 °C for 75 min. It was treated with 5 mL of 1 N NaOH. The solid was filtered and rinsed with 2 x 1 mL of water. The filtrate was discarded. The solid was rinsed with 2 x 2 mL of ether, collected and purified on a silica gel column (5% MeOH in DCM followed by 5-10% of 2 M NH3 in MeOH in DCM) to provide (£)-N-(3-(2-((4-(2-(dimethylamino)ethoxy)-2- methoxyphenyl)amino)-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)but-2- enamide (Example B40, 175 mg, 0.33 mmol, 61% yield) as a yellow crystalline solid. !H NMR (400 MHz, DMSO-d6) δ ppm 10.14 (1 H, s), 8.82 (1 H, s), 8.16 (1 H, br.), 7.81 (1 H, d, J=8.0 Hz), 7.59 (1 H, br.), 7.49 (1 H, t, J=7.9 Hz), 7.33 (1 H, d, J=8.6 Hz), 6.96 (1 H, d, J=7.6 Hz), 6.80 (1 H, dd, J=14.9, 7.6 Hz), 6.54 (1 H, ), 6.34 (1 H, s), 6.13 (1 H, d, J=15.5 Hz), 6.06 (1 H, br.), 3.96 (2 H, m), 3.79 (3 H, s), 2.60 (2 H, m), 2.47 (3 H, s), 2.23 (6 H, s), 1.86 (3 H, d, J=6.7 Hz), m/z (ESI, +ve ion) 529.3 (M+H)+.
Although the pharmacological properties of the compounds of Formula I-IVa vary with structural change, in general, activity possessed by compounds of Formula I- IVa may be demonstrated in vivo. The pharmacological properties of the compounds of this invention may be confirmed by a number of pharmacological in vitro assays. The exemplified pharmacological assays which follow have been carried out with the compounds according to the invention and their salts.
It has been surprisingly found that provided compounds selectively inhibit each of the EGFR activating and deletion mutations. Moreover, provided compounds are sparing for WT EGFR and associated dose-limiting toxicities. This stands in contrast to other known EGFR inhibitors (e.g., BIBW2992 and HKI- 272) which are only somewhat effective against mutants but retain activity against WT EGFR and are therefore limited by toxicities associated with inhibition of WT EGFR.
BIOLOGICAL EVALUATION
Detection of pEGFR on non-small cell lung cancer [NSCLC] cell lines.
Detection of pEGFR on NSCLC cell lines.
The effects of compounds on the phosphorylation of wild-type, T790M mutant, and Exonl9 deletion (Δ746-750) EGFR were monitored using Mesoscale™ multiplex assays (MSD), in which levels of phosphorylated EGFR protein were determined using total PRAS40 levels to normalize. HI 975 (T790M/L858R), HCC827 (Δ746-750) and A431 (wild type) cells were seeded in 6-well tissue culture plates, serum starved overnight and treated with 10 concentrations of compound starting at 10 μΜ (5-fold serial dilutions) for 60 min. A431 cells were challenged with 100 ng/mL EGF for 15 min before collection. Cells were lysed according to manufacturer's instructions and lysates were processed for MSD assay. The results are in Table Al.
Table Al. The Inhibition of pEGFR on Three Cell Lines
Detection of pEGFR on NSCLC cell lines.
The effects of compounds on the phosphorylation of wild-type, T790M mutant, and Exonl9 deletion (Δ746-750) EGFR were monitored using Mesoscale™ multiplex assays (MSD), in which levels of phosphorylated EGFR protein were determined using total PRAS40 levels as a control. H1975 (T790M/L858R), HCC827 (Δ746-750) and A549 (wild-type EGFR) NSCLC cells were plated on 6-well tissue culture plates, serum starved for overnight and treated with 9 concentrations of compound starting at 2 μΜ (5- fold dilutions) for 60 min. Wild-type A549 cells were challenged with 100 ng/ml EGF for 15 min before collection. Cells were lysed according to manufacturer's instructions and lysates processed for analysis in the MSD multiplex plate reader. The results are in Table 1.
Inhibition of proliferation of NSCLC cell lines. NSCLC cell lines H1975 (T790M/L858R), HCC827 (Δ746-750) and A549
(wild-type) were seeded in 96-well tissue culture plates (Corning, Lowell, MA) at 5,000 cells/well (HI 975) and 4,000 cells/well (HCC827 and A549) in 95μΙ, of cell growth media overnight. Compounds starting at 10 mM concentration and diluted 8 times (4- fold dilutions) in DMSO were diluted 50 fold in RPMI then 5 was added to cells. After 72 h, viable cell signal was quantified using Cell Titer Glow (Promega, Madison, WI) and a SpectraMax M5 plate reader (Molecular Devices, Sunnyvale, CA) per manufacturer's instructions. Final DMSO concentration in test and control wells was 0.1 %. No DSMO effect was noted on cell growth. The results are in Table 1.
Table 1. The Inhibition of pEGFR in cell lines s and cell killing
Example H1975 HCC827 A549 H1975 HCC827
pEGFR pEGFR pEGFR cell killing cell killing
# IC50 IC50 IC50 IC50 IC50
(nM) (nM) (nM) (nM) (nM)
1 3.2 3.4 76 8 4
2 NT NT NT undefined NT
3 NT NT NT 326 126
4 NT NT NT 0.7 1
5 2.8 8 323 4 10
6 4.3 NT 8.2 12 1.7
7 NT NT NT undefined 2.81
8 NT NT NT 92 21
9 NT NT NT 361 53
10 2 NT 84 4 4
1 1 6 5 155 9.6 3
12 NT NT NT 680 18
13 NT NT NT 128 76
14 NT NT NT 190 24
15 NT NT NT 1 1 3.5
16 NT NT NT 22 18
17 NT NT NT 3.6 7.3
Inhibition of proliferation of NSCLC cell lines NSCLC cell lines H1975 (T790M/L858R), HCC827 (Δ746-750) and epithelial carcinoma cell line A431 (wild type) were seeded in 96-well tissue culture plates (Corning, Lowell, MA) at 5,000 cells/well (H1975 and HCC827) and 7,000 cells/well (A431) in 95 μΐ, of cell growth media overnight. Compounds starting at 10 mM concentration and diluted 8 times (4-fold serial dilutions) in DMSO were diluted 50 fold in RPMI then 5 μΐ^ was added to cells. After 72 h, viable cell signal was quantified using CellTiter-Glo (Promega, Madison, WI) and a SpectraMax M5 plate reader (Molecular Devices, Sunnyvale, CA) per manufacturer's instructions. Final DMSO concentration in test and control wells was 0.1%. The results are in Table B2.
Table B2. The Inhibition of Cell Proliferation on Three Cell Lines
H 1975 HCC 827 A431 pEGFR pEGFR pEGFR
Example IC50 (nM) IC50 (nM) IC50 (nM)
B1 8 22 1400
B2 8 23 >1000
B3 714 NT >1000
B4 62 77 16640
B5 162 305 >1000
B6 175 NT >1000
B7 16 22 1248
B8 91 1 NT >1000
B9 51 76 1335
B10 16 30 2870
B11 7 2 >1000
B12 53 NT >1000
B13 1 1 27 >1000
B14 4 28 2400
B15 762 NT >1000
B16 42 249 2412
B17 35 483 1689
B18 180 NT >1000
B19 101 NT >1000
B20 13 21 3098
B21 310 1051 1825
C22 4 18 250
B23 10.3 173/17 21 1 1
B24 28 86 1258
B25 4.7 46 832
B26 9 17/10 1029
B27 5.8 36 653
C28 272 61 201
B29 176 401 6670
B30 10 41 1387 B31 9 236 4268
B32 2 68 1590
B33 27 159 1547
B34 108 401 4237
B35 18 49 1275
B36 128 272 1411
B37 9 124 1149
B38 336 1372 17960
B39 24 83 884
B40 870 1480 24751
Tumor growth inhibition of NSCLC cell lines.
HI 975 Tumor Xenograft
Female athymic nude mice were implanted with 5x106 HI 975 tumor cells in 33% matrigel (subcutaneously, 0.2 mL injection volume). On day 7 the tumors were measured for baseline values and the mice were randomized into new groups with similar mean tumor volumes (n=10/group). Example Bl was dosed orally at 3, 10, and 30 mg/kg (QD) beginning on day 7. Tumor volume was measured 2X/week until the tumors in the formulation control group had reached 1600 mm3 on day 20. Tumor growth inhibition on day 20 was 20% (3 mg/kg, p= 0.093), 48% (10 mg/kg, p< 0.0001) and 82% (30 mg/kg, p< 0.0001).
HCC-827 Tumor Xenograft
Female SHO mice were implanted with 5x106 HCC-827 tumor cells in 33% matrigel (subcutaneously, 0.2 mL injection volume). On day 13 the tumors were measured for baseline values and the mice were randomized into new groups with similar mean tumor volumes (n=10/group). Example Bl was dosed orally at 10 and 30 mg/kg (QD) along with 30 mg/kg (BID) beginning on day 13. Tumor volume was measured 2X/week until the tumors in the formulation control group had reached 400 mm3 at day 38. Tumor growth inhibition on day 38 was 48% (10 mg/kg QD, p= 0.0004), 121% (30 mg/kg QD, p< 0.0001) and 137% (30 mg/kg BID, p< 0.0001).
HI 975 Tumor Xenograft
Female athymic nude mice were implanted with 5x106 HI 975 tumor cells in 33% matrigel (subcutaneously, 0.2 mL injection volume). On day 7 the tumors were measured for baseline values and the mice were randomized into new groups with similar mean tumor volumes (n=10/group). Example B14 was dosed orally at 3, 10, and 30 mg/kg (QD) beginning on day 7. Tumor volume was measured 2X/week until the tumors in the formulation control group had reached 1400 mm3 on day 17. Tumor growth inhibition on day 17 was 33% (3 mg/kg, p= 0.064), 75% (10 mg/kg, p< 0.0001) and 89% (30 mg/kg, p< 0.0001). Statistical significance between treated and control group was assessed at the end of the of each study by Repeated Measures Anova followed by Dunnett's post-hoc analysis (JMP software).
Formulations Also embraced within this invention is a class of pharmaceutical compositions comprising the active compounds of Formula I-IVa in association with one or more nontoxic, pharmaceutically -acceptable carriers and/or diluents and/or adjuvants (collectively referred to herein as "carrier" materials) and, if desired, other active ingredients. The active compounds of the present invention may be administered by any suitable route, preferably in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended. The compounds and compositions of the present invention may, for example, be administered orally, mucosally, topically, rectally, pulmonarily such as by inhalation spray, or parentally including intravascularly, intravenously, intraperitoneally, subcutaneously, intramuscularly intrasternally and infusion techniques, in dosage unit formulations containing conventional
pharmaceutically acceptable carriers, adjuvants, and vehicles.
The pharmaceutically active compounds of this invention can be processed in accordance with conventional methods of pharmacy to produce medicinal agents for administration to patients, including humans and other mammals.
For oral administration, the pharmaceutical composition may be in the form of, for example, a tablet, capsule, suspension or liquid. The pharmaceutical composition is preferably made in the form of a dosage unit containing a particular amount of the active ingredient. Examples of such dosage units were tablets or capsules. For example, these may contain an amount of active ingredient from about 1 to 2000 mg, preferably from about 1 to 500 mg, more preferably from about 5 to 150 mg. A suitable daily dose for a human or other mammal may vary widely depending on the condition of the patient and other factors, but, once again, can be determined using routine methods. The amount of compounds which were administered and the dosage regimen for treating a disease condition with the compounds and/or compositions of this invention depends on a variety of factors, including the age, weight, sex and medical condition of the subject, the type of disease, the severity of the disease, the route and frequency of administration, and the particular compound employed. Thus, the dosage regimen may vary widely, but can be determined routinely using standard methods. A daily dose of about 0.01 to 500 mg/kg body weight, preferably between about 0.5 and about 50 mg/kg body weight and most preferably between about 0.1 to 20 mg/kg body weight, may be appropriate may be appropriate. The daily dose can be administered in one to four doses per day.
For therapeutic purposes, the active compounds of this invention are ordinarily combined with one or more adjuvants appropriate to the indicated route of
administration. If administered per os, the compounds may be admixed with lactose, sucrose, starch powder, cellulose esters of alkanoic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate,
polyvinylpyrrolidone, and/or polyvinyl alcohol, and then tableted or encapsulated for convenient administration. Such capsules or tablets may contain a controlled-release formulation as may be provided in a dispersion of active compound in
hydroxypropylmethyl cellulose.
Formulations suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin (e.g., liniments, lotions, ointments, creams, or pastes) and drops suitable for administration to the eye, ear, or nose. A suitable topical dose of active ingredient of a compound of the invention is 0.1 mg to 150 mg administered one to four, preferably one or two times daily. For topical administration, the active ingredient may comprise from 0.001% to 10% w/w, e.g., from 1 % to 2% by weight of the formulation, although it may comprise as much as 10% w/w, but preferably not more than 5% w/w, and more preferably from 0.1% to 1% of the formulation.
When formulated in an ointment, the active ingredients may be employed with either paraffinic or a water-miscible ointment base. Alternatively, the active ingredients may be formulated in a cream with an oil-in-water cream base. If desired, the aqueous phase of the cream base may include, for example at least 30% w/w of a polyhydric alcohol such as propylene glycol, butane- 1, 3 -diol, mannitol, sorbitol, glycerol, polyethylene glycol and mixtures thereof. The topical formulation may desirably include a compound which enhances absorption or penetration of the active ingredient through the skin or other affected areas. Examples of such dermal penetration enhancers include dimethylsulfoxide and related analogs.
The compounds of this invention can also be administered by a transdermal device. Preferably transdermal administration will be accomplished using a patch either of the reservoir and porous membrane type or of a solid matrix variety. In either case, the active agent is delivered continuously from the reservoir or microcapsules through a membrane into the active agent permeable adhesive, which is in contact with the skin or mucosa of the recipient. If the active agent is absorbed through the skin, a controlled and predetermined flow of the active agent is administered to the recipient. In the case of microcapsules, the encapsulating agent may also function as the membrane.
The oily phase of the emulsions of this invention may be constituted from known ingredients in a known manner. While the phase may comprise merely an emulsifier, it may comprise a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil. Preferably, a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabilizer. It is also preferred to include both an oil and a fat. Together, the emulsifier(s) with or without stabilizer(s) make-up the so-called emulsifying wax, and the wax together with the oil and fat make up the so-called emulsifying ointment base which forms the oily dispersed phase of the cream formulations. Emulsifiers and emulsion stabilizers suitable for use in the formulation of the present invention include Tween 60, Span 80, cetostearyl alcohol, myristyl alcohol, glyceryl monostearate, sodium lauryl sulfate, glyceryl distearate alone or with a wax, or other materials well known in the art.
The choice of suitable oils or fats for the formulation is based on achieving the desired cosmetic properties, since the solubility of the active compound in most oils likely to be used in pharmaceutical emulsion formulations is very low. Thus, the cream should preferably be a non-greasy, non-staining and washable product with suitable consistency to avoid leakage from tubes or other containers. Straight or branched chain, mono- or dibasic alkyl esters such as di-isoadipate, isocetyl stearate, propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a blend of branched chain esters may be used. These may be used alone or in combination depending on the properties required. Alternatively, high melting point lipids such as white soft paraffin and/or liquid paraffin or other mineral oils can be used. Formulations suitable for topical administration to the eye also include eye drops wherein the active ingredients were dissolved or suspended in suitable carrier, especially an aqueous solvent for the active ingredients. The active ingredients were preferably present in such formulations in a concentration of 0.5 to 20%, advantageously 0.5 to 10% and particularly about 1.5% w/w. Formulations for parenteral administration may be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions. These solutions and suspensions may be prepared from sterile powders or granules using one or more of the carriers or diluents mentioned for use in the formulations for oral administration or by using other suitable dispersing or wetting agents and suspending agents. The compounds may be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, tragacanth gum, and/or various buffers. Other adjuvants and modes of administration are well and widely known in the pharmaceutical art. The active ingredient may also be administered by injection as a composition with suitable carriers including saline, dextrose, or water, or with cyclodextrin (ie. Captisol), cosolvent solubilization (ie. propylene glycol) or micellar solubilization (ie. Tween 80). The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed, including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables. For pulmonary administration, the pharmaceutical composition may be administered in the form of an aerosol or with an inhaler including dry powder aerosol. Suppositories for rectal administration of the drug can be prepared by mixing the drug with a suitable non-irritating excipient such as cocoa butter and polyethylene glycols that are solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum and release the drug.
The pharmaceutical compositions may be subjected to conventional
pharmaceutical operations such as sterilization and/or may contain conventional adjuvants, such as preservatives, stabilizers, wetting agents, emulsifiers, buffers etc. Tablets and pills can additionally be prepared with enteric coatings. Such compositions may also comprise adjuvants, such as wetting, sweetening, flavoring, and perfuming agents. Pharmaceutical compositions of this invention comprise a compound of the formulas described herein or a pharmaceutically acceptable salt thereof; an additional agent selected from a kinase inhibitory agent (small molecule, polypeptide, antibody, etc.), an immunosuppressant, an anticancer agent, an anti-viral agent, antiinflammatory agent, antifungal agent, antibiotic, or an anti-vascular hyperproliferation compound; and any pharmaceutically acceptable carrier, adjuvant or vehicle. Alternate compositions of this invention comprise a compound of the formulae described herein or a
pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier, adjuvant or vehicle. Such compositions may optionally comprise one or more additional therapeutic agents, including, for example, kinase inhibitory agents (small molecule, polypeptide, antibody, etc.), immunosuppressants, anti-cancer agents, anti-viral agents, antiinflammatory agents, antifungal agents, antibiotics, or anti-vascular
hyperproliferation compounds.
The term "pharmaceutically acceptable carrier or adjuvant" refers to a carrier or adjuvant that may be administered to a patient, together with a compound of this invention, and which does not destroy the pharmacological activity thereof and is nontoxic when administered in doses sufficient to deliver a therapeutic amount of the compound. Pharmaceutically acceptable carriers, adjuvants and vehicles that may be used in the pharmaceutical compositions of this invention include, but were not limited to, ion exchangers, alumina, aluminum stearate, lecithin, self-emulsifying drug delivery systems (SEDDS) such as d-a-tocopherol polyethyleneglycol 1000 succinate, surfactants used in pharmaceutical dosage forms such as Tweens or other similar polymeric delivery matrices, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat. Cyclodextrins such as α-, β-, and γ-cyclodextrin, or chemically modified derivatives such as hydroxyalkylcyclodextrins, including 2- and 3-hydroxypropyl-cyclodextrins, or other solubilized derivatives may also be advantageously used to enhance delivery of compounds of the formulae described herein. The pharmaceutical compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, emulsions and aqueous suspensions, dispersions and solutions. In the case of tablets for oral use, carriers which were commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, were also typically added. For oral administration in a capsule form, useful diluents include lactose and dried corn starch. When aqueous suspensions and/or emulsions were administered orally, the active ingredient may be suspended or dissolved in an oily phase is combined with emulsifying and/or suspending agents. If desired, certain sweetening and/or flavoring and/or coloring agents may be added. The pharmaceutical compositions of this invention may comprise formulations utilizing liposome or microencapsulation techniques. Such techniques were known in the art. The pharmaceutical compositions of this invention may be administered by nasal aerosol or inhalation. Such compositions were prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other solubilizing or dispersing agents known in the art.
The foregoing is merely illustrative of the invention and is not intended to limit the invention to the disclosed compounds. Variations and changes which are obvious to one skilled in the art are intended to be within the scope and nature of the invention which are defined in the appended claims.
From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.
All mentioned references, patents, applications and publications, are hereby incorporated by reference in their entirety, as if here written.

Claims

What is Claimed is:
1. A compound of Formula I
wherein Ring A is 5 membered heteroaryl;
wherein Ring T is phenyl or 6 membered heteroaryl;
wherein R2 is H, F, CI or methyl;
wherein R3 is H, C1-C6 alkyl or C1-C6 dialkylamino- C1-C6 alkyl;
wherein R5 is unsubstituted or substituted 5-6 membered saturated heterocyclyl or
substituted 4-7 membered heterocyclylamino;
wherein R6 is H, C1-C6 alkoxy, Q-C6 haloalkoxy or halo; and
wherein X is CH or N;
provided R5 is not 4-morpholinyl;
and pharmaceutically acceptable salts thereof.
2. Compound of Claim 1 wherein X is CH; and pharmaceutically acceptable salts thereof.
3. Compound of Claim 1 wherein R3 is H; and pharmaceutically acceptable salts thereof.
4. Compound of Claim 1 wherein R2 is H or methyl; and pharmaceutically acceptable salts thereof.
5. Compound of Claim 1 wherein R2 is methyl; and pharmaceutically acceptable salts thereof.
6. Compound of Claim 1 wherein R1 is substituted phenyl; and pharmaceutically acceptable salts thereof.
7. Compound of Claim 1 wherein R1 is substituted pyridyl or substituted pyrimidinyl; and pharmaceutically acceptable salts thereof.
8. Compound of Claim 1 wherein R5 is optionally substituted piperazinyl, optionally substituted piperidinyl, optionally substituted pyrrolidinyl, optionally substituted diazepanyl, or optionally substituted azetidinylamino; wherein the piperazinyl, piperidinyl, pyrrolidinyl, diazepanyl, and azetidinyl rings are optionally substituted with one or more substituents selected from Ci_3 alkyl, Ci_3 haloalkyl, Ci_4 alkoxycarbonyl, Ci_3 alkylamino, optionally substituted 5-6 membered heterocyclyl, C1.4 alkylcarbonyl, C1.4 alkylsulfonyl, aminosulfonyl, C1.4 hydroxyalkylcarbonyl, C1.4 alkylaminocarbonyl, and C1.4 haloalkylcarbonyl and pharmaceutically acceptable salts thereof.
9. Compound of Claim 1, and pharmaceutically acceptable salts thereof, wherein R1 is
10. Compound of Claim 1, and pharmaceutically acceptable salts thereof, wherein R5 is l-fluoroethylazetidin-3-ylamino.
11. Compound of Claim 1, and pharmaceutically acceptable salts thereof, wherein R6 is H, methoxy or chloro.
12. Compound of Claim 1, and pharmaceutically acceptable salts thereof , selected from
N-(3-(2-((2 -methoxy -4-(4-methyl-l-piperazinyl)phenyl)amino)-7-oxopyrido[2, 3- d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
(2ii)-N-(3-(2-((2-methoxy-4-(4-methyl-l-piperazinyl)phenyl)amino)-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)-2-butenamide;
N-(3-(2-((4-(4-methyl-l-piperazinyl)phenyl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H) yl)phenyl)-2-propenamide;
N-(3-(2-((2 -methoxy -4-(4-methyl-l-piperazinyl)phenyl)amino)-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
N-(3-(6-ethyl-2-((2-methoxy-4-(4-methyl-l-piperazinyl)phenyl)amino)-7-oxopyrido[2,3 d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
N-(3-(2-((4-methoxy-6-(4-methyl-l-piperazinyl)-3-pyridinyl)amino)-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
(2ii)-4-(dimethylamino)-N-(3-(2-((2-methoxy-4-(4-methyl-l-piperazinyl)phenyl)amino)
7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-butenamide;
N-(4-fluoro-3-(2-((2-methoxy-4-(4-methyl-l-piperazinyl)phenyl)amino)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide; N-(3-(2-((4-((l-(2-fluoroethyl)-3-azetidinyl)amino)-2-methoxyphenyl)amino)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
2-chloro-N-(3-(2-((2-methoxy-4-(4-methyl-l-piperazinyl)phenyl)amino)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acetamide;
3-(dimethylamino)-N-(3-(2-((2-methoxy-4-(4-methylpiperazin- 1 -yl)phenyl)amino)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)propanamide;
N-(3-(2-((4-((l-acetylazetidin-3-yl)amino)-2-methoxyphenyl)amino)-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)acrylamide;
N-(3-(2-((2-chloro-4-(4-methyl-l-piperazinyl)phenyl)amino)-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
N-(3-(2-((4-((l-(2-fluoroethyl)-3-azetidinyl)amino)-2-methoxyphenyl)amino)-5-methyl-
7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
N-(3-(5-methyl-2-((4-(4-methylpiperazin-l-yl)phenyl)amino)-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)acrylamide;
A^-(3-(2-((2-methoxy-4-(piperazin-l -yl)phenyl)amino)-5-methyl-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)acrylamide
N-(3-(2-((2-methoxy-4-(l-methylpiperidin-4-yl)phenyl)amino)-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide; and
N-(3-(2-((4-(4-acetylpiperazin-l-yl)-2-methoxyphenyl)amino)-5-methyl-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)acrylamide.
13. A compound of Formula II
wherein R2 is H or methyl;
wherein Ra is optionally substituted piperazinyl, optionally substituted piperidinyl,
optionally substituted pyrrolidinyl, optionally substituted diazepanyl, optionally optionally substituted azetidinylamino; and
wherein Rb is H or methoxy; and pharmaceutically acceptable salts thereof.
14. Compound of Claim 13 wherein R2 is methyl; and pharmaceutically acceptable salts thereof.
15. Compound of Claim 13 wherein Rb is located at position 3 on the phenyl ring and pharmaceutically acceptable salts thereof.
16. Compound of Claim 13 wherein Ra is optionally substituted piperazinyl, optionally substituted piperidinyl, optionally substituted pyrrolidinyl, or optionally substituted diazepanyl; wherein the piperazinyl, piperidinyl, pyrrolidinyl and diazepanyl rings are optionally substituted with one or more substituents selected from Ci_3 alkyl, Q. 3 haloalkyl, C1.4 alkoxycarbonyl, Cu alkylamino, optionally substituted 5-6 membered heterocyclyl, Ci_4 alkylcarbonyl, Ci_4 alkylsulfonyl, aminosulfonyl, Ci_4
hydroxyalkylcarbonyl, C1.4 alkylaminocarbonyl, and C1.4 haloalkylcarbonyl; and pharmaceutically acceptable salts thereof.
17. Compound of Claim 13 wherein Ra is azetidinylamino; wherein the azetindinyl is optionally substituted with one or more substituents selected from Cu alkyl, C1.3 haloalkyl, C1 alkoxycarbonyl, C1.3 alkylamino, optionally substituted 5-6 membered heterocyclyl, Ci_4 alkylcarbonyl, Ci_4 alkylsulfonyl, aminosulfonyl, Ci_4 hydroxyalkylcarbonyl, Ci_4 alkylaminocarbonyl, and Ci_4 haloalkylcarbonyl; and pharmaceutically acceptable salts thereof.
18. A compound of Formula la
wherein
R is
unsubstituted or substituted phenyl or unsubstituted or substituted 4-6 membered heterocyclyl;
R12 is H, or methyl;
R14 is H, Ci-C6 alkyl, Ci-C6 alkoxy or phenyl- Ci-C6 alkyl; and R17 is H or methyl;
and pharmaceutically acceptable salts thereof;
provided Rn is not 3-methoxy-4-methylpiperazin-l-yl-phenyl or phenyl when R
benzacrylamide, R12 is methyl and R14 is H;
further provided Rn is not 3-methoxy-4-methylpiperazin-l-yl-phenyl when R is
benzacrylamide, R12 is H and R14 is benzyl;
further provided R14 is not methyl or methoxy when R12 is H.
19. Compound of Claim 18 wherein R is ; and pharmaceutically acceptable salts thereof.
20. Compound of Claim 18 wherein R14 is H, benzyl, or methoxy; and pharmaceutically acceptable salts thereof.
21. Compound of Claim 18 wherein R14 is H; and pharmaceutically acceptable salts thereof.
22. Compound of Claim 18 wherein R12 is methyl; and pharmaceutically acceptable salts thereof.
23. Compound of Claim 18 wherein Rn is
wherein Ring A is 5 membered heteroaryl; wherein Ring T is phenyl; wherein R15 is unsubstituted or substituted 6-membered nitrogen containing heterocyclyl, Ci_4 alkylamino- C1 alkylamino, C1.4 hydroxyalkylamino, 5-membered nitrogen containing heterocyclyl-Ci_4 alkylamino, 5-membered nitrogen containing heterocyclyl-oxy, C1.4 alkylamino- C1 alkoxy, or C1.4 alkoxy- C1.4 alkoxy; wherein R16 is one or more substituents selected from Ci_4 alkyl, Ci_4 alkoxy, chloro, fluoro, H, Ci_4haloalkoxy and Ci_4 haloalkyl; and wherein R18 is C1.4 alkyl, C1.4 alkylamino- C1.4 alkyl, unsubstituted or substituted 5-membered nitrogen containing heterocyclyl or unsubstituted or substituted 6-membered nitrogen containing heterocyclyl; and pharmaceutically acceptable salts thereof.
24. Compound of Claim 18 wherein Rn is substituted phenyl; and
pharmaceutically acceptable salts thereof.
25. Compound of Claim 18 wherein Rn is substituted pyrazolyl; and pharmaceutically acceptable salts thereof.
26. Compound of Claim 18 wherein R15 is optionally substituted piperazinyl, optionally substituted piperidinyl, N-(N',N'-dimethylaminoethyl)-N-methylamino, N- hydroxy ethyl-N-methylamino, N-(2-oxo- 1 -pyrrolidinylethyl)-N-methylamino, N-( 1 - pyrrolidinylethyl)-N-methylamino, l-methyl-3-pyrrolidinyoxy, N,N- dimethylaminopropoxy, Ν,Ν-dimethylaminoethoxy, or methoxyethoxy; wherein the piperazinyl, and piperidinyl rings are optionally substituted with one or more substituents selected from methyl, trifluoromethyl, 1 -hydroxy- 1-methylethyl and acetyl; and pharmaceutically acceptable salts thereof.
27. Compound of Claim 18 wherein R16 is methyl, methoxy, chloro, fluoro, H, trifluoromethyl or difluoromethoxy; and pharmaceutically acceptable salts thereof.
28. Compound of Claim 18 wherein R18 is methyl, ethyl, isopropyl, N,N- dimethylaminoethyl, 1-methyl-pyrrolidinyl, or 1 -methylpiperidinyl; and
pharmaceutically acceptable salts thereof.
29. Compound of Claim 18, and pharmaceutically acceptable salts thereof, wherein Rl 1 is
30. A compound of Formula Ila wherein Ral is unsubstituted or substituted 6-membered nitrogen containing heterocyclyl; and wherein Rbl is one or more substituents selected from Ci_4 alkyl, Ci_4 alkoxy, chloro, fluoro, H, and pharmaceutically acceptable salts thereof;
provided Ral is not l-methyl-4-piperazinyl when Rbl is 3-methoxy.
31. Compound of Claim 30 wherein Rbl is located at position 3 on the phenyl ring; and pharmaceutically acceptable salts thereof.
32. Compound of Claim 30 wherein Ral is piperidinyl or piperazinyl; wherein the piperidinyl or piperazinyl ring is optionally substituted with one or more substituents selected from Cu alkyl, C1.4 alkylcarbonyl, or C1.4 hydroxyalkyl; and pharmaceutically acceptable salts thereof.
33. Compound of Claim 30, and pharmaceutically acceptable salts thereof,
34. Compound of Claim 30 wherein R is methyl, methoxy, chloro, fluoro, H, trifluoromethyl or difluoromethoxy; and pharmaceutically acceptable salts thereof.
35. A compound of Formula Ilia
wherein
R31 is substituted 5 membered heteroaryl;
R32 is H or methyl;
R34 is H, Ci-C6 alkyl, Ci-C6 alkoxy or phenyl-Ci-C6 alkyl; and
R31 is substituted with one or more substituents selected from Ci_4 alkyl, Ci_4 alkoxy, chloro, fluoro, C^ haloalkoxy, C^ haloalkyl, C1.4 alkylamino-Ci.4 alkyl, unsubstituted or substituted 5-membered nitrogen containing heterocyclyl and unsubstituted or substituted 6-membered nitrogen containing heterocyclyl; and and pharmaceutically acceptable salts thereof.
36. Compound of Claim 35 wherein R31 is optionally substituted pyrazolyl, optionally substituted isoxazolyl, optionally substituted thiadiazolyl, or optionally substituted imidazolyl; wherein the pyrazolyl, isoxazolyl, thiadiazolyl, or imidazolyl rings are substituted with one or more substituents selected from methyl, ethyl, isopropyl, methoxy, chloro, fluoro, trifluoromethyl, difluoromethoxy, Ν,Ν-dimethylaminoethyl, 1- methyl-pyrrolidinyl or 1-methylpiperidinyl; and pharmaceutically acceptable salts thereof.
37. Compound of Claim 35 wherein R31 is optionally substituted pyrazolyl; wherein the pyrazolyl ring is substituted with one or more substituents selected from methyl, ethyl, isopropyl, methoxy, chloro, fluoro, trifluoromethyl, difluoromethoxy, N,N- dimethylaminoethyl, 1 -methyl-pyrrolidinyl and 1-methylpiperidinyl; and
pharmaceutically acceptable salts thereof.
38. Compound of Claim 35 wherein R31 is
and pharmaceutically acceptable salts thereof.
39. Compound of Claim 35 wherein R34 is H, benzyl, or methoxy; and pharmaceutically acceptable salts thereof.
40. A compound of Formula IVa
wherein Ra is Q_4 alkylamino-Ci.4 alkylamino, C1.4 hydroxylalkylamino, 5-membered nitrogen containing heterocyclyl-Ci.4 alkylamino, 5-membered nitrogen containing heterocyclyl-oxy, C1.4 alky lamino-C 1.4 alkoxy, or C1.4 alkoxy-Ci.4 alkoxy; and wherein RM is one or more substituents selected from Ci_4 alkyl, Ci_4 alkoxy, chloro, fluoro, H, and pharmaceutically acceptable salts thereof.
41. Compound of Claim 40 wherein Ra4 is N-(N',N'-dimethylaminoethyl)-N- methylamino, N-hydroxyethyl-N-methylamino, N-(2-oxo- 1 -pyrrolidinylethyl)-N- methylamino, N-(l-pyrrolidinylethyl)-N-methylamino, l-methyl-3-pyrrolidinyoxy, N,N- dimethylaminopropoxy, Ν,Ν-dimethylaminoethoxy, or methoxyethoxy; and pharmaceutically acceptable salts thereof.
42. Compound of Claim 40 wherein RM is methyl, methoxy, chloro, fluoro, H, trifluoromethyl or difluoromethoxy; and pharmaceutically acceptable salts thereof.
43. Compound of Claim 18, and a pharmaceutically acceptable salt thereof, selected from
N-(3-(2-((4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-5- methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide; N-(3-(2-((4-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)amino)-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
N-(3-(2-((3-fluorophenyl)amino)-5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)- yl)phenyl)-2-propenamide;
N-(3-(5-methyl-2-((l-methyl-lH-pyrazol-4-yl)amino)-7-oxopyrido[2,3-d]pyrimidin-
8(7H)-yl)phenyl)-2-propenamide;
N-(3-(2-((l-(2-(dimethylamino)ethyl)-lH-pyrazol-4-yl)amino)-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
8-(((3 S)- 1 -acryloyl-3 -pyrrolidinyl)methyl)-2-((2-methoxy-4-(4-methyl- 1 - piperazinyl)phenyl)amino)-5-methylpyrido[2,3-d]pyrimidin-7(8H)-one;
N-(3-(2-((l,3-dimethyl-lH-pyrazol-4-yl)amino)-5-methyl-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
N-(3-(2-((l-ethyl-lH-pyrazol-5-yl)amino)-5-methyl-7-oxopyrido[2,3-d]pyrimidin-
8(7H)-yl)phenyl)-2-propenamide;
N-(3-(2-((4-(2-(dimethylamino)ethoxy)-2-fluorophenyl)amino)-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
N-(3-(2-((3-chloro-l -methyl- lH-pyrazol-4-yl)amino)-5-methyl-7-oxopyrido[2, 3- d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
N-(3-(2-((l,3-dimethyl-lH-pyrazol-4-yl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)- yl)phenyl)-2-propenamide;
N-(3-(5 -methyl-2-(( 1 -methyl-3 -(trifluoromethyl)- 1 H-pyrazol-4-yl)amino)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
N-(3-(5-methyl-2-((4-(l-methyl-4-piperidinyl)phenyl)amino)-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
N-(3-(2-((4-(2-(dimethylamino)ethoxy)-2-methoxyphenyl)amino)-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
N-(3-(2-(( 1 ,3 -dimethyl- 1 H-pyrazol-5 -yl)amino)-5-methyl-7-oxopyrido [2,3 - d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
N-(3-(2-((4-(2-methoxyethoxy)phenyl)amino)-5-methyl-7-oxopyrido[2,3-d]pyrimidin- 8(7H)-yl)phenyl)-2-propenamide;
N-(3-(2-((4-((2-hydroxyethyl)(methyl)amino)-2-methoxyphenyl)amino)-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
N-(3-(5-methyl-7-oxo-2-((4-(4-piperidinyl)phenyl)amino)pyrido[2,3-d]pyrimidin-
8(7H)-yl)phenyl)-2-propenamide; N-(3-(5-methyl-2-((l-(l-methylethyl)-lH-pyrazol-4-yl)amino)-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
N-(3-(2-((2-chloro-4-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)amino)-5- methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
N-(3-(5-methyl-2-((3-methyl-l-(l -methyl -4-piperidinyl)-lH-pyrazol-4-yl)amino)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
N-(3-(5-methyl-2-((5-methyl-l-(l -methyl -4-piperidinyl)-lH-pyrazol-4-yl)amino)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
(S)-N-(3-(2-((2-methoxy-4-((l-methylpyrrolidin-3-yl)oxy)phenyl)amino)-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide 2,2,2-trifluoroacetate;
N-(3-(2-((3-fluoro-4-(4-methyl-l-piperazinyl)phenyl)amino)-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
N-(3-(2-((2-chloro-4-(2-(dimethylamino)ethoxy)phenyl)amino)-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
N-(3-(2-((4-(2-(dimethylamino)ethoxy)phenyl)amino)-5-methyl-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)acrylamide;
N-(3-(5-methyl-2-((3-methyl-4-(4-methyl-l-piperazinyl)phenyl)amino)-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
N-(3-(2-((4-(4-( 1 -hydroxy- 1 -methylethyl)-l -piperidinyl)phenyl)amino)-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
N-(3-(6-methoxy-2-((2-methoxy-4-(4-methyl-l-piperazinyl)phenyl)amino)-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
N-(3-(2-((4-(4-acetyl-l-piperazinyl)-2-chlorophenyl)amino)-5-methyl-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
N-(3-(2-((4-((3R)-3,4-dimethyl-l-piperazinyl)-2-methoxyphenyl)amino)-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
N-(3-(2-((4-((3S)-3,4-dimethyl-l-piperazinyl)-2-methoxyphenyl)amino)-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
N-(3-(2-((4-(3-(dimethylamino)propoxy)phenyl)amino)-5-methyl-7-oxopyrido[2,3- d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
N-(3-(2-((2-methoxy-4-(methyl(2-(2-oxo-l-pyrrolidinyl)ethyl)amino)phenyl)amino)-5- methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
N-(3-(5-methyl-2-((3-methyl-l-((3S)-l-methyl-3-pyrrolidinyl)-lH-pyrazol-4- yl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide; N-(3-(2-((2-methoxy-4-(methyl(2-(l-pyrrolidinyl)ethyl)amino)phenyl)am
methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
N-(3-(2-((4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methylphenyl)am
methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide;
(2E)-N-(3-(2-((4-((2-(dimethylamino)ethyl)(methyl)am
5-methyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-butenamide;
N-(3-(2-((4-(2-(dimethylamino)ethoxy)-2-fluorophenyl)amino)-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-propenamide ; and
(2E)-N-(3-(2-((4-(2-(dimethylamino)ethoxy)-2-methoxyphenyl)amino)-5-methyl-7- oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)-2-butenamide.
44. A pharmaceutical composition comprising a pharmaceutically-acceptable carrier and a compound of any of Claims 1-43.
45. A method of treating cancer in a subject, said method comprising administering an effective amount of a compound of any of Claims 1-43.
46. A method of treating EGFR/ErbB2 related disorders in a mammal, said method comprising administering an effective amount of a compound of any of Claims 1- 43.
47. A method of treating EGFR mutant related disease in a subject, said method comprising administering an effective amount of a compound of any of Claims 1-43.
48. The method of Claim 47 wherein the EGFR mutant related disease is lung cancer.
49. The method of Claim 47 wherein the EGFR mutant related disease is non- small cell lung cancer.
50. A compound of any one of Claims 1-43 for use as a therapeutic agent.
EP14710724.7A 2013-03-01 2014-02-27 Substituted 7-oxo-pyrido [2, 3-d]pyrimidines and their use for the treatment of egfr / erbb2 related disorders Withdrawn EP2961750A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361771582P 2013-03-01 2013-03-01
US201361900156P 2013-11-05 2013-11-05
PCT/US2014/019030 WO2014134308A1 (en) 2013-03-01 2014-02-27 Substituted 7-oxo-pyrido [2, 3-d] pyrimidines and their use for the treatment of egfr / erbb2 related disorders

Publications (1)

Publication Number Publication Date
EP2961750A1 true EP2961750A1 (en) 2016-01-06

Family

ID=50288304

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14710724.7A Withdrawn EP2961750A1 (en) 2013-03-01 2014-02-27 Substituted 7-oxo-pyrido [2, 3-d]pyrimidines and their use for the treatment of egfr / erbb2 related disorders

Country Status (7)

Country Link
EP (1) EP2961750A1 (en)
JP (1) JP2016510029A (en)
AU (1) AU2014223396A1 (en)
CA (1) CA2903040A1 (en)
TW (1) TW201522332A (en)
UY (1) UY35359A (en)
WO (1) WO2014134308A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015296322B2 (en) 2014-07-26 2019-09-19 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as CDK inhibitors and uses thereof
BR112017024163A2 (en) * 2015-05-12 2018-07-17 Kalyra Pharmaceuticals Inc bicyclic compounds
CN106632313B (en) * 2016-03-04 2021-04-09 上海贤鼎生物科技有限公司 Important intermediate of anticancer drug palbociclib and synthesis process
BR112020018286A2 (en) 2018-03-09 2020-12-29 Recurium Ip Holdings, Llc 1,2-DI-HYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES SUBSTITUTED
KR102328435B1 (en) * 2018-09-11 2021-11-18 재단법인 대구경북첨단의료산업진흥재단 Novel pyrido-pyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating protein kinase related disease containing the same as an active ingredient
CN114901659A (en) 2019-11-26 2022-08-12 施万生物制药研发Ip有限责任公司 Fused pyrimidinone compounds as JAK inhibitors
CN114210238A (en) * 2021-12-02 2022-03-22 上海旭东海普南通药业有限公司 Fluorouracil refining method and device

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI546290B (en) * 2008-06-27 2016-08-21 賽基艾維洛米斯研究股份有限公司 Heteroaryl compounds and uses thereof
US8619856B2 (en) 2008-10-03 2013-12-31 Qualcomm Incorporated Video coding with large macroblocks
ES2659725T3 (en) * 2009-05-05 2018-03-19 Dana-Farber Cancer Institute, Inc. EGFR inhibitors and disorder treatment procedure
EP2637502B1 (en) 2010-11-10 2018-01-10 Celgene CAR LLC Mutant-selective egfr inhibitors and uses thereof
CN102816162B (en) * 2011-06-10 2016-04-27 中国科学院广州生物医药与健康研究院 Pyrimido-pyrimidine ketone compounds and medicinal compositions thereof and application
WO2013170671A1 (en) * 2012-05-14 2013-11-21 华东理工大学 Pteridine ketone derivative and applications thereof as egfr, blk, and flt3 inhibitor
CN103012399B (en) * 2012-11-22 2015-06-17 中国科学院广州生物医药与健康研究院 7-oxopyridinopyrimidine compound as well as medicinal composition and application thereof

Also Published As

Publication number Publication date
AU2014223396A1 (en) 2015-08-27
WO2014134308A1 (en) 2014-09-04
TW201522332A (en) 2015-06-16
UY35359A (en) 2014-09-30
JP2016510029A (en) 2016-04-04
CA2903040A1 (en) 2014-09-04

Similar Documents

Publication Publication Date Title
US7115617B2 (en) Amino-substituted pyrimidinyl derivatives and methods of use
US7531553B2 (en) Heterocyclic compounds and methods of use
EP1664023B1 (en) Sustituted isoquinoline derivatives and methods of use
US6822097B1 (en) Compounds and methods of uses
US7320992B2 (en) Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
EP1802586B1 (en) Heteroaryl-substituted alkyne compounds and method of use
AU2002329826A1 (en) 2-amino-4-heteroarylaminopyrimidine derivatives for use in the treatment of cancer
US20040063705A1 (en) Substituted pyrimidinyl derivatives and methods of use
US20030229068A1 (en) 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use
US20060241151A1 (en) Pyrid-2-one derivatives and methods of use
WO2014134308A1 (en) Substituted 7-oxo-pyrido [2, 3-d] pyrimidines and their use for the treatment of egfr / erbb2 related disorders
AU2002336390A1 (en) 2,4-disubstituted pyrimidinyl derivatives for use as anticancer agents
CA2830780A1 (en) Azole compounds as pim inhibitors
EP1385833A1 (en) Triazinyl amide derivatives as angiogenesis inhibitors
US9346801B2 (en) Substituted 7-oxo-pyrido[2,3-d]pyrimidines and methods of use
EP1507776B1 (en) 2-oxo-1,3,4-trihydroquinazolinyl derivatives for the treatment of cell proliferation-related disorders

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150910

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

17Q First examination report despatched

Effective date: 20160905

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170316